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Background 
In pharmacogenetic studies, researchers explore how genetic variants impact individuals’ 
responses to drugs. Implementation of pharmacogenetic tests in clinical practice can 
improve treatment efficacy and reduce toxicity. For health service providers to implement 
pharmacogenetic testing in clinical practice, the pharmacogenetic association of interest 
must be supported by strong evidence. Performing meta-analyses of pharmacogenetic 
studies increases sample size and power, and is therefore an indispensable tool to 
researchers striving to improve the strength of evidence for pharmacogenetic associations. 
The aim of this thesis is to identify and resolve challenges that reviewers might encounter 
when synthesising evidence from primary pharmacogenetic studies. 
Methods 
We explored methods of evidence synthesis for pharmacogenetic studies and applied them 
to undertake a systematic review and meta-analysis of associations between genetic 
variants and anti-tuberculosis drug-related toxicity. We applied both standard methods of 
meta-analysis, and more complex methods of meta-analysis that account for correlation 
between related effect sizes for each genetic variant. Conducting this systematic review 
and meta-analysis enabled us to identify that key information was often poorly reported in 
the primary pharmacogenetic studies. In order to improve the reporting of 
pharmacogenetic studies with a view to facilitating the evidence synthesis process, we used 
consensus methodology to develop a reporting guideline for pharmacogenetic studies, 
known as the STROPS (Strengthening The Reporting Of Pharmacogenetic Studies) guideline.  
Results 
Our systematic review of the association between genetic variants and anti-tuberculosis 
drug-related toxicity included 70 studies. Slow acetylators are more likely to experience 
anti-TB drug-induced hepatotoxicity than intermediate/rapid acetylators. We also observed 
associations between the CYP2E1 RsaI and GSTM1 null polymorphisms and hepatotoxicity. 
Key information, such as the ethnicity of included patients, methodological quality, and 
patient cohort overlap, was poorly reported. We also found that improvements in the 
reporting of outcome data would give systematic reviewers greater freedom in terms of 
their analysis approach. As part of the development of the STROPS guideline, 52 individuals 
from key stakeholder groups participated in two rounds of a Delphi survey. A total of eight 
individuals participated in a consensus meeting, before the 54-item STROPS guideline was 
finalised.  
Conclusions 
Our systematic review showed that pharmacogenetic testing may be useful in clinical 
practice in terms of risk stratification for hepatotoxicity during TB treatment. More studies 
are needed to overcome methodological limitations of the existing studies and to assess 
the feasibility and cost-effectiveness of a stratified medicine approach. It is currently 
challenging to synthesise pharmacogenetic evidence, due to poor reporting of primary 
studies. We encourage authors to adhere to the STROPS guideline when publishing 
pharmacogenetic studies. The STROPS guideline will not only improve the transparency of 
reporting of pharmacogenetic studies, but will also facilitate the conduct of high-quality 
systematic reviews and meta-analyses, and thus improve the power to detect 
pharmacogenetic associations.   
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1.1 Introduction to pharmacogenetics 
Pharmacogenetics has been defined as the study of how genetic differences influence the 
variability in patient’s responses to drugs.1 Patient response to a particular drug may be 
defined in terms of both benefits (therapeutic effect) and harms (adverse effectsb). For 
example, in a study conducted by Trivedi et al.,2 only approximately 30% of patients 
receiving the antidepressant drug, citalopram, for major depressive disorder achieved an 
adequate treatment response, i.e. full remission. However, 4% of patients from the Trivedi 
et al. study2 experienced at least one serious adverse event.  
Variability in patient response to any given drug is likely to be highly complex and may be 
attributable to a number of physiological and environmental factors, such as age, sex, 
smoking status, and levels of physical activity. A lack of adherence to the recommended 
dose and interactions with concurrent medications may also impact treatment response in 
terms of both efficacy and toxicity. Furthermore, it is widely accepted that genetic variation 
can also contribute to the variation in drug response observed between different 
individuals.  
The concept that genetic variants might account for variability in drug responses was first 
proposed by Garrod in 1909,3 and the term ‘pharmacogenetics’ was introduced by Vogel in 
1959.4 As the study of pharmacogenetics allows researchers to explore reasons for inter-
individual variability in drug response, pharmacogenetics is viewed as an important field 
which may lead to improvements in drug therapy and future prescribing practices.5  
Another term, ‘pharmacogenomics’, is also used throughout the literature. PharmGKB 
(www.pharmgkb.org), a pharmacogenomics knowledge resource,6 advises that 
‘pharmacogenetics usually refers to how variation in one single gene influences the 
response to a single drug’, and that ‘pharmacogenomics is a broader term, which studies 
how all of the genes (the genome) can influence responses to drugs’. It is also stated that 
these terms are often used interchangeably.7 Throughout this thesis, the term 
‘pharmacogenetics’ is used, since the focus of the work is on studies which aim to identify 
specific genetic variants that cause individuals to respond to drugs differently. 
                                                          
b Definitions are provided for terms in italics in the glossary 
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1.2 The human genome and DNA 
The human genome contains the information required to produce all the proteins needed 
by a human being, and is inscribed in a material known as DNA. DNA is built from molecules 
called ‘nucleotides’, each of which contains one of four bases: adenine (A), thymine (T), 
guanine (G) and cytosine (C). The order in which these bases are arranged determines 
which proteins are produced by specifying a sequence of amino acids.  
In the human body, almost every cell has a nucleus, which serves as the cell’s control centre 
and directs the cell’s activities. Each nucleus contains a full copy of the individual’s DNA, 
which is packaged into large molecules known as chromosomes. Human cells contain two 
sets of 23 chromosomes, with one set inherited from each parent. A chromosome contains 
many genes, each of which is a section of DNA that codes for a specific protein. Although 
each cell contains a full copy of the individual’s DNA, cells use genes selectively depending 
on the proteins required for the function of that particular cell. 
In addition to the sections of DNA that are genes, the genome also contains sections of DNA 
between genes, or ‘intergenic regions’. Intergenic regions make up a large proportion of the 
human genome, but little is known about the function of most intergenic DNA.8 
Furthermore, within genes, there are coding regions (exons), which code for protein, and 
non-coding regions, such as introns and regulatory sequences, both of which have functions 
relating to the regulation of gene expression.  
1.3 Genetic variation 
Humans are approximately 99.9% identical to each other in terms of their DNA sequence. 
Differences in the DNA sequence among individuals are known as genetic variation, and can 
influence many characteristics, including physical appearance, behaviour, and susceptibility 
to disease. The most common type of genetic variation among humans is a single 
nucleotide polymorphism (SNP). Each SNP is a locus i.e. a fixed location on a chromosome, 
where the type of nucleotide base (A, T, C, or G) present can differ between individuals. The 
different types of nucleotide bases that can be observed at a given locus are known as 
alleles.  
SNPs are most commonly bi-allelic, i.e. all individuals have one of two alleles. The allele that 
is most commonly observed at a particular locus for a given population is known as the 
‘wild-type allele’ while the less common allele is known as the ‘mutant-type allele’. For 
example, at a SNP where most individuals have the C nucleotide base, but some individuals 
have the T nucleotide base, the wild-type allele is C and the mutant-type allele is T.  
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For any given locus, an individual possesses two alleles, one on each chromosome. 
Therefore, if the locus is a bi-allelic SNP, three distinct combinations of alleles are possible. 
These combinations are referred to as ‘genotypes’. For the previous example, an individual 
may have the CC genotype, where the C allele occurs at the locus of interest on both 
chromosomes, the CT genotype, where the C allele occurs on one chromosome and the T 
allele occurs on the other, or the TT genotype, where the T allele occurs on both 
chromosomes. In more general terms, an individual with two copies of the wild-type allele 
at the locus of interest is said to be ‘homozygous wild-type’, an individual with two copies 
of the mutant-type allele is ‘homozygous mutant-type’, and an individual with one copy of 
each allele is ‘heterozygous’.  
The focus of this work is the investigation of associations between SNPs and treatment 
outcomes; however, it should be noted that there are other types of genetic variation. For 
example, the term ‘indel’ refers to either the insertion or deletion of a stretch of nucleotide 
bases in the DNA sequence, which may range from one base to thousands of bases in 
length. 
1.4 SNPs and drug response 
SNPs may occur in both coding and non-coding regions of genes, and in intergenic regions. 
A SNP in a coding region is either non-synonymous or synonymous; non-synonymous SNPs 
alter the amino acid sequence of the protein produced by the gene, while synonymous 
SNPs have no impact on this sequence. A non-synonymous SNP may therefore affect the 
structure and/or function of the protein. Historically, synonymous SNPs were thought to be 
inconsequential, and were widely referred to as ‘silent SNPs’. However, there is a growing 
body of research demonstrating a variety of mechanisms by which synonymous SNPs may 
alter the structure, function, and/or expression level of proteins.9 Furthermore, recent 
research has identified functional SNPs in non-coding regions of genes and in intergenic 
regions.10  
Proteins produced by genes have specific functions within cells, which may relate to how 
the body interacts with drugs. Interactions between the human body and drugs are usually 
described in terms of two distinct processes; ‘pharmacokinetics’ and ‘pharmacodynamics’. 
Pharmacokinetics is the study of the relationship between drug dose and the resulting 
plasma and tissue drug concentrations, and is usually subdivided into the processes of 
absorption, distribution, metabolism, and excretion. SNPs in genes coding for proteins 
involved in pharmacokinetic processes can affect the concentration of the drug within the 
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body; individuals may experience a lack of efficacy if plasma drug levels are too low, and 
may experience toxicity if plasma drug levels are too high. Pharmacodynamics is the study 
of the relationship between drug concentration at the target and the physiological and 
biochemical effect of a drug. SNPs in genes which encode drug targets can alter how a drug 
binds to its target, and consequently the effect of the drug on the body. Finally, SNPs in 
genes involved in the disease pathway itself may also lead to variation in drug response. 
Although individuals may have the same disease, genetic factors contributing towards the 
disease may differ from one patient to another. If a drug acts by counteracting a specific 
disease pathway, then treatment response may vary from one individual to the next.  
1.5 Pharmacogenetic association studies 
In order to determine whether genetic variants are associated with response to a given 
drug, researchers may perform a pharmacogenetic association study. In such a study, 
participants are subject to a process called ‘genotyping’, whereby their genotype is 
determined for any number of genetic variants. Data are also collected on participants’ 
responses to this drug, in terms of efficacy and/or toxicity. Statistical analyses can then be 
performed to determine whether there is a statistically significant association between 
genotype and drug response.  
Studies designed to identify associations between genetic variants and treatment-related 
outcomes are usually carried out using either a case-control or cohort study design. Table 1 
provides a description of how each of these designs would be applied to identify 
pharmacogenetic associations.   
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Table 1 Study designs used for pharmacogenetic association studies 
Study design Description 
Case-control study The ‘case’ group consists of patients who have received the treatment of 
interest and subsequently experienced some treatment-related outcome 
(i.e. a measure of either efficacy or toxicity). The ‘control’ group may 
consist of ‘true controls’, who have been exposed to the relevant 
treatment but have not developed the outcome of interest, or ‘population 
controls’, i.e. individuals who can be assumed to be controls, although we 
cannot ascertain whether they would have developed the outcome of 
interest if they had been exposed to the relevant treatment. Genotype 
frequencies are compared between the case and control groups. 
Cohort study A sample of patients receiving the drug treatment of interest are recruited 
according to the study’s inclusion criteria. Following enrolment, data are 
collected on genotype and treatment response for these patients. 
Treatment responses can then be compared between genotype groups. 
 
Participants may be followed prospectively over time to determine their 
treatment response, or this information may be collected retrospectively 
from existing records. However, the STROBE guideline11 recommends that 
authors refrain from simply calling a study ‘prospective’ or ‘retrospective’ 
as there is no clear consensus on the definition of these terms. When 
describing cohort studies, authors should instead report how and when 
data collection took place for the variables and outcomes of interest. 
STROBE: STrengthening the Reporting of OBservational studies in Epidemiology 
 
It is possible that researchers conducting studies designed for the primary purpose of 
comparing different treatment regimens may also collect and report data that can be used 
to identify pharmacogenetic associations. For example, in an RCT, or a non-randomised 
study designed to compare different interventions, participants may be genotyped to 
perform additional pharmacogenetic analyses. If data on genotype and a treatment-related 
outcome are obtained for a group of participants all receiving a particular treatment of 
interest, then this data may be used to investigate whether pharmacogenetic associations 
exist.  
In addition to identifying pharmacogenetic associations, studies may be conducted to 
address other pharmacogenetic-related questions, such as: i) whether an individual’s 
genotype modifies the treatment effect of some intervention of interest versus some 
comparator of interest; ii) whether prescribing treatments according to genotype is 
beneficial in terms of efficacy and/or safety outcomes. Alternative study designs to the 
case-control and cohort designs described in Table 1 would be required to address these 
questions. However, the focus of this thesis is studies that investigate whether 
pharmacogenetic associations exist, and studies that address other pharmacogenetic-
related questions are not discussed in detail.  
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Pharmacogenetic association studies may be described in terms of the scale of genotyping 
conducted. Researchers may genotype all known SNPs in the human genome, in a ‘genome-
wide association study’ (GWAS), or they may choose to genotype a comparatively small set 
of SNPs which are likely to affect treatment response, in a ‘candidate gene study’. There are 
strengths and limitations to each of these approaches, and researchers may choose to use 
either approach for a variety of different reasons. 
A pharmacogenetic association study using a candidate gene approach focuses on SNPs 
within genes that play a role in pharmacokinetic or pharmacodynamic processes, or within 
genes that are believed to be involved in the pathway of the disease being treated. As 
previously discussed in Section 1.4, these types of SNPs are most likely to affect drug 
response. As prior knowledge of the function of the selected genes is required for a 
candidate gene approach, this type of study is therefore not capable of identifying new 
genes (or gene combinations) of unknown function that have an important effect on drug 
response. Conducting a GWAS is more expensive, since hundreds of thousands of SNPs 
must be genotyped in order to provide coverage of the entire human genome. However, a 
GWAS is capable of identifying genes that may be important in terms of drug response, 
even when the function of these genes is unknown. 
In addition, due to the number of SNPs genotyped, the number of statistical tests 
performed for a GWAS is inevitably very large in comparison to the number of tests 
performed for a candidate gene study. In order to control the overall probability of false 
positive results being reported, researchers conducting GWASs may lower the threshold at 
which calculated p-values would indicate statistical significance. Such an adjustment for the 
large number of statistical tests performed would mean that the GWAS would have lower 
power compared to a candidate gene study with the same sample size.  
1.6 Clinical implications of pharmacogenetic studies 
The key motivation for performing pharmacogenetic studies and identifying associations 
between SNPs and treatment outcomes is that eventually these findings might inform 
clinical practice. If a genetic variant has been linked to an increased risk of toxicity or poor 
efficacy outcome for a particular treatment in pharmacogenetic studies, a health care 
provider may choose to genotype patients before administering the treatment. This would 
allow the health care provider to make an informed decision regarding the choice of 
prescribed drug and dosage. In more general terms, implementing the findings of 
pharmacogenetic studies is a step towards a stratified medicine approach to health care. 
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The terms ‘stratified medicine’, ‘personalised medicine’ and ‘precision medicine’ are often 
used interchangeably in the literature; there is no consensus on how these concepts differ 
in practice. For simplicity, in this thesis, we use the term ‘stratified medicine’ to describe 
the concept of tailoring medical treatment to the individual characteristics of a patient. 
In recent years there has been a dramatic rise in our knowledge of pharmacogenetic 
associations; for example, the Clinical Pharmacogenetics Implementation Consortium (CPIC) 
has published pharmacogenetic guidelines for 62 drugs as of July 2020.12 However, few 
pharmacogenetic tests are routinely used in clinical practice.13, 14 There are a variety of 
reasons why the findings of a pharmacogenetic study may not be implemented in clinical 
practice, including: logistical challenges and costs associated with introducing 
pharmacogenetic tests, inexperience of clinicians in interpreting and acting on results of 
these tests, and a lack of RCTs demonstrating the benefits of genotype-guided therapy in 
comparison to standard therapy.13 
Despite these barriers, it is becoming increasingly apparent that implementation of 
pharmacogenetic tests in clinical practice can reduce adverse effects, improve treatment 
efficacy, and consequently be a cost-effective use of health care providers’ budgets. For 
example, Verhoef et al.15 demonstrated that genotype-guided dosing of warfarin in patients 
with atrial fibrillation is cost effective in the UK. Another study16 based in the UK 
investigated pre-prescription pharmacogenetic testing in HIV patients, as HLA B*5701 is 
known to be a genetic risk factor for abacavir hypersensitivity in Caucasians. The authors 
concluded that pharmacogenetic-guided prescribing to prevent abacavir hypersensitivity is 
a cost-effective strategy. Indeed, testing for HLA B*5701 is now widely performed in clinical 
practice prior to prescription of abacavir. Another example of pharmacogenetic testing in 
widespread use is TPMT testing (either genotyping or measurement of TMPT enzyme 
levels) prior to thiopurine prescription.14 
In order to to encourage researchers to conduct high-quality RCTs of genotype-guided 
prescribing practices, it is crucial in the first instance that strong evidence exists from 
pharmacogenetic association studies. Once high-quality RCTs have been performed, or the 
evidence from association studies suggests a sufficiently large effect that RCTs are not 
required, health service providers may consider the implementation of pharmacogenetic 
testing in clinical practice.  
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1.7 How systematic reviews and meta-analysis can improve the strength of 
the evidence base 
Outcomes from pharmacogenetic studies are often likely to be complex traits; genetic 
influence may be explained by several genetic variants each having only a small effect on 
outcome.17 It is unlikely that a common genetic variant will have a large impact on 
treatment response; it is more likely that the variant will be rare and/or the impact on 
treatment response will be small to moderate.18 Therefore, large sample sizes are required 
to provide sufficient power to identify pharmacogenetic associations. It is often not feasible 
for pharmacogenetic studies to be conducted on a large scale due to insufficient funding 
and/or resources.  
Meta-analysis is a statistical technique for combining the results of a number of individual 
studies to produce a summary result, and can therefore be used to improve sample size 
and increase the power to detect pharmacogenetic associations. Researchers often 
perform meta-analysis as part of a systematic review, which aims to identify all published 
and unpublished evidence relevant to a specific research question, and to methodologically 
summarise this evidence base. Meta-analysis may also be performed outside the context of 
a systematic review; researchers may wish to consolidate data from multiple studies 
without performing a systematic search for all available evidence. However, the focus 
within this thesis is on the conduct of meta-analyses within the context of systematic 
reviews, as systematic reviews of all available evidence are widely considered to be the 
most reliable source of evidence to inform clinical practice. 
An additional challenge to consider when conducting pharmacogenetic studies is the 
possibility of false positives occurring, where a statistically significant association is 
identified despite there being no association between the genetic variant and drug 
response outcome in reality. This is referred to as a ‘type 1 error’. For each hypothesis test 
performed (i.e. a test of association between a single SNP and outcome), the type 1 error 
rate determines the probability that a statistically significant result is a false positive 
finding. When conducting a single hypothesis test, and assuming the usual type 1 error rate 
of 5%, there is a 5% chance of observing a false positive. As the number of statistical tests 
increases, the number of false positives likely to be observed also increases. For example, if 
20 statistical tests are performed, each with a type 1 error rate of 5%, the risk of at least 
one false positive finding is 64%. Increasing the number of tests to 100 increases the chance 
of at least one false positive finding to over 99%. Therefore, due to the large number of 
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SNPs typically investigated, pharmacogenetic studies are at particular risk of type 1 errors. 
When a study reports a pharmacogenetic association to be statistically significant, 
researchers may therefore be interested in whether other studies also provide evidence to 
support the association of interest. If other studies have replicated the association (in terms 
of magnitude, direction and possibly statistical significance), this can improve confidence 
that the original finding was not a type 1 error.  
However, replication of findings is particularly uncommon among genetic association 
studies. Ioannidis et al.19 examined the results of 55 meta-analyses of genetic association 
studies, and identified that only nine meta-analyses (16%) were free from heterogeneity 
and bias, and identified significant and replicated genetic associations. In this study, genetic 
associations were determined to be sufficiently replicated when the results of the meta-
analysis remained statistically significant after excluding the study or studies that first 
reported the significant association.  
To date, there has been no study published on failure to replicate findings in 
pharmacogenetic studies in particular, although there have been many instances where 
initial reports of pharmacogenetic associations have not been replicated in subsequent 
studies. For example, Smeraldi et al.20 were the first group of researchers to report that 
individuals carrying at least one copy of the long (l) allele at the serotonin-transporter-
linked polymorphism (5-HTTLPR) showed a better response to the antidepressant drug 
fluvoxamine than individuals with two copies of the short (s) allele. However, many studies 
have subsequently investigated this association, with conflicting results. A systematic 
review and meta-analysis conducted by Taylor et al.21 identified that l allele carriers were 
no more likely to experience remission than those with the ss genotype.  
Failure to replicate a pharmacogenetic association, whether this is purely in terms of the 
observed magnitude and direction of effect, or whether this also requires the rejection of a 
null hypothesis to indicate statistical significance, does not necessarily invalidate the initial 
study’s finding. There are various reasons why a pharmacogenetic association may not be 
replicated in subsequent studies. Study settings and populations may vary in terms of 
environmental factors that modify the pharmacogenetic effect; indeed, Keers et al.22 
reported that an interaction between stressful life events and the 5-HTTLPR polymorphism 
predicts response to antidepressant treatment. In scenarios where environmental factors 
impact the pharmacogenetic association, it would be expected that findings would differ 
between studies conducted in different settings and populations.  
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Furthermore, varying patterns of linkage disequilibrium and differences in allele frequencies 
between populations may cause replication failure of pharmacogenetic associations. 
Linkage disequilibrium describes the extent to which the frequency of a combination of 
alleles at two loci differs to the frequency that would be expected if the loci were 
independent and associated randomly. If two SNPs are in strong linkage disequilibrium, and 
one of these SNPs has a causal relationship with a drug response outcome, a significant 
association may be observed between the non-causal SNP and the outcome due to the 
correlation between the observed alleles at the two loci. If a particular allele is strongly 
associated with drug response outcome in one population, but not in another, this may be 
due to varying extents of linkage disequilibrium between the genotyped SNP and the causal 
SNP in the different populations as opposed to a true absence of association in the second 
population. In addition, a study may not replicate a previously identified statistically 
significant association if the allele of interest is observed in smaller frequencies in the 
replication study population than in the original study population, due to reduced power.  
Finally, studies may vary considerably in terms of their methodological quality; Jorgensen 
and Williamson18 identified key issues relating to the methodological quality of 
pharmacogenetic studies. These issues may introduce bias into studies, and cause 
replication failure across pharmacogenetic studies. 
An important component of any well conducted meta-analysis (within a systematic review) 
is an exploration of heterogeneity between studies. Authors conducting meta-analyses are 
able to investigate how a pharmacogenetic association varies according to covariates such 
as study setting or population, by performing subgroup analyses or meta-regression.23 
Furthermore, authors of systematic reviews and meta-analyses ought to assess the 
methodological quality of included studies; such an assessment may highlight important 
methodological differences between studies, which could cause differences in overall 
findings. Authors may even choose to perform sensitivity analyses, in which studies of 
particularly poor methodological quality are excluded from meta-analyses.  
Therefore, to researchers striving to improve the strength of evidence bases for 
pharmacogenetic associations, meta-analysis is an indispensable tool. Performing a 
systematic review and meta-analysis can not only improve power to detect 
pharmacogenetic associations, but also can enable investigations of heterogeneity and the 
impact of methodological quality on study results. Performing these investigations may 
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shed light on why pharmacogenetic associations have not been replicated across studies, or 
they may highlight the possibility that initial significant associations were spurious findings.  
1.8 Thesis aim and structure 
The aim of this thesis is to improve the strength of the evidence base for pharmacogenetic 
associations, by: 
i) Identifying challenges that reviewers might encounter when synthesising evidence from 
pharmacogenetic studies; 
ii) Resolving these challenges with the development of new methodology and guidance that 
will facilitate future evidence synthesis within pharmacogenetics.  
In Chapter 2, we outline methodology for evidence synthesis, i.e. performing systematic 
reviews and meta-analyses, of pharmacogenetic studies. In Chapters 3 and 4, we 
demonstrate how these methods can be applied in practice, by conducting a large 
systematic review and meta-analysis of pharmacogenetic studies investigating associations 
between genetic variants and anti-tuberculosis (TB) drug-related toxicity. In Chapter 5, we 
explore more complex methods of meta-analysis and apply these methods to data from our 
systematic review. In the process of performing the systematic review and meta-analysis, 
we identified that improvements in the reporting of pharmacogenetic studies would enable 
researchers to perform high-quality meta-analyses that include all relevant evidence. In 
Chapter 6 therefore, we develop a reporting guideline for pharmacogenetic studies using 
widely accepted and robust methodology. In Chapter 7, we summarise the overall findings 
and implications of this thesis, outline areas for future work, and make concluding remarks.   
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2 Methods of evidence synthesis for pharmacogenetic studies 
To date, there has been no widely disseminated guidance specifically for evidence synthesis 
of pharmacogenetic studies. However, guidance on evidence synthesis methods for genetic 
association studies is available in the HuGENet HuGE Review Handbook,24 and the methods 
outlined are applicable to evidence synthesis of pharmacogenetic studies. Since the 
development of the HuGENet HuGE Review Handbook,24 Jorgensen and Williamson18 have 
developed a checklist of methodological issues to be considered by primary researchers 
when conducting a pharmacogenetic study. The authors confirm that the checklist can also 
be used to assess the methodological quality of studies included in a systematic review and 
meta-analysis of pharmacogenetic studies. In this chapter, we summarise and reflect on the 
key issues from the HuGENet HuGE Review Handbook24 and Jorgensen and Williamson’s 
checklist,18 which ought to be considered when synthesising evidence from 
pharmacogenetic studies.  
2.1 Searching for studies 
The HuGENet HuGE Review Handbook24 emphasises the importance of conducting a 
comprehensive search, as systematic reviews of genetic association studies are at particular 
risk of being affected by reporting biases. Reporting bias occurs when decisions about how, 
when or where to report results of studies are influenced by the findings of the study.25 
Considering the huge number of outcome and genetic variant combinations that are 
possible, it is clear that the number of genetic associations under investigation at any one 
time is likely to be vast. It is also therefore probable that only the most exciting results will 
be published in easily accessible journals.  
Key types of reporting biases are publication bias, and language bias. Publication bias 
occurs when investigators submit manuscripts for publication, or reviewers and editors 
accept manuscripts for publication, based on the direction or strength of their findings.26 
Language bias occurs when choice of language for publication depends on the nature of the 
findings.25 If only published studies, or only studies published in a certain language are 
included in the review, the estimates of effect reported in the included studies may not be 
reflective of the true relationship between the variables of interest. It is therefore impotant 
that review authors attempt to identify all relevant studies, regardless of publication status, 
and language. 
The HuGENet HuGE Review Handbook24 recommends including non-English language 
journals in the search, which may not be indexed in commonly searched databases, such as 
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PubMed, ISI Science Citation Index, EMBASE and BIOSIS. It is also recommended that 
authors attempt to identify unpublished studies by searching ‘grey literature’, such as 
conference proceedings, technical reports and books, and include any studies identified, 
providing there is sufficient information to perform a thorough quality assessment.24 
Checking the reference lists of existing reviews on the topic and articles identified for 
inclusion in the review may also identify unpublished or published studies not identified by 
the initial search.  
2.2 Assessment of methodological quality of pharmacogenetic studies 
An assessment of the internal validity of a study’s results is a key component of any good 
systematic review. Such an assessment guides the systematic reviewer’s approach to 
analysis, interpretation of results and conclusions.25 Jorgensen and Williamson18 have 
developed a quality assessment checklist to be referred to by researchers when conducting 
pharmacogenetic studies. The checklist may also be used by researchers conducting 
systematic reviews and meta-analyses of pharmacogenetic studies.  
It is important to note here that concerns relating to methodological quality may not 
always have an impact on the internal validity of a study’s findings; in other words, poor 
standards of conduct may not necessarily lead to overestimation or underestimation of the 
true effect. Similarly, it is possible that a study’s results may be impacted by sources of bias 
that even a study conducted to the highest possible standard would not be able to 
overcome. It is for these reasons that in recent years, there has been a shift among the 
evidence synthesis research community, from performing assessments of methodological 
quality, to assessing the risk that bias may have affected particular numerical results.  
To the best of our knowledge, no tool exists that has been designed to assess the risk of 
bias in pharmacogenetic studies. Although not specifically tailored for this purpose, 
Jorgensen and Williamson’s checklist18 may help systematic reviewers identify issues that 
would impact the internal validity of a pharmacogenetic study’s results. Systematic 
reviewers using the tool ought to be aware that some of the listed criteria would not have 
implications for the internal validity of a pharmacogenetic study’s results, and therefore 
would not need to be highlighted in the review as particular issues of concern. In addition, 
there are some potential sources of bias not described in the checklist; these are discussed 
further in Section 2.5. 
In this chapter, we summarise the key issues of methodological quality identified by 
Jorgensen and Williamson.18 In Chapter 3, we apply the checklist to a set of 
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pharmacogenetic studies, and highlight instances where criteria are of little relevance to 
the validity of study results included in a systematic review. 
Choosing which genes and SNPs to genotype 
As previously discussed in Section 1.7, pharmacogenetic studies that investigate a large 
number of SNPs are at particular risk of type 1 errors due to the large number of statistical 
tests performed. There are various methods available that can be used to overcome the 
issue of multiple testing in genetic association studies, each of which has its own strengths 
and limitations. Bouaziz et al.27 discuss the most common methods of multiplicity 
adjustment used in genetic association studies, and provide advice for researchers on how 
to choose with method to use. Ultimately, the statistical significance of a result and 
conclusions of a study may vary according to the method of adjustment for multiple testing. 
For clarity, pharmacogenetic studies ought to describe any methods used to adjust for 
multiple testing.18  
The problem of multiplicity becomes particularly prominent for GWASs, in which hundreds 
of thousands of SNPs are investigated. Furthermore, there may be no theoretical basis for 
associations identified between SNPs and drug response outcomes in a GWAS, and so 
particular caution ought to be taken when interpreting statistically significant results.  
On the other hand, in a candidate-gene study, SNPs have been selected for investigation as 
there is a plausible biological explanation for association between the SNP and drug 
response. Therefore, multiple testing is often a less concerning, although certainly not 
negligible, issue for consideration. It is important that researchers conducting a candidate 
gene study choose the genes and SNPs to be investigated in a systematic way, using prior 
knowledge to guide their decisions. Jorgensen and Williamson18 outline a procedure for the 
systematic selection of genes and SNPs in candidate gene studies. Such an approach 
ensures that the resources allocated to the study are used efficiently by prioritising genetic 
variants that are likely to influence drug response. Furthermore, having strong prior 
evidence can improve confidence that a statistically significant association is genuine, 
rather than a type 1 error. Clear rationale also instils confidence in the reader that all 
analyses performed have been reported, rather than only statistically significant results. 
Therefore, Jorgensen and Williamson18 recommend that study authors report their 
rationale for investigating all chosen genes and SNPs.  
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Sample size 
An important challenge for researchers conducting pharmacogenetic association studies is 
achieving sufficient statistical power. As previously outlined in Section 1.7, large sample 
sizes are required to provide sufficient power to identify pharmacogenetic associations. 
Indeed, Jorgensen and Williamson18 identified that in the majority of hypothetical scenarios 
considered, thousands of patients would be required to detect a pharmacogenetic 
association, assuming 80% power.  
Software programmes are available that can be used to perform power calculations for 
pharmacogenetic studies with binary and continuous outcomes,28-30 and time-to-event 
outcomes,31 although authors may of course use other methods. Jorgensen and 
Williamson18 recommend that authors of pharmacogenetic studies provide details of the 
sample size calculation and the a priori power to detect effect sizes of varying degrees, so 
that the reader is aware of the likelihood of false negative results (i.e. type 2 errors) 
occurring.  
Study design 
Pharmacogenetic studies can be conducted using either a case-control, cohort or RCT 
design (see Section 1.5, Table 1,). It is important for study design to be clearly described in 
pharmacogenetic study reports, to allow the reader to take this into consideration when 
interpreting the findings and comparing results with other studies. For example, case-
control studies and cohort studies where covariate data were collected retrospectively may 
be at risk of recall bias. Recall bias is a systematic error caused by differences in the 
accuracy or completeness of recollected data between those who did and did not 
experience the outcome of interest.32 It is only environmental factors that may be recalled 
differentially between participants; however, the overestimation or underestimation of 
environmental effects may subsequently lead to an unreliable estimate of the contribution 
of genetic factors. In cohort studies where outcome status is unknown at the time of 
recruitment and covariate data collection (i.e. participants are followed up prospectively), 
recall bias is unlikely to be an issue of concern.  
However, it is often impractical to perform a cohort study and follow patients 
prospectively. In particular, if the outcome is rare, the study would require a large number 
of participants to ensure that an adequate number of patients experience the outcome of 
interest. Case-control designs are often chosen as participants are recruited based on their 
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case-control status, and researchers can ensure that a sufficient number of cases are 
included. 
Jorgensen and Williamson18 make specific recommendations for case-control studies. 
Firstly, the case and control groups ought to be clearly defined so that researchers 
attempting to replicate the study’s findings would know which individuals to recruit. 
Secondly, it is recommended that cases and controls should be genotyped in mixed 
batches, rather than in separate batches, to ensure that genotyping quality is comparable 
between groups.  
Reliability of genotypes 
A variety of genotyping methods are available to researchers conducting pharmacogenetic 
studies, each of which has its own strengths and weaknesses.33 Genotyping error rates vary 
between these methods, and are often non-negligible; error rates per locus of between 
0.2% and 15% have previously been reported.34 Genotyping errors can lead to loss of 
power35 and an increase in type 1 error rates36 in genetic association studies. It is therefore 
essential that researchers quality assess their genotyping results by re-genotyping all or a 
random sample of participants.18 Comparing the observed genotype frequencies to those 
reported in previous studies can also provide an indication of the reliability of genotyping 
results.18 
For studies in which human inference is part of the genotyping procedure, Jorgensen and 
Williamson18 recommend that genotyping is undertaken by two individuals separately, who 
are blinded to outcome status, with any discrepancies in genotyping results resolved by a 
third individual. Using such methodology ought to reduce the likelihood of bias due to 
incorrect genotype allocation. It is also recommended that researchers describe genotyping 
methods and quality control methods, and report the findings of quality checks.18 
Missing genotype data 
If an individual’s genotype cannot be determined using the chosen genotyping method, 
then the genotype will be recorded as missing. Researchers may decide to re-genotype 
certain SNPs or individuals with large proportions of missing data. However, it is likely that 
some genotype data will still be missing following this re-genotyping.  
Jorgensen and Williamson18 recommend that authors of pharmacogenetic studies report 
the extent of missing genotype data, and summarise reasons for this missing data. If the 
extent of missing data is minimal, it may be acceptable to simply exclude individuals with 
missing genotype data from the analysis. If the extent of missing data is not minimal, 
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genotypes can be imputed to avoid loss of power by excluding individuals.37-39 Regardless of 
whether missing data are imputed or not, authors should report how many individuals 
were included in each analysis as an indication of the available power. 
It is important to consider whether data are missing at random,18 i.e. the fact that the 
genotype is missing for an individual is unrelated to the individual’s true genotype. If study 
authors exclude individuals with missing genotype data from the analyses, the results may 
be biased if the missing data are not missing at random. Missing genotype data are unlikely 
to be missing at random, as heterozygotes are notoriously more difficult to call than 
homozygotes. In practice, even carefully designed studies, such as the HapMap project,40 
have missing genotype data that are not missing at random.41 If authors decide to impute 
missing genotype data, it is particularly important to consider whether data are likely to be 
missing at random so that an appropriate method of imputation can be chosen. Jorgensen 
and Williamson provide guidance on testing whether data are missing at random.18  
Population stratification 
Population stratification exists when the studied population contains subpopulations that 
differ in terms of allele frequencies due to ethnic diversity. Population stratification can be 
problematic for pharmacogenetic association studies when the prevalence of the relevant 
outcome also differs between the different subpopulations. In this case, subpopulation 
therefore influences both genotype and outcome, and can confound the relationship 
between the two. If not properly accounted for in analyses, population stratification can 
cause false positive findings to occur in pharmacogenetic studies. 
Researchers conducting pharmacogenetic studies may choose a study design that reduces 
the likelihood of confounding due to population stratification. For example, the eligibility 
criteria for a study might state that each participant’s four grandparents must all be from a 
specific ethnic population. Although such a method would minimise ethnic diversity within 
the study population, subtle differences may still exist and the effects of population 
stratification may not be completely eradicated.42 These subtle differences between 
subpopulations, that might not be instantly recognisable to the researchers, are sometimes 
referred to as ‘cryptic population stratification’.  
Jorgensen and Williamson recommend performing tests to detect cryptic population 
stratification, and if necessary, adjusting for cryptic population stratification in the 
analyses.18 In a recent review, Hellwege et al.43 summarise well-established and more novel 
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methods for detecting the presence of, and accounting for, cryptic population stratification, 
and outline the capabilities and limitations of each method.  
Hardy-Weinberg equilibrium 
The Hardy-Weinberg equilibrium (HWE) principle states that when mating is random in a 
large population, and there are no disturbing factors, genotype and allele frequencies for a 
bi-allelic SNP will remain constant from one generation to the next. If a population is in 
HWE, and a bi-allelic SNP has wild-type and mutant-type allele frequencies, p and q, 
respectively, then then the frequency of wild-type homozygotes, mutant-type 
homozygotes, and heterozygotes, will be p2, q2, and 2pq, respectively.  
Human populations rarely meet the assumptions underlying HWE exactly; disturbing factors 
such as natural selection, mutations and migration all act on human populations (and most 
other large populations). Therefore, allele frequencies are likely to vary from generation to 
generation. However, as a null hypothesis, it is reasonable to expect that HWE holds in a 
population of healthy controls.24 
A variety of methods are available for testing and/or measuring deviation of genotype 
frequencies from HWE.44 Although deviations from HWE may be due to disturbing factors 
which the researcher has no control over, it is also possible that deviation may be caused 
by genotyping errors,45 by the existence of population stratification or by biased selection 
of controls.46 It is therefore crucial that researchers conducting pharmacogenetic studies 
should assess deviation from HWE for each investigated SNP, and explore possible reasons 
for deviation from HWE where applicable. Jorgensen and Williamson18 recommend that 
study authors outline details of the method used to test deviation from HWE and highlight 
any SNPs that were found to deviate.  
Mode of inheritance 
Mode of inheritance refers to the way in which a genetic trait is passed from one 
generation to the next. In humans, there are two alleles present at almost all loci, one from 
each parent; the mode of inheritance determines what the observed phenotype will be for 
each combination of alleles. An exception to this rule occurs on the sex chromosomes; 
males have one X chromosome and one Y chromosome (XY), while females have two X 
chromosomes (XX). The Y chromosome is smaller than the X chromosome, and contains a 
number of genes which are involved in the initiation and maintenance of maleness, but 
lacks copies of most of the genes that are found on the X chromosome. Therefore, males 
will only have one allele present at some loci. Modes of inheritance for genetic variants on 
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the sex chromosomes differ to modes of inheritance for genetic variants on the autosomes 
(i.e. the non-sex chromosomes), and are not discussed further here. 
For genetic variants on the autosomes, there are various modes of inheritance, some of 
which are described in Table 2. For simplicity, it is assumed that the hypothetical genetic 
variant described for each mode of inheritance is solely responsible for an observable trait, 
whereas in reality, observable traits are likely to be controlled by multiple genetic variants.  
Table 2 Examples of different modes of inheritance 
Mode of 
inheritance 
Description  Example 
Dominant The phenotype associated with a 
particular allele is observed when an 
individual has one copy of the allele 
(heterozygous) or two copies of the 
allele (homozygous). 
Seed shape in peas: allele R is 
dominant and associated with round 
seed shape, allele r is associated with 
wrinkled seed shape. RR and Rr 
genotypes will result in round seed 
shape, rr genotype will result in 
wrinkled seed shape. 
Recessive The phenotype associated with a 
particular allele is only observed when 
an individual has two copies of the 
allele (homozygous). 
Sickle cell disease: only individuals who 
have two copies of the allele which is 
associated with sickle cell disease will 
have the condition. 
Co-dominant Homozygous individuals display the 
phenotype associated with the allele 
that they have two copies of. Both 
alleles are simultaneously expressed in 
heterozygous individuals. 
Blood type: A and B alleles code for 
proteins that exist on the surface of red 
blood cells. Heterozygous individuals, 
with one copy of the A allele and one 
copy of the B allele, form a new blood 
group, AB, and both A and B proteins 
are expressed on the surface of red 
blood cells equally.  
 
 
When investigating association between a SNP and a treatment response outcome, 
researchers may assume a specific mode of inheritance. The analysis plan can then be 
tailored to the chosen mode of inheritance, improving the power to detect 
pharmacogenetic associations. For example, if the mode of inheritance for a particular 
allele is assumed to be dominant, there are only 2 observable phenotypes; one will be 
shown in individuals who are homozygous for the dominant allele or heterozygous, the 
other will be shown in individuals who are homozygous for the non-dominant (recessive) 
allele. It is therefore only necessary to make comparisons between two genotype groups, 
rather than all three genotypes. Jorgensen and Williamson demonstrate how regression 
models might be structured if other modes of inheritance are assumed, to ensure that the 
analysis is as efficient as possible.18  
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Authors of pharmacogenetic studies may use statistical methods to guide their choice of 
genetic model selection,47 or consider data from functional studies. However, strong 
evidence to support a particular mode of inheritance is often lacking, and if this is the case, 
authors should carefully consider their options.18  
Authors may choose to assume a specific mode of inheritance, taking into consideration the 
possible benefits and risks of such an approach; statistical power may be improved if the 
assumed mode is true, but may be reduced if the assumed mode is incorrect. It is also 
possible to perform analyses making no assumptions about the underlying mode of 
inheritance (i.e. two pairwise comparisons of the following genotypes: heterozygous versus 
homozygous wild-type, and homozygous mutant-type versus homozygous wild-type). In this 
case, Jorgensen and Williamson18 recommend that authors explain the limitations of such 
an approach; namely, that statistical power will be reduced in comparison to the power 
that would be achieved by using an approach tailored to the true mode of inheritance. 
Finally, authors may undertake multiple analyses, each making a different assumption 
about the underlying mode of inheritance, or making no assumption about the mode of 
inheritance. In this case, adjustments for multiple comparisons ought to be made.18  
As there are various approaches to the analyses of pharmacogenetic data, readers of 
pharmacogenetic study reports may have concerns regarding selective reporting of results. 
Selective reporting would have occurred if authors performed multiple analyses assuming 
various modes of inheritance, but only reported the most interesting, or most statistically 
significant results. To reassure readers that analyses were not selectively reported, study 
authors ought to report all analyses that were undertaken, and provide justification for 
performing each of these analyses.18  
Choice and definition of outcomes 
Pharmacogenetic studies aim to identify how treatment response is influenced by genetic 
variants. In some cases, researchers may be interested in a single measure of treatment 
response, such as score on a self-report depression scale. However, treatment response is 
often multifaceted; there may be various ways to measure treatment efficacy, and also 
adverse events to be considered.  
Due to the fact that a variety of relevant outcomes often exist for pharmacogenetic studies, 
selective reporting of outcomes is an issue of concern. In particular, authors may only 
report outcomes for which statistically significant results were observed. Omitting non-
statistically significant findings from the study publication distorts the results, and 
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conclusions ought to be interpreted with caution. It is therefore essential that study 
authors clearly list all investigated outcomes, and provide justification for their choice of 
outcomes.18  
Outcome definitions across pharmacogenetic studies have previously been reported to be 
heterogenous.48, 49 Jorgensen and Williamson18 recommend that study authors provide 
clear definitions for all investigated outcomes, so that readers are able to interpret the 
results correctly and compare results across studies.  
Treatment adherence 
In Jorgensen and Williamson’s18 checklist, the term ‘compliance’ is used. Here, we use the 
term ‘adherence’, as in recent years, bodies such as the World Health Organization (WHO)50 
and in the UK, the National Co-ordinating Centre for NHS Service Delivery and Organisation 
(NCCSDO)51 have demonstrated a preference for this term.  
Treatment adherence can be defined as the extent to which a patient’s drug-taking history 
coincides with the prescribed drug regimen. In general, treatment adherence is not an issue 
of primary concern for non-pharmacogenetic studies of drug efficacy. This is because the 
aim of these studies is to estimate how effective the drug will be when used in a real-world 
setting; in reality, patients are likely to occasionally be non-adherent with the prescribed 
regimen, and so primary trial results will be reflective of clinical practice. Effects of adhering 
to the drug can also of course be explored, by adopting a per-protocol approach to analysis, 
but these are usually secondary concerns. In contrast, the primary aim of a 
pharmacogenetic study is typically to estimate how much impact genetic variants have on 
the drug’s biologic pathway through the body. Taking too much or too little of the 
prescribed drug undoubtedly may also impact the body’s response to the drug. Therefore, 
unless adherence is adjusted for, the estimates of association between genetic factors and 
the treatment-related outcome of interest may be underestimated or overestimated. 
Treatment adherence should therefore be of primary concern when undertaking statistical 
analyses of pharmacogenetic studies, and consequently extent of this adherence should be 
measured as accurately as possible.  
Generally, adjusting for a non-confounding covariate (such as treatment adherence) can 
explain variability in the outcome, consequently reducing noise and increasing power to 
detect pharmacogenetic associations.52 However, it is important to note that when the drug 
response outcome is binary, and individuals are recruited according to case or control 
status, adjusting for the covariate can actually reduce power.53 Nevertheless, methods have 
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been developed to overcome this issue,54-56 which account for non-confounding covariates 
while increasing power to detect genetic associations in case-control studies. It is therefore 
advisable to account for treatment adherence when investigating pharmacogenetic 
associations, even in the analyses of case-control studies (providing careful consideration is 
given to the choice of analysis method). Indeed, Jorgensen and Williamson18 recommend 
both measuring and adjusting for treatment adherence.  
2.3 Analysis methods 
Methods of meta-analysis are well-established for RCTs. There is a wealth of information 
available for researchers who wish to meta-analyse data from RCTs, including the Cochrane 
Handbook,25 the Centre for Reviews and Dissemination’s (CRD) guidance for undertaking 
reviews in health care,57 and the PRISMA (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) statement.58 The application of meta-analysis methods to 
observational studies has been controversial, due to the greater potential for biased 
results, and the extreme diversity in study designs that is likely to be observed.59 However, 
it has been argued that genetic association studies are more closely-related to RCTs than 
other types of observational study, due to the concept of ‘Mendelian randomisation’.60 
Mendelian randomisation refers to the random assortment of alleles at the time of gamete 
formation, and the use of this random assortment to make inferences about 
environmentally modifiable exposures. In some circumstances, genetic association study 
designs can therefore be thought of as akin to randomised comparisons.  
The HuGENet HuGE Review Handbook24 strongly encourages quantitative synthesis of the 
results of genetic association studies, with a specific focus on the investigation of 
heterogeneity; exploring possible reasons for variability between the included studies can 
help to identify important sources of bias.  
Data synthesis 
For a meta-analysis of genetic association studies, authors may be comparing groups 
determined by the presence of a particular allele i.e. carrier versus non-carrier, or they may 
be comparing groups determined by genotype. Generally, authors should perform analyses 
by comparing genotype or allele groups without any adjustment for confounding.24 
However, it may be informative to also extract confounder-adjusted measures of 
association from the original study reports for comparative purposes.  
Standard methods of meta-analysis (i.e. those applied in meta-analysis of RCTs) can be used 
when there are two groups to compare. Clearly, these methods can easily be applied to 
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comparisons based on carrier or non-carrier status of a given allele. For comparisons of 
different genotypes, there are usually three genotype groups to be compared, since most 
SNPs are bi-allelic. Therefore, to apply standard methods of meta-analysis, authors must 
reduce these three groups to two. For a bi-allelic SNP with two alleles, A and a, where A is 
thought to be associated with a particular outcome (i.e. treatment response or toxicity in a 
meta-analysis of pharmacogenetic studies), the following analysis approaches are possible:  
i. Assuming a dominant mode of inheritance, thus comparing ‘AA+Aa’ to ‘aa’ 
ii. Assuming a recessive mode of inheritance, thus comparing ‘AA’ to ‘Aa + aa’ 
iii. Assuming a co-dominant mode of inheritance, where the effect of the Aa genotype is 
mid-way between the effect of AA and aa  
iv. Performing two separate pairwise comparisons (i.e. ‘Aa’ versus ‘AA’ and ‘aa’ versus 
‘AA’) 
v. Using a ‘genetic model-free’ approach61 
 
As previously discussed in Section 2.2, analyses that assume a specific mode of inheritance 
(i.e. approaches i-iii) may improve statistical power if the assumed mode is true, but may 
reduce power if the assumed mode is incorrect. The HuGENet HuGE Review Handbook24 
recommends presenting separate effect estimates for heterozygotes and homozygotes 
where possible; this allows the reader to make their own judgements regarding the most 
likely mode of inheritance. Approaches iv and v can both be used to obtain these separate 
effect estimates, and make no assumption about the underlying mode of inheritance. 
Approach v developed by Minelli et al.61 is more complex than the other approaches (all of 
which use standard methods of meta-analysis) and will be discussed further in Chapter 5. 
If a particular mode of inheritance was proposed at the time of the first reporting of an 
association, and it seems unlikely that selective reporting of this particular analysis 
occurred, meta-analysts ought to also perform analyses assuming this mode of 
inheritance.24 If analyses assuming other modes of inheritance are to be undertaken, these 
ought to be pre-specified in the analysis plan, and reported in full in the publication of the 
review.24  
Investigation of heterogeneity 
Methods that would be used for an investigation of heterogeneity in a systematic review of 
RCTs can be applied to a systematic review of genetic association studies. Statistical tests 
can be used to detect the presence of heterogeneity, and statistics such as the I2 statistic 
can be used to quantify heterogeneity.25 Subgroup analyses, meta-regression and 
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sensitivity analyses are all tools that can be used to explore potential sources of 
heterogeneity.  
Specifically, the HuGENet HuGE Review Handbook24 recommends performing sensitivity 
analyses to investigate how results from meta-analyses are impacted by HWE deviation; 
Trikalinos et al.62 reported that excluding HWE-violating studies or making adjustments for 
deviations from HWE can impact the statistical significance of meta-analysis results and the 
extent of between study-heterogeneity observed. Since the HuGENet HuGE Review 
Handbook was published,24 Minelli et al.63 have performed an empirical evaluation of how 
studies that deviate from HWE are handled in meta-analyses, and concluded that HWE 
studies ought not to be automatically excluded. The authors argue that departure from 
HWE does not necessarily indicate that a study’s results are biased, and that the exclusion 
of large studies with small departures from HWE may be detrimental rather than beneficial. 
The authors also advise that when sensitivity analyses are performed to compare meta-
analysis results when studies that deviate from HWE are excluded and included, reviewers 
should tend toward accepting the analysis that includes all studies.  
An examination of how the results of studies change over time may also be informative. 
The ‘Proteus phenomenon’ has been observed among meta-analyses of genetic association 
studies, whereby the earliest study included in a meta-analysis demonstrates the strongest 
effect, and the next earliest study demonstrates the strongest effect in the opposite 
direction.64 It is hypothesised that the phenomenon may be prominent in the field of 
genetic research, due to the enormous number of outcome, genetic variant and mode of 
inheritance combinations that researchers may choose to investigate.65 Consequently, it is 
inevitable that some spurious findings will be identified and reported, and subsequent 
studies will fail to replicate the results. If the ‘proteus phenomenon’ has occurred, the 
earliest studies will report the most extreme results which are not representative of the 
true association. The HuGENet HuGE Review Handbook24 advises routinely checking the 
results of the earliest study/studies against subsequent research as a way of investigating 
whether this phenomenon has occurred.  
Due to the possibility of confounding by population stratification (see Section 2.2), it is 
recommended that meta-analyses are always stratified by ethnicity. Pooling of results 
should only be performed if effect estimates for different ethnic groups appear sufficiently 
similar.24  
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Furthermore, as previously discussed in Section 1.7, a significant association between a SNP 
and a treatment response outcome does not necessarily indicate a causal relationship; it is 
possible that the association only exists due to the SNP of interest being in strong linkage 
disequilibrium with the causal SNP. Patterns of linkage disequilibrium vary from one 
population to the next,66 and therefore heterogeneity may be observed across the results 
of studies conducted in different populations. This provides further rationale for stratifying 
all meta-analyses by ethnicity.  
2.4 Assessment of publication bias 
As outlined in Section 2.1, genetic association studies are at particular risk of being affected 
by publication bias. The HuGENet HuGE Review Handbook24 advises that there is no way to 
definitively confirm the existence or non-existence of publication bias within a systematic 
review. Funnel plots may be used to visually explore the possibility that publication bias has 
occurred, with or without accompanying statistical tests to detect asymmetry in the funnel 
plot.67-70 However, it has been reported that funnel plots can be misleading, and only a 
limited number of researchers are able to correctly interpret these graphs.71 Furthermore, 
the tests for detecting funnel plot asymmetry also have their limitations, as outlined by 
Sterne et al.72 It is particularly important to note that visually examining funnel plots and 
statistical tests can only highlight that asymmetry exists in the funnel plot, suggesting that 
small studies give different results to larger studies. However, publication bias is just one of 
several possible explanations of these ‘small study effects’. Other possible sources of 
asymmetry in funnel plots, or ‘small study effects’, include differences in methodological 
quality between smaller and larger studies, and true heterogeneity, i.e. the true effect size 
varies according to study size.67  
As it is difficult to determine whether publication bias exists in a systematic review, it is 
important to take measures to minimise this bias when searching for studies to include in 
the review. Such measures are outlined in Section 2.1. 
2.5 Discussion  
Due to the rapid growth of the field of pharmacogenetics in recent years, the potential for 
synthesising evidence from multiple pharmacogenetic studies has increased. Researchers 
wishing to conduct systematic reviews and/or meta-analyses of pharmacogenetic data 
ought to follow guidance outlined in the HuGENet HuGE Review Handbook,24 and assess the 
quality of included studies using the checklist developed by Jorgensen and Williamson.18 
Using such methodology will ensure that findings from the review are valid and interpreted 
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appropriately, and that readers are aware of any important limitations of the evidence 
base.  
Review authors ought to be aware that there may be sources of bias in pharmacogenetic 
studies not covered by Jorgensen and Williamson’s checklist.18 In particular, there are issues 
relating to the recruitment of participants that may impact the validity of a study’s reported 
results. Firstly, if patients are recruited to studies after treatment has commenced, and 
patients are less likely to be recruited to the study if they experience early adverse 
reactions to the drug treatment of interest, this will introduce selection bias. However, 
some studies that recruit patients after treatment initiation would inherently provide data 
on events occurring prior to recruitment (case-control studies would commonly be 
conducted in this way), and post-treatment enrolment in these circumstances is unlikely to 
be an issue of concern. Secondly, if participants are less likely to be recruited to the study 
due to results of previously conducted genotyping (for example, if investigators believe that 
the study treatment will lead to toxicity in patients with a particular genotype), then this 
would also introduce selection bias to the study.  
In addition, although there is a criterion in Jorgensen and Williamson’s checklist18 that 
considers whether case and control groups are well-defined, it may also be informative for 
reviewers to assess whether cases and controls are from the same underlying patient 
population. There should be no important differences between the populations in terms of 
factors that may influence treatment outcome, such as the distribution of genotypes within 
the population, or history of treatment prior to recruitment.  
There are also two issues relating to measurement of outcomes that it would be beneficial 
for reviewers to consider when assessing the internal validity of pharmacogenetic study 
results. Although Jorgensen and Williamson’s checklist18 has a criterion which assesses 
whether genotyping personnel were blinded to outcome status, the tool does not consider 
whether those assessing outcome status were blinded to patients’ genotypes; a lack of 
blinding of outcome assessors could introduce detection bias to the study. Finally, there is 
no explicit consideration of whether evidence exists to suggest that researchers assessed 
outcomes according to multiple definitions, and selectively reported only the most 
interesting or statistically significant results. This issue is of particular importance when 
composite definitions of outcomes are used, as the potential for selective reporting 
increases as the number of possible outcome definitions increases. Seeking out study 
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protocols or analysis plans may provide evidence that reported outcome measures differed 
to those specified prior to study initiation.  
In this chapter, we focus on methods for aggregate data meta-analysis, whereby summary 
data obtained from study reports or communication with study authors are synthesised. 
We do not discuss methods for individual participant data (IPD) meta-analysis, which 
involves the collection of detailed data for each participant from each trial. Although there 
are advantages to conducting IPD meta-analysis, such as the possibility of standardising 
definitions of outcomes and covariates, and more flexibility in terms of the analysis 
strategy, IPD meta-analysis is also significantly more resource-intensive than aggregate data 
meta-analysis. It is often the case for research teams that it would not be feasible to 
conduct an IPD meta-analysis, due to a lack of time and/or funds to commit to the project. 
Furthermore, authors of pharmacogenetic studies may be unwilling or unable to share data 
for the purposes of IPD meta-analysis. There may be data security issues or data sharing 
restrictions; these are likely to differ between countries and will also depend on the initial 
consent given for use of the genetic data. For these reasons, throughout this chapter, and 
the thesis as a whole, our focus is on aggregate data meta-analysis of pharmacogenetic 
studies.  
Finally, it is important to note that here we have outlined guidance on methods of evidence 
synthesis for genetic association studies,24 which can be applied to evidence synthesis of 
pharmacogenetic studies. However, this guidance was made available in 2006, and since 
this time, new methods for meta-analysis of genetic association studies have been 
proposed. Namely, Salanti and Higgins73 have developed methodology to enable the 
synthesis of data from studies that report data for each genotype group separately and 
studies that report data for combined genotype groups. Verzilli et al.74 have introduced 
methodology which enables the synthesis of data from studies investigating different, but 
highly correlated, SNPs; this method maximises power to detect true genetic associations. 
Finally, Thompson et al.75 have developed the work of Minelli et al.,61 demonstrating how 
combining information from related meta-analyses of genetic association studies can lead 
to increases in the precision of estimated genetic effects. We do not discuss these methods 
in further detail in this thesis; it is beyond the scope of our work to explore all methodology 
that has been developed in this area. Instead, we focus on methods outlined in the 
available guidance on evidence synthesis for genetic association studies, as these methods 
are most likely to be used by future researchers who wish to undertake systematic reviews 
of pharmacogenetic studies.   
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3 Influence of genetic variants on toxicity related to anti-
tuberculosis drugs: a systematic review 
We have previously discussed how systematic reviews and meta-analyses can improve the 
strength of the evidence base for pharmacogenetic associations (Section 1.7), and outlined 
methodology for evidence synthesis of pharmacogenetic studies (Chapter 2). In this 
chapter, and the following chapter (Chapter 4) we demonstrate how these methods can be 
applied in practice, by conducting a systematic review and meta-analysis of associations 
between genetic variants and anti-TB drug-related toxicity. Many studies have investigated 
the pharmacogenetics of anti-TB drugs, making this topic area a prime candidate for the 
application of evidence synthesis methods. In the process of conducting the systematic 
review and meta-analysis, we hoped to identify whether obstacles exist which hinder the 
potential for reviewers to conduct high-quality and well-powered meta-analyses of 
pharmacogenetic studies. 
In order to identify the total accumulated evidence base on the pharmacogenetics of anti-
TB drug-related toxicity, we conducted a systematic review in accordance with the methods 
described in Chapter 2. This included a thorough quality assessment of each included study 
using the checklist developed by Jorgensen and Williamson.18 In this chapter, we summarise 
the studies identified for inclusion in the systematic review, and the results of the quality 
assessment. Where appropriate, data from studies included in the systematic review were 
synthesised in meta-analyses for each combination of genetic variant and toxicity outcome; 
methods and results of the meta-analyses are provided in Chapter 4. 
3.1 Background 
TB is an infectious disease caused by Mycobacterium tuberculosis bacteria and is the 
leading cause of death from a single infectious agent (ranking above HIV/AIDS).76 For 
individuals with drug-susceptible TB, the WHO currently recommends combination 
treatment with four first-line drugs: isoniazid, rifampicin, ethambutol and pyrazinamide.76 
Treatment with anti-TB drugs may cause patients to experience serious adverse effects, 
such as anti-TB drug-induced hepatotoxicity (ATDH). Incidence rates of ATDH for patients 
treated with the standard combination treatment have been reported to vary from 2% to 
28%, depending on the treatment regimen, patient characteristics (e.g. age, race and sex), 
and definition of ATDH.77 ATDH may be fatal, with reported mortality rates of 6–12% if 
treatment is not stopped promptly.78 ATDH and other anti-TB drug-related toxicity 
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outcomes may also lead to poor patient adherence, which in turn may result in treatment 
failure, relapse and the emergence of drug resistance.77  
Proposed genetic risk factors for ATDH include polymorphisms of the N-acetyltransferase 2 
(NAT2), cytochrome P450 2E1 (CYP2E1), glutathione S-transferase mu 1 (GSTM1) and 
glutathione S-transferase theta 1 (GSTT1) genes. These genes encode drug-metabolizing 
enzymes,79 and therefore polymorphisms of these genes may affect enzyme activity, 
altering the metabolic pathway of anti-TB drugs in the liver. Consequently, hepatic adverse 
reactions may occur. Toxic metabolites may also cause other adverse reactions, such as 
peripheral neuropathy and maculopapular eruption, although hepatotoxicity is the most 
widely studied outcome in pharmacogenetic studies of anti-TB drugs.  
Isoniazid is the anti-TB drug for which mechanisms of the genetic contribution to ATDH 
have been most widely studied. Specifically, it is thought that NAT2 acetylator status may 
be associated with increased risk of isoniazid-related hepatic adverse reactions, as NAT2 is 
the main enzyme involved in the metabolism of isoniazid in the liver. There are three 
phenotypes of acetylator status. Individuals who are slow NAT2 acetylators acetylate 
isoniazid slowly, resulting in high plasma drug levels.80 This may be beneficial for treatment 
efficacy, but slow acetylators may also experience an accumulation of toxic metabolites; 
there is uncertainty surrounding which specific metabolites are responsible for causing this 
toxicity. Fast acetylators have lower plasma drug levels, and so, treatment may be not only 
less effective but also less toxic, and intermediate acetylators fall between these two 
extremes.  
Acetylator status is governed by polymorphisms in a number of alleles on the NAT2 gene, 
making the genetic definition of acetylator status difficult to standardise. Classification of 
acetylator status according to genetic information varies between studies. For example, 
Azuma et al.81 classified individuals with two copies of the NAT2*4 allele as rapid 
acetylators, individuals with one copy to be intermediate acetylators, and those with no 
copies to be slow acetylators. Alternatively, Ho et al.82 classified individuals with two copies 
of any of the following NAT2 alleles: NAT2*4, NAT2*11A, NAT2*12A, NAT2*12B, 
NAT2*12C, NAT2*13; to be rapid acetylators, individuals with one of these alleles and one 
allele associated with slow acetylation activity (NAT2*5, NAT2*6, NAT2*7, and NAT2*14) to 
be intermediate acetylators, and those with two slow acetylation alleles to be slow 
acetylators. 
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Another enzyme that may be involved in the metabolism of isoniazid is the CYP2E1 enzyme, 
although its precise role in the pathway remains uncertain. The RsaI (1053C-T; rs2031920) 
PstI (1293G-C; rs3813867) and DraI (7632T-A; rs6413432) polymorphisms are the most 
widely studied polymorphisms of the CYP2E1 gene in relation to hepatotoxicity. The RsaI 
and PstI polymorphisms have been shown to be in complete linkage disequilibrium in East 
Asian populations83 and to change the transcriptional activity of CYP2E1 in vitro.84 It is 
uncertain whether the DraI polymorphism itself modifies CYP2E1 expression; the DraI 
polymorphism has been reported to be in linkage disequilibrium with the RsaI 
polymorphism,85 although the DraI polymorphic allele may be observed at higher 
frequencies than the RsaI polymorphic allele.85, 86 
Finally, it has been proposed that the GST enzyme may detoxify toxic metabolites from 
earlier in the metabolic pathway of isoniazid, although these specific metabolites have not 
been identified.87 Two functionally important polymorphisms of GST genes (GSTM1 and 
GSTT1 null polymorphisms) have been widely studied in relation to isoniazid-induced 
hepatotoxicity, although a biological basis for an association between these polymorphisms 
and hepatotoxicity is uncertain. Due to the proposed impact of genetic variants of NAT2, 
CYP2E1, and GST genes on the metabolism of isoniazid in the liver, studies investigating the 
genetic contribution to anti-TB drug-related toxicity have mostly focused on variants of 
these genes. 
Considering the other drugs that are administered as part of the WHO recommended 
regimen for drug-susceptible TB, rifampicin and pyrazinamide have also been reported to 
cause hepatotoxicity.88 However, the biological mechanisms for rifampicin- and 
pyrazinamide-induced hepatotoxicity remain unknown.89 The OATP1B1*15 haplotype has 
been reported to be an important risk factor for rifampicin-induced liver injury,90 while no 
research into genetic risk factors for pyrazinamide-induced hepatotoxicity has been 
reported.91 Ethambutol has not previously been reported to cause hepatotoxicity.88 
The aim of this systematic review and meta-analysis was to evaluate the current evidence 
for associations between genetic variants and anti-TB drug-related toxicity. Meta-analyses 
investigating the association between NAT2, CYP2E1, GSTM1 and GSTT1 genetic variants 
and hepatotoxicity had previously been published92-102 when we started the review. 
However, despite the informative nature of the previously conducted meta-analyses, we 
identified some important methodological limitations of these reviews: 
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• Cai et al.,92 Deng et al.,94 Du et al.,95 Li et al.,96 Sheng et al.,97 Shi et al.,98 Tang et al.,100 
Wang et al.101 and Wang et al.102 all excluded studies if data required for meta-analysis 
were not included in the study report.  
• Cai et al.92 excluded three studies that were non-RCTs, and Cai et al.,93 Deng et al.,94 Li 
et al.,96 Sheng et al.,97 Shi et al.,98 Sun et al.,99 Tang et al.100 and Wang et al.101 all 
included only case-control studies. Important evidence may have been omitted from 
these reviews, as pharmacogenetic data may be reported in RCTs, case-control studies, 
or cohort studies. 
• Cai et al.,92 Cai et al.,93 Du et al.95 and Li et al.96 did not assess the methodological 
quality of included studies. The other previously conducted meta-analyses used a 
checklist developed by Little et al.103 to assess study quality. 
• None of the previously conducted meta-analyses aimed to identify and synthesise data 
for genetic variants other than NAT2, CYP2E1, GSTM1 and GSTT1 genetic variants, or for 
outcomes other than hepatotoxicity; such exclusions may limit evidence-based 
recommendations. 
 
We planned to overcome these limitations in our systematic review by: contacting study 
authors to obtain data required for meta-analysis when it was not included in the study 
report; including relevant studies regardless of their design; and performing a rigorous 
quality assessment of included studies. In addition, we did not exclude studies that did not 
report hepatotoxicity, and we aimed to identify and synthesise data for all genetic variants. 
Therefore, the scope of our review is wider than the previously conducted meta-analyses.  
3.2 Methods 
The methods described in the following section were pre-specified in a published protocol 
(PROSPERO registration number: CRD42017068448).104 
Selection criteria 
Types of studies 
Eligible study designs were cohort studies, case-control studies and RCTs.  
Types of participants 
We included studies that recruited TB patients who were either already established on anti-
TB treatment or were commencing treatment (at least one of isoniazid, rifampicin, 
pyrazinamide, or ethambutol), and who were genotyped, in order to investigate the 
association between genetic variants and anti-TB drug-related toxicity outcomes. 
Specifically, we only included studies where over 50% of included patients were TB patients 
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receiving anti-TB treatment; we contacted study authors to obtain data specifically for the 
subgroup of TB patients if these data were not available in the study publication. 
Types of outcomes 
Studies that measured any anti-TB drug-related toxicity outcomes were eligible for 
inclusion.  
Search strategy 
We designed the search strategy with assistance from an information specialist. MEDLINE, 
PubMed, EMBASE, BIOSIS and Web of Science were searched for relevant studies. Details of 
the number of records identified in each of these databases are provided in Appendix 1, 
together with the full search strategy for EMBASE. We hand-searched the reference lists of 
relevant studies, and contacted clinical experts to identify further eligible studies. Only 
studies published in English were included, but we did not restrict by year of publication or 
by publication status.  
Study selection 
We imported the results of the search into Covidence.105 One researcher (MC) removed 
duplicates and scanned the study abstracts to remove obviously irrelevant studies. A 
sample of 10% of studies were independently screened by one of three researchers (ALJ, JK 
or KD). One reviewer (MC) obtained the full text for each potentially relevant study and 
assessed eligibility based on the eligibility criteria. A sample of 10% of studies were 
independently screened by one of three researchers (ALJ, JK or KD). Any disagreements 
between the two reviewers at both the abstract and full-text screening stages were 
resolved through discussion, or by consulting a third researcher if necessary.  
After full-text screening, we decided to exclude studies that only reported data for 
associations between HLA genes and anti-TB drug-related toxicity outcomes. We did not 
include these studies as HLA genes have many possible variations, with some having 
hundreds of alleles.106 The standard methods of meta-analysis described in Chapter 2 
therefore cannot be used to synthesise data for the association between HLA genetic 
variants and treatment response outcomes. Finally, we excluded articles that included 
patient cohorts for whom data were also reported in other articles, if clear data for 
additional genetic variants were not reported.107-110 If multiple articles reported clear data 
for the same set of genetic variants, we included the more recent article. 
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Outcomes 
The primary outcome of our review was hepatotoxicity by any definition used by the 
original investigators. The secondary outcomes were all other toxicity outcomes reported in 
the included studies.  
Data extraction 
We pre-piloted a data extraction form, which was designed to enable collection of data on 
study design, participant characteristics, treatment regimen, genotype groups and 
outcomes. One researcher (MC) extracted data, following methods described in the 
HuGENet HuGE Review Handbook.24 A second researcher (ALJ, JK or KD) independently 
extracted all outcome data. Any disagreements between the two reviewers were resolved 
through discussion, or by consulting a third researcher if necessary. We contacted study 
authors if relevant outcome data were not reported in the required format for meta-
analysis. 
We examined author lists, locations, dates of recruitment and other study characteristics to 
identify cases of multiple articles reporting data for overlapping or identical patient cohorts. 
If we suspected that this may be the case, we contacted authors to clarify whether patient 
cohorts were distinct. If an author clarified that multiple articles reported outcomes for the 
same patient cohort or overlapping cohorts, or if we suspected this based on reported 
study characteristics, we assigned a group identifier (GI) to these articles. Assigning this GI 
ensured that data for each patient cohort were only included once in any meta-analysis.  
We extracted data for each article rather than each patient cohort, as key details such as 
sample size and genetic variants investigated often varied between multiple articles 
reporting data for overlapping or identical patient cohorts.  
Quality assessment 
One researcher (MC) used the criteria developed by Jorgensen and Williamson18 specifically 
for pharmacogenetic studies, to assess the methodological quality of each included study. A 
second researcher (ALJ) independently assessed the quality of a sample of 10% of studies. 
Any disagreements between the two reviewers were resolved through discussion. We 
summarised the number of studies meeting each criterion in the text.  
We quality assessed each article rather than each patient cohort, as different methods may 
have been used across multiple articles reporting data for overlapping or identical patient 
cohorts.  
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3.3 Results  
Included and excluded studies 
A PRISMA flowchart, showing selection and elimination of studies during the literature 
search, is provided in Figure 1. We identified 70 relevant articles (51 distinct cohorts of 
patients). We contacted 15 study authors to obtain clarification on whether patient cohorts 
were distinct, overlapping or identical to other patient cohorts, or for clarification on 
reported outcome data. We obtained responses from 11 study authors. 
 
Figure 1 PRISMA flowchart showing inclusion and exclusion of studies in the systematic review 
 
In this review, we include data from 70 articles81, 82, 86, 90, 111-176 (51 distinct patient cohorts). 
Key characteristics of studies included in our systematic review are provided in Table 3. 
Thirty-six articles described cohort studies, although as recommended by the STROBE 
(STrengthening the Reporting of Observational Studies in Epidemiology) guideline,11 we do 
not attempt to categorise these studies as ‘retrospective cohort’ or ‘prospective cohort’ 
here, as there is no clear consensus on the definitions of these terms. Thirty-three articles 
described case-control studies, and one article described a RCT of pharmacogenetic-guided 
therapy versus standard therapy. 









Full-text articles assessed 
for eligibility (n=204) 
Full-text articles excluded 
(n=134) 
 
Non-English language (n=13) 
Conference abstract (n=31) 
No genotyping (n=37) 
Wrong intervention (n=2) 
Wrong population (n=4) 
Wrong study design (n=7) 
Wrong outcomes (n=33) 
HLA genes (n=3) 
Duplicate cohorts (n=4) 
Articles included in review 
(n=70) 
Additional records identified 





Table 3 Key characteristics of studies included in the systematic review 
Study  Design Country Follow-up 
time  





China NR All patients took INH 600 mg, RIF 600 mg (or 450 mg if body 
weight was <50 kg), PZA 2,000 mg and EMB 1,250 mg every 
other day for the first 2 months (re-treatment patients were 
injected with SM 750 mg each time simultaneously). Then 
with the same regimen, PZA and EMB were discontinued for 
primary patients, whereas PZA and SM were discontinued 
for re-treatment patients, the rest of the drugs were 
continued for another 4 months. 










China 6-9 months  All patients took INH (600 mg), RIF (600 mg, or 450 mg if 
body weight was <50 kg), PZA (2,000 mg) and EMB (1,250 
mg) every other day in the first 2 months; INH and RIF were 
continued for another 4/6 months. Re-treatment patients 
took SM (750 mg) every other day in the first 2 months and 
continued EMB for another 6 months. 












All patients took INH 600 mg, RIF 600 mg (or 450 mg if body 
weight was <50 kg), PZA 2,000 mg and EMB 1,250 mg every 
other day for the first 2 months (re-treatment patients were 
injected with SM 750 mg each time simultaneously). PZA 
and EMB were then discontinued for primary patients, 
whereas INH and RIF were continued for another 4 months. 
PZA and SM were discontinued for re-treatment patients, 
whereas INH, RIF and EMB continued. 
445 Hepatotoxicity CYP2E1 DraI  
GSTM1 null  
















Study  Design Country Follow-up 
time  















China NR All primary/re-treatment patients with pulmonary TB were 
treated with a combination regimen including INH (600 mg), 
RIF (600 mg, or 450 mg if body weight was <50 kg), PZA 
(2,000 mg) and EMB (1,250 mg) for the first 2 months (re-
treatment patients were injected with SM 750 mg each time 
simultaneously) and then with the same regimen, without 
PZA and EMB, for another 4 months for primary patients 
and with the same regimen, without PZA and SM, for 
another 6 months for re-treatment patients. 












China NR Patients were given INH (600 mg), RIF (600 or 450 mg if 
body weight was <50 kg), PZA (2,000 mg) and EMB (1,250 
mg) for the first 2 months (re-treatment patients were 
injected with SM 750 mg each time) and then the same 
regimen, without PZA and EMB, for another 4 months for 
primary patients and the same regimen, without PZA and 
SM, for another 6 months for re-treatment patients. 
445 Hepatotoxicity IL4 rs2243289 






Study  Design Country Follow-up 
time  
Drugs and dosage Sample 
size 
Outcomes Genetic variants 
An 2012 111 Case-
control 
China 6 months  Daily treatment with INH, RIF, PZA and EMB for 2 months, 
followed by 4 months treatment with INH and RIF, with 
dosages calculated according to body weight: 
 
Body weight <45 kg: RIF 300 mg, INH 200 mg, PZA 1,000 mg 
Body weight of 45–55 kg: RIF 450 mg, INH 300 mg, PZA 
1,500 mg 
Body weight >55 kg: RIF 600 mg, INH 400 mg, PZA 2,000 mg 
208 Hepatotoxicity NAT2 acetylator status 











RCT Japan 6 months 6-month regimen comprising INH, RIF, PZA, and EMB/SM for 
the first 2 months followed by RIF and INH for 4 months. All 
patients started taking the standard oral dose (approx. 5 
mg/kg body weight, once daily). For pharmacogenetic-
guided treatment patients, dosages were adjusted based on 
individual NAT2 status within 3 days. Modified daily INH 
doses were approximately 7.5, 5 and 2.5 mg/kg for rapid, 
intermediate and slow acetylators, respectively. Regarding 
the other drugs for the standard regimen, standard daily 
doses of RIF (10 mg/kg, max 600 mg/body), PZA (25 mg/kg, 
1,500 mg/body), EMB (15 (20) mg/kg, 750 (1,000) mg/body), 
and SM (15 mg/kg, 750 mg/body) were recommended with 
the following dose ranges allowed at the discretion of the 
physician: RIF, 8–12 mg/kg; PZA, 20–30 mg/kg; EMB, 15–20 
mg/kg; SM, 12–18 mg/kg. 
172  Hepatotoxicity; 
peripheral 
neuropathy 
NAT2 acetylator status  
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Study  Design Country Follow-up 
time  
Drugs and dosage Sample 
size 
Outcomes Genetic variants 
Bose 2011 
112 
Cohort India 8 weeks All patients received ATT (RIF, INH, EMB, and PZA) according 
to their body weight. All 4 drugs were given for 2 months. 
PZA and EMB were discontinued, while INH and RIF were 
continued for another 4 months. 
RIF, body weight (kg): mg/day: ≤35: 300; 36–50: 450; >50: 
600 
INH, body weight (kg): mg/day: ≤35: 200; >35: 400 
PZA, body weight (kg): g/day: ≤50: 1.0; >50: 1.5 




NAT2 acetylator status  





Cohort Turkey NR Patients received INH 5 mg/kg (max 300 mg/day), RIF 10 
mg/kg (max 600 mg/day), PZA 25 mg/kg (max 2,000 
mg/day), and EMB 15-25 mg/kg (max 1,500 mg/day). 







Cohort Argentina NR The patients began a standard TB-treatment protocol for the 
first 2 months (INH: 5 mg/kg/day, max 300 mg/day; RIF: 10 
mg/kg/day, max 600 mg/day; PZA: 20 mg/kg/day; EMB: 20 
mg/kg/day), followed by INH and RIF for 4 months or more, 
depending on the disease severity or the presence of 
extrapulmonary foci. 
175 Hepatotoxicity NAT2 acetylator status  
CYP2E1 PstI  
Chang 2012 
115 




UGT1A1 TA6→TA7 at 
the promoter region 
UGT1A1 1091C-T 
39 
Study  Design Country Follow-up 
time  
Drugs and dosage Sample 
size 





India NR ATD regimens comprising of INH, RIF and PZA as per the 
Revised National Tuberculosis Control Program of India – 
DOTS 
151 Hepatotoxicity GSTM1 null 
GSTT1 null  
Cho 2007 118 Cohort Korea End of 
treatment 
All patients received oral INH (300 mg), RIF (600 mg), PZA 
(20 mg/kg body weight), and EMB (800 mg) daily for the first 
2 months. PZA was then discontinued, while INH, RIF and 
EMB were continued for another 4 months. 




Cohort Brazil NR All patients were treated with INH (300 mg/kg/day), RIF (300 
mg/kg/day), and PZA (1,500 mg/kg/day) for the first 2 
months, and then INH and RIF for a further 4 months. 
129 ADRs NAT2 acetylator status 
CYP2E1 DraI 
CYP2E1 PstI  
GSTM1 null  





Zimbabwe NR NR Unclear - 









China 6 months Treatment with ATD regimens at the usual dosage, including 
300 mg/day INH, 450 mg/day RIF, and 1,500 mg/day PZA 
346 Hepatotoxicity NAT2 acetylator status  
CYP2E1 RsaI  
CYP2E1 PstI  
GSTM1 null  
GSTT1 null  
Fredj 2016 
123  
Cohort Tunisia End of 
treatment 
INH (5 mg/kg per day), RIF (10 mg/kg per day), PZA (25 
mg/kg per day) and EMB (15 mg/kg per day) for the first 2 
months, followed by INH and RIF for 4 to 7 additional 
months, depending on TB clinical presentation 
71 Hepatotoxicity NAT2 acetylator status  
CYP2E1 RsaI  
CYP2E1 DraI 









Cohort India 6-9 months INH: 5 mg/kg (max 300 mg/day); RIF: 10 mg/kg (max 600 
mg/day); PZA: 25 mg/kg (max 2,000 mg/day); EMB: 15-25 
mg/kg (max 1,500 mg/day) 
296 Hepatotoxicity GSTM1 null 
GSTT1 null  
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Study  Design Country Follow-up 
time  
Drugs and dosage Sample 
size 




Cohort India End of 
treatment  
Combination regimen including INH 5 mg/kg (max 300 mg 
daily), RIF 10 mg/kg (max 600 mg daily), PZA 25 mg/kg (max 
1,500 mg daily), and EMB 15–25 mg/kg (max 2,000 mg daily) 
for a period of 2 months and then for an additional 4 
months with INH and RIF 
215 Hepatotoxicity NAT2 acetylator status  
CYP2E1 RsaI 
CYP2E1 DraI  
NAT2 481C-T 
NAT2 590G-A 
He 2015 127 Case-
control 
China 6 months Daily 2S(E)HRZ4HR: S, streptomycin; E, ethambutol; H, 
isoniazid, R, rifampicin; Z, pyrazinamide; dose increased for 
2 months and then consolidated for 4 months 





Cohort Japan NR Treated with an INH (400 mg/day) and RIF (450 mg/day) 




NAT2 acetylator status  
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Study  Design Country Follow-up 
time  




Cohort Japan NR Treatment including INH (400 mg/day) and RIF (450 mg/day) 
for 6-9 months 


























Study  Design Country Follow-up 
time  
Drugs and dosage Sample size Outcomes Genetic variants 
Ho 2013 82 Cohort Taiwan 180 days Oral INH 300 mg, RIF 600 mg (or 450 mg if body weight was 
<50 kg), PZA 25 mg/kg body weight (max daily dose: 2,000 
mg), and EMB 15 mg/kg body weight daily (max daily dose: 
1,600 mg) for the first 2 months. PZA was then discontinued; 
INH, RIF, and EMB were continued for another 4 months. 





Cohort Taiwan End of 
treatment 
The standard daily anti-TB regimen for the first 2 months 
included INH (300 mg), RIF (600 mg or 450 mg if body weight 
was <50 kg), PZA (20 mg/kg body weight), and EMB (25 
mg/kg body weight). PZA was then discontinued; INH, RIF, 
and EMB (15 mg/kg body weight) were continued for 
another 4 months. 







Taiwan NR NR 230 (126 
on ATDs)  
Hepatotoxicity GSTM1 null  
GSTT1 null  
NQO1 609C-T 
(rs1800566) 
SOD2 (MnSOD) 47T-C 
(rs4880) 
Jung 2015 131 Cohort Korea 4 weeks  INH (5 mg/kg, usually 300 mg), RIF (450 mg for <50 kg or 600 
mg for ≥50 kg body weight), EMB (15 mg/kg), and PZA (20–
30 mg/kg), given daily for 2 months and followed by INH and 
RIF with or without EMB for 4 months 





Iran 2 months Treated daily with INH (300 mg), RIF (600 mg), PZA (20 
mg/kg), EMB (15 mg/kg) for the first 2 months followed by 
INH and RIF daily for 4 additional months 
100  Hepatotoxicity NAT2 acetylator status  
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Study  Design Country Follow-up 
time  





Korea NR All patients with pulmonary TB were treated daily with a 
combination regimen including INH (300-400 mg daily), RIF 
(450-600 mg daily), EMB (600-800 mg daily) and PZA (1,000-
1,500 mg daily) for 2 months and then without PZA for 4 or 
more following months. Doses of each drug were adjusted 
based on body weight. 




























GSTM1 null  
GSTT1 null  
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Study  Design Country Follow-up 
time  



































Study  Design Country Follow-up 
time  



























Korea NR Same as Kim 2009 (GI: KIM) 321 Hepatotoxicity SOD1 rs2070424 








Korea 14 days ATDs 238 (not all 
on TB 
drugs)b 
Hepatotoxicity TXNRD1 rs10735393  
TXNRD1 rs4964287  
TXNRD1 rs4595619  
TXNRD1 rs10861201  
TXNRD1 rs11111997  
TXNRD1 rs4246270  
TXNRD1 rs4246271  
46 
Study  Design Country Follow-up 
time  
Drugs and dosage Sample size Outcomes Genetic variants 
Lee 2010 141 Cohort Taiwan NR All patients received oral INH 300 mg, RIF 600 mg (or 450 mg 
if body weight was <50 kg), PZA 200 mg/kg body weight and 
EMB 800 mg daily for the first 2 months. PZA was then 
discontinued, while INH, RIF and EMB were continued for 
another 4 months. 









Spain NR Regimens that included at least INH, RIF and PZA at the 
usual drug dosages (INH 5 mg/kg/day – max 300 mg/day, RIF 
10 mg/kg/day – max 600 mg/day and PZA 25–30 mg/kg/day 
– max 2,500 mg/day) 







Spain End of 
treatment 
Treatment with regimens that included INH, RIF and PZA at 
the usual dosages (INH 5 mg/kg/day to max 300 mg/day, RIF 
10 mg/kg/day to max 600 mg/day and PZA 25–30 
mg/kg/day to max 2,500 mg/day) 
117 Hepatotoxicity NAT2 acetylator status  
Li 2012 90 Case-
control 
China NR RIF treatment 273 Hepatotoxicity SLCO1B1 rs2306283 
SLCO1B1 rs4149056 
Liu 2014 144 Case-
control 
China NR INH 10–20 mg/kg/day (max 300 mg/day), RIF 10–20 
mg/kg/day (max 450 mg/day), PZA 20–30 mg/kg/day (max 
1,500 mg/day), EMB 15–25 mg/kg/day, and SM 20–30 
mg/kg/day (max 750 mg/day) 










Cohort Brazil NR Ongoing TB treatment 177 Hepatotoxicity GSTM1 null  
GSTT1 null  
47 
Study  Design Country Follow-up 
time  
Drugs and dosage Sample 
size 
Outcomes Genetic variants 








NR All patients were prescribed INH with all but 1 patient also 
taking additional ATDs. Patients were prescribed 300 mg 
INH/day. 
127 Hepatotoxicity NAT2 acetylator status  
NTUH: Wang 
2011 166 
Cohort Taiwan End of 
treatment 
All participants received a standard ATT of daily INH, RIF, 
EMB, and PZA in the first 2 months, and daily INH and RIF for 
the succeeding 4 months. The regimen was modified if 
necessary by the primary care physician. 
360 Hepatotoxicity NAT2 acetylator status  
CYP2E1 RsaI  
NTUH: Wang 
2015b 168 
Cohort Taiwan 6 months Daily INH, RIF, EMB, and PZA in the first 2 months, and daily 
INH and RIF for the next 4 months. The daily dosage of each 





















Cohort Japan 3 months Initial chemotherapy always included INH (400 mg/day) and 
RIF (450 mg/day); the third drug used was EMB or SM. 
77 Hepatotoxicity NAT2 acetylator status  
48 
Study  Design Country Follow-up 
time  
Drugs and dosage Sample 
size 
Outcomes Genetic variants 
POSSUELO: 
Brito 2014 86 
Cohort Brazil NR Daily treatment with INH, RIF, and PZA for the first 2 
months, followed by INH and RIF for an additional 4 months 
245 Hepatotoxicity CYP2E1 RsaI 
CYP2E1 DraI  
CYP2E1 PstI  
GSTM1 null  




Cohort Brazil NR Treatment daily with INH, RIF, and PZA for the first 2 months 
followed by INH and RIF daily for 4 additional months. Drug 
dosages used were calculated according to body weight 
(weight <45 kg: RIF 300 mg, INH 200 mg, PZA 1,000 mg; 45–
55 kg: RIF 450 mg, INH 300 mg, PZA 1,500 mg; >55 kg: RIF 




NAT2 acetylator status  
Rana 2014 
152 
Cohort India End of 
treatment 
Daily ATT for the first 2 months included INH (300 mg), RIF 
(600 or 450 mg for body weight <50 kg), PZA (20 mg/kg body 
weight) and EMB (25 mg/kg body weight). After 2 months, 
EMB and PZA were discontinued, whereas INH and RIF were 
continued for an additional 4 months. 




Roy 2001 153 Case-
control 
India NR Cases and controls were treated daily with the same drug 
regimen for the first 2 months: INH (300 mg), RIF (450 mg), 
PZA (1,500 mg) and EMB (800 mg). Subsequently, INH and 
RIF were continued for a further 4 months. 
66 Hepatotoxicity GSTM1 null 
GSTT1 null 
Roy 2006 154 Cohort India NR Most of the patients were treated with INH (5 mg/kg body 
weight per day); RIF (10 mg/kg body weight per day) and 
PZA (20–35 mg/kg body weight per day). A few patients with 
TB meningitis also received EMB (20 mg/kg body weight per 
day). After 2 months, PZA and EMB were discontinued and 
INH and RIF were continued for the next 4 months. 
109 Hepatotoxicity CYP2E1 RsaI  




Study  Design Country Follow-up 
time  




Cohort Brazil NR INH, RIF, and PZA for the first 2 months, followed by INH and 
RIF daily for 4 months 





Cohort Brazil NR Treatment with INH, RIF and PZA for the first 2 months, 
followed by INH and RIF daily for 4 months 
270 Hepatotoxicity NAT2 acetylator status  
CYP2E1 RsaI  
CYP2E1 DraI  












India NR INH, RIF, PZA, EMB; dosages administered to patients 
according to body weight: 
RIF, body weight (kg): mg/day: ≤35: 300; 36–50: 450; >50: 
600 
INH, body weight (kg): mg/day: ≤35: 200; >35: 300 
PZA, body weight (kg): g/day: ≤50: 1.0; >50: 1.5 
EMB, 15 mg/kg/day 
314 Hepatotoxicity CYP2E1 RsaI  
GSTM1 null  
Shimizu 
2006 157 
Cohort Japan 3 months Treatment with INH and RIF. The dose of INH ranged from 
300 to 400 mg, and that of RIF ranged from 300 to 450 mg. 
42 Hepatotoxicity NAT2 acetylator status  
Singla 2014 
158 
Cohort India NR NR 408 Hepatotoxicity NAT2 acetylator status  
CYP2E1 RsaI 
GSTM1 null  
GSTT1 null  
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Study  Design Country Follow-up 
time  
Drugs and dosage Sample size Outcomes Genetic variants 
Sotsuka 
2011 159 
Cohort Japan 3 months INH, RIF and PZA, plus EMB or SM during the first 2 months, 
followed by administration of INH and RIF plus EMB or SM 
during the final 4 months 
144 Hepatotoxicity NAT2 acetylator status  
CYP2E1 RsaI  
CYP2E1 DraI 
GSTM1 null  





Brazil NR ATD regimens that include INH at the usual dosage (400 
mg/day) 
167 Hepatotoxicity NAT2 acetylator status  
CYP2E1 RsaI  
GSTM1 null  
GSTT1 null  
Vuilleumier 
2006 164 
Cohort Switzerland NR INH 300 mg daily and vitamin B6 40 mg per day for a period 
of 6 months 





China NR INH, RIF, PZA, and EMB for 2 months followed by INH and 
RIF for 4 months  
215 Hepatotoxicity CYP2E1 RsaI  
GSTM1 null  
Xiang 2014 
170 
Cohort China 2 months All patients were prescribed INH (600 mg), RIF (600 mg, or 
450 mg if the body weight was <50 kg), PZA (2,000 mg), 
and EMB (1,250 mg) every other day in the first 2 months. 
After 2 months, INH and RIF were continued for a further 4 
to 6 months. Re-treatment patients in addition received SM 
(750 mg) every other day in the first 2 months and 
continued receiving EMB for another 6 months. 
2244 Hepatotoxicity NAT2 acetylator status  
CYP2E1 RsaI  
GSTM1 null  







Cohort Canada 9 months INH 300 mg 170 Hepatotoxicity NAT2 acetylator status  




Cohort Canada 9 months INH 300 mg 170 Hepatotoxicity CES1 – 28 variantsc 
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Study  Design Country Follow-up 
time  
Drugs and dosage Sample 
size 
Outcomes Genetic variants 
Yimer 2011 
173 
Cohort Ethiopia 56 weeks All study participants received RIF based short-course 
chemotherapy for TB following the national TB treatment 
guideline.  
353 Hepatotoxicity NAT2 acetylator status  
CYP2B6 rs3745274 



















Cohort Brazil End of 
treatment 
600 mg/day of RIF, 400 mg/day of INH and 2 g/day of PZA 
for all patients with corporal weight >45 kg or adjusted for 
corporal weight <45 kg. After 2 months of therapy, PZA was 
discontinued. 
131 Hepatotoxicity NAT2 acetylator status  
CYP2E1 RsaI  




Cohort Indonesia 1 month after 
last ATD 
therapy 
All patients received FDC-ATD category I intensive phase (RIF 
150 mg, INH 75 mg, PZA 400 mg and EMB 275 mg per tablet) 
and FDC-ATD category I continuation phase (RIF 150 mg and 
INH 150 mg) in 6 months of therapy. The dosage of ATDs 
was selected according to the patient’s weight. 
106 Hepatotoxicity PXR rs3814055 
Group identifier is provided before the name of the study where applicable. 
a For CYP2E1 RsaI polymorphism, results were only reported for hepatotoxicity, and not for adverse DIH outcome. 
b We were unable to obtain data (from the report or through contact with trial authors) specifically for the subgroup of TB patients, so no outcome data from this study are 
presented in this review. 
c The outcome data presented in this study were unclear, and we were unable to obtain clarification from trial authors; no outcome data from this study are presented in 
this review.
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ADR: adverse drug reaction; ATD: anti-tuberculosis drug; ATT: anti-tuberculosis treatment; DIH: drug-induced hepatotoxicity; DOTS: directly observed treatment, short-
course; EMB: ethambutol; FDC: fixed-dose combination; INH: isoniazid; MPE: maculopapular eruption; NR: not reported; PZA: pyrazinamide; RCT: randomised controlled 
trial; RIF: rifampicin; SM: streptomycin; TB: tuberculosis; WHO: World Health Organization  
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The ethnicity of included patients was poorly reported across the included studies; only 17 
studies (24%) provided this information.119, 138, 139, 142, 143, 147, 149, 151, 157, 164, 167, 169-172, 174, 175 
Therefore, in Table 3, we have instead provided the country in which each study was 
conducted. The majority of studies were conducted in Asia (50/70, 71%). The remaining 
studies were conducted in South America (9 studies), Europe (4 studies), Africa (4 studies), 
North America (Canada, 2 studies) and Turkey (a transcontinental country, 1 study). The 
median sample size across the included studies was 218 (interquartile range 131–314). 
Quality assessment 
Here, summary results are presented for each criterion of Jorgensen and Williamson’s 
quality assessment checklist,18 grouped by the particular issue of methodological quality 
they relate to. Full quality assessment results for each study are provided in Appendix 2.  
Choosing which genes and SNPs to genotype 
The assessment criteria for this issue of methodological quality, and the results of our 
assessment are provided in Table 4. The criteria relating to methods of adjustment for 
multiple testing and the reporting of precise p-values were not assessed, as we extracted 
raw data (i.e. the number of patients in each genotype group and outcome data for each 
genotype group) for inclusion in our meta-analyses, rather than the results of statistical 
analyses. Hence, the reporting of precise p-values and adjustment for multiple testing 
would have no impact on the validity of data included in our meta-analyses. 
Table 4 Choosing which genes and SNPs to genotype: quality assessment summary 
Criteria Results 
Was a literature review undertaken and the findings summarized? Yes: 70 (100%) 
No: 0 (0%) 
Are reasons given for choosing the genes and SNPs genotyped?a Yes: 49 (70%) 
No: 21 (30%) 
If reasons include previous association studies are key details from 
these provided? 
Yes: 0 (0%) 
No: 67 (96%) 
N/A: 3 (4%) 
If reasons include functional studies are supporting data provided? Yes: 0 (0%) 
No: 45 (64%) 
N/A: 25 (36%) 
Is method to adjust for multiple testing described? Not assessed 
Are precise p-values provided for all associations? Not assessed 
a We marked this as ‘yes’ if reasons were given for all genes and SNPs genotyped. 
N/A: not applicable; SNP: single nucleotide polymorphism 
 
All studies appeared to have reviewed the literature and summarised their findings, and 
most (49/70, 70%) provided justification for investigating the chosen genes and SNPs. 
However, when the justification included previous association studies or functional studies, 
no studies reported key details from these studies, such as odds ratios (ORs), or p-values.  
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Sample size 
The assessment criteria for this issue of methodological quality, and the results of our 
assessment are provided in Table 5. 
Table 5 Sample size: quality assessment summary 
Criteria Results 
What is the sample size?  Median: 218 (IQR: 131-314)a 
Are details given of how the sample size was calculated? Yes: 5 (7%) 
No: 65 (93%) 
Are details given of the a priori power to detect effect sizes of 
varying degrees, or a justified specific effect size?b 
Yes: 3 (4%) 
No: 67 (96%) 
a Sample size for one study was unclear so we did not include this study in our calculation of median 
and IQR. 
b We modified this criterion from Jorgensen and Williamson’s checklist18 to include ‘or a justified 
specific effect size’, as we deemed it satisfactory for a study to have calculated a priori power for a 
justified specific effect size, or for effect sizes of varying degrees. 
IQR: interquartile range 
 
Very few studies provided details of how the sample size was determined (5/70, 7%) or of 
the a priori power detect effect sizes of varying degrees, or a justified specific effect size 
(3/70, 4%). 
Study design 
The assessment criteria for this issue of methodological quality, and the results of our 
assessment are provided in Table 6. 
Table 6 Study design: quality assessment summary 
Criteria Results 
What is the study design?  Cohort: 36 (51%) 
Case-control: 33 (47%)  
RCT: 1 (1%) 
If study is case-control, are the two groups clearly defined? Yes: 31 (94%) 
No: 2 (6%) 
If study is case-control, were they genotyped in mixed batches? Yes: 1 (3%) 
Unclear: 32 (97%) 
RCT: randomised controlled trial 
 
Amongst the 33 case-control studies, most (31/33, 94%) clearly defined the case and 
control groups. However, only one of the case-control studies reported that the two groups 
were genotyped in mixed batches;127 for the remaining studies, it was unclear whether the 
case and control groups had been genotyped in mixed or separate batches.  
Reliability of genotypes 
The assessment criteria for this issue of methodological quality, and the results of our 
assessment are provided in Table 7. 
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Table 7 Reliability of genotypes: quality assessment summary 
Criteria Results 
Is the genotyping procedure described?  Yes: 69 (99%) 
No: 1 (1%) 
Are the primers described?  Yes: 47 (67%)a 
No: 22 (31%)b 
Available upon request: 1 (1%) 
Were quality control methods used and described? Yes: 14 (20%)c 
Not mentioned: 56 (80%) 
Were findings from quality control methods, if used, 
described? 
Yes: 8 (11%) 
No: 6 (9%) 
N/A: 56 (80%) 
Are any genotype frequencies previously reported quoted? Yes: 38 (54%)d 
No: 32 (46%) 
Were genotyping personnel blinded to outcome status? Yes: 47 (67%) 
Not mentioned: 23 (33%) 
If human inference required, was this independently 
undertaken by at least two people? 
Yes: 6 (9%) 
Not mentioned: 5 (7%)  
Not known if applicable: 58 (83%)  
N/A: 1 (1%) 
a For five of these studies, primers were reported for a subset of the investigated genes, and for 
three of these five studies, primers may be inherent to the assays used for genes for which primers 
were not reported. 
b For 12 of these studies, primers may be inherent to the assays used. 
c For two studies, quality control methods were described for a subset of investigated genetic 
variants only. 
d For 20 studies, previously reported genotype frequencies were quoted for a subset of investigated 
genetic variants only, and for one study, previously reported haplotype frequencies were reported. 
 
Almost all studies (69/70, 99%) described the genotyping procedure, but fewer studies 
(47/70, 67%) provided details of the primers used. Only 14 studies used and described 
genotype quality control checks, and only eight of these studies reported the findings of 
these checks. Around half of the studies (38/70, 54%) quoted previously reported genotype 
frequencies, although only 17 studies did this for all investigated genetic variants.  
For the criterion ‘Were genotyping personnel blinded to outcome status’, if genotyping 
personnel were blinded to outcome status, or outcome status was unknown at the time of 
genotyping, or genotyping calls were made wholly using technology rather than personnel, 
we marked this criterion as ‘yes’ (47/70, 67%). It was not reported for 23 studies (23/70, 
33%) whether genotyping personnel were blinded to outcome status. 
For the criterion, ‘If human inference required, was this independently undertaken by at 
least two people?’, it was unknown for most studies (58/70, 83%) if human inference was 
required for genotyping, and consequently whether the criterion was applicable. For one 
study,138 it was clear that the criteria did not apply, as genotyping calls were made wholly 
by technology rather than personnel. For the remaining 10 studies, only six reported that 
genotyping was independently undertaken by at least two people.  
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Missing genotype data 
The assessment criteria for this issue of methodological quality, and the results of our 
assessment are provided in Table 8. 
Table 8 Missing genotype data: quality assessment summary 
Criteria Results 
Is extent of missing data summarised?  
 
Yes: 54 (77%)a 
No: 16 (23%) 
If yes, are reasons for missing data given? 
 
Yes: 4 (6%)  
No: 4 (6%) 
N/A: 62 (89%) 
If yes, are checks for missingness at random reported?  No: 8 (11%) 
N/A: 62 (89%) 
Are missing genotype data imputed?  
 
No: 24 (34%) 
N/A: 46 (66%)b 
Does paper quote number of patients contributing to each 
analysis? 
Yes: 66 (94%)c 
No: 4 (6%) 
If paper does quote number of patients contributing to analyses, 
does this agree to sample size? 
Yes: 46 (66%) 
No: 20 (29%) 
N/A: 4 (6%) 
a For one study, the extent of missing data was summarised for a subset of investigated genetic 
variants only. 
b This criterion was not applicable to studies were there were no missing genotype data. 
c For one study, we spotted errors in the reported numbers of patients contributing to each analysis, 
and we emailed authors to obtain corrected data. 
N/A: not applicable 
 
Most studies quoted the number of patients contributing to each analysis (66/70, 94%). It 
was therefore possible to compare the number of participants included in the analyses with 
the study sample size, and determine that there were no missing genotype data for 46 
studies (66%). This approach assumes that no studies reported the sample size as the 
number of patients with genotype data as opposed to the number recruited. For the 
remaining 24 studies, only eight studies summarised the extent of missing data, and only 
four provided reasons for missing data. No studies described checking whether missing 
data were randomly distributed, or reported that imputations were performed for missing 
data.  
Population stratification 
The assessment criteria for this issue of methodological quality, and the results of our 
assessment are provided in Table 9. The criterion relating to whether cryptic population 
stratification was adjusted for in the analyses was not assessed, as adjustments for cryptic 
population stratification would have no impact on the reliability of the raw data included in 
our meta-analyses.  
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Table 9 Population stratification: quality assessment summary 
Criteria Results 
Are tests undertaken for cryptic population stratification? Yes: 2 (3%) 
No: 68 (97%) 
If so, are results quoted?  Yes: 2 (3%) 
N/A: 68 (97%) 
Is cryptic population stratification adjusted for in the analyses? Not assessed 
 
N/A: not applicable 
 
Two studies122, 155 mentioned undertaking tests for population stratification; no population 
stratification was identified. One study158 used a study design that ensured that the 
included patients were from a non-diverse ethnic group, however, cryptic population 
stratification may still exist, and no testing was performed. No other studies reported 
testing for cryptic population stratification. 
Hardy-Weinberg equilibrium 
The assessment criteria for this issue of methodological quality, and the results of our 
assessment are provided in Table 10. 
Table 10 Hardy-Weinberg equilibrium: quality assessment summary 
Criteria Results 
What test is undertaken to check for HWE?  
 
Chi-square: 27 (39%)a 
Other: 5 (7%) 
Test not described: 10 (14%)b 
Testing for HWE not mentioned: 28 (40%) 
Where test undertaken, is p-value threshold applied to 
determine deviation from HWE quoted? 
Yes: 31 (44%) 
No: 11 (16%) 
N/A: 28 (41%) 
Where test undertaken, are SNPs deviating from HWE 
highlighted? 
 
Yes: 26 (37%)c 
No: 16 (23%) 
N/A: 28 (40%) 
Where test undertaken, and some SNPs found to 
deviate, are steps taken to explore deviation from 
HWE reported? 
No: 6 (9%) 
N/A: 64 (91%) 
Where test undertaken, and some SNPs found to 
deviate, are deviating SNPs excluded from further 
analysis? 
Yes: 2 (3%) 
No: 4 (6%) 
N/A: 64 (91%) 
a Testing of HWE was only mentioned for a subset of investigated SNPs in one study. 
b Testing of HWE was only mentioned for a subset of investigated SNPs in two studies. 
c For 20 studies, no SNPs deviated. 
HWE: Hardy-Weinberg equilibrium; N/A: not applicable; SNP: single nucleotide polymorphism 
 
Thirty-nine studies reported testing for HWE for all investigated SNPs, and a further three 
studies reported testing for HWE for a subset of SNPs. The remaining 28 studies did not 
report testing for HWE.  
Among the 42 studies that mentioned testing for HWE, 31 studies quoted the p-value 
threshold applied to determine deviation from HWE. In six studies, SNPs deviating from 
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HWE were highlighted, and in a further 20 studies, it was clear that no SNPs deviated. 
Among the six studies where deviating SNPs were highlighted, no studies reported that 
steps were taken to explore deviation from HWE, and only two studies119, 172 excluded 
deviating SNPs from further analysis.  
It is important to note that a systematic reviewer would be able to perform their own tests 
for deviation from HWE if the trial authors have reported (or provided on request) the 
number of individuals in each genotype group. However, if problems with the data were 
flagged by HWE testing, it is rare that a systematic reviewer would have access to the 
necessary data to explore potential reasons for deviation from HWE, such as population 
stratification or genotyping errors.  
Mode of inheritance 
The assessment criteria for this issue of methodological quality, and the results of our 
assessment are provided in Table 11. Two criteria were not assessed (‘If no mode of 
inheritance is assumed does the paper explain limitations of this?’ and ‘If several analyses 
are undertaken under different assumptions, are they adjusted for multiple testing?’) as 
satisfying these criteria would have no impact on the validity of the raw data included in 
our meta-analyses.  
Table 11 Mode of inheritance: quality assessment summary 
Criteria Results 
Is a specific mode of inheritance assumed? If so 
which? 
 
Additive: 1 (1%) 
Dominant: 20 (29%) 
Different modes for different genetic 
variants: 14 (20%) 
Multiple modes assumed: 16 (23%) 
N/A: 2 (3%)a 
None: 9 (13%) 
Unclear: 8 (11%) 
Is justification provided for assumptions made 
regarding mode of inheritance? 
 
Yes: 5 (7%) 
No: 55 (78%) 
N/A: 10 (14%)b 
If no mode of inheritance is assumed does the paper 
explain limitations of this? 
Not assessed 
 
If several analyses are undertaken under different 
assumptions, are they adjusted for multiple testing? 
Not assessed 
 
a This criterion was not applicable to two studies where no homozygous mutant-type individuals 
were identified. 
b This criterion was not applicable to eight studies for which the assumptions made regarding mode 
of inheritance were unclear, and two studies where no homozygous mutant-type individuals were 
identified. 
N/A: not applicable 
 
Thirty-five studies made a specific assumption (i.e. assumed an additive mode, a dominant 
mode, or different modes for different SNPs) regarding the underlying mode of inheritance. 
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Only five studies provided justification for the assumptions made regarding mode of 
inheritance (i.e. no mode, or specific mode/modes).  
Choice and definition of outcomes 
The assessment criteria for this issue of methodological quality, and the results of our 
assessment are provided in Table 12. 
Table 12 Choice and definition of outcomes: quality assessment summary 
Criteria Results 
Does the paper clearly define all outcomes 
investigated? 
Yes: 62 (89%) 
No: 8 (11%) 
Is justification provided for the choice of 
outcomes? 
Yes: 58 (83%) 
No: 12 (17%) 
Are results shown for all outcomes mentioned 
for all variants investigated in the paper?a  
 
Yes: 56 (80%) 
No, but the authors provided reasons to 
measure some outcomes only for certain 
variants: 4 (6%) 
No: 10 (14%) 
a We modified this criterion from Jorgensen and Williamson’s checklist18 to include ‘for all variants 
investigated in the paper’, as we thought it was important to highlight studies that only reported 
some outcomes for certain variants. 
 
Most studies clearly defined the outcomes investigated (62/70, 89%), and provided 
justification for the choice of outcomes (58/70, 83%). For the studies that did not provide 
justification for the choice of outcomes, we judged the outcomes to be in line with the main 
aims of the study. Most studies presented results for all pre-specified outcomes for all 
variants investigated in the study (56/70, 80%), or provided rationale for having measured 
some outcomes for certain variants only (4/70, 6%).  
There was large variation in definition of hepatotoxicity across the included studies (Table 
13). Of the 66 studies reporting hepatotoxicity data, two did not provide a definition, three 
provided vague definitions, and the remaining 61 studies provided 43 different definitions. 
Definitions of other toxicity outcomes were generally not sufficiently detailed (Table 14).  
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Table 13 Definitions of hepatotoxicity in the included studies 
Study  Definition 
An 2012  An increase of > twice the ULN range in ALT or conjugated bilirubin levels or a 
concurrent increase in AST levels, according to the criteria developed at an 
international consensus meeting177 
Azuma 2013 INH-induced hepatotoxicity was assessed according to the diagnostic criteria of 
the Manual for Serious Side-Effects of Drug-induced Liver Injury from the 
Ministry of Health, Labor and Welfare of Japan.178, 179 In brief, hepatocellular 
injury was defined as a >2-fold increase in the ULN concentration of ALT alone or 
a serum ALT ratio/ALP ratio >5, where the ALT ratio=ALT value/ULN of ALT, and 
ALP ratio=ALP value/ULN of ALP. Cholestatic injury was defined as an increase of 
> twice the ULN range of ALP or a serum ALT ratio/ALP ratio <2. Mixed injury was 
defined as a serum ALT ratio/ALP ratio of between 2 and 5. Causality 
assessments showed a relationship to the INH administration if the total score 
was >3, i.e. ‘possible’. 
Bose 2011, 
Yimer 2011 
Defined according to the international consensus criteria.177 Liver biochemical 





Criteria for the diagnosis of hepatotoxicity was an elevation in liver function 
tests, AST and/or ALT of >3-fold the ULN (reference values: 40 and 65 U/L, 
respectively) and/or total bilirubin up to >2.0 mg/dL in the presence of 
gastrointestinal symptoms such as anorexia, nausea, vomiting and/or jaundice, 
with serum ALT level normalisation after anti-TB drug discontinuation. 
Çetintaş 2008 Hepatotoxicity criteria were defined as follows: 
• An increase in AST and ALT levels of >3-fold above normal or >5-fold 
above starting level or, 
• a greater than normal increase in ALT and AST levels together with 
hepatitis symptoms or, 
• a high bilirubin level. 
Chamorro 
2013 
Hepatotoxicity was defined as when serum transaminase concentrations were ≥3 
times the ULN (normal values: AST between 0–32 IU/L and ALT between 0–31 
IU/L) with report of jaundice (bilirubin normal values: 0–1 mg/dL) and/or 
hepatitis symptoms (nausea, vomiting, abdominal pain), or >5 times the ULN 
with or without symptoms. 




Hepatotoxicity was defined as: a rise of serum (i) ALT level ≥3 times the ULN or 
(ii) total bilirubin >1.0 mg⁄dL or, (iii) ALT <3 times the ULN but associated with 







(all GI: ADACS) 
Hepatotoxicity was defined as: (i) an increase to > twice the ULN in ALT or a 
combined increase in AST and total bilirubin, provided one of them was > twice 
the ULN; (ii) causality was assessed as certain, probable or possible based on the 
WHO Uppsala Monitoring Center criteria.180 
 
Cho 2007, Jung 
2015, Lee 2010 
An increase in serum ALT level to > twice the ULN value after anti-TB treatment, 
according to the criteria of drug-induced liver injuries developed by the 
international consensus meeting177 
Feng 2014, 
Teixeira 2011, 
An increase in serum transaminase values to >3 times the ULN value (40 IU/L ALT 
in Feng 2014) and symptoms compatible with hepatitis 
Fernandes 
2015, Santos 
2013 (both GI: 
SANTOS) 
An increase in serum ALT level >3 times the ULN after treatment 
Fredj 2016 The causality of drug-induced hepatotoxicity was determined according to the 
report of an international consensus meeting.177 These criteria include (i) an 
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Study  Definition 
increase of liver transaminases levels of > twice the normal value (<40 UI per 
litre) for AST and ALT (ii) an improvement of this pattern after the drug 
withdrawal, and (iii) the absence of alternative causes of this disorder. 
Gogtay 2016 Patients with symptoms/signs such as anorexia, nausea, vomiting, malaise, 
icterus, and raised serum aminotransferase levels > twice the ULN or >5 times 








An increase in ALT > twice the ULN or a combined increase in AST and bilirubin 
levels, provided one of them is > twice the ULN, was defined as hepatotoxicity 
according to the international consensus meeting.177  
 
ULN ranges - ALT: normal ≤42 IU/L; AST: normal ≤33 IU/L; total bilirubin: normal 
≤1.5 mg/dL. 
He 2015 Defined according to the Danan criteria promulgated in 1990.177, 181 No further 
information was provided. 
Higuchi 2007 
(GI: HIGUCHI) 
Defined according to the criteria of the international consensus meeting,177 i.e. 
development of an increase in serum ALT level ≥ 2 times the ULN (≤42 IU/L), or a 
combined increase of >2N in serum AST (N ≤33 IU/L) and total bilirubin (N ≤1.5 
mg/dL) 
Ho 2013 An elevation in liver-function tests, AST and/or ALT of >5 times the ULN; or AST 
and/or ALT of >3 times the ULN in the presence of symptoms such as nausea, 
vomiting, poor appetite, abdominal pain, or jaundice; or AST and/or ALT of >3 
times the ULN in the presence of total bilirubin of >2 times the ULN. 
Huang 2003 
(GI: HUANG) 
Hepatotoxicity was diagnosed as: (i) an increase in serum ALT level > twice the 
ULN during treatment, according to the criteria established by the international 
consensus meeting;177 (ii) negative serum hepatitis B virus surface antigen, IgM 
antibody to hepatitis A virus, and antibody to hepatitis C virus when ALT or AST is 
elevated; (iii) without any other major hepatic or systemic diseases that may 
induce elevation of liver biochemical tests, such as alcoholic liver disease, 
autoimmune hepatitis, congestive heart failure, hypoxia, and bacteraemia; and 
(iv) a causality assessment score >5 (classified as ‘probable’ or ‘highly probable’ 
drug-induced hepatitis), as derived from the international consensus meeting.177 
Huang 2007 
(GI: HUANG) 
The inclusion criteria of hepatotoxicity patients were based on the suggestion of 
the Drug-induced Liver Injury Network182 as follows: (i) an increase in serum ALT 
or AST level >5 times the ULN, or an elevation in ALP > twice the ULN, confirmed 
on at least two consecutive blood draws; (ii) if baseline ALT, AST or ALP are 
known and elevated, then ALT or AST >5 times the baseline value, or ALP > twice 
the baseline level on at least 2 consecutive blood draws; (iii) any elevation of 
serum ALT, AST, or ALP, associated with an increased serum total bilirubin (>2.5 
mg/dL), in the absence of prior diagnosis of liver disease, Gilbert’s syndrome, or 
evidence of haemolysis; (iv) a causality assessment score178 >5. 
Khalili 2011 Hepatotoxicity was defined as: (i) increased levels of liver transaminases >3 times 
the normal value (<40UL-1 for AST and ALT) with any other clinical signs and 
symptoms; or (ii) elevation of transaminases >5 times the ULN, if patients had no 
symptoms. For evaluation of causality, The Roussel Uclaf Causality Assessment 
Method scoring system was used.178 
Kim 2009, Kim 
2012b (both 
GI: KIM) 
An elevation in the serum levels of ALT > twice the ULN range (≤40 U/mL) during 
treatment and normalisation of these values after cessation of medication 
according to the criteria from the international consensus meeting177 






An elevation in the serum level of ALT or AST >3 times the ULN range (≤40 U/L) 
during treatment, according to the American Thoracic Society guidelines183 
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Study  Definition 
Kim 2015 (GI: 
KIM) 
Elevation in the serum levels of AST or ALT of >3 times the ULN during treatment 
and normalisation of these values after cessation of treatment 





Increase in serum transaminase (either AST or ALT) to values >3 times the ULN 
(i.e. >120 IU/L) at any time during the treatment period 
Li 2012 Serum ALT levels ≥3 times the ULN, and/or serum bilirubin levels ≥2 times the 
ULN 
Liu 2014 The diagnostic criteria of hepatotoxicity were based on international 
consensus:177, 178, 184 (i) serum ALT > twice the ULN (40 IU/L); or (ii) serum direct 
bilirubin > twice the ULN (6.8 μmol/L); or (iii) increases of serum AST (40 IU/L), 
ALP (220 IU/L), and total bilirubin (19.0 μmol/L); moreover, one of them > twice 
the ULN; or (iv) any index mentioned above > the ULN and associated with liver 
damage symptoms, such as skin or sclera yellow dye, severe anorexia, nausea, 
vomiting, fever, rash, itching. 
Lv 2012 (GI: 
ADACS) 
Hepatotoxicity was designated as:  
• An increase of > twice the ULN value in ALT or a combined increase in 
AST and total bilirubin provided one of them is > twice the ULN. In this 
study, the ULN of ALT, AST and total bilirubin were 40 U/L, 40 U/L and 
19 µmol/L, respectively. 
• Causality assessment result was highly probable, probable or possible 
based on the CIOMS scale.185 
Mahmoud 
2012 
Hepatotoxicity was diagnosed as: 
• an increase in serum ALT level > twice the ULN during the treatment, 
according to the criteria established by the international consensus 
meeting;177  
• negative serum hepatitis B virus surface antigen, IgM antibody to 
hepatitis A virus, and antibody to hepatitis C virus when ALT or AST was 
elevated;  
• without any other major hepatic or systemic diseases that may induce 
elevation of liver biochemical tests, such as alcoholic liver disease, 
autoimmune hepatitis, congestive heart failure, hypoxia, and 
bacteremia;  
• when the French imputability score186 was classified as ‘‘probable’’ or 





Increase in serum ALT levels beyond twice the ULN (ALT ≥42 IU/L), or at least a 2-
fold increase in ALT initial levels for those patients with a baseline ALT of >84 
IU/L, during the treatment period 
Ng 2014 All cases met at least one of the following biochemical criteria for enrolment into 
this study: (a) ALT >5 times the ULN, (b) ALP > twice the ULN, or (c) ALT >3 times 
the ULN and bilirubin > twice the ULN. 
Ohno 2000 AST and/or ALT >1.5 times the ULN and 2 times the level observed before 
treatment administration 
Rana 2014 Hepatotoxicity was defined according to international consensus criteria.177 
Patients with a rise in serum AST or ALT levels ≥5 times the ULN, irrespective of 
symptoms and serum bilirubin levels, or patients with rise in serum AST or ALT 
levels ≥ twice the ULN with hyperbilirubinaemia and an absence of serological 
evidence of infection with hepatitis viruses (A, B, C and E) were considered as 
having hepatotoxicity. 
Roy 2001 Defined according to the international consensus criteria177 with regard to 
chronology and causation for drug-induced liver diseases. However, only icteric 
hepatitis cases (serum bilirubin >3.0 mg/dL), among those fulfilling the above 
criteria, were included in the study. No further information was provided. 
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Study  Definition 
Roy 2006 NR 
Sharma 2014 Hepatotoxicity was diagnosed if any one of criteria (i), (ii) or (iii) were present 
along with criteria (iv) and (v). The criteria were: (i) an increase of 5 times the 
ULN (50 IU/L) of serum AST and/or ALT levels on one occasion or >3 times (>150 
IU/L) on 3 consecutive occasions; (ii) serum total bilirubin level >1.5 mg/dL; (iii) 
any increase in serum AST and/or ALT above pre-treatment values, together with 
anorexia, nausea, vomiting and jaundice; (iv) absence of serological evidence of 
infection with hepatitis viruses A, B, C or E; and (v) improvement in liver function 
(serum bilirubin <1 mg/dL, AST and ALT <100 IU/L) after the withdrawal of anti-
TB drugs.  
Shimizu 2006 ALT and/or AST level > twice the institutional ULN, according to the modified 
criteria of the international consensus meeting for drug-induced liver 
disorders.177 The ULN for AST was 33 IU/L and that for ALT was 42 IU/L. 
Singla 2014 International consensus criteria177 define hepatotoxicity as development of > 
twice the ULN value of ALT and AST. The ULN values used in this study were 35 
U/L ALT and 40 U/L AST. 
Sotsuka 2011 The severity of hepatotoxicity (hepatotoxicity A-D) was judged by the increase in 
either AST or ALT levels from the ULN range (AST, 33 U/L; ALT, 42 U/L): 
hepatotoxicity A, above the upper limit and <2-fold increase; hepatotoxicity B, 2- 
to 3-fold increase; hepatotoxicity C, 3- to 4-fold increase; hepatotoxicity D, >4-
fold increase. Results for grades B–D of hepatotoxicity were used in this review 
as clinical opinion was that the hepatotoxicity A patients would not have met the 
criteria for hepatotoxicity in many of the other studies included in this review. 
Vuilleumier 
2006 
Criteria for the diagnosis of INH-H consisted of a 4-fold elevation in AST and/or 
ALT levels above the upper reference limit (168 IU/L) with or without symptoms. 
Clinical diagnostic scales were used to assess the likelihood of drug involvement 
when INH-H was suspected.187 Based on the clinical diagnostic scales, causality 
assessment of INH-H was then categorised as definite (score >17), probable (14–
17), possible (10–13), unlikely (6–9) or excluded (<6). INH-H with possible to 
probable scores were considered for statistical analysis; unlikely scores were still 
considered when no other factor was identifiable. 
Wang 2010 The selection criteria for hepatotoxicity were as follows: (i) ALT ≥ twice the ULN; 
(ii) increased AST/ALT/serum proteins (i.e. liver damage based on an increase in 
ALT or bilirubin ≥ twice the ULN, or an increase in AST, ALP and total bilirubin 
with at least one of these being ≥ twice the ULN); (iii) negative for hepatitis A 
antibody, hepatitis B surface antigen and hepatitis C marker; (iv) no other factors 
influencing the levels of AST/ALT/serum proteins, such as alcohol-induced liver 
disease, hypoxia, auto-immune disease, congestive heart failure and 
bacteraemia; and (v) causality assessment score >5. 
Wang 2011 
(GI: NTUH) 
Among patients with normal baseline liver function (including AST, ALT, and total 
bilirubin), hepatotoxicity was defined as increased serum AST and/or ALT >3 
times the ULN in symptomatic, or >5 times the ULN in asymptomatic patients. 
Among those with increased baseline AST and/or ALT, hepatotoxicity was 




Hepatotoxicity was defined as increased serum AST and/or ALT >3 times the ULN 
in symptomatic patients, or >5 times the ULN in asymptomatic patients. The 
diagnosis of INH- or RIF-induced hepatitis required a positive re-challenge test (at 
least doubling of serum AST or ALT levels and recurrence of clinical symptoms of 
hepatitis after re-challenge), whereas PZA-induced hepatitis was diagnosed 
either by a positive re-challenge test or by exclusion. Results are presented for 
overall drug-induced hepatotoxicity and INH-induced hepatotoxicity separately. 
In this review, we used the results for overall drug-induced hepatotoxicity as our 
review focusses on hepatotoxicity induced by any anti-TB drug. 
Xiang 2014 ALT, AST or bilirubin value > twice the ULN value. The ULN used in the study was 
40 U/L for ALT, 40 U/L for AST, and 19 mmol/L for total bilirubin. 
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Increase in serum AST level > twice the ULN during 9 months of treatment with 
INH according to the criteria of the international consensus meeting in Paris;177 
normalisation of serum AST level after discontinuation of isoniazid; and a 





Zazuli 2015 ALT and/or AST levels above the normal threshold on the 2nd, 4th and 6th months 
of monitoring during TB treatment 
ALP: alkaline phosphatise; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CIOMS: 
Council for International Organizations of Medical Science; IgM: immunoglobulin M; INH: isoniazid; 
NR: not reported; PZA: pyrazinamide; RIF: rifampicin; TB: tuberculosis; ULN: upper limit of normal; 
WHO: World Health Organization 
 
Table 14 Definitions of other toxicity outcomes in the included studies 
Outcome Study  Outcome definition 
Peripheral neuropathy Azuma 2013 NR 
Dhoro 2013 NR 
Adverse DIH outcome  Bose 2011 ‘16 [patients] showed an adverse outcome of anti-TB 
treatment hepatotoxicity with icterus, severe nausea, 
and vomiting’. No further details reported 
ADRs Costa 2012 The presence of at least one of the following symptoms 
during the follow-up period: gastric, joint, 
neuromuscular, or skin reactions; and hepatotoxicity (in 
accordance with the criteria of drug-induced liver 
injuries developed by the international consensus 
meeting)183 
Skin rash Higuchi 2007 
(GI: HIGUCHI) 
NR 
Eosinophilia Higuchi 2007 
(GI: HIGUCHI) 
The presence of >450 eosinophils/mL  
ATD-induced 
cutaneous reactions 
Kim 2010  
(GI: KIM) 
The development of any cutaneous symptom or skin 
lesion after receiving ATD medication 
ATD-induced MPE 
 
Kim 2011,  
Kim 2012a 
(both GI: KIM) 
The development of MPE after receiving first-line ATD 
and the disappearance of MPE after discontinuing ATD 
Gastrointestinal ADRs Possuelo (2008)  
(GI: POSSUELO) 
Anorexia, nausea, vomiting, and/or abdominal pain 
ATD: anti-tuberculosis drug; ADR: adverse drug reaction; DIH: drug-induced hepatotoxicity; GI: group 
identifier; MPE: maculopapular eruption; NR: not reported; TB: tuberculosis 
 
Treatment adherence 
As previously outlined in Section 2.2, we use the term ‘adherence’ as opposed to 
‘compliance’, which is used in Jorgensen and Williamson’s18 checklist. The assessment 
criteria for this issue of methodological quality, and the results of our assessment are 
provided in Table 15.  
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Table 15 Treatment adherence: quality assessment summary 
Criteria Results 
Is adherence to treatment measured?  Yes: 11 (16%) 
No: 56 (80%) 
N/A: 3 (4%)a 
If adherence is measured, are adjustments for 
non-adherence made in the analyses? 
Yes: 7 (10%) 
No: 2 (3%) 
N/A: 61 (87%) 
a This criteria was not applicable to studies that reported that treatment was administered by 
directly observed therapy, short-course (DOTS). 
N/A: not applicable 
 
A small proportion of studies (11/70, 16%) mentioned assessing treatment adherence. 
Three studies116, 158, 176 reported that treatment was administered by directly observed 
therapy, short-course (DOTS), so it was unnecessary to measure adherence. Of the 11 
studies that reported assessing adherence, two studies151, 172 did not report adjusting the 
analyses for adherence. It was not necessary to adjust the analyses of two studies that 
measured adherence,118, 119 as patients were reported to have good treatment adherence. 
3.4 Discussion 
Characteristics of included studies  
The included studies varied greatly in terms of how hepatotoxicity was defined (43 different 
definitions across 66 studies). Jorgensen et al.48 and Contopoulos-Ioannidis et al.49 have 
previously made similar observations about the variability of outcome definitions across 
pharmacogenetics studies. It would be beneficial for consensus to be reached between 
experts in this clinical area on the definitions of outcomes that are commonly reported in 
studies of anti-TB drug-related toxicity. We observed that several studies provided a 
reference to an international consensus meeting for drug-induced liver disorders177 when 
defining hepatotoxicity, but the definitions were still not consistent between this subset of 
included studies.  
Since this commonly referred to international consensus meeting177 was conducted, it has 
been argued that the recommended threshold for drug-induced liver injury (DILI) as an 
elevation in the serum concentration of alanine aminotransferase (ALT), conjugated 
bilirubin, or alkaline phosphatase exceeding two times the upper limit of normal (ULN), may 
be too low.188 Such a low threshold may lead to unnecessary investigations of temporary 
and modest ALT elevations that would revert to baseline even if drug therapy were to be 
continued, and potentially withdrawal of efficacious drug treatment. Non-alcoholic fatty 
liver disease may also lead to elevations in liver parameters, and withdrawal of drugs 
suspected to be hepatotoxic in these instances would also be unnecessary. For these 
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reasons, an international DILI expert working group recommended raising the cut-off level 
of ALT elevation to five times the ULN in order to exclude clinically unimportant DILI, and 
elevations in liver parameters unrelated to treatment with potentially hepatotoxic drugs.188 
The working group developed an algorithm to firstly identify cases of DILI, and then to 
assess the pattern, causality, severity and chronicity of the identified DILI. These 
recommendations ought to ensure consistency when classifying the wide spectrum of 
conditions that constitute DILI.  
The COMET (Core Outcome Measures in Effectiveness Trials) Initiative189 encourages the 
development of standardised sets of outcomes, known as ‘core outcome sets’ for specific 
conditions. If a core outcome set exists for a particular condition, all trials of this condition 
ought to measure and report data for these outcomes. If a core outcome set were to be 
developed for studies of anti-TB drug-related toxicity, outcomes would be comparable 
between studies and synthesis of data from these studies would become more clinically 
meaningful.  
We also observed that evidence from studies conducted in Africa, where TB is endemic, 
was very limited. Only four studies included in this review were conducted in Africa; two 
were conducted in Tunisia,123, 146 one in Ethiopia,173 and one in Zimbabwe.120 Therefore, 
most of the evidence included in this review is not representative of the global population 
most affected by TB. Furthermore, genotype frequencies vary greatly across the African 
continent,190 and it is therefore often not appropriate to extrapolate results from one 
African ancestral group to another. To better understand how the relationship between 
genetic variants and anti-TB drug-related toxicity outcomes varies across different African 
populations, more pharmacogenetic studies are required from this setting. However, it is 
important to note that investigating anti-TB drug-related toxicity in African countries may 
be complicated by the fact that a considerable proportion of TB patients in these settings 
are likely to be co-infected with HIV. It can therefore be difficult to determine whether 
adverse events such as hepatotoxicity have been caused by anti-HIV drugs, anti-TB drugs, or 
both.  
Finally, the lack of reporting of ethnicity of participants in the included studies was 
particularly problematic. As previously discussed in Section 2.3, the HuGENet HuGE Review 
Handbook24 recommends that meta-analyses of genetic association studies are stratified by 
ethnicity, and that pooling of results should only be performed if effect estimates for 
different ethnic groups appear sufficiently similar. Based on the small number of studies 
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that reported the required information, we concluded that it would not be possible to 
stratify our meta-analyses by ethnicity.  
Quality assessment of included studies 
A key feature of our systematic review was the quality assessment using the criteria 
developed by Jorgensen and Williamson18 specifically for pharmacogenetic studies. The 
primary purpose of this assessment was to highlight potential issues that may impact the 
internal validity of the results of the studies included in our review. This would allow us to 
determine the appropriate level of caution to use when drawing conclusions based on the 
results of the included studies, and syntheses of these studies.  
It is important to note here that Jorgensen and Williamson’s tool18 is not explicitly designed 
to comprehensively assess risk of bias (see Section 2.2 for discussion of the differences 
between assessing risk of bias and assessing methodological quality). However, it is feasible 
that many of the issues raised by Jorgensen and Williamson18 would impact the internal 
validity of a pharmacogenetic study’s results.  
We did not assess some criteria that clearly would have no impact on the reliability of the 
data included in our systematic review, such as whether results were adjusted for multiple 
testing, or cryptic population stratification, as we used only raw data in our meta-analyses. 
However, we did assess some criteria that would be unlikely to have an impact on the 
reliability of the data included in our systematic review: for example, we assessed the 
criteria relating to sample size, as this highlighted the benefits of performing meta-analysis 
for this set of studies.  
Systematic reviewers using the tool ought to be aware that some of the listed criteria 
would not have implications for the internal validity of a pharmacogenetic study’s results, 
and therefore would not necessarily need to be highlighted in the review as particular 
issues of concern. Importantly, there are also some potential sources of bias not addressed 
by the checklist; these are discussed further under the “Limitations” heading of this section. 
Overall, future work developing Jorgensen and Williamson’s checklist18 further, to create a 
tool that could be used to comprehensively address risk of bias in systematic reviews of 
pharmacogenetic studies would undoubtedly be beneficial. 
The quality of included studies was variable, with many areas of concern. An important 
issue relating to the conduct of pharmacogenetic studies is the possibility that authors may 
selectively report results based on their statistical significance or perceived importance. 
Selective reporting may occur in relation to genetic variants, assumed mode of inheritance, 
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and/or outcomes. Some studies did not provide rationale for investigating all genes and 
SNPs investigated; a clear rationale would provide reassurance that results were not 
selectively reported. Furthermore, very few studies justified their assumed mode of 
inheritance, or the lack of assumed mode. A reader may therefore have concerns that 
multiple analyses might have been performed and the results selectively reported. We 
identified that justification for the choice of outcomes was more widely reported, and most 
studies presented results for all listed outcomes for all variants investigated in the study, or 
provided rationale for having measured some outcomes for certain variants only.  
Most studies were significantly smaller than typically required to provide sufficient power.18 
The typically small sample sizes of the studies that form the evidence base suggest that 
performing meta-analyses to increase power to detect genetic associations is essential in 
this area of research.  
All but one of the studies employed case-control or cohort designs; the remaining study 
was a RCT81 where patients were randomised to receive genotype-guided therapy or 
standard therapy. For the case-control studies, only one study reported that cases and 
controls were genotyped in mixed batches; for all other case-control studies, we do not 
know whether the genotyping quality was comparable between cases and controls.18 
Furthermore, few studies provided information regarding genotyping quality procedures, 
so it is difficult to assess the likelihood of bias due to incorrect genotype allocation in the 
included studies.  
The fact that no studies described checking that missing data were missing at random is a 
concern; missing genotype data are unlikely to be missing at random, as heterozygotes are 
notoriously more difficult to call than homozygotes.18 Analyses including only individuals 
with non-missing genotype data may be biased if the missing data are not missing at 
random.  
Very few studies reported on testing for population stratification, and so the results 
reported in most studies are at risk of confounding by population stratification. Testing for 
deviation from HWE can highlight that there may be probems with the data, such as cryptic 
population stratification or genotyping errors;18 however, a considerable number of studies 
did not report any testing of HWE, and no studies took steps to explore reasons for SNPs 
deviating from HWE.  
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Finally, most studies did not report that treatment adherence had been measured, so it is 
not possible to consider the impact that adherence may have had on outcomes in these 
studies.18 
It is important to note here, we could only judge a study to have met a particular criterion if 
sufficient relevant information was provided in the study publication. Lack of information 
for a particular criterion suggests that the study may be of poor methodological quality, as 
we do not have enough detail to judge the study as high quality. However, lack of 
information does not necessarily indicate that a study is poor quality, or at high risk of bias. 
For example, in 30% of studies included in our review, authors did not provide reasons for 
choosing the genes and SNPs investigated in their study. However, it is entirely possible 
that these authors did have valid reasons for choosing the genes and SNPs investigated, but 
these reasons were not explicitly stated in the study publication. For many criteria in the 
checklist, it is feasible that if more information on methodology was available in the study 
publications, our overall confidence in the findings of these studies would improve. 
Limitations 
A limitation of this systematic review is that it was not possible to adhere completely to the 
HuGENet HuGE Review Handbook24 guidance on searching for studies. Due to a lack of 
expertise and funding, we did not include studies published in languages other than English, 
nor did we search grey literature for relevant studies. Therefore, there may be relevant 
evidence that was not included in our systematic review from studies published in non-
English languages and unpublished studies. We were however able to check the reference 
lists of existing reviews in our topic area, which can sometimes identify unpublished 
studies. In this case, no unpublished studies were identified.  
Furthermore, during the study selection process, it was necessary to make some additions 
to the pre-specified eligibility criteria, as outlined in Section 3.2. When we designed the 
search strategy, we did not anticipate that we would identify multiple articles reporting 
data for the same genetic variants and same patient cohort. We also did not anticipate that 
we would identify studies investigating HLA alleles, that we would be unable to apply the 
standard methods of evidence synthesis to. Although the decisions to exclude these studies 
were post-hoc, we made these decisions by considering whether it would be sensible to 
include these studies in our review, rather than based on the results of these studies. We 
are therefore confident that these exclusions would not introduce bias to the results of our 
systematic review and meta-analysis.  
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Due to the number of references identified by the search strategy and the number of 
studies included in this review, dual abstract screening, full text assessments and quality 
assessments were only performed for a sample of the included studies. At the abstract 
screening stage, if there was any uncertainty about the relevance of an abstract, the 
abstract would be included. At the full text eligibility assessment and quality assessment 
stages, agreement was good and all discrepancies were minor. All outcome data were 
extracted independently by two reviewers. Therefore, we believe that any errors during 
study selection, quality assessment and data extraction are likely to be minimal and unlikely 
to influence the results of our review. 
As outlined in Section 2.5, there are some additional sources of bias not listed in Jorgensen 
and Williamson’s checklist18 that could impact the validity of the results reported by studies 
included in our systematic review. It was outside the scope of this work to develop the tool 
further and formally assess each of these additional issues. However, considering studies 
that recruited patients already established on TB treatment, there was no reason to believe 
that any of these studies selectively recruited patients who had not already experienced 
early adverse drug reactions. Studies that recruited patients already established on TB 
treatment employed case-control designs, and therefore inherently provided data on 
relevant events occurring prior to recruitment. Considering whether results of genotyping 
tests performed prior to recruitment may have introduced selection bias to the included 
studies, it was often difficult to determine precisely when genotyping was performed in the 
included studies (i.e. pre- or post-recruitment), and so we consider it may be difficult for 
future review authors to assess the risk of bias in relation to this issue. 
For the case-control studies included in this systematic review, cases and controls were 
almost always recruited from the same underlying patient population, and only differed in 
terms of outcome status. One exception to this was a case-control study149 that used 
population controls; there was limited information about the underlying population that 
these controls were sampled from. Furthermore, two studies90, 120 did not provide clear 
definitions of case and control groups. For all other studies, we did not have concerns about 
differences between case and control populations in terms of factors that may influence 
treatment outcome.  
Regarding the issues relating to measurement of outcomes, limited information was 
available in the included study reports on blinding of outcome assessors. It is possible that 
detection bias may impact the results of the studies included in this review. Finally, it is 
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important to note that without access to the trial protocols or pre-specified analysis plans 
for each study (which were unavailable for the majority of included studies), it is very 
difficult to rule out the possibility of selective reporting of outcomes. Study authors may 
have measured more outcomes than are listed in the published paper. Indeed, the wide 
variety of possible definitions of hepatotoxicity (as indicated by Table 13), including 
complex composite definitions, raises concerns that outcome definitions in the included 
studies may have been influenced by the magnitude, statistical significance or perceived 
importance of observed effect sizes. 
3.5 Conclusion 
There is a substantial evidence base for the association between genetic variants and anti-
TB drug-related toxicity outcomes, as previously identified and as our systematic review 
confirmed. However, by considering the characteristics of included studies and performing 
a rigorous quality assessment, we established that performing robust synthesis of the 
evidence base would be challenging. Studies varied substantially in terms of definition of 
outcomes, and in terms of methodological quality. Reporting of key details, such as the 
ethnicity of included patients and aspects of methodological quality, was poor across the 
included studies.   
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4 Influence of genetic variants on toxicity related to anti-
tuberculosis drugs: meta-analyses 
The aim of this chapter was to perform meta-analyses of the studies identified in the 
systematic review presented in Chapter 3. It was hoped that synthesising the identified 
studies would improve the power to detect associations between genetic variants and anti-
TB drug related toxicity outcomes. Each meta-analysis was performed for a specific 
combination of genetic variant and anti-TB drug related toxicity outcome. Here, we outline 
the methods used to perform the meta-analyses, the results generated, and our 
interpretation of these results.  
4.1 Methods 
Primary analyses 
To inform our decisions regarding which analyses would be the primary analyses, we 
examined the existing literature and consulted clinical experts. The primary analyses 
focused on hepatotoxicity, as this is the most widely studied anti-TB drug-related toxicity 
outcome, and on key genetic variants that researchers have hypothesised may play a role in 
the biological pathway between anti-TB treatment and hepatotoxicity (NAT2 acetylator 
status; CYP2E1 RsaI, PstI and DraI polymorphisms; and GSTM1 and GSTT1 null 
polymorphisms; see Section 3.1).  
Clinical advice was that a comparison of slow and intermediate NAT2 acetylator groups 
combined versus the rapid acetylator group would be clinically useful. For the CYP2E1, 
GSTM1 and GSTT1 polymorphisms, combinations of particular genotype groups have been 
consistently used throughout the literature. For the key CYP2E1 polymorphisms, 
homozygous mutant-type and heterozygous genotype groups are commonly combined, 
whereas for the GSTM1 and GSTT1 null polymorphisms, heterozygous and homozygous 
present (or ‘non-null’) genotype groups are commonly combined. The evidence base 
therefore suggested that assuming a dominant mode of inheritance for the CYP2E1 
polymorphisms, and a recessive mode of inheritance for the GSTM1 and GSTT1 null 
polymorphisms would be appropriate. Consequently, the primary analyses compared the 
likelihood of experiencing hepatotoxicity for:  
 NAT2 slow/intermediate acetylators versus rapid acetylators  
Results were combined from studies that reported data for each acetylator group 
separately together with data from studies that combined slow and intermediate acetylator 
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groups. Data from studies that combined intermediate and rapid acetylator groups were 
included in sensitivity analyses (see below). 
 Homozygous mutant-type or heterozygous individuals versus homozygous wild-type 
individuals for the RsaI, PstI and DraI polymorphisms of CYP2E1 
Results were combined from studies that reported data for each genotype group separately 
with data from studies that combined homozygous mutant-type and heterozygous 
genotype groups. No studies combined homozygous wild-type and heterozygous genotype 
groups. 
 Individuals with homozygous null genotype versus those with heterozygous or 
homozygous present genotype for GSTM1 and GSTT1  
Results were combined from studies that reported data for each genotype group separately 
and studies that combined homozygous present and heterozygous genotype groups. No 
studies combined homozygous null and heterozygous genotype groups. 
The following sensitivity analyses were conducted to investigate the robustness of the 
primary analyses:  
• NAT2 acetylator status: Pairwise comparisons of slow versus rapid acetylators, and 
intermediate versus rapid acetylators, using data from studies that reported data for 
each acetylator group separately 
• NAT2 acetylator status: Comparison of slow versus rapid/intermediate acetylators, 
using data from studies that combined data for intermediate and rapid acetylator 
groups, and from studies that reported data for each acetylator group separately 
• CYP2E1 polymorphisms: Pairwise comparisons of heterozygous versus homozygous 
wild-type genotype, and homozygous mutant-type versus homozygous wild-type 
genotype for the CYP2E1 RsaI, PstI and DraI polymorphisms, using data from studies 
that reported data for each genotype group separately 
• GSTM1/GSTT1 null polymorphisms: Pairwise comparisons of heterozygous versus 
homozygous present genotype, and homozygous null versus homozygous present 
genotype for both GSTM1 and GSTT1, using data from studies that reported data for 
each genotype group separately. 
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Prior to undertaking meta-analyses, we performed an exact test for HWE within each study. 
A significance level of p<0.05 was used to indicate deviation from HWE. We did not test 
HWE for NAT2 acetylator status, as acetylator status is a trait defined by several NAT2 SNPs. 
Furthermore, if we did not have the number of individuals in each genotype group (i.e. 
homozygous wild-type, heterozygous, homozygous mutant-type) for a particular study, it 
was not possible to test for HWE. Where genotypes for a study were found to deviate from 
HWE (p<0.05), a sensitivity analysis was conducted excluding that study.  
We produced funnel plots for each of the primary analyses to investigate the possibility of 
small study effects (such as publication bias). We would not have produced a funnel plot for 
a primary analysis if less than 10 studies had been included, as a sizeable number of studies 
are required to visually assess a funnel plot for small study effects.191 
Secondary analyses  
The secondary analyses investigated all other associations between genetic variants and 
anti-TB drug-related toxicity outcomes. We performed meta-analyses according to the 
following strategy: 
• For SNPs where all studies presented data for each genotype group separately, we 
performed two pairwise comparisons; heterozygous versus homozygous wild-type 
genotype, and homozygous mutant-type versus homozygous wild-type genotype.  
• For SNPs where all studies presented data for the same combined genotype groups, we 
performed one comparison of the combined genotype groups.  
• For SNPs where the approach varied between studies, we performed both pairwise 
comparisons (using data from studies that reported on each genotype group 
separately), and a comparison of the combined genotype groups (using data from all 
studies). 
 
Data synthesis  
All meta-analyses were performed using the metan package in Stata 14;192 ORs with 95% CIs 
were the chosen measure of effect. A random-effects model was employed because we 
anticipated both methodological heterogeneity (due to differences in study design and 
quality of methods) and clinical heterogeneity (due to differences in participants’ ethnic 
backgrounds and outcome definitions). The DerSimonian and Laird random-effects model, 
193 which makes use of a ‘moment-based’ estimate of the heterogeneity variance, was 
implemented; Cochran’s Q was used as the homogeneity statistic. We assessed statistical 
heterogeneity by visually examining the forest plots, and by referring to the I2 statistic. 
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We considered performing meta-analysis for all associations between a genetic variant and 
a toxicity outcome that were investigated by at least two studies; however, we would not 
have pooled data if we judged that clinical, methodological or statistical heterogeneity 
would render the overall effect estimate to be meaningless.  
If no events occurred in one of the genotype groups for a particular study, a continuity 
correction of 0.5 was applied.25 If there were no patients in one of the genotype groups for 
a particular study, data from this study were excluded from the meta-analysis.  
The HuGENet HuGE Review Handbook recommends that meta-analyses of genetic 
association studies are stratified by ethnicity, and that pooling of results should only be 
performed if effect estimates for different ethnic groups appear sufficiently similar.24 
Information on participants’ ethnicity was not commonly reported; however, in an attempt 
to follow this recommendation, we stratified our analyses by the countries in which studies 
were performed. 
For SNPs investigated by one study only, ORs comparing genotype groups and 
corresponding 95% confidence intervals (CIs) were calculated and reported in tables. 
4.2 Results 
Primary analyses: NAT2 acetylator status and hepatotoxicity 
A total of 22 studies reported data for each NAT2 acetylator group separately, or for 
combined slow and intermediate acetylator groups versus rapid acetylators, and were 
therefore included in the primary analysis for NAT2 acetylator status and hepatotoxicity. A 
forest plot displaying the results of this primary analysis is provided in Figure 2.   
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Figure 2 NAT2 acetylator status and hepatotoxicity; slow/intermediate versus rapid acetylator status 
*Vuilleumier 2006164 and Yamada 2009171 were both conducted in the latent TB population. 
**Caucasian: 38 (43%), Hispanic: 8 (9%), African: 22 (25%), South American: 15 (17%), Asian: 5 (6%), 
Middle Eastern: 1 (1%)  
*** Asian: 72 (42%), Caucasian: 49 (29%), South Asian: 22 (13%), Hispanic: 7 (4%), Middle Eastern: 8 
(5%), First nations: 5 (3%), other/mixed/unknown: 7 (4%) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; IA: intermediate acetylators; OR: odds ratio; RA: rapid 
acetylators; SA: slow acetylators; TB: tuberculosis 
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Slow/intermediate acetylators were significantly more likely to experience hepatotoxicity 
than rapid acetylators (OR=1.59, 95% CI: 1.26 to 2.01). No heterogeneity was detected in 
this analysis (I2=0.0%).  
Interestingly, the result from a sensitivity analysis comparing the likelihood of 
hepatotoxicity for slow versus rapid/intermediate acetylators (Figure 3) resulted in a 
stronger estimate of association (OR=3.12, 95% CI: 2.45 to 3.97, I2=59.0%) than the primary 
analysis (of slow/intermediate versus rapid acetylator status). A total of 34 studies reported 
data for each NAT2 acetylator group separately, or for combined rapid and intermediate 




Figure 3 NAT2 acetylator status and hepatotoxicity sensitivity analysis: slow versus rapid/intermediate 
acetylator status  
* Vuilleumier 2006164 and Yamada 2009171 were both conducted in the latent TB population. 
**Caucasian: 38 (43%), Hispanic: 8 (9%), African: 22 (25%), South American: 15 (17%), Asian: 5 (6%), 
Middle Eastern: 1 (1%)  
*** Asian: 72 (42%), Caucasian: 49 (29%), South Asian: 22 (13%), Hispanic: 7 (4%), Middle Eastern: 8 
(5%), First nations: 5 (3%), other/mixed/unknown: 7 (4%) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; IA: intermediate acetylators; OR: odds ratio; RA: rapid 
acetylators; SA: slow acetylators; TB: tuberculosis 
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Results of the pairwise comparison sensitivity analyses for NAT2 acetylator status and 
hepatotoxicity are provided in Appendix 3. Results from the pairwise comparisons 
suggested that slow acetylators were significantly more likely to experience hepatotoxicity 
than rapid acetylators (OR=3.68, 95% CI: 2.23 to 6.09, I2=60.0%, 21 studies), but that there 
were no significant differences between intermediate and rapid acetylators (OR=1.12, 95% 
CI: 0.87 to 1.45, I2=0.0%, 21 studies). A comparison of the results obtained by applying 
different approaches to the analysis of NAT2 acetylator status and hepatotoxicity, i.e. 
assuming a dominant mode of inheritance (slow/intermediate versus rapid acetylators), 
assuming a recessive mode of inheritance (slow versus intermediate/rapid acetylators), and 
performing pairwise comparisons, is provided in Figure 4. 
 
Figure 4 Summary of the results obtained by applying different approaches to the analysis of NAT2 acetylator 
status and hepatotoxicity 
CI: confidence interval 
 
The funnel plot for the analysis of slow/intermediate acetylators versus rapid acetylators 
for the outcome of hepatotoxicity (Figure 5) provided no evidence of small study effects. 
Pairwise: Slow vs rapid
























Figure 5 Funnel plot for the analysis of NAT2 slow/intermediate versus rapid acetylator status and hepatotoxicity 
 
Primary analyses: Key CYP2E1 SNPs and hepatotoxicity 
Forest plots displaying the results of the primary analyses for the CYP2E1 key SNPs are 
provided in Figure 6, Figure 8 and Figure 10. 
A total of 23 studies reported data for each CYP2E1 RsaI genotype group separately, or for 
combined homozygous mutant-type (TT) and heterozygous (CT) groups versus the 
homozygous wild-type group (CC), and were therefore included in the primary analysis for 
the CYP2E1 RsaI polymorphism and hepatotoxicity. Patients with TT or CT genotype at the 
CYP2E1 RsaI polymorphism were significantly less likely to experience hepatotoxicity than 
patients with CC genotype (OR=0.75, 95% CI: 0.56 to 1.00) (Figure 6). Moderate 
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Figure 6 CYP2E1 RsaI polymorphism and hepatotoxicity: homozygous mutant-type (TT) or heterozygous (CT) 
versus homozygous wild-type (CC)  
* Yamada 2009171 was conducted in the latent TB population. 
**Asian: 72 (42%), Caucasian: 49 (29%), South Asian: 22 (13%), Hispanic: 7 (4%), Middle Eastern: 8 
(5%), First Nations: 5 (3%), other/mixed/unknown: 7 (4%) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio; TB: tuberculosis 
 
The results of the sensitivity analyses for key CYP2E1 SNPs and hepatotoxicity are provided 
in Appendix 3. For the CYP2E1 RsaI polymorphism, when three studies152, 158, 159 were 
excluded due to deviation from HWE, the association remained statistically significant, and 
heterogeneity was slightly reduced (OR=0.64, 95% CI: 0.48 to 0.84, I2=47.2%, 20 studies). 
No significant differences were observed for either pairwise comparison (CT versus CC: 
OR=0.80, 95% CI: 0.58 to 1.10, I2=48.4%, 18 studies; TT versus CC: OR=1.03, 95% CI: 0.68 to 
1.55, I2=2.7%, 18 studies). A comparison of the results obtained by applying different 
approaches to the analysis of CYP2E1 RsaI polymorphism and hepatotoxicity, i.e. assuming 
a dominant mode of inheritance (TT/CT versus CC), excluding studies due to deviation from 
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HWE from this dominant analysis approach, and performing pairwise comparisons, is 
provided in Figure 7. 
 
Figure 7 Summary of the results obtained by applying different approaches to the analysis of CYP2E1 RsaI 
polymorphism and hepatotoxicity 
CI: confidence interval; HWE: Hardy-Weinberg equilibrium 
 
Eight studies reported data for each CYP2E1 DraI genotype group separately, or for 
combined homozygous mutant-type (AA) and heterozygous (TA) groups versus the 
homozygous wild-type (TT) group, and were therefore included in the primary analysis for 
the CYP2E1 DraI polymorphism and hepatotoxicity. There was no significant difference in 
the likelihood of hepatotoxicity between patients with AA or TA genotype at the CYP2E1 
DraI polymorphism and patients with TT genotype (OR=1.23, 95% CI: 0.92 to 1.66) (Figure 
8). Minimal heterogeneity was observed in this analysis (I2=3.1%).  
Pairwise: TT vs CC
Pairwise: CT vs CC























Figure 8 CYP2E1 DraI polymorphism and hepatotoxicity: homozygous mutant-type (AA) or heterozygous (AT) 
versus homozygous wild-type (TT) 
None of the included studies reported ethnicity so this information is not provided on the forest plot. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
 
The sensitivity analysis excluding two studies112, 126 where genotypes were found to deviate 
from HWE also showed no significant association (OR=1.27, 95% CI: 0.86 to 1.87, I2=14.2%, 
6 studies). Furthermore, the two pairwise comparisons showed no significant differences 
between genotype groups (TA versus TT: OR=1.28, 95% CI: 0.93 to 1.77, I2=6.4%, 7 studies; 
AA versus TT: OR=1.34, 95% CI: 0.57 to 3.16, I2=29.4%, 7 studies) (Appendix 3). A 
comparison of the results obtained by applying different approaches to the analysis of 
CYP2E1 DraI polymorphism and hepatotoxicity, i.e. assuming a dominant mode of 
inheritance (AA/TA versus TT), excluding studies due to deviation from HWE from this 
dominant analysis approach, and performing pairwise comparisons, is provided in Figure 9. 
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Figure 9 Summary of the results obtained by applying different approaches to the analysis of CYP2E1 DraI 
polymorphism and hepatotoxicity 
CI: confidence interval; HWE: Hardy-Weinberg equilibrium 
 
Eight studies reported data for each CYP2E1 PstI genotype group separately, or for 
combined homozygous mutant-type (CC) and heterozygous (GC) groups versus the 
homozygous wild-type (GG) group, and were therefore included in the primary analysis for 
the CYP2E1 PstI polymorphism and hepatotoxicity. There was no significant difference in 
the likelihood of experiencing hepatotoxicity between patients with CC or GC genotype at 
the CYP2E1 PstI polymorphism and patients with GG genotype (OR=0.78, 95% CI: 0.46 to 
1.34) (Figure 10). Moderate heterogeneity was observed in this analysis (I2=50.3%).   
Pairwise: AA vs TT
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Figure 10 CYP2E1 PstI polymorphism and hepatotoxicity: homozygous mutant-type (CC) or heterozygous (GC) 
versus homozygous wild-type (GG) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
 
The sensitivity analysis excluding one study114 where genotypes deviated from HWE 
(Appendix 3) also showed no significant association (OR=0.74, 95% CI: 0.40 to 1.37, 
I2=48.1%, 7 studies). The pairwise comparisons also showed no significant differences 
between genotype groups (GC versus GG: OR=1.05, 95% CI: 0.66 to 1.65, I2=0.0%, 6 studies; 
CC versus GG: OR=1.04, 95% CI: 0.36 to 2.99, I2=0.0%, 6 studies) (Appendix 3). A comparison 
of the results obtained by applying different approaches to the analysis of CYP2E1 PstI 
polymorphism and hepatotoxicity, i.e. assuming a dominant mode of inheritance (CC/GC 
versus GG), excluding studies due to deviation from HWE from this dominant analysis 
approach, and performing pairwise comparisons, is provided in Figure 11. 
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Figure 11 Summary of the results obtained by applying different approaches to the analysis of CYP2E1 PstI 
polymorphism and hepatotoxicity 
CI: confidence interval; HWE: Hardy-Weinberg equilibrium 
 
We produced a funnel plot for each of the primary analyses for the CYP2E1 gene (Figure 12 
to Figure 14). There was no evidence to suggest that small study effects were an issue of 
concern.  
 
Figure 12 Funnel plot for the analysis of CYP2E1 RsaI polymorphism and hepatotoxicity: homozygous mutant-
type (TT) or heterozygous (CT) versus homozygous wild-type (CC) 
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Figure 13 Funnel plot for the analysis of CYP2E1 DraI polymorphism and hepatotoxicity: homozygous mutant-
type (AA) or heterozygous (AT) versus homozygous wild-type (TT) 
 
 
Figure 14 Funnel plot for the analysis of CYP2E1 PstI polymorphism and hepatotoxicity: homozygous mutant-
type (CC) or heterozygous (GC) versus homozygous wild-type (GG) 
 
Primary analyses: GSTM1/GSTT1 and hepatotoxicity 
Forest plots displaying the results of the primary analyses for GSTM1 and GSTT1 are 
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A total of 18 studies reported data for each GSTM1 genotype group separately, or for 
combined homozygous present and heterozygous groups versus the homozygous null 
group, and were therefore included in the primary analysis for the GSTM1 null 
polymorphism and hepatotoxicity. For GSTM1, patients with homozygous null genotype 
were significantly more likely to experience hepatotoxicity than patients with heterozygous 
or homozygous present genotype (OR=1.44, 95% CI: 1.15 to 1.82) (Figure 15). Moderate 
heterogeneity was observed in this analysis (I2=51.2%).  
 
Figure 15 GSTM1 null polymorphism and hepatotoxicity: homozygous null versus heterozygous or homozygous 
present 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
 
The results of the sensitivity analyses for the GSTM1 null polymorphism and gene are 
provided in Appendix 3. It was only possible to test deviation from HWE for one study,144 
which provided data for each genotype group separately. Genotypes were found to deviate 
from HWE for this study, and so we conducted a sensitivity analysis excluding this study, 
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which also showed a statistically significant association (OR=1.46, 95% CI: 1.15 to 1.85, 
I2=53.7%, 17 studies). No significant differences were observed for either pairwise 
comparison (heterozygous versus homozygous present: OR=0.42, 95% CI: 0.02 to 8.18, 1 
study; homozygous null versus homozygous present: OR=0.97, 95% CI: 0.35 to 2.71, 1 
study). Data for these pairwise comparisons came from a single study,144 and so we did not 
calculate the I2 statistic.  
A comparison of the results obtained by applying different approaches to the analysis of 
GSTM1 null polymorphism and hepatotoxicity, i.e. assuming a recessive mode of 
inheritance (homozygous null versus heterozygous or homozygous present), excluding 
studies due to deviation from HWE from this recessive analysis approach, and performing 
pairwise comparisons, is provided in Figure 16. 
 
Figure 16 Summary of the results obtained by applying different approaches to the analysis of GSTM1 null 
polymorphism and hepatotoxicity 
CI: confidence interval; het: heterozygous; hom: homozygous; HWE: Hardy-Weinberg equilibrium 
 
A total of 16 studies reported data for each GSTT1 genotype group separately, or for 
combined homozygous present and heterozygous groups versus the homozygous null 
group, and were therefore included in the primary analysis for the GSTT1 null 
polymorphism and hepatotoxicity. For GSTT1, there was no significant difference in the 
likelihood of experiencing hepatotoxicity between patients with homozygous null genotype 
and patients with heterozygous or homozygous present genotype (OR=1.06, 95% CI: 0.85 to 
1.32) (Figure 17). A relatively small amount of heterogeneity was observed in this analysis 
(I2=27.1%).  
 
Pairwise: Hom null vs hom present
Pairwise: Het vs hom present
Hom null vs het or hom present (HWE sensitivity analysis)






















Figure 17 GSTT1 null polymorphism and hepatotoxicity: homozygous null versus heterozygous or homozygous 
present  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
 
It was only possible to test deviation from HWE for two studies, Liu 2014144 and Teixera 
2011,163 which both reported data for each genotype group separately. We did not identify 
any deviation from HWE, so we did not perform a sensitivity analysis to investigate the 
impact of deviation from HWE. The sensitivity analyses (two pairwise comparisons) also 
showed no significant differences between genotype groups (heterozygous versus 
homozygous present: OR=0.67, 95% CI: 0.29 to 1.55; I2=0.0%, 2 studies; homozygous null 
versus homozygous present: OR=0.61, 95% CI: 0.22 to 1.66; I2=0.0, 2 studies) (Appendix 3). 
A comparison of the results obtained by applying different approaches to the analysis of 
GSTT1 null polymorphism and hepatotoxicity, i.e. assuming a recessive mode of inheritance 
(homozygous null versus heterozygous or homozygous present) and performing pairwise 
comparisons, is provided in Figure 18. 
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Figure 18 Summary of the results obtained by applying different approaches to the analysis of GSTT1 null 
polymorphism and hepatotoxicity 
CI: confidence interval; het: heterozygous; hom: homozygous 
 
We produced funnel plots for the primary analyses of the GSTM1 and GSTT1 genes (Figure 
19 and Figure 20). There was no evidence to suggest that small study effects were an issue 
of concern.  
 
Figure 19 Funnel plot for the analysis of GSTM1 null polymorphism and hepatotoxicity: homozygous null versus 
heterozygous or homozygous present  
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Figure 20 Funnel plot for the analysis of GSTT1 null polymorphism and hepatotoxicity: homozygous null versus 
heterozygous or homozygous present  
 
Heterogeneity in the primary analyses 
Moderate heterogeneity was observed in the primary analyses for the CYP2E1 RsaI and PstI 
polymorphisms, and in the primary analysis for the GSTM1 null polymorphism. 
Furthermore, although no heterogeneity was observed in the primary analysis for NAT2 
acetylator status, heterogeneity was observed in the sensitivity analyses of slow versus 
rapid acetylator status, and slow versus rapid/intermediate acetylator status. Heterogeneity 
in these analyses may have been caused by the variable distribution of genotypes in 
different ethnic populations. Previous studies have suggested that there is a considerable 
amount of genetic diversity across different ethnic populations for NAT2 acetylator 
status,194 for the CYP2E1 RsaI and PstI polymorphisms195 and for the GSTM1 null 
polymorphism.196 We stratified all analyses by country (as a proxy variable for ethnicity); 
however, it is is difficult to draw conclusions about the effect of country on the investigated 
genetic associations, due to the small numbers of studies conducted in each country. 
Heterogeneity may also have been introduced by differences in the definitions of 
hepatotoxicity across included studies. Performing subgroup analyses according to 
definition of hepatotoxicity was not possible, considering the number of different 
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Finally, we followed advice given in the HuGENet HuGE Review Handbook24 and explored 
the possibility that the ‘Proteus phenomenon’ might have occurred for any of the primary 
analyses (see Section 2.3). It is interesting that in the primary analyses of NAT2 acetylator 
status and the GSTM1 null polymorphism, the most extreme result was observed in the 
earliest studies (NAT2 acetylator status, Ohno 2000;150 GSTM1 null polymorphism, Roy 
2001153). However, in both analyses, the majority of subsequent studies suggested effect 
estimates in the same direction, so it does not seem likely that the associations are 
spurious.  
There is no evidence to suggest that the Proteus phenomenon occurred for the primary 
analyses of the CYP2E1 RsaI or DraI polymorphisms; however for the analysis of the CYP2E1 
PstI polymorphism, the most extreme result is observed in the earliest study (Roy 2006154), 
and results from subsequent studies are very different. Similarly, in the analysis of the 
GSTT1 null polymorphism, the most extreme result is observed in the earliest study (Roy 
2001153), and all but one of the subsequent studies do not detect an association between 
homozygous null genotype and hepatotoxicity. Therefore, it is possible that these early 
findings were spurious, and consequently introduce heterogeneity to the analyses of the 
CYP2E1 PstI polymorphism and the GSTT1 null polymorphism.  
Secondary analyses: NAT2 SNPs and hepatotoxicity 
The included studies reported data for the association between 12 NAT2 SNPs and 
hepatotoxicity. A summary of this data is provided in Table 16. There were sufficient data to 
perform meta-analyses for six SNPs. Forest plots showing the results of these meta-
analyses are provided in Appendix 4.  
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Table 16 Results of the secondary analyses: NAT2 SNPs and hepatotoxicity 
NAT2 SNP Comparison Country (# studies) Ethnicity OR (95% CI)  # casesa # controlsb I2 
190C-T Het (CT) vs Hom WT (CC) China (1 study)111 NR 0.21 (0.01 to 4.38) 101 107 N/A 
Hom MT (TT) vs Hom WT (CC) China (1 study)111 NR Data excludedc 
191G-A 
(rs1801279) 
Het (GA) vs Hom WT (GG) 
 
Taiwan (1 study)168 NR Data excludedc 
Turkey (1 study)113 NR Data excludedc 
Hom MT (AA) vs Hom WT (GG) 
 
Taiwan (1 study)168 NR Data excludedc 
Turkey (1 study)113 NR Data excludedc 
282C-T 
(rs1041983) 
Het (CT) vs Hom WT (CC) China (1 study)111 NR 1.28 (0.67 to 2.44) 65 98 N/A 
Taiwan (1 study)168 NR 0.50 (0.06 to 4.06) 70 284 N/A 
Indonesia (1 study)174 100% Indonesian 1.25 (0.51 to 3.05) 27 148 N/A 
Brazil (1 study)155 NR 1.67 (0.56 to 5.00) 14 216 N/A 
All (4 studies)111, 155, 168, 174 1.27 (0.80 to 2.02) 176 746 0.0% 
Hom MT (TT) vs Hom WT (CC) 
 
China (1 study)111 NR 7.00 (2.89 to 16.98) 60 51 N/A 
Taiwan (1 study)168 NR 1.33 (0.05 to 32.91) 69 277 N/A 
Indonesia (1 study)174 100% Indonesian 3.41 (1.38 to 8.40) 31 94 N/A 
Brazil (1 study)155 NR 2.07 (0.59 to 7.25) 12 185 N/A 
All (4 studies)111, 155, 168, 174 3.95 (2.21 to 7.05) 172 607 5.5% 
341T-C 
(rs1801280) 
Het (TC) vs Hom WT (TT) China (1 study)111 NR 1.63 (0.45 to 5.94) 101 107 N/A 
Taiwan (2 studies)141, 168 NR 1.26 (0.58 to 2.75) 114 376 0.0% 
Indonesia (1 study)174 100% Indonesian 1.13 (0.54 to 2.35) 49 188 N/A 
Brazil (1 study)155 NR 0.66 (0.18 to 2.42) 10 187 N/A 
All (5 studies)111, 141, 155, 168, 174 1.15 (0.72 to 1.82) 274 858 0.0% 
Hom MT (CC) vs Hom WT (TT) China (1 study)111 NR Data excludedc 
Taiwan (2 studies)141, 168 NR 1.18 (0.08 to 16.93) 105 355 41.4% 
Indonesia (1 study)174 100% Indonesian 1.32 (0.13 to 13.01) 38 149 N/A 
Brazil (1 study)155 NR 1.75 (0.50 to 6.13) 12 122 N/A 
All (4 studies)141, 155, 168, 174 1.54 (0.58 to 4.04) 155 626 0.0% 
95 
NAT2 SNP Comparison Country (# studies) Ethnicity OR (95% CI)  # casesa # controlsb I2 
481C-T 
(rs1799929) 
Het (CT) vs Hom WT (CC) 
 
China (3 studies)111, 145, 
170 
1 study - 100% Chinese, 2 studies - NR 1.66 (1.11 to 2.48) 259 2027 0.0% 
Taiwan (1 study)168 NR 4.12 (0.25 to 66.63) 70 285 N/A 
Indonesia (1 study)174 100% Indonesian 1.01 (0.47 to 2.14) 49 188 N/A 
India (1 study)126 NR 1.82 (0.89 to 3.71) 39 154 N/A 
Tunisia (1 study)146 NR 1.33 (0.29 to 6.06) 8 42 N/A 
Turkey (1 study)113 NR 2.17 (0.88 to 5.36) 28 63 N/A 
Brazil (1 study)155 NR 0.44 (0.14 to 1.37) 14 216 N/A 
All (9 studies)111, 113, 126, 145, 146, 155, 168, 170, 174 1.48 (1.12 to 1.97) 467 2975 0.0% 
Hom MT (TT) vs Hom WT (CC) China (3 studiesd)111, 145, 
170 
1 study - 100% Chinese, 2 studies - NR 0.81 (0.19 to 3.41) 41 1155 N/A 
Taiwan (1 study)168 NR Data excludedc 
Indonesia (1 study)174 100% Indonesian 1.28 (0.13 to 12.66) 39 149 N/A 
India (1 study)126 NR 5.38 (1.99 to 14.49) 27 97 N/A 
Tunisia (1 study)146 NR 3.60 (0.83 to 15.57) 10 34 N/A 
Turkey (1 study)113 NR 0.93 (0.17 to 5.08) 14 46 N/A 
Brazil (1 study)155 NR 1.19 (0.34 to 4.09) 13 132 N/A 
All (6 studies)113, 126, 146, 155, 170, 174 1.91 (0.93 to 3.92) 144 1613 34.1% 
499G-A Het (GA) vs Hom WT (GG) China (1 study)111 NR 0.21 (0.01 to 4.38) 101 107 N/A 
Hom MT (AA) vs Hom WT (GG) China (1 study)111 NR Data excludedc 
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Het (GA) vs Hom WT (GG) 
 
China (3 studies)111, 145, 
170 
1 study - 100% Chinese, 2 studies - NR 1.19 (0.86 to 1.66) 236 1921 15.6% 
Taiwan (2 studies)141, 168 NR 1.16 (0.74 to 1.82) 104 356 0.0% 
South Korea (1 study)133 NR 1.99 (1.06 to 3.74) 57 145 N/A 
Indonesia (1 study)174 100% Indonesian 1.17 (0.58 to 2.36) 38 173 N/A 
India (1 study)126 NR 1.38 (0.70 to 2.72) 45 137 N/A 
Tunisia (1 study)146 NR 0.77 (0.22 to 2.77) 12 50 N/A 
Turkey (1 study)113 NR 2.63 (1.00 to 6.87) 24 67 N/A 
Brazil (1 study)155 NR 2.36 (0.27 to 20.76) 18 247 N/A 
All (11 studies)111, 113, 126, 133, 141, 145, 146, 155, 168, 170, 174 1.30 (1.06 to 1.59) 534 3096 0.0% 
Hom MT (AA) vs Hom WT (GG) China (3 studies)111, 145, 
170 
1 study - 100% Chinese, 2 studies - NR 1.63 (0.66 to 4.00) 165 1356 58.1% 
Taiwan (2 studies)141, 168 NR 1.52 (0.68 to 3.40) 74 250 0.0% 
South Korea (1 study)133 NR 5.26 (1.61 to 17.26) 39 107 N/A 
Indonesia (1 study)174 100% Indonesian 3.29 (1.34 to 8.08) 29 102 N/A 
India (1 study)126 NR 0.64 (0.22 to 1.88) 25 100 N/A 
Tunisia (1 study)146 NR 3.71 (0.44 to 31.26) 9 28 N/A 
Turkey (1 study)113 NR 9.11 (1.91 to 43.46) 15 44 N/A 
Brazil (1 study)155 NR 1.25 (0.07 to 23.62) 17 246 N/A 
All (11 studies)111, 113, 126, 133, 141, 145, 146, 155, 168, 170, 174 2.05 (1.24 to 3.40) 373 2233 47.7% 
803A-G 
(rs1208) 
Het (AG) vs Hom WT (AA) China (1 study)111 NR 1.63 (0.45 to 5.94) 101 107 N/A 
Taiwan (1 study)168 NR 1.36 (0.14 to 13.30) 70 285 N/A 
Indonesia (1 study)174 100% Indonesian 1.15 (0.55 to 2.41) 49 187 N/A 
Brazil (1 study)155 NR 0.82 (0.27 to 2.52) 13 219 N/A 
All (4 studies)111, 155, 168, 174 1.14 (0.67 to 1.96) 233 798 0.0% 
Hom MT (GG) vs Hom WT (AA) China (1 study)111 NR Data excludedc 
Taiwan (1 study)168 NR Data excludedc 
Indonesia (1 study)174 100% Indonesian 0.99 (0.11 to 9.09) 38 150 N/A 
Brazil (1 study)155 NR 2.32 (0.69 to 7.78) 12 140 N/A 
All (2 studies)155, 174 1.90 (0.66 to 5.52) 50 290 0.0% 
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NAT2 SNP Comparison Country (# studies) Ethnicity OR (95% CI)  # casesa # controlsb I2 
857G-A 
(rs1799931) 
Het (GA) vs Hom WT (GG) China (3 studies)111, 145, 
170 
1 study - 100% Chinese, 2 studies - NR 1.28 (0.74 to 2.22) 
254 2069 
61.5% 
Taiwan (2 studies)141, 168 NR 1.13 (0.70 to 1.82) 103 368 0.0% 
South Korea (1 study)133 NR 1.11 (0.56 to 2.20) 65 150 N/A 
Indonesia (1 study)174 100% Indonesian 1.41 (0.72 to 2.75) 49 190 N/A 
Tunisia (1 study)146 NR 0.70 (0.03 to 15.34) 14 52 N/A 
Turkey (1 study)113 NR 3.39 (0.84 to 13.67) 29 69 N/A 
Brazil (1 study)155 NR 2.19 (0.73 to 6.55) 17 250 N/A 
All (10 studies)111, 113, 133, 141, 145, 146, 155, 168, 170, 174 1.30 (1.03 to 1.64) 531 3148 0.9% 
Hom MT (AA) vs Hom WT (GG) China (3 studies)111, 145, 
170 
1 study - 100% Chinese, 2 studies - NR 0.98 (0.38 to 2.51) 
184 1677 
0.0% 
Taiwan (2 studies)141, 168 NR 5.05 (0.47 to 54.88) 82 268 74.2% 
South Korea (1 study)133 NR 1.18 (0.10 to 13.36) 50 118 N/A 
Indonesia (1 study)174 100% Indonesian 4.31 (0.26 to 70.80) 33 139 N/A 
Tunisia (1 study)146 NR Data excludedc 
Turkey (1 study)113 NR 2.71 (0.16 to 45.03) 25 66 N/A 
Brazil (1 study)155 NR 8.75 (0.74 to 103.44) 13 212 N/A 
All (9 studies)111, 113, 133, 141, 145, 155, 168, 170, 174 1.99 (1.02 to 3.91) 387 2480 11.3% 
Rs1495741 Het (AG) vs Hom WT (AA) Taiwan (1 study)82 NR 0.19 (0.07 to 0.52) 19 249 N/A 
Hom MT (GG) vs Hom WT (AA) Taiwan (1 study)82 NR 0.07 (0.01 to 0.56) 14 152 N/A 
Rs4646244 Het (TA) vs Hom WT (TT) South Korea (1 study)133 NR 2.03 (1.09 to 3.78) 57 152 N/A 
Hom MT (AA) vs Hom WT (TT) South Korea (1 study)133 NR 4.06 (1.36 to 12.13) 37 110 N/A 
Rs4646267 Het (AG) vs Hom WT (AA) South Korea (1 study)133 NR 0.50 (0.25 to 0.98) 52 127 N/A 
Hom MT (GG) vs Hom WT (AA) South Korea (1 study)133 NR 0.63 (0.27 to 1.45) 35 66 N/A 
Emboldened text is used for results from meta-analyses. 
a Total number of patients who experienced hepatotoxicity across the two genotype groups being compared  
b Total number of patients who did not experience hepatotoxicity across the two genotype groups being compared 
c Data were excluded due to zero patients in one of the genotype groups. 
d Data from 2111, 145 of the 3 Chinese studies were excluded due to zero counts. 
CI: confidence interval; Het: heterozygous; Hom: homozygous; MT: mutant-type; N/A: not applicable; NR: not reported; OR: odds ratio; SNP: single nucleotide 
polymorphism; WT: wild-type
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The main findings from these meta-analyses are: 
• For 282C-T, there was strong evidence against the null hypothesis of no association for 
the comparison of TT genotype versus CC genotype, with the observed OR indicating an 
almost 4-fold increase in the odds of experiencing hepatotoxicity among patients with 
TT genotype (OR=3.95, 95% CI: 2.21 to 7.05, p<0.001); minimal heterogeneity was 
observed between the four studies included in this analysis (I2=5.5%). However, there 
was no evidence to support an important association for the comparison of CT 
genotype versus CC genotype for this same SNP (OR=1.27, 95% CI: 0.80 to 2.02, 
p=0.302, I2=0.0%, 4 studies).  
• For 481C-T, there was some evidence to suggest that individuals with the CT genotype 
were more likely to experience hepatotoxicity in comparison to individuals with the CC 
genotype (OR=1.48, 95% CI: 1.12 to 1.97, p=0.006, I2=0.0%, 9 studies). The point 
estimate of the OR suggested a greater association for the comparison of TT genotype 
versus CC genotype (OR=1.91, 95% CI: 0.93 to 3.92, p=0.076, I2=34.1%, 9 studies); 
however, the 95% CIs were wide due to the relatively small number of homozygous 
mutant-type (TT) patients (n=162) among the patients contributing data to this analysis 
(n=1757). The evidence of an association for this comparison is therefore weak.  
• For 590G-A and 857G-A, there was some evidence of an association for both 
comparisons between heterozygous and homozygous wild-type genotypes, and 
between homozygous mutant-type and homozygous wild-type genotypes (590G-A: GA 
versus GG, OR=1.30, 95% CI: 1.06 to 1.59, p=0.011, I2=0.0%, 11 studies; AA versus GG, 
OR=2.05, 95% CI: 1.24 to 3.40, p=0.005, I2=47.7%, 11 studies; 857G-A: GA versus GG, 
OR=1.30, 95% CI: 1.03 to 1.64, p=0.026, I2=0.9%, 10 studies; AA versus GG, OR=1.99, 
95% CI: 1.02 to 3.91, p=0.045, I2=11.3%, 10 studies). 
 
Results were relatively homogeneous between studies for most comparisons, except for 
the comparison between the AA and GG genotypes for the 590G-A SNP (I2=47.7%). This 
moderate heterogeneity may be due to the variable distribution of genotypes in different 
geographic areas, or due to differences in definitions of hepatotoxicity in the 11 included 
studies111, 113, 126, 133, 141, 145, 146, 155, 168, 170, 174 (one study did not provide the definition of 
hepatotoxicity and the remaining 10 studies used 10 different definitions of hepatotoxicity).  
Secondary analyses: NAT2 variants and other toxicity outcomes 
A summary of all data for the association between NAT2 variants and toxicity outcomes 
(other than hepatotoxicity) is provided in Table 17. Each reported result is based on data 
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from a single study, as there were no comparisons where more than one study provided 
data. 
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Table 17 Results of the secondary analyses: NAT2 genetic variants and other toxicity outcomes 
Outcome Variant Study  Country  Ethnicity Comparison OR (95% CI)  # casesa # controlsb 
Peripheral 
neuropathy 
Acetylator status Azuma 201381 Japan NR Intermediate vs rapid 1.36 (0.32 to 5.75) 8 104 
Slow vs rapid 4.29 (0.66 to 27.8) 6 67 
191G-A (rs1801279) Dhoro 2013120 Zimbabwe  NR Het (GA) vs Hom WT (GG) 0.69 (0.33 to 1.41) 102 56 
Hom MT (AA) vs Hom WT (GG) 2.48 (0.12 to 53.02) 79 38 
341T-C (rs1801280) Dhoro 2013120 Zimbabwe 
 
NR Het (TC) vs Hom WT (TT) 1.01 (0.50 to 2.07) 84 48 
Hom MT (CC) vs Hom WT (TT) 1.34 (0.32 to 5.62) 54 30 
Adverse DIH 
outcome  
Acetylator status Bose 2011112 India  NR Slow vs rapid/intermediate  3.31 (1.03 to 10.62) 16 202 






Slow vs rapid/intermediate 3.20 (1.31 to 7.80) 40 47 
Skin rash Acetylator status Higuchi 2007 (GI: 
HIGUCHI)128 
Japan  NR Intermediate vs rapid 0.83 (0.32 to 2.19) 22 68 
Slow vs rapid 1.21 (0.27 to 5.46) 15 41 
Eosinophilia Acetylator status Higuchi 2007 (GI: 
HIGUCHI)128 
Japan NR Intermediate vs rapid 1.44 (0.60 to 3.45) 31 59 





Kim 2011  
(GI: KIM)135 
South Korea  NR Hom MT (AA) or Het (GA) vs Hom 
WT (GG) 





South Korea  NR Hom MT (AA) or Het (GA) vs Hom 
WT (GG) 
1.65 (0.86 to 3.18) 59 152 
-9796T-A (rs4646244) Kim 2011 
(GI: KIM)135 
South Korea  NR Hom MT (AA) or Het (TA) vs Hom 
WT (TT) 
1.08 (0.59 to 2.00) 62 159 
-9601A-G (rs4646267) Kim 2011 
(GI: KIM)135 
South Korea NR Hom MT (GG) or Het (AG) vs Hom 
WT (AA) 
0.65 (0.33 to 1.27) 61 159 
Gastrointestinal 
ADRs 
Acetylator status Possuelo 2008 
(GI: POSSUELO)151 
Brazil  57% White Slow vs rapid/intermediate 1.18 (0.51 to 2.70) 33 207 
ATD: anti-tuberculosis drug; ADR: adverse drug reaction; CI: confidence interval; DIH: drug-induced hepatotoxicity; GI: group identifier; Het: heterozygous; Hom: 
homozygous; MPE: maculopapular eruption; MT: mutant-type; NR: not reported; OR: odds ratio; WT: wild-type 
a Total number of cases across the genotype groups being compared  
b Total number of controls across the genotype groups being compared 
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Some evidence existed to suggest that slow acetylators are more likely to experience 
“adverse drug-induced hepatotoxicity outcomes” (definition unclear; OR=3.31, 95% CI: 1.03 
to 10.62, 1 study) and “adverse drug reactions” (ADRs, defined as at least one of the 
following: gastric, joint, neuromuscular or skin reactions, hepatotoxicity; OR=3.20, 95% CI: 
1.31 to 7.80, 1 study). The point estimates of the ORs suggest that these associations are 
large in magnitude; however 95% CIs around these estimates were wide due to fairly small 
numbers of patients contributing data to these analyses (adverse drug-induced 
hepatotoxicity outcomes, n=218; ADRs, n=87). Otherwise, the strength of the evidence to 
support associations between NAT2 genetic variants and anti-TB drug-induced toxicity 
outcomes (other than hepatotoxicity) was weak or non-existent.  
Secondary analyses: CYP genetic variants and hepatotoxicity 
The included studies reported data for the association between 24 SNPs of eight CYP genes 
(in addition to the key CYP2E1 SNPs reported in the primary analyses) and hepatotoxicity. A 
summary of all data for the association between CYP genetic variants (other than the key 
CYP2E1 SNPs) and hepatotoxicity is provided in Table 18. There were sufficient data to 
perform meta-analyses for three SNPs, and forest plots showing the results of these meta-
analyses are provided in Appendix 4.
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Table 18 Results of the secondary analyses: CYP genetic variants and hepatotoxicity 
Gene Variant Comparison Country (# studies) Ethnicity OR (95% CI)  # casesa # controlsb I2 
CYP2E1 rs2080672 Het (AG) vs Hom WT (AA) China (1 study)161 NR 1.16 (0.72 to 1.89) 86 334 N/A 
Hom MT (GG) vs Hom WT (AA) China (1 study)161 NR 0.69 (0.19 to 2.42) 54 228 N/A 
rs915908 Het (GA) vs Hom WT (GG) China (1 study)161 NR 0.89 (0.47 to 1.69) 79 318 N/A 
Hom MT (AA) vs Hom WT (GG) China (1 study)161 NR 1.09 (0.52 to 2.32) 75 292 N/A 
rs8192775 Het (GA) vs Hom WT (GG) China (1 study)161 NR 1.17 (0.72 to 1.90) 85 333 N/A 
Hom MT (AA) vs Hom WT (GG) China (1 study)161 NR 0.76 (0.25 to 2.29) 55 234 N/A 
rs2515641 Het (CT) vs Hom WT (CC) China (1 study)161 NR 1.20 (0.73 to 1.99) 85 342 N/A 
Hom MT (TT) vs Hom WT (CC) China (1 study)161 NR 1.31 (0.41 to 4.18) 60 252 N/A 
rs2515644 Het (CA) vs Hom WT (CC) China (1 study)161 NR 1.26 (0.74 to 2.15) 73 285 N/A 
Hom MT (AA) vs Hom WT (CC) China (1 study)161 NR 1.04 (0.52 to 2.08) 42 186 N/A 
rs2070672 Het (AG) vs Hom WT (AA) South Korea (1 study)133 NR 1.74 (0.93 to 3.25)  63 149 N/A 
Hom MT (GG) vs Hom WT (AA) South Korea (1 study)133 NR 0.94 (0.18 to 4.85) 41 116 N/A 
rs2070673c Het (TA) vs Hom WT (TT) South Korea (1 study)133 NR 0.88 (0.48 to 1.63) 59 134 N/A 
Hom MT (AA) vs Hom WT (TT) South Korea (1 study)133 NR 0.75 (0.28 to 1.96) 37 84 N/A 
96-bp (deletion-
insertion SNP) 
Het (DI) vs Hom WT (DD) India (1 study)154 NR 1.13 (0.22 to 5.88) 6 98 N/A 
Brazil (1 study)155 NR 0.25 (0.01 to 4.26) 18 228 N/A 
All (2 studies)154, 155 0.77 (0.19 to 3.21) 24 326 0.0% 
Hom MT (II) vs Hom WT (DD) India (1 study)154 NR 11.56 (1.37 to 97.67) 5 55 N/A 
Brazil (1 study)155 NR 3.72 (0.15 to 94.60) 18 207 N/A 
All (2 studies)154, 155 8.20 (1.38 to 48.68) 23 262 0.0% 
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Gene Variant Comparison Country (# studies) Ethnicity OR (95% CI)  # casesa # controlsb I2 
CYP2C9 rs4918758d Het (TC) vs Hom WT (TT) China (1 study)162 NR 0.78 (0.46 to 1.33) 69 285 N/A 
South Korea (1 study)133 NR 1.66 (0.85 to 3.23) 59 127 N/A 
All (2 studies)133, 162 1.11 (0.53 to 2.31) 128 412 66.7% 
Hom MT (CC) vs Hom WT (TT) China (1 study)162 NR 0.94 (0.49 to 1.80) 51 188 N/A 
South Korea (1 study)133 NR 0.72 (0.27 to 1.95) 24 80 N/A 
All (2 studies)133, 162 0.87 (0.51 to 1.50) 75 268 0.0% 
rs9332098 Het (GA) vs Hom WT (GG) China (1 study)162 NR 0.32 (0.07 to 1.38) 88 354 N/A 
Hom MT (AA) vs Hom WT (GG) China (1 study)162 NR Data excludede 
rs9332096 Het (CT) vs Hom WT (CC) South Korea (1 study)133 NR 0.63 (0.27 to 1.47) 66 156 N/A 
Hom MT (TT) vs Hom WT (CC) South Korea (1 study)133 NR 0.73 (0.03 to 18.24) 58 129 N/A 
rs1057910 Het (AC) vs Hom WT (AA) South Korea (1 study)133 NR 1.00 (0.34 to 2.97) 64 154 N/A 
Hom MT (CC) vs Hom WT (AA) South Korea (1 study)133 NR Data excludede 
CYP2B6 rs3745274 Het (GT) vs Hom WT (GG) Brazil (1 study)122 NR 1.57 (0.71 to 3.45) 30 176 N/A 
Ethiopia (1 study)173 NR 1.42 (0.68 to 2.98) 35 145 N/A 
All (2 studies)122, 173 1.49 (0.87 to 2.55) 65 321 0.0% 
Hom MT (TT) vs Hom WT (GG) Brazil (1 study)122 NR 0.58 (0.07 to 4.81) 13 103 N/A 
Ethiopia (1 study)173 NR 1.98 (0.66 to 5.87) 22 94 N/A 
All (2 studies)122, 173 1.51 (0.55 to 4.13) 35 197 4.2% 
CYP3A4 rs12333983 Het (TA) vs Hom WT (TT) China (1 study)162 NR 1.33 (0.81 to 2.18) 78 312 N/A 
Hom MT (AA) vs Hom WT (TT) China (1 study)162 NR 1.33 (0.62 to 2.86) 47 204 N/A 
-392A-G Het (GA) vs Hom WT (AA) Brazil (1 study)175 42% white, 58% 
non-white 
0.69 (0.32 to 1.47) 45 69 N/A 
Hom MT (GG) vs Hom WT (AA) Brazil (1 study)175 42% white, 58% 
non-white 




Gene Variant Comparison Country (# studies) Ethnicity OR (95% CI)  # casesa # controlsb I2 
CYP2C19 rs11568732 
 
Het (TG) vs Hom WT (TT) China (1 study)162 NR 0.54 (0.25 to 1.19) 87 350 N/A 
Hom MT (GG) vs Hom WT (TT) China (1 study)162 NR 0.93 (0.10 to 8.47) 80 229 N/A 
rs4986894 
 
Het (TC) vs Hom WT (TT) China (1 study)162 NR 0.95 (0.57 to 1.59) 72 302 N/A 
Hom MT (CC) vs Hom WT (TT) China (1 study)162 NR 1.11 (0.53 to 2.32) 48 191 N/A 
rs17878465 
 
Het (CT) vs Hom WT (CC) South Korea (1 study)133 NR 0.99 (0.50 to 1.94) 65 153 N/A 
Hom MT (TT) vs Hom WT (CC) South Korea (1 study)133 NR 0.33 (0.02 to 6.58) 49 118 N/A 
rs4986893 Het (GA) vs Hom WT (GG) South Korea (1 study)133 NR 0.69 (0.31 to 1.56) 66 156 N/A 
Hom MT (AA) vs Hom WT (GG) South Korea (1 study)133 NR 0.74 (0.03 to 18.42) 57 128 N/A 
CYP3A5 rs776746 Het (AG) vs Hom WT (AA) Brazil (1 study)122 NR 1.84 (0.83 to 4.05) 31 189 N/A 
Hom MT (GG) vs Hom WT (AA) Brazil (1 study)122 NR Data excludede 
Number of 
CYP3A5*1 
One copy vs zero copies Ethiopia (1 study)173 NR 1.56 (0.76 to 3.20) 39 151 N/A 
Two copies vs zero copies Ethiopia (1 study)173 NR 1.02 (0.21 to 5.05) 24 110 N/A 
CYP1A1 MspI Hom MT or Het vs Hom WT China (1 study)127 NR 1.33 (0.81 to 2.19) 127 127 N/A 
CYP2D6 rs1080983 Het (GA) vs Hom WT (AA) South Korea (1 study)133 NR 0.83 (0.43 to 1.61) 65 152 N/A 
Hom MT (GG) vs Hom WT (AA) South Korea (1 study)133 NR 0.56 (0.06 to 5.11) 50 113 N/A 
rs1080989 Het (GA) vs Hom WT (AA) South Korea (1 study)133 NR 0.89 (0.45 to 1.74) 50 121 N/A 
Hom MT (GG) vs Hom WT (AA) South Korea (1 study)133 NR 1.03 (0.47 to 2.27) 36 80 N/A 
Emboldened text is used for results from meta-analyses 
a Total number of patients who experienced hepatotoxicity across the genotype groups being compared  
b Total number of patients who did not experience hepatotoxicity across the genotype groups being compared 
c The paper (Kim 2009)133 reports WT to be A and MT to be T, but data suggest that WT is T and MT is A. 
d One of the studies (Kim 2009)133 reports WT to be C and MT to be T, but the other study (Tang 2013b),162 and the data, suggest that WT is T and MT is C 
e Data were excluded due to zero counts in one of the genotype groups. 
CI: confidence interval; Het: heterozygous; Hom: homozygous; MT: mutant-type; N/A: not applicable; NR: not reported; OR: odds ratio; WT: wild-type 
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For the 96-bp deletion-insertion SNP of the CYP2E1 gene, there was some evidence to 
suggest that individuals with the II genotype were more likely to experience hepatotoxicity 
in comparison to individuals with the DD genotype (OR=8.20, 95% CI: 1.38 to 48.68, 
p=0.021, I2=0.0%, 2 studies). The point estimate of the OR suggests that this association is 
large in magnitude; however the 95% CI around the estimate is extremely wide, and it is 
therefore difficult to draw firm conclusions about this association. There was no evidence 
of an association for the comparison of DI genotype versus DD genotype for this same SNP 
(OR=0.77, 95% CI: 0.19 to 3.21, p=0.722, I2=0.0%, 2 studies). The meta-analyses conducted 
for the rs4918758 SNP of the CYP2C9 gene and the rs3745274 SNP of the CYP2B6 gene also 
provided no evidence of associations between these genetic variants and hepatotoxicity.  
Heterogeneity was minimal in the meta-analyses conducted for these three SNPS, with the 
exception of the TC versus TT comparison for the rs4918758 SNP of the CYP2C9 gene 
(I2=66.7%). This heterogeneity may be due to the variable distribution of genotypes in 
different geographic areas, or due to the fact that the two studies (Kim 2009133 and Tang 
2013b162) included in this meta-analysis used different definitions of hepatotoxicity (see 
Table 13).  
Secondary analyses: CYP genetic variants and other toxicity outcomes 
A summary of all data for the association between CYP genetic variants and toxicity 
outcomes (other than hepatotoxicity) is provided in Table 19. It was not possible to perform 
meta-analyses for any toxicity outcomes other than hepatotoxicity as there were no 
comparisons for which more than one study provided data, so each reported result is based 
on data from a single study.  
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Table 19 Results of the secondary analyses: CYP genetic variants and other toxicity outcomes 






Bose 2011112 India NR Hom MT (AA) or Het (TA) vs 
Hom WT (TT) 
0.40 (0.13 to 1.23) 16 202 
ADR CYP2E1 7632T-A/DraI 
(rs6413432) 
Costa 2012119 Brazil 84% Black/mixed 
race, 16% other 
Het (TA) vs Hom WT (TT) Data excludedc  
Hom MT (AA) vs Hom WT (TT) Data excludedc 
1293G-C/PstI 
(rs3813867) 
Costa 2012119 Brazil  84% Black/mixed 
race, 16% other 
Het (GC) vs Hom WT (GG) Data excludedc 










NR Hom MT (TT) or Het (CT) vs 
Hom WT (CC) 







NR Hom MT (GG) or Het (AG) vs 
Hom WT (AA) 







NR Hom MT (AA) or Het (TA) vs 
Hom WT (TT) 







NR Hom MT (CC) or Het (TC) vs 
Hom WT (TT) 







NR Hom MT (TT) or Het (CT) vs 
Hom WT (CC) 







NR Hom MT (CC) or Het (AC) vs 
Hom WT (AA) 







NR Hom MT (AA) or Het (GA) vs 
Hom WT (GG) 
0.30 (0.10 to 0.88) 61 157 




NR Hom MT (TT) or Het (CT) vs 
Hom WT (CC) 
0.57 (0.27 to 1.23) 59 156 
a Total number of cases across the two genotype groups being compared  
b Total number of controls across the two genotype groups being compared 
c Data were excluded due to zero counts. 
d The study (Kim 2011)135 refers to this SNP as -1055C-T. 
ATD: anti-tuberculosis drug; ADR: adverse drug reaction; CI: confidence interval; DIH: drug-induced hepatotoxicity; GI: group identifier; Het: heterozygous; Hom: 
homozygous; MPE: maculopapular eruption; MT: mutant-type; NR: not reported; OR: odds ratio; SNP: single nucleotide polymorphism; WT: wild-type 
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For the rs9332096 SNP of the CYP2C9 gene and the rs4986893 SNP of the CYP2C19 gene, 
some evidence existed to suggest that individuals with homozygous mutant-type or 
heterozygous genotype were less likely to experience anti-TB drug-induced maculopapular 
eruption in comparison to individuals with homozygous wild-type genotype (rs9332096: 
OR=0.23, 95% CI: 0.07 to 0.78, 1 study; rs4986893: OR=0.30, 95% CI: 0.10 to 0.88, 1 study). 
The point estimates of these ORs are indicative of a considerable protective effect; however 
95% CIs around these estimates were wide due to the fairly small number of patients 
contributing data to these analyses (n=218 for both analyses). Otherwise, the strength of 
the evidence to support associations between CYP genetic variants and anti-TB drug-
induced toxicity outcomes (other than hepatotoxicity) was weak or non-existent.  
Secondary analyses: Other genetic variants and hepatotoxicity 
The included studies reported data for 27 genes (83 SNPs) other than the NAT2, CYP and 
GST genes. A summary of all data for associations between other genetic variants and 
hepatotoxicity is provided in Table 20. There were sufficient data to perform meta-analyses 
for 14 SNPs of six different genes. Forest plots showing the results of these meta-analyses 
are provided in Appendix 4. 
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Table 20 Results of the secondary analyses: other genetic variants and hepatotoxicity 





ABCB1 Rs1045642c Het (CT) vs Hom WT (CC) South Korea (1 study)137 NR 1.13 (0.61 to 2.09) 58 137 N/A 
Ethiopia (1 study)173 NR 0.43 (0.18 to 1.06) 36 154 N/A 
All (2 studies)137, 173 0.74 (0.29 to 1.89) 94 291 67.0% 
Hom MT (TT) vs Hom WT (CC) South Korea (1 study)137 NR 1.01 (0.40 to 2.56) 35 88 N/A 
Ethiopia (1 study)173 NR 2.84 (0.81 to 10.00) 34 105 N/A 
All (2 studies)137, 173 1.55 (0.57 to 4.23) 69 193 41.0% 
Rs10261685 Het (TG) vs Hom WT (TT) South Korea (1 study)137 NR 0.72 (0.32 to 1.62) 65 159 N/A 
Hom MT (GG) vs Hom WT (TT) South Korea (1 study)137 NR 6.93 (0.28 to 172.71) 57 130 N/A 
ABCC2 1774G-deld Het (G/-) vs Hom WT (GG) South Korea (1 study)137 NR 0.60 (0.32 to 1.14) 58 137 N/A 
Hom MT (-/-) vs Hom WT (GG) South Korea (1 study)137 NR 0.69 (0.26 to 1.79) 33 63 N/A 
Rs1885301 Het (GA) vs Hom WT (GG) South Korea (1 study)137 NR 1.18 (0.65 to 2.15) 61 149 N/A 
Hom MT (AA) vs Hom WT (GG) South Korea (1 study)137 NR 1.87 (0.56 to 6.29) 39 96 N/A 
Rs717620 Het (CT) vs Hom WT (CC) South Korea (1 study)137 NR 1.10 (0.61 to 2.01) 64 149 N/A 
Hom MT (TT) vs Hom WT (CC) South Korea (1 study)137 NR 0.81 (0.16 to 4.18) 40 98 N/A 
Rs2804400 Het (CT) vs Hom WT (CC) South Korea (1 study)137 NR 1.27 (0.70 to 2.30) 63 152 N/A 
Hom MT (TT) vs Hom WT (CC) South Korea (1 study)137 NR 1.53 (0.42 to 5.56) 38 98 N/A 
Rs2273697 Het (GA) vs Hom WT (GG) South Korea (1 study)137 NR 0.48 (0.17 to 1.32) 66 157 N/A 
Hom MT (AA) vs Hom WT (GG) South Korea (1 study)137 NR 0.44 (0.02 to 9.25) 61 136 N/A 
Rs3740070 Het (GA) vs Hom WT (GG) South Korea (1 study)137 NR 1.00 (0.34 to 2.97) 66 159 N/A 
Hom MT (AA) vs Hom WT (GG) South Korea (1 study)137 NR Data excludede 61 147 N/A 
Rs3740066 Het (CT) vs Hom WT (CC) South Korea (1 study)137 NR 1.21 (0.66 to 2.21) 61 147 N/A 
Hom MT (TT) vs Hom WT (CC) South Korea (1 study)137 NR 1.44 (0.45 to 4.61) 40 100 N/A 
BACH1 rs2300301 Het (AG) vs Hom WT (AA) Japan (1 study)148 NR 0.40 (0.13 to 1.29) 14 73 N/A 
Hom MT (GG) vs Hom WT (AA) Japan (1 study)148 NR 1.33 (0.31 to 5.72) 11 30 N/A 
rs1153285 Het (GA) vs Hom WT (GG) Japan (1 study)148 NR 1.21 (0.39 to 3.75) 15 76 N/A 
Hom MT (AA) vs Hom WT (GG) Japan (1 study)148 NR 2.83 (0.55 to 14.54) 9 40 N/A 
rs2070401 Het (TC) vs Hom WT (TT) Japan (1 study)148 NR 1.13 (0.37 to 3.50) 15 81 N/A 
Hom MT (CC) vs Hom WT (TT) Japan (1 study)148 NR 17.00 (1.59 to 182.14) 12 52 N/A 
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GSTP1 Ile105Val Hom WT vs Het or Hom MT China (1 study)127 NR 1.84 (1.10 to 3.07) 127 127 N/A 
HMOX1 rs2071746 Het (TA) vs Hom WT (TT) Japan (1 study)148 NR 2.67 (0.69 to 10.31) 15 70 N/A 
Hom MT (AA) vs Hom WT (TT) Japan (1 study)148 NR 2.33 (0.41 to 13.26) 6 40 N/A 
rs2071749 Het (GA) vs Hom WT (GG) Japan (1 study)148 NR 2.44 (0.77 to 7.67) 16 78 N/A 
Hom MT (AA) vs Hom WT (GG) Japan (1 study)148 NR 4.10 (0.59 to 28.38) 7 45 N/A 
rs5755720 Het (AG) vs Hom WT (AA) Japan (1 study)148 NR 0.81 (0.26 to 2.55) 16 61 N/A 
Hom MT (GG) vs Hom WT (AA) Japan (1 study)148 NR 0.32 (0.06 to 1.76) 8 41 N/A 
HSPA1L rs2227956 Het (TC) vs Hom WT (TT) China (1 study)167 100% Chinese 1.98 (1.21 to 3.23) 82 321 N/A 
Hom MT (CC) vs Hom WT (TT) China (1 study)167 100% Chinese 1.16 (0.45 to 3.00) 42 223 N/A 
IL4 rs2243289 Het (GA) vs Hom WT (GG) China (1 study)169 100% Chinese 0.84 (0.50 to 1.41) 85 341 N/A 
Hom MT (AA) vs Hom WT (GG) China (1 study)169 100% Chinese 1.43 (0.37 to 5.54) 64 240 N/A 
rs2243250 Het (TC) vs Hom WT (TT) China (1 study)169 100% Chinese 0.82 (0.49 to 1.38) 86 346 N/A 
Hom MT (CC) vs Hom WT (TT) China (1 study)169 100% Chinese 1.62 (0.41 to 6.46) 65 242 N/A 
rs2070874 Het (TC) vs Hom WT (TT) China (1 study)169 100% Chinese 0.80 (0.47 to 1.35) 85 343 N/A 
Hom MT (CC) vs Hom WT (TT) China (1 study)169 100% Chinese 1.62 (0.41 to 6.44) 65 241 N/A 
IL6 rs2066992 Het (GT) vs Hom WT (GG) China (1 study)167 100% Chinese 1.15 (0.69 to 1.92) 79 335 N/A 
Hom MT (TT) vs Hom WT (GG) China (1 study)167 100% Chinese 2.35 (1.03 to 5.36) 60 242 N/A 
rs2069837 Het (AG) vs Hom WT (AA) China (1 study)167 100% Chinese 1.41 (0.85 to 2.33) 87 335 N/A 
Hom MT (GG) vs Hom WT (AA) China (1 study)167 100% Chinese 0.57 (0.13 to 2.57) 59 259 N/A 
rs1524107 Het (CT) vs Hom WT (CC) China (1 study)167 100% Chinese 1.18 (0.71 to 1.96) 80 333 N/A 
Hom MT (TT) vs Hom WT (CC) China (1 study)167 100% Chinese 1.99 (0.85 to 4.63) 59 241 N/A 
IL10 rs1800896 Het (AG) vs Hom WT (AA) China (1 study)169 100% Chinese 0.90 (0.43 to 1.87) 88 353 N/A 
Hom MT (GG) vs Hom WT (AA) China (1 study)169 100% Chinese 3.96 (0.25 to 64.0) 79 310 N/A 
rs1800871 Het (TC) vs Hom WT (TT) China (1 study)169 100% Chinese 1.11 (0.68 to 1.82) 79 316 N/A 
Hom MT (CC) vs Hom WT (TT) China (1 study)169 100% Chinese 1.13 (0.52 to 2.46) 52 213 N/A 
rs1800872 Het (AC) vs Hom WT (AA) China (1 study)169 100% Chinese 1.12 (0.68 to 1.84) 78 314 N/A 
Hom MT (CC) vs Hom WT (AA) China (1 study)169 100% Chinese 1.18 (0.54 to 2.57) 51 210 N/A 
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KEAP1 rs1048290 Het (GC) vs Hom WT (GG) Japan (1 study)148 NR 1.12 (0.30 to 4.13) 12 64 N/A 
Hom MT (CC) vs Hom WT (GG) Japan (1 study)148 NR 1.92 (0.47 to 7.83) 10 41 N/A 
rs11545829 Het (CT) vs Hom WT (CC) Japan (1 study)148 NR 0.97 (0.31 to 3.06) 14 71 N/A 
Hom MT (TT) vs Hom WT (CC) Japan (1 study)148 NR 1.82 (0.45 to 7.39) 11 46 N/A 
MAFF rs2413508 Het (CG) vs Hom WT (CC) Japan (1 study)148 NR 1.04 (0.32 to 3.41) 13 72 N/A 
Hom MT (GG) vs Hom WT (CC) Japan (1 study)148 NR 2.83 (0.71 to 11.27) 11 44 N/A 
rs2267373 Het (TC) vs Hom WT (TT) Japan (1 study)148 NR 1.86 (0.55 to 6.27) 13 67 N/A 
Hom MT (CC) vs Hom WT (TT) Japan (1 study)148 NR 2.40 (0.60 to 9.52) 10 51 N/A 
rs2235264 Het (AG) vs Hom WT (AA) Japan (1 study)148 NR 1.49 (0.36 to 6.14) 11 67 N/A 
Hom MT (GG) vs Hom WT (AA) Japan (1 study)148 NR 3.73 (0.83 to 16.71) 10 39 N/A 
rs4821765 Het (TC) vs Hom WT (TT) Japan (1 study)148 NR 0.56 (0.17 to 1.88) 17 82 N/A 
Hom MT (CC) vs Hom WT (TT) Japan (1 study)148 NR 11.89 (0.46 to 308.42) 14 53 N/A 
MAFK rs4720833 Het (GA) vs Hom WT (GG) Japan (1 study)148 NR 4.03 (1.30 to 12.52) 18 74 N/A 
Hom MT (AA) vs Hom WT (GG) Japan (1 study)148 NR 0.49 (0.02 to 9.64) 5 53 N/A 
rs3808337 Het (TC) vs Hom WT (TT) Japan (1 study)148 NR 2.28 (0.76 to 6.81) 17 74 N/A 
Hom MT (CC) vs Hom WT (TT) Japan (1 study)148 NR 0.85 (0.09 to 8.09) 7 49 N/A 
NFE2L2 rs2886161 Het (CT) vs Hom WT (CC) Japan (1 study)148 NR 1.25 (0.41 to 3.75) 16 65 N/A 
Hom MT (TT) vs Hom WT (CC) Japan (1 study)148 NR 0.54 (0.10 to 2.88) 9 49 N/A 
rs4243387 Het (TC) vs Hom WT (TT) Japan (1 study)148 NR 0.76 (0.24 to 2.37) 17 76 N/A 
Hom MT (CC) vs Hom WT (TT) Japan (1 study)148 NR 0.68 (0.07 to 6.20) 13 55 N/A 
rs6726395 Het (GA) vs Hom WT (GG) Japan (1 study)148 NR 0.41 (0.12 to 1.40) 15 72 N/A 
Hom MT (AA) vs Hom WT (GG) Japan (1 study)148 NR 1.04 (0.24 to 4.44) 14 48 N/A 
rs2001350 Het (AG) vs Hom WT (AA) Japan (1 study)148 NR 0.64 (0.19 to 2.19) 16 76 N/A 
Hom MT (GG) vs Hom WT (AA) Japan (1 study)148 NR 1.39 (0.25 to 7.76) 14 56 N/A 
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NOS2A rs10459953 Het (CG) vs Hom WT (CC) Japan (1 study)148 NR 0.55 (0.17 to 1.79) 14 59 N/A 
Hom MT (GG) vs Hom WT (CC) Japan (1 study)148 NR 0.52 (0.13 to 2.04) 11 44 N/A 
rs3794764 Het (GA) vs Hom WT (GG) Japan (1 study)148 NR 1.05 (0.36 to 3.04) 17 80 N/A 
Hom MT (AA) vs Hom WT (GG) Japan (1 study)148 NR 2.40 (0.20 to 29.10) 11 50 N/A 
rs12944039 Het (GA) vs Hom WT (GG) Japan (1 study)148 NR 1.22 (0.42 to 3.58) 16 80 N/A 
Hom MT (AA) vs Hom WT (GG) Japan (1 study)148 NR 5.50 (0.67 to 44.90) 10 46 N/A 
rs11080344 Het (CT) vs Hom WT (CC) Japan (1 study)148 NR 0.40 (0.13 to 1.19) 17 69 N/A 
Hom MT (TT) vs Hom WT (CC) Japan (1 study)148 NR 0.20 (0.02 to 1.74) 12 42 N/A 
rs2314810 Het (GC) vs Hom WT (GG) Japan (1 study)148 NR 0.91 (0.32 to 2.58) 18 80 N/A 
Hom MT (CC) vs Hom WT (GG) Japan (1 study)148 NR 0.83 (0.04 to 18.41) 11 49 N/A 
rs3729966 Het (CT) vs Hom WT (CC) Japan (1 study)148 NR 0.73 (0.25 to 2.14) 16 76 N/A 
Hom MT (TT) vs Hom WT (CC) Japan (1 study)148 NR 1.33 (0.23 to 7.89) 10 38 N/A 
rs944722 Het (TC) vs Hom WT (TT) Japan (1 study)148 NR 0.84 (0.29 to 2.42) 17 79 N/A 
Hom MT (CC) vs Hom WT (TT) Japan (1 study)148 NR 1.43 (0.13 to 15.26) 11 46 N/A 
rs2255929 Het (AT) vs Hom WT (AA) Japan (1 study)148 NR 0.68 (0.23 to 2.02) 16 73 N/A 
Hom MT (TT) vs Hom WT (AA) Japan (1 study)148 NR 0.84 (0.15 to 4.59) 11 43 N/A 
rs3794756 Het (CT) vs Hom WT (CC) Japan (1 study)148 NR 0.31 (0.08 to 1.20) 15 79 N/A 
Hom MT (TT) vs Hom WT (CC) Japan (1 study)148 NR 3.67 (0.65 to 20.54) 15 47 N/A 
NQO1 609C-T 
(rs1800566) 
Het (CT) vs Hom WT (CC) Taiwan (1 study)130 NR 0.93 (0.40 to 2.16) 53 49 N/A 
Japan (1 study)148 NR 1.45 (0.47 to 4.41) 16 71 N/A 
All (2 studies)130, 148 1.09 (0.56 to 2.14) 69 120 0.0% 
Hom MT (TT) vs Hom WT (CC) Taiwan (1 study)130 NR 0.63 (0.22 to 1.83) 27 29 N/A 
Japan (1 study)148 NR 1.00 (0.18 to 5.70) 8 44 N/A 
All (2 studies)130, 148 0.72 (0.29 to 1.78) 35 73 0.0% 
rs689452 Het (CG) vs Hom WT (CC) Japan (1 study)148 NR 1.29 (0.44 to 3.82) 16 71 N/A 
Hom MT (GG) vs Hom WT (CC) Japan (1 study)148 NR 0.91 (0.17 to 4.91) 10 51 N/A 
rs2917669 Het (CT) vs Hom WT (CC) Japan (1 study)148 NR 1.37 (0.46 to 4.05) 16 71 N/A 
Hom MT (TT) vs Hom WT (CC) Japan (1 study)148 NR 0.93 (0.17 to 5.03) 10 52 N/A 
rs10517 Het (CT) vs Hom WT (CC) Japan (1 study)148 NR 1.71 (0.56 to 5.22) 16 71 N/A 
Hom MT (TT) vs Hom WT (CC) Japan (1 study)148 NR 1.09 (0.19 to 6.20) 8 47 N/A 
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Het (CT) vs Hom WT (CC) Taiwan (2 studiesf)168  NR 1.19 (0.75 to 1.88) 99 414 0.0% 
Indonesia (1 study)176 NR 1.07 (0.43 to 2.66) 30 69 N/A 
All (3 studies)168, 176 1.16 (0.77 to 1.75) 129 483 0.0% 
Hom MT (TT) vs Hom WT (CC) Taiwan (2 studiesf)168  NR 1.19 (0.43 to 3.32) 68 298 0.0% 
Indonesia (1 study)176 NR 5.88 (1.05 to 32.85) 25 49 N/A 
All (3 studies)168, 176 1.86 (0.65 to 5.33) 93 347 23.4% 
Rs12488820 
 
Het (CT) vs Hom WT (CC) Taiwan (2 studiesf)168  NR Data excludede 
Hom MT (TT) vs Hom WT (CC) Taiwan (2 studiesf)168  NR 0.93 (0.31 to 2.81) 103 432 0.0% 
Rs2461823 
 
Het (GA) vs Hom WT (GG) Taiwan (2 studiesf)168  NR 0.84 (0.52 to 1.36) 83 377 0.0% 
Hom MT (AA) vs Hom WT (GG) Taiwan (2 studiesf)168 NR 1.60 (0.86 to 2.98) 59 211 0.0% 
Rs7643645 
 
Het (AG) vs Hom WT (AA) Taiwan (2 studiesf)168 NR 1.29 (0.59 to 2.80) 74 334 48.6% 
Hom MT (GG) vs Hom WT (AA) Taiwan (2 studiesf)168 NR 1.64 (0.89 to 3.04) 52 226 0.0% 
Rs6785049 
 
Het (GA) vs Hom WT (GG) Taiwan (2 studiesf)168 NR 1.12 (0.70 to 1.80) 94 360 0.0% 
Hom MT (AA) vs Hom WT (GG) Taiwan (2 studiesf)168 NR 0.56 (0.26 to 1.19) 44 213 0.0% 
Rs3814057 
 
Het (AC) vs Hom WT (AA) Taiwan (2 studiesf)168 NR 1.98 (1.06 to 3.69) 78 343 0.0% 
Hom MT (CC) vs Hom WT (AA) Taiwan (2 studiesf)168 NR 2.18 (1.07 to 4.44) 40 193 0.0% 
SLC10A1 rs4646285 Het (GA) vs Hom WT (GG) China (1 study)117 NR 1.05 (0.61 to 1.80) 86 348 N/A 
Hom MT (AA) vs Hom WT (GG) China (1 study)117 NR 2.05 (0.50 to 8.41) 67 268 N/A 
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SLCO1B1 Rs4149013 Het (AG) vs Hom WT (AA) China (1 study)117 NR 1.61 (0.95 to 2.73) 88 349 N/A 
South Korea (1 study)137 NR 1.76 (0.93 to 3.31) 66 150 N/A 
All (2 studies)117, 137 1.67 (1.12 to 2.50) 154 499 0.0% 
Hom MT (GG) vs Hom WT (AA) China (1 study)117 NR 0.89 (0.10 to 7.78) 63 282 N/A 
South Korea (1 study)137 NR 0.24 (0.01 to 4.46) 43 120 N/A 
All (2 studies)117, 137 0.56 (0.10 to 3.19) 106 402 0.0% 
Rs4149014g Het (TG) vs Hom WT (TT) China (1 study)117 NR 0.86 (0.54 to 1.39) 87 309 N/A 
South Korea (1 study)137 NR 0.78 (0.43 to 1.45) 61 147 N/A 
All (2 studies)117, 137 0.83 (0.57 to 1.21) 148 456 0.0% 
Hom MT (GG) vs Hom WT (TT) China (1 study)117 NR 0.15 (0.03 to 0.63) 48 197 N/A 
South Korea (1 study)137 NR 1.21 (0.38 to 3.87) 43 92 N/A 
All (2 studies)117, 137 0.44 (0.05 to 3.82) 91 289 81.5% 
Rs2306283h Het (GA) vs Hom WT (GG) China (2 studies)90, 117 NR 1.10 (0.76 to 1.57) 188 471 0.0% 
South Korea (1 study)137 NR 1.12 (0.61 to 2.06) 59 145 N/A 
Ethiopia (1 study)173 NR 0.69 (0.32 to 1.50) 32 140 N/A 
All (4 studies)90, 117, 137, 173 1.03 (0.77 to 1.38) 279 756 0.0% 
Hom MT (AA) vs Hom WT (GG) China (2 studies)90, 117 NR 1.31 (0.71 to 2.41) 135 330 0.0% 
South Korea (1 study)137 NR 1.40 (0.48 to 4.11) 39 96 N/A 
Ethiopia (1 study)173 NR 1.59 (0.60 to 4.21) 24 73 N/A 
All (4 studies)90, 117, 137, 173 1.38 (0.87 to 2.21) 198 499 0.0% 
Rs4149056 Het (TC) vs Hom WT (TT) China (2 studies)90, 117 NR 1.58 (0.42 to 5.89) 204 505 88.8% 
South Korea (1 study)137 NR 1.23 (0.65 to 2.32) 66 153 N/A 
Ethiopia (1 study)173 NR 1.05 (0.50 to 2.21) 40 156 N/A 
All (4 studies)90, 117, 137, 173 1.35 (0.74 to 2.43) 310 814 69.4% 
Hom MT (CC) vs Hom WT (TT) China (2 studies)90, 117 NR 3.98 (0.64 to 24.66) 158 417 0.0% 
South Korea (1 study)137 NR 0.35 (0.02 to 6.88) 46 116 N/A 
Ethiopia (1 study)173 NR 0.99 (0.11 to 9.23) 28 111 N/A 
All (4 studies)90, 117, 137, 173 1.62 (0.45 to 5.79) 232 644 0.0% 
Rs2291075 Het (CT) vs Hom WT (CC) China (1 study)117 NR 0.95 (0.54 to 1.65) 68 262 N/A 
Hom MT (TT) vs Hom WT (CC) China (1 study)117 NR 0.81 (0.42 to 1.56) 45 185 N/A 
114 





SOD1 rs2070424 Hom MT (GG) or Het (GA) vs Hom 
WT (AA) 





Hom MT (CC) or Het (CT) vs Hom WT 
(TT) 
Taiwan (1 study)130 NR 2.40 (1.12 to 5.16) 63 63 N/A 
South Korea (1 study)139 100% Korean 1.27 (0.71 to 2.27) 83 237 N/A 
All (2 studies)130, 139 1.66 (0.89 to 3.08) 146 300 40.9% 
Het (TC) vs Hom WT (TT) Taiwan (1 study)130 NR 2.56 (1.12 to 5.81) 59 60 N/A 
Hom MT (CC) vs Hom WT (TT) Taiwan (1 study)130 NR 1.78 (0.37 to 8.44) 40 51 N/A 
SOD3 rs1799895 Hom MT (AA) or Het (GA) vs Hom 
WT (GG) 
South Korea (1 study)139 100% Korean 1.03 (0.62 to 1.71) 83 234 N/A 
rs2536512 Hom MT (GG) or Het (CG) vs Hom 
WT (CC) 
South Korea (1 study)139 100% Korean 1.81 (0.72 to 4.54) 84 237 N/A 
STAT3 rs1053004 Het (TC) vs Hom WT (TT) China (1 study)167 100% Chinese 0.90 (0.54 to 1.48) 78 300 N/A 
Hom MT (CC) vs Hom WT (TT) China (1 study)167 100% Chinese 0.75 (0.36 to 1.58) 49 191 N/A 
rs1053023 Het (AG) vs Hom WT (AA) China (1 study)167 100% Chinese 1.26 (0.72 to 2.19) 64 293 N/A 
Hom MT (GG) vs Hom WT (AA) China (1 study)167 100% Chinese 2.15 (1.14 to 4.07) 49 187 N/A 
rs1053005 Het (AG) vs Hom WT (AA) China (1 study)167 100% Chinese 1.00 (0.61 to 1.63) 80 310 N/A 
Hom MT (GG) vs Hom WT (AA) China (1 study)167 100% Chinese 0.79 (0.36 to 1.76) 49 199 N/A 
TNF-alpha -308G-A Het (GA) vs Hom WT (GG) South Korea (1 study)138 100% Korean 1.80 (0.95 to 3.43) 75 228 N/A 
Hom MT (AA) vs Hom WT (GG) South Korea (1 study)138 100% Korean 6.81 (0.61 to 76.44) 59 195 N/A 
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UGT1A1 211G-A  
(rs4148323)  
 
Het (GA) vs Hom WT (GG) Taiwan (1 study)115 NR 0.99 (0.31 to 3.12) 17 81 N/A 
South Korea (1 study)133 NR 1.03 (0.55 to 1.93) 61 145 N/A 
All (2 studies)115, 133 1.02 (0.59 to 1.77) 78 226 0.0% 
Hom MT (AA) vs Hom WT (GG) Taiwan (1 study)115 NR Data excludede 
South Korea (1 study)133 NR 1.20 (0.39 to 3.73) 45 106 N/A 
rs3755319 Het (CA) vs Hom WT (AA) South Korea (1 study)133 NR 1.55 (0.86 to 2.80) 63 150 N/A 
Hom MT (CC) vs Hom WT (AA) South Korea (1 study)133 NR 0.83 (0.16 to 4.21) 33 97 N/A 
rs2003569 Het (GA) vs Hom WT (GG) South Korea (1 study)133 NR 0.96 (0.49 to 1.87) 64 155 N/A 
Hom MT (AA) vs Hom WT (GG) South Korea (1 study)133 NR 1.20 (0.11 to 13.53) 49 117 N/A 
686C-A Het (CA) vs Hom WT (CC) Taiwan (1 study)115 NR 5.27 (0.69 to 40.35) 17 81 N/A 
Hom MT (AA) vs Hom WT (CC) Taiwan (1 study)115 NR Data excludede 
TA6→TA7 at the 
promoter region 
Het (TA7TA6) vs Hom WT (TA6TA6) Taiwan (1 study)115 NR 1.12 (0.28 to 4.46) 17 81 N/A 
Hom MT (TA7TA7) vs Hom WT 
(TA6TA6) 
Taiwan (1 study)115 NR Data excludede 
1091C-T Het (CT) vs Hom WT (CC) Taiwan (1 study)115 NR 5.00 (0.30 to 84.17) 17 81 N/A 
Hom MT (TT) vs Hom WT (CC) Taiwan (1 study)115 NR Data excludede 
UGT1A3 rs2008584 Het (GA) vs Hom WT (AA) South Korea (1 study)133 NR 1.62 (0.89 to 2.93) 63 149 N/A 
Hom MT (GG) vs Hom WT (AA) South Korea (1 study)133 NR 1.26 (0.31 to 5.17) 34 98 N/A 
rs6431625 Het (TC) vs Hom WT (TT) South Korea (1 study)133 NR 1.36 (0.64 to 2.89) 54 143 N/A 
Hom MT (CC) vs Hom WT (TT) South Korea (1 study)133 NR 8.42 (0.34 to 210.83) 42 116 N/A 
UGT2B7 Rs7662029i Het (GA) vs Hom WT (AA) Ethiopia (1 study)173 NR 0.69 (0.32 to 1.50) 36 124 N/A 
Hom MT (GG) vs Hom WT (AA) Ethiopia (1 study)173 NR 0.38 (0.12 to 1.15) 19 74 N/A 
XPO1 rs7606167 Het (GC) vs Hom WT (GG) Japan (1 study)148 NR 0.90 (0.29 to 2.80) 15 73 N/A 
Hom MT (CC) vs Hom WT (GG) Japan (1 study)148 NR 1.56 (0.35 to 6.92) 12 51 N/A 
rs11125883 Het (AC) vs Hom WT (AA) Japan (1 study)148 NR 0.33 (0.10 to 1.07) 16 64 N/A 
Hom MT (CC) vs Hom WT (AA) Japan (1 study)148 NR 0.27 (0.05 to 1.38) 13 45 N/A 
rs1050567 Het (GA) vs Hom WT (GG) Japan (1 study)148 NR 0.59 (0.18 to 1.91) 14 76 N/A 
Hom MT (AA) vs Hom WT (GG) Japan (1 study)148 NR 2.89 (0.67 to 12.42) 13 45 N/A 
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Emboldened text is used for results from meta-analysis. 
a Total number of patients who experienced hepatotoxicity across the genotype groups being compared  
b Total number of patients who did not experience hepatotoxicity across the genotype groups being compared 
c One of the studies (Kim 2012b)137 reports WT to be T and MT to be C, but the other study (Yimer 2011),173 and the data, suggest that WT is C and MT is T. 
d The study (Kim 2012b)137 reports WT to be del (-) and MT to be G, but the data suggest that WT is G and MT is del (-). 
e Data were excluded due to zero counts. 
f Reported in the same paper (Wang 2015b),168 but two separate cohorts of patients 
g One of the studies (Kim 2012b)137 reports WT to be G and MT to be T, but the other study (Chen 2015),117 and the data, suggest that WT is T and MT is G. 
h Three of the studies (Chen 2015,117 Li 201290 and Yimer 2011173) report WT to be A and MT to be G, but the other study (Kim 2012b),137 and the data, suggest that WT is G 
and MT is A. 
i The paper (Yimer 2011)173 reports WT to be G and MT to be A, but the data suggest that WT is A and MT is G. 
CI: confidence interval; Het: heterozygous; Hom: homozygous; MT: mutant-type; N/A: not applicable; NR: not reported; OR: odds ratio; WT: wild-type
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For the rs3814057 polymorphism of the PXR gene, there was some evidence to suggest that 
individuals with AC and CC genotypes are more likely to experience hepatotoxicity in 
comparison to individuals with AA genotype (AC versus AA: OR=1.98, 95% CI: 1.06 to 3.69, 
p=0.032, I2=0.0%, 2 patient cohorts reported in the same article; CC versus AA: OR=2.18, 
95% CI: 1.07 to 4.44, p=0.032, I2=0.0%, 2 patient cohorts reported in the same article). The 
meta-analysis for the rs4149013 polymorphism of the SLCO1B1 gene also provided 
evidence that individuals with AG genotype are more likely to experience hepatotoxicity in 
comparison to individuals with AA genotype (OR=1.67, 95% CI: 1.12 to 2.50, p=0.013, 
I2=0.0%, 2 studies). However, the evidence for the comparison between GG genotype and 
AA genotype at this SNP was inconclusive, with the 95% CI for the OR including both 
considerable protective and harmful effects (OR=0.56, 95% CI: 0.10 to 3.19, p=0.515, 
I2=0.0%, 2 studies). The strength of the evidence for associations from the meta-analyses 
for the remaining 12 SNPs and hepatotoxicity was either weak or non-existent. 
Substantial heterogeneity was observed in the meta-analyses comparing: i) CT versus CC 
genotype for the rs1045642 SNP of the ABCB1 gene; ii) GG versus TT genotype for the 
rs4149014 SNP of the SLCO1B1 gene; iii) TC versus TT genotype for the rs4149056 SNP of 
the SLCO1B1 gene. In each of these meta-analyses, each included study applied a different 
definition of hepatotoxicity. Variable frequencies of genotypes across the countries where 
studies were conducted may also be a source of heterogeneity in these analyses.  
Secondary analyses: GSTM1/GSTT1 and other toxicity outcomes 
Data for the association between GST genetic variants and toxicity outcomes (other than 
hepatotoxicity) are summarised in Table 21. Each reported result is based on data from a 
single study.  
One study119 investigated associations between GSTM1 and GSTT1 homozygous null 
genotypes and ADRs (defined as the presence of at least one of the following symptoms 
during the follow-up period: gastric, joint, neuromuscular, or skin reactions; and 
hepatotoxicity). Another study134 examined whether GSTM1 and GSTT1 homozygous null 
genotypes increased the likelihood of experiencing anti-TB drug-induced cutaneous 
reactions. Neither study provided evidence of an important association between GSTM1 or 
GSTT1 homozygous null genotypes and these toxicity outcomes.  
118 
Secondary analyses: Other genetic variants and other toxicity outcomes 
Data for the association between other genetic variants and toxicity outcomes (other than 
hepatotoxicity) are summarised in Table 21. Each reported result is based on data from a 
single study.  
One study136 investigated associations between polymorphisms of the ABCB1 and ABCC2 
genes and anti-TB drug-induced maculopapular eruption. For the rs1885301 and rs2804400 
polymorphisms of the ABCC2 gene, there was some evidence to suggest that homozygous 
mutant-type individuals are more likely to experience anti-TB drug-induced maculopapular 
eruption in comparison to homozygous wild-type individuals (rs1885301: OR=3.39, 95% CI: 
1.13 to 10.14, 1 study; rs2804400: OR=3.47, 95% CI: 1.16 to 10.36, 1 study). The point 
estimates of these ORs suggest important effects; however, 95% CIs around these 
estimates were wide due to the fairly small number of patients contributing data to these 
analyses (rs1885301, n=134; rs2804400, n=136). There was no evidence to suggest that 
heterozygous genotype has an important impact on anti-TB drug-induced maculopapular 
eruption in comparison to homozygous wild-type genotype for either polymorphism. The 
strength of the evidence from this study136 to support associations between other genetic 
variants of the ABCB1 and ABCC2 genes and anti-TB drug-induced maculopapular eruption 
was weak or non-existent.
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Table 21 Results of the secondary analyses: association between GST and other genetic variants and toxicity outcomes (other than hepatotoxicity)  
Study  Country  Ethnicity Outcome Gene Variant Comparison OR (95% CI)  # casesa # controlsb 
Costa 
(2012)119 
Brazil 84% Black/ 
mixed race, 
16% other 
ADRs GSTM1  Null or present  Hom null vs Het or Hom present 1.06 (0.42 to 2.72) 43 45 












Het (CT) vs Hom WT (CC) 1.02 (0.55 to 1.89) 57 137 
Hom MT (TT) vs Hom WT (CC) 0.49 (0.15 to 1.55) 32 88 
-114918T-G 
(rs10261685) 
Het (TG) vs Hom WT (TT) 1.10 (0.52 to 2.32) 61 159 
Hom MT (GG) vs Hom WT (TT) 7.91 (0.32 to 197.42) 50 130 
ABCC2 1774G-delc Het (G/-) vs Hom WT (GG) 0.62 (0.32 to 1.18) 54 137 
Hom MT (-/-) vs Hom WT (GG) 0.75 (0.29 to 1.96) 31 63 
-1549G-A 
(rs1885301) 
Het (GA) vs Hom WT (GG) 1.19 (0.63 to 2.23) 54 149 
Hom MT (AA) vs Hom WT (GG) 3.39 (1.13 to 10.14) 38 96 
-24C-T 
(rs717620) 
Het (CT) vs Hom WT (CC) 1.12 (0.60 to 2.10) 56 149 
Hom MT (TT) vs Hom WT (CC) 2.79 (0.84 to 9.25) 39 98 
IVS3-49C-T 
(rs2804400) 
Het (CT) vs Hom WT (CC) 1.19 (0.64 to 2.23) 54 152 
Hom MT (TT) vs Hom WT (CC) 3.47 (1.16 to 10.36) 38 98 
V417L 
(rs2273697) 
Het (GA) vs Hom WT (GG) 1.01 (0.44 to 2.32) 61 157 
Hom MT (AA) vs Hom WT (GG) 1.29 (0.11 to 14.52) 53 136 
S978S 
(rs3740070) 
Het (GA) vs Hom WT (GG) 0.84 (0.26 to 2.73) 62 159 
Hom MT (AA) vs Hom WT (GG) Data excludedd 
I1324I 
(rs3740066) 
Het (CT) vs Hom WT (CC) 1.40 (0.75 to 2.63) 54 147 









GSTM1 Null or present  Hom null vs Het or Hom present 1.22 (0.74 to 2.01) 94 190 
GSTT1 Null or present  Hom null vs Het or Hom present 1.19 (0.72 to 1.96) 94 190 
a Total number of cases across the genotype groups being compared  
b Total number of controls across the genotype groups being compared 
c The study (Kim 2012a)136 reports WT to be del (-) and MT to be G, but the data suggest that WT is G and MT is del (-). 
d Data were excluded due to zero counts. 
ADR: adverse drug reaction; ATD: anti-tuberculosis drug; CI: confidence interval; GI: group identifier; Het: heterozygous; Hom: homozygous; MPE: maculopapular eruption; 
MT: mutant-type; NR: not reported; OR: odds ratio; WT: wild-type
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4.3 Discussion 
Our systematic review and meta-analysis has demonstrated that performing robust 
synthesis of the evidence base for associations between genetic variants and toxicity 
outcomes related to anti-TB drugs is challenging. The included studies varied in terms of the 
genetic variants selected for investigation, choice and definition of outcomes, how 
genotype groups were combined for analysis, ethnicity of participants and methodological 
quality. While conducting our review, we carefully considered these challenges, and 
stratified our meta-analyses by genetic variant, choice of genotype groups to be combined, 
and outcome. We also stratified further by the country in which the study was conducted 
as a proxy for ethnicity, which was not widely reported.  
Meta-analyses 
Where possible, meta-analyses were undertaken to improve power to estimate 
pharmacogenetic associations. It is important to note that we were only able to perform 
meta-analyses for the outcome of hepatotoxicity; there were insufficient data to perform 
pooled analyses for any other outcome. Included studies investigated the influence of 
genetic variants on various outcomes other than hepatotoxicity, including maculopapular 
eruption, peripheral neuropathy, skin rash, eosinophilia, and gastrointestinal ADRs. Very 
few statistically significant associations were observed; however, it is possible that some 
true associations were not identified due to the small sample sizes of the included studies. 
More studies investigating outcomes other than hepatotoxicity, and synthesis of the total 
evidence base would improve power to detect particular magnitudes of association as 
statistically significant, and also allow researchers to investigate the possibility that 
statistically significant associations identified in the initial studies may be spurious. 
Considering the meta-analyses performed for hepatotoxicity, we found that NAT2 
slow/intermediate acetylators were significantly more likely to experience this outcome 
than NAT2 rapid acetylators. This result is consistent with the findings of several meta-
analyses,92, 95, 98, 101 but is not consistent with the findings of the meta-analysis reported by 
Sun et al.,99 who did not identify a significant association between slow acetylator status 
and hepatotoxicity. However, the search date for Sun et al.99 (May 2007) is several years 
earlier than the search dates for the other meta-analyses, and many relevant studies have 
been published in recent years. As more studies are published, the power to detect 
particular magnitudes of association as statistically significant increases.  
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Interestingly, the result from a sensitivity analysis comparing the likelihood of 
hepatotoxicity for slow versus rapid/intermediate acetylators resulted in a stronger 
estimate of association (OR=3.12, 95% CI: 2.45 to 3.97) than our primary analysis (of 
slow/intermediate versus rapid acetylator status, OR=1.59, 95% CI: 1.26 to 2.01). This 
suggests that the way in which acetylator status groups are combined can have a 
considerable impact on the effect estimate observed. It is also worth noting that more 
studies combined rapid and intermediate acetylators than combined slow and intermediate 
acetylators, so the sensitivity analysis included data for a larger number of participants 
(n=7916) than the primary analysis for acetylator status (n=5036), and so was even more 
well-powered.  
A recently conducted GWAS197 in a Thai population also identified a strong association 
between NAT2 acetylator status (where phenotypes were inferred by using NAT2 
rs1495741 as a tag SNP) and ATDH when assuming a recessive mode of inheritance, i.e. 
slow versus intermediate/rapid acetylators (OR=6.01, 95% CI: 3.42 to 10.57, p=6.86e-11). 
There were no other genes for which associations were identified that met the threshold 
for genome-wide significance (p<5e-8); this study therefore identified NAT2 as the most 
important risk factor for ATDH in Thai TB patients. 
Considering previously conducted meta-analyses of CYP2E1 polymorphisms, three of these 
meta-analyses94, 97, 102 performed analyses for the RsaI and PstI polymorphisms combined, 
presumably because these polymorphisms have been reported to be in linkage 
disequilibrium.83 The approach taken for the analysis of CYP2E1 polymorphisms in two 
other meta-analyses92, 99 was unclear. However, we identified studies reporting data for 
these two polymorphisms separately,86, 121 so we performed separate meta-analyses for 
each polymorphism.  
We found that patients with homozygous wild-type (TT) or heterozygous (CT) genotype at 
the CYP2E1 RsaI polymorphism were significantly less likely to experience hepatotoxicity 
than patients with homozygous mutant-type (CC) genotype. This result is consistent with 
the findings of four previously conducted meta-analyses.94, 97, 99, 102 We observed no 
significant association for the CYP2E1 DraI polymorphism and hepatotoxicity, a result which 
is consistent with previous meta-analyses.97, 102 We also observed no significant association 
for the CYP2E1 PstI polymorphism and hepatotoxicity; this result is not consistent with the 
findings of previously conducted meta-analyses.94, 97, 102 This may be because we only 
included studies that explicitly stated that results were for the PstI polymorphism or the 
122 
RsaI/PstI polymorphisms combined (if these alleles were in complete linkage disequilibrium 
in the study population). The previous meta-analyses synthesised data for the RsaI/PstI 
polymorphisms combined, and therefore may have additionally included data from studies 
that stated that reported data were for the RsaI polymorphism (without mentioning the 
PstI polymorphism). The number of studies contributing data to the analysis of the CYP2E1 
PstI polymorphism was relatively small (n=8) compared with the number of studies 
contributing data to the analysis of the CYP2E1 RsaI polymorphism (n=23).  
We found that for GSTM1, patients with homozygous null genotype were significantly more 
likely to experience hepatotoxicity than patients with heterozygous or homozygous present 
genotype. We also found that for GSTT1, there was no significant difference in the 
likelihood of experiencing hepatotoxicity between patients with homozygous null genotype 
and those with heterozygous or homozygous present genotype. These results are 
consistent with the findings of previously conducted meta-analyses, which all identified a 
significant association between GSTM1 null genotype and hepatotoxicity, and no significant 
association between GSTT1 null genotype and hepatotoxicity.92, 93, 96, 99, 100 In particular, Cai 
et al.92 and Tang et al.100 reported very similar ORs for both the GSTM1 and GSTT1 
homozygous null genotypes to those reported in the current review.  
We also identified: for the 96-bp deletion-insertion SNP of the CYP2E1 gene, there was 
some evidence to suggest that homozygous mutant-type (II) individuals are more likely to 
experience hepatotoxicity than homozygous wild-type (DD) individuals; for the rs3814057 
polymorphism of the PXR gene, both the heterozygous (AC) and homozygous mutant-type 
(CC) genotypes were associated with an increased likelihood of hepatotoxicity risk in 
comparison to homozygous wild-type (AA) genotype. The data for the analysis of the PXR 
rs3814057 SNP came from two independent cohorts (a derivation cohort and a validation 
cohort) from a single study.168 By combining results from these two cohorts in meta-
analyses, the power to detect associations increases. However, it is important to note that 
the number of hepatotoxicity cases included in the analyses of both the 96-bp deletion-
insertion SNP of the CYP2E1 gene and the rs3814057 polymorphism of the PXR gene were 
fairly small, and therefore 95% CIs were wide. More data are required before it is possible 
to draw firm conclusions on the association between these two SNPs and hepatotoxicity. 
To the best of our knowledge, no meta-analyses on genetic variants other than variants of 
the NAT2, CYP2E1, GSTM1 and GSTT1 genes have been published in this field, and therefore 
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our results add to the existing understanding of the association between genetic variants 
and ATDH. 
Limitations 
Firstly, it could be argued that there are limitations to performing primary analyses for 
variants of four different genes (NAT2, CYP2E1, GSTM1 and GSTT1). Considering the existing 
literature, researchers have hypothesised that variants of each of these genes may play a 
role in the in the biological pathway between anti-TB treatment and hepatotoxicity; 
however, the NAT2 enzyme is the main isoniazid metabolising enzyme, and its activity has 
clearly been shown to be affected by common NAT2 polymorphisms. Evidence for the 
relevance of CYP2E1, GSTM1 and GSTT1 gene polymorphisms is less clear. In line with this 
existing knowledge, the strongest evidence of association between a genetic variant and 
hepatotoxicity identified in our meta-analyses was for NAT2 acetylator status, and this 
ought to be considered as the main finding of our systematic review.  
As discussed in Section 3.3, most included studies did not report the ethnic background of 
participants. We therefore performed analyses stratified by the country in which the study 
was conducted as a proxy variable for ethnicity. It is clear that this approach is not ideal as 
the population of any given country is often ethnically diverse. However, stratifying by 
country was deemed the most suitable approach in the absence of definitive information 
on ethnicity. 
Our quality assessment using criteria developed by Jorgensen and Williamson18 highlighted 
that there were many areas of methodological concern across the included studies, which 
we considered could introduce bias into the results of our analyses. As the quality 
assessment was qualitative rather than quantitative, it was not possible to exclude studies 
from our meta-analyses based on a single summary score. However, there were no studies 
which satisfied all criteria of the quality assessment checklist, and therefore, we advise that 
caution be applied when interpreting the results of the meta-analyses. 
We also found that it was often difficult to identify distinct patient cohorts from the 
included articles. If multiple articles report data for the same patient cohort, data for this 
patient cohort must only be included in any given meta-analysis once, otherwise a unit-of-
analysis error occurs.25 We found that it was often not possible to determine from articles 
alone whether patient cohorts were distinct, overlapping, or identical. We contacted 
several study authors for clarification. For three articles,108, 109, 152 we did not receive a 
response and, consequently, data from the older articles108, 109 were excluded from meta-
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analyses. If these three articles reported data for distinct patient cohorts, then information 
would have been lost by excluding two articles. Furthermore, there may have been cases of 
multiple articles reporting outcomes for the same patient cohorts that we did not identify; 
if this was the case, some patients may have been double-counted in the meta-analyses. It 
would be highly beneficial (for both systematic reviewers and the general reader) if 
pharmacogenetic researchers were to highlight in their study reports when the included 
patient cohort overlaps or is identical to the patient cohort of other articles.  
An additional challenge encountered was the inconsistent use of SNP nomenclature, which 
made gathering data for meta-analyses problematic. For example, the CYP2E1 SNPs 
considered in the primary analyses were referred to in various ways in the included studies. 
In particular, the CYP2E1 SNP identified by rs2031920 was referred to in articles using one 
or more of the following: rs2031920, ‘RsaI polymorphism’, ‘CYP2E1 1053C-T’, ‘CYP2E1 -
1019C-T’, ‘CYP2E1 -1055C-T’. Since rs numbers are unique to each SNP, in the first instance 
we identified studies reporting data for the same SNPs by using the rs numbers. If an article 
did not report the rs number, then we searched the literature to match the reported SNP 
(whatever nomenclature was used) to the rs number for that SNP. This process was 
especially challenging, as often the nomenclature used did not appear in standard 
databases, such as dbSNP198 or pharmGKB.6 We would recommend that where possible, 
authors of pharmacogenetic studies should state the unique rs number of each genotyped 
SNP. As discussed in the STREGA (STrengthening the REporting of Genetic Association 
studies) Statement,199 guidelines are available for how to define variants that are not listed 
in dbSNP.200, 201 
Furthermore, the considerable variability in the definitions of hepatotoxicity across the 
included studies (see Section 3.4) introduced heterogeneity into the meta-analyses. 
Interpretation of meta-analyses that include data for a variety of different outcome 
definitions is difficult, as there is not a single outcome definition that the estimate of 
association relates to. As previously discussed in Section 3.4, the development of a core 
outcome set for studies of anti-TB drug-related toxicity would be valuable; consistent 
outcome definitions would help to reduce heterogeneity and increase the robustness of 
findings from meta-analyses. 
Finally, for the meta-analyses presented in this chapter, we either performed two pairwise 
comparisons, or assumed a specific mode of inheritance, so that standard methods of 
meta-analysis could be applied (see Section 2.3). However, these methods are not without 
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their limitations. If a specific mode of inheritance is assumed incorrectly, power to detect 
pharmacogenetic associations will be reduced. Furthermore, performing pairwise 
comparisons ignores any correlation between the effect estimates induced by the common 
baseline group; this is therefore an inefficient approach since the two effect estimates do 
not borrow strength from one another as they would in a bivariate analysis. We explore 
more complex methods of meta-analysis that have the potential to overcome the 
limitations of standard methods of meta-analysis in Chapter 5.  
4.4 Conclusion 
This review showed that slow acetylators were significantly more likely to experience ATDH 
than intermediate/rapid acetylators. We also observed significant associations between the 
CYP2E1 RsaI and GSTM1 null polymorphisms and ATDH. Therefore, pharmacogenetic 
testing may be useful in clinical practice in terms of risk stratification for ATDH during 
treatment of TB. Whilst the findings from our meta-analyses alone lack the strength of 
evidence required to support a stratified medicine approach at this time, they suggest that 
comprehensive genotyping in a wider range of populations (including African populations) 
is required to establish the value of pharmacogenetic testing in the treatment of TB. More 
studies are needed to overcome the reported methodological limitations of the existing 
studies and to assess if a stratified medicine approach might be feasible and cost effective. 
Throughout the process of conducting this review, we observed that improvements in the 
reporting of pharmacogenetic studies would firstly, and importantly, enable readers to fully 
assess the strengths and weaknesses of individual studies, and interpret the results 
accordingly. However, improvements in the reporting of pharmacogenetic studies would 
also enable systematic reviewers to gain more insight into the methodological quality of 
included studies, include more data in meta-analyses, and tailor their analysis approaches 
based on information reported in study reports, such as ethnic background and patient 
cohort overlap.  
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5 Further analyses of the association between genetic variants 
of the NAT2 data and hepatotoxicity 
5.1 Introduction 
For the meta-analyses described in Chapter 4, we used the following approach for our 
analyses: 
• For genetic variants where all studies presented data for each genotype group 
separately, we performed two separate pairwise comparisons, as we had no reason to 
make an assumption about the underlying mode of inheritance. 
• For genetic variants where all studies presented data for combined genotype groups, 
we performed one comparison of the combined genotype groups (i.e. we assumed a 
recessive or a dominant model, depending on which genotype groups were combined), 
as the evidence base suggested that assuming a particular mode of inheritance would 
be valid. 
• For genetic variants where the approach varied between studies, we performed one 
comparison of the combined genotype groups, and also separate pairwise comparisons, 
which included studies that reported data for each genotype group separately. This 
approach allowed us to consider the robustness of our findings to the chosen analysis 
approach. 
 
However, these analyses are subject to limitations. Specifically, if a specific mode of 
inheritance is assumed incorrectly, power to detect pharmacogenetic associations will be 
reduced. Furthermore, performing pairwise comparisons ignores any correlation between 
the effect estimates induced by the common baseline group; this is therefore an inefficient 
approach since the two effect estimates do not borrow strength from one another as they 
would in a bivariate analysis.  
In 2005, Minelli et al.61 introduced the genetic model-free method of meta-analysis for 
pharmacogenetic studies. This method does not require any assumptions about the 
underlying mode of inheritance, nor does it ignore the correlation between effect estimates 
induced by the common baseline group. This method is therefore potentially able to 
overcome the limitations of the standard methods of meta-analysis. 
In this chapter, we introduce the genetic model-free method and describe how we used the 
method to analyse data from our systematic review of genetic variants and anti-TB drug-
related toxicity. We then present the results of these analyses, and compare these results 
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to those from simple pairwise comparisons. We applied the genetic model-free method of 
meta-analysis for variants of the NAT2 gene only; these data were sufficient to allow us to 
investigate the impact of meta-analysis approach on findings from a systematic review. 
In addition to allowing comparisons between standard and more complex methods of 
meta-analysis, we also hoped that exploring alternative methods of meta-analysis would 
allow us to gain further insight into the process of synthesising pharmacogenetic evidence. 
In particular, we aimed to identify whether any barriers exist that might prevent 
researchers from performing meta-analyses of pharmacogenetic studies using the optimal 
statistical approach.  
5.2 Genetic model-free and bivariate meta-analysis approaches 
Minelli et al.61 have developed a method of meta-analysis that does not specify any 
particular mode of inheritance in advance; the mode of inheritance is instead estimated 
from data from the included studies. This method is known as the genetic model-free 
approach. However, this method does require the assumption that the unknown genetic 
model is common to all studies included in the meta-analysis. If the assumption of a 
common mode of inheritance across all studies is violated, a bivariate approach to meta-
analysis may be more suitable. The bivariate approach models the two effect sizes (i.e. 
heterozygotes versus homozygous wild-types, ‘Gg’ versus ‘GG’, and homozygous mutant-
types versus homozygous wild-types, ‘gg’ versus ‘GG’) separately whilst still accounting for 
the correlation between them.202 Before specifying the genetic model-free approach, it is 
useful to first specify the bivariate method of meta-analysis.  
Bivariate approach specification 
The following notation is used:  
G: wild-type allele at SNP of interest  
g: mutant-type allele at SNP of interest  
µji: true effect size for comparison j (j=1, comparison of Gg versus GG; j=2, comparison 
of gg versus GG) for study i 
zji: effect size for comparison j (e.g. log OR) estimated in study i 
 












where νji is the within-study variance for effect size µji and ν12i is the within-study covariance 
between the two effect sizes for study i. The variances and covariances can be derived from 


































where GGcases, Ggcases, and ggcases are the number of cases in the homozygous wild-type, 
heterozygous, and homozygous mutant-type groups of study i, respectively, and GGcontrols, 
Ggcontrols, and ggcontrols are the number of controls in the homozygous wild-type, 
heterozygous, and homozygous mutant-type groups of study i, respectively.  
If we assume that the studies come from a population in which the true effect sizes are also 











where τj is the between-study variance for effect size j and τ12 is the between-study 
covariance between the two effect sizes. With this approach, the between-study variance is 
therefore allowed to differ between the two contrasts.  








𝜈1𝑖 + 𝜏1 𝑣12𝑖 + 𝜏12
𝑣12𝑖 + 𝜏12 𝑣2𝑖 + 𝜏2
]} , 
from which a likelihood can be formed and maximised to estimate the parameters.  
Genetic model-free approach specification 
The genetic model-free approach is similar to the bivariate model. A parameter, λ, is 
introduced, which determines the relationship between µ1 and µ2. The relationship 
between the two effect sizes is given by: 
µ1 = λµ2 
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The value of λ is determined by the underlying mode of inheritance, i.e. a value of 0 
represents a recessive mode of inheritance, a value of 0.5 represents an additive mode of 
inheritance, and a value of 1 represents a dominant mode of inheritance. So, the genetic 












The variances and covariances can be derived from the number of cases and controls in 
each genotype group in study i as described previously for the bivariate model.  
As for the bivariate model, we assume that the studies come from a population in which 
the true effect sizes are also normally distributed. Specifically, we assume that µ2i is 
normally distributed with mean µ2 and variance τ. Since the following mathematical 
properties are true:  
i. the variance of a variable multiplied by a constant, λ, is equal to the variance of the raw 
variable multiplied by λ2; and  
ii. the covariance between a variable and that variable multiplied by a constant, λ, is equal 
to the variance of the variable, multiplied by λ,  
 












Here, it is assumed that the effect sizes share a common random component of variance, τ, 
due to the relationship between the effect sizes defined by λ (µ1 = λµ2). Combining 4) and 










2𝜏 𝑣12𝑖 + 𝜆𝜏
𝑣12𝑖 + 𝜆𝜏 𝑣2𝑖 + 𝜏
]} , 
and once again the likelihood can be formed and the parameters estimated.  
It is important to note that it is possible to implement the genetic model-free method in a 
Bayesian framework.203 The Bayesian approach may be preferable to a frequentist 
approach when there is external information relating to the magnitude of the effect sizes or 
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underlying mode of inheritance, such as expert opinion or data from studies not included in 
the meta-analysis.61 In this chapter, we implemented all analyses in the frequentist 
framework, as no such external information was available. Furthermore, estimates of effect 
size obtained from the frequentist approach would be more directly comparable with those 
obtained in Chapter 4. 
5.3 Methods 
Model selection 
In order to decide whether to use the genetic model-free or the bivariate approach for each 
genetic variant, we first needed to investigate whether the assumption of a common mode 
of inheritance across all studies included in the meta-analysis was valid. To do this, we 
plotted the log OR for Gg versus GG (z1i) against the log OR for gg versus GG (z2i) for each 
study. If the relationship between the two true effect sizes was of the form µ1=λµ2, we 
would expect the plot to demonstrate a linear relationship between the two log ORs. This 
plot allowed us to assess the extent of heterogeneity in λ between studies, as shown by 
deviation from the linear relationship. We also plotted the value of λ and its bootstrapped 
95% CI for each study. This allowed us to determine whether heterogeneity in λ between 
studies could be attributed to sampling error, or if the assumption of a constant λ across 
studies was violated.61  
We generated and plotted bootstrapped 95% CIs for λ using the gplots package204 in R 
3.5.1.205 Firstly, for each study, we generated 100,000 estimates of µ1 and µ2 (𝜇1̂ and 𝜇2̂). 
We assumed that the number of events occurring in each genotype group of each study 
followed a binomial distribution, with the parameters ‘p’ (the observed proportion of 
patients experiencing an event in the genotype group) and ‘n’ (the total number of patients 
in the genotype group). For each simulation, we generated values for the number of events 
occurring in each genotype group from these binomial distributions, and calculated 𝜇1̂ and 
𝜇2̂ using the following formulae: 
𝜇1̂ = 𝑙𝑛 
(a+0.5)(B−b+0.5)
(A−a+0.5)(b+0.5)




where a and A are the number of events and patients, respectively, in the homozygous 
wild-type group; b and B are the number of events and patients, respectively, in the 
heterozygous group; and c and C are the number of events and patients, respectively, in the 
homozygous group. A continuity correction of 0.5 was applied in these formulae to ensure 
that 𝜇1̂ and 𝜇2̂ were always defined. 
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We then ordered these ?̂? values, and used the 2,500th and 97,500th values to be the lower 
and upper limit of the CI, respectively. However, we encountered some difficulties when 
producing these bootstrapped CIs. If any of the simulated values of 𝜇2̂ were equal to zero, 
this meant that ?̂? would be undefined, and the bootstrapped CIs could not be calculated. To 
overcome this problem, we tried both 1) excluding zero values of 𝜇2̂, and 2) replacing them 
with a small value (0.001). For all of our datasets, we observed that CIs were similar 
between the two approaches when few zeros were observed. As the number of zero values 
observed increased, we saw that CIs became increasingly wider when we replaced zero 
values with a small number, in comparison to when we excluded zero values. We therefore 
used the method of excluding the zeros, as this was the more conservative approach for 
investigating whether the assumption of constant λ across studies was valid.  
For each genetic variant, if we decided that the assumption of a constant λ across studies 
was reasonable, we analysed the data using the genetic model-free approach. However, we 
also performed analyses using the bivariate approach, in order to investigate the 
robustness of our results, as the assessments of the appropriateness of the constant λ 
assumption were subjective. If we had found sufficient evidence to suggest that the 
constant λ assumption was violated, we would have performed the analysis using the 
bivariate approach only. For genetic variants where the validity of the constant λ 
assumption was unclear, we performed analyses using both the genetic model-free and 
bivariate approaches. 
Fixed or random effects  
We modelled µ2 as having a random effect for all our analyses using the genetic model-free 
approach due to heterogeneity between studies in terms of study design, quality of 
methods, ethnic background of participants, and outcome definitions. Technically, it is 
possible to assume that the mode of inheritance varies slightly between studies, by 
assuming λ to have a random effect. However, it is usually not possible to model both µ2 
and λ as random-effects parameters, as it is difficult to disentangle the heterogeneity of λ 
from the heterogeneity of µ2 without obtaining additional information .61 We therefore 
treated λ as a fixed-effects parameter in our analyses. 
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For the bivariate approach, we modelled both µ1 and µ2 as having random effects, once 
again due to clinical and methodological heterogeneity between studies. 
Heterosis 
If the occurrence of heterosis (where the effect of the heterozygous genotype is greater 
than that of the homozygous mutant-type genotype) is biologically implausible, it is 
recommended that λ is restricted to lie within the interval [0-1].61 We did not have 
sufficient information on the NAT2 genetic variants to rule out the possibility of heterosis, 
so we did not specify limits within which λ had to lie. 
Continuity correction 
In the systematic review described in Chapter 3 and Chapter 4, there were sufficient data to 
perform meta-analyses for only one outcome, hepatotoxicity. We summarised 
hepatotoxicity data for each study according to the following contingency table: 
Table 22 Contingency table to be completed for each study  
Study ID Genetic 
variant 

















Study X        
Het: heterozygous; Hom: homozygous; MT: mutant-type; WT: wild-type 
 
If any of the cells in the contingency table were zero, we added a continuity correction of 
0.5 to each cell in the table before using the genetic model-free or bivariate methods of 
meta-analysis.  
Sensitivity analyses  
Prior to undertaking a meta-analysis for a SNP, a test for HWE was undertaken for each 
study separately. We did not test HWE for NAT2 acetylator status, as acetylator status is a 
trait defined by several NAT2 SNPs. Where genotypes for a study were found to deviate 
from HWE (p<0.05), a sensitivity analysis was conducted excluding that study.  
Software and code 
We used Stata 14192 to perform the genetic model-free and bivariate analyses; parameters 
were estimated in all analyses by maximum likelihood using the ml command. We used 
code provided in online supplementary materials to an article published by Bagos,206 which 




We examined the plot of z1i versus z2i, and the bootstrapped 95% CIs for λ for each study 
(Appendix 5) for each NAT2 genetic variant. For NAT2 acetylator status, NAT2 481C-T, NAT2 
590G-A, and NAT2 857G-A, we concluded that the assumption of constant λ seemed 
reasonable. For NAT2 282C-T, NAT2 341T-C, NAT2 803A-G, there were few studies 
contributing data to each of these analyses, and considerable variability in the estimates of 
λ. We therefore concluded that the validity of the assumption of constant λ was unclear. 
Results from both the genetic model-free and bivariate approaches are provided for all 
genetic variants investigated.  
Association between NAT2 genetic variants and hepatotoxicity 
The results of the genetic model-free analyses and bivariate analyses are presented in Table 
23 to Table 29. We also present the results of simple pairwise comparisons for comparative 
purposes. 
It should be noted that some results from simple pairwise comparisons presented in this 
chapter differ slightly to those presented in Chapter 4. These differences are due to a 
change in how we handled studies that did not identify any patients belonging to one of the 
relevant genotype groups. For the pairwise comparisons presented in Chapter 4, we 
excluded these studies from meta-analysis. For the pairwise comparisons presented in this 
chapter, we applied continuity correction (by adding 0.5 to each cell in the contingency 
table) so that the results were directly comparable with those obtained from the genetic 
model-free and bivariate approaches.  
NAT2 acetylator status 
Results from the genetic model-free and bivariate analyses were very similar to those from 
the simple pairwise comparisons. All analyses suggested that slow acetylators were 
significantly more likely to experience hepatotoxicity than rapid acetylators, and that there 
was no significant difference between intermediate and rapid acetylators (Table 23). The 
estimated value of λ from the genetic model-free analysis is close to zero (λ=0.12, 95% CI: -
0.08 to 0.32), and therefore there is evidence to suggest that the mode of inheritance for 
NAT2 acetylator status may be recessive.  
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Table 23 Association between NAT2 acetylator status and hepatotoxicity: results of the genetic model-free 
analysis, bivariate analysis and simple pairwise comparisons 
Analysis 
approach 
λ (95% CI) OR for intermediate 
vs rapid acetylators 
(95% CI) 
I2 OR for slow vs rapid 




0.12 (-0.08 to 0.32) 1.17 (0.88 to 1.56) 0.0% 3.76 (2.32 to 6.09) 60.0% 
Bivariate N/A 1.17 (0.87 to 1.57) 0.0% 3.76 (2.32 to 6.08) 60.0% 
Pairwise 
comparisons 
N/A 1.12 (0.87 to 1.45) 0.0% 3.68 (2.23 to 6.09) 60.0% 
CI: confidence interval; N/A: not applicable; OR: odds ratio 
 
A graphical comparison of the results obtained in this chapter for the analysis of NAT2 
acetylator status and hepatotoxicity, with the analyses performed in Chapter 4 (assuming a 
dominant mode of inheritance, i.e. slow/intermediate versus rapid acetylators, and a 
recessive mode of inheritance, i.e. slow versus intermediate/rapid acetylators), is provided 
in Figure 21. 
 
Figure 21 Summary of the results obtained by applying different approaches to the analysis of NAT2 acetylator 
status and hepatotoxicity 
CI: confidence interval 
 
NAT2 282C-T  
Results from the genetic model-free analysis and bivariate analysis were very similar to 
those from the simple pairwise comparisons. All three analyses suggested that homozygous 
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mutant-type (TT) patients were significantly more likely to experience hepatotoxicity than 
homozygous wild-type (CC) patients, and that there was no significant difference between 
heterozygous (CT) patients and homozygous wild-type (CC) patients (Table 24). The 
estimated value of λ from the genetic model-free analysis is close to zero (λ=0.16, 95% CI: -
0.15 to 0.47), and therefore there is evidence to suggest that the mutant-type allele, T, may 
be recessive.  
Table 24 Association between NAT2 282C-T and hepatotoxicity: results of the genetic model-free analysis, 
bivariate analysis and simple pairwise comparisons 
Analysis 
approach 
λ (95% CI) OR for CT vs CC  
(95% CI) 
I2 OR for TT vs CC 




0.16 (-0.15 to 0.47) 1.24 (0.79 to 1.95) 0.0% 3.83 (2.24 to 6.54) 5.5% 
Bivariate N/A 1.24 (0.79 to 1.95) 0.0% 3.83 (2.24 to 6.54) 5.5% 
Pairwise 
comparisons 
N/A  1.27 (0.80 to 2.02) 0.0% 3.95 (2.21 to 7.05) 5.5% 
CI: confidence interval; N/A: not applicable; OR: odds ratio 
 
We identified that genotype data from Santos 2013155 deviated from HWE, and so 
performed a sensitivity analysis excluding data from this study. The exclusion of Santos 
2013155 had little impact on the results (Appendix 6).  
NAT2 341T-C 
Results from the genetic model-free analysis and bivariate analysis were very similar to 
those from the simple pairwise comparisons. All three analyses suggested that there were 
no significant differences between either heterozygous (TC) patients and homozygous wild-
type (TT) patients, or homozygous mutant-type (CC) patients and homozygous wild-type 
(TT) patients (Table 25). The most noticeable difference was between the OR calculated for 
CC versus TT by the simple pairwise comparison (OR=1.51, 95% CI: 0.59 to 3.85) and the 
ORs calculated for CC versus TT by the genetic model-free approach (OR=1.96, 95% CI: 0.85 
to 4.49) and the bivariate approach (OR=1.96, 95% CI: 0.85 to 4.48). The estimated value of 
λ from the genetic model-free analysis is close to zero (λ=0.19, 95% CI: -0.47 to 0.86), and 
therefore there is some evidence to suggest that the mutant-type allele, C, may be 
recessive. However, the 95% CI for λ is wide, and it is therefore difficult to draw firm 
conclusions about the true mode of inheritance of the NAT2 341T-C SNP.  
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Table 25 Association between NAT2 341T-C and hepatotoxicity: results of the genetic model-free analysis, 
bivariate analysis and simple pairwise comparisons 
Analysis 
approach 
λ (95% CI) OR for TC vs TT 
 (95% CI) 





0.19 (-0.47 to 0.86) 1.14 (0.72 to 1.79) 0.0% 1.96 (0.85 to 4.49) 0.0% 
Bivariate N/A 1.13 (0.72 to 1.78) 0.0% 1.96 (0.85 to 4.48) 0.0% 
Pairwise 
comparisons 
N/A 1.15 (0.72 to 1.82) 0.0% 1.51 (0.59 to 3.85) 0.0% 
CI: confidence interval; N/A: not applicable; OR: odds ratio 
 
We identified that genotype data from Lee 2010141 deviated from HWE, and so performed a 
sensitivity analysis excluding data from this study. The exclusion of Lee 2010141 had little 
impact on the results (Appendix 6).  
NAT2 481C-T  
The ORs for heterozygous (CT) patients versus homozygous wild-type (CC) patients 
calculated by the genetic model-free and bivariate analyses were almost identical to that 
calculated by the simple pairwise comparison. All analyses identified a significant difference 
between homozygous mutant-type (TT) patients and homozygous wild-type (CC) patients. 
The estimated value of λ from the genetic model-free analysis is close to 0.5 (λ=0.47, 95% 
CI: 0.08 to 0.86), and therefore there is some evidence to suggest that the mode of 
inheritance for this SNP may be additive. However, the 95% CI for λ is wide, and it is 
therefore difficult to draw firm conclusions about the true mode of inheritance of the NAT2 
481C-T SNP. 
Table 26 Association between NAT2 481C-T and hepatotoxicity: results of the genetic model-free analysis, 
bivariate analysis and simple pairwise comparisons 
Analysis 
approach 
λ (95% CI) OR for CT vs CC  
(95% CI) 





0.47 (0.08 to 0.86) 1.49 (1.12 to 1.97) 0.0% 2.32 (1.36 to 3.94) 0.0% 
Bivariate N/A 1.48 (1.10 to 2.00) 0.0% 2.16 (1.14 to 4.11) 0.0% 
Pairwise 
comparisons 
N/A 1.48 (1.12 to 1.97) 0.0% 2.13 (1.23 to 3.67) 0.0% 
CI: confidence interval; N/A: not applicable; OR: odds ratio 
 
NAT2 590G-A 
Results from the genetic model-free and bivariate analyses were very similar to those from 
the simple pairwise comparisons. All analyses suggested that heterozygous (AG) patients 
were significantly more likely to experience hepatotoxicity than homozygous wild-type (GG) 
patients, and that homozygous mutant-type (AA) patients were significantly more likely to 
experience hepatotoxicity than homozygous wild-type (GG) patients (Table 27). The 
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estimated value of λ from the genetic model-free analysis (λ=0.35, 95% CI: 0.09 to 0.62) is 
not indicative of a particular mode of inheritance for the NAT2 590G-A SNP. 
Table 27 Association between NAT2 590G-A and hepatotoxicity: results of the genetic model-free analysis, 
bivariate analysis and simple pairwise comparisons 
Analysis 
approach 
λ (95% CI) OR for AG vs GG (95% 
CI) 





0.35 (0.09 to 0.62) 1.30 (1.03 to 1.64) 0.0% 2.11 (1.31 to 3.39) 47.7% 
Bivariate N/A 1.33 (1.06 to 1.68) 0.0% 2.01 (1.21 to 3.34) 47.7% 
Pairwise 
comparisons 
N/A 1.30 (1.06 to 1.59) 0.0% 2.05 (1.24 to 3.40) 47.7% 
CI: confidence interval; N/A: not applicable; OR: odds ratio 
 
Excluding data from the Xiang 2014170 and Santos 2013155 studies, which we found to 
deviate from HWE, had little impact on the results of these analyses (Appendix 6).  
NAT2 803A-G 
Results from the genetic model-free analysis and bivariate analysis were similar to those 
from the simple pairwise comparisons. There were no statistically significant differences 
between either heterozygous (GA) patients and homozygous wild-type (AA) patients, or 
homozygous mutant-type (GG) patients and homozygous wild-type (AA) patients for any of 
the three analyses (Table 28). Once again, the most noticeable difference was between the 
OR calculated for GG versus AA by the simple pairwise comparison (OR=1.93, 95% CI: 0.71 
to 5.21) and the ORs calculated for GG versus AA by the genetic model-free approach 
(OR=2.21, 95% CI: 0.86 to 5.70) and the bivariate approach (OR=2.21, 95% CI: 0.86 to 5.69). 
The estimated value of λ from the genetic model-free analysis is close to zero (λ=0.18, 95% 
CI: -0.47 to 0.84), and therefore there is some evidence to suggest that the mutant-type 
allele, G, may be recessive. However, the 95% CI for λ is wide, and it is therefore difficult to 
draw firm conclusions about the true mode of inheritance of the NAT2 803A-G SNP. 
Table 28 Association between NAT2 803A-G and hepatotoxicity: results of the genetic model-free analysis, 
bivariate analysis and simple pairwise comparisons 
Analysis 
approach 
λ (95% CI) OR for GA vs AA (95% 
CI) 





0.18 (-0.47 to 0.84) 1.16 (0.68 to 1.96) 0.0% 2.21 (0.86 to 5.70) 0.0% 
Bivariate N/A 1.15 (0.68 to 1.96) 0.0% 2.21 (0.86 to 5.69) 0.0% 
Pairwise 
comparisons 
N/A 1.14 (0.67 to 1.96) 0.0% 1.93 (0.71 to 5.21) 0.0% 




Results from all three analyses suggested that heterozygous (GA) patients were significantly 
more likely to experience hepatotoxicity than homozygous wild-type (GG) patients (Table 
29).The results for the comparison of homozygous mutant-type (AA) and homozygous wild-
type (GG) patients were also similar between the three analysis approaches, although the 
result from the genetic model-free analysis did not reach statistical significance. 
 The estimated value of λ from the genetic model-free analysis is close to 0.5 (λ=0.46, 95% 
CI: -0.16 to 1.08), and therefore there is some evidence to suggest that the mode of 
inheritance for this SNP may be additive. However, the 95% CI for λ is wide, and it is 
therefore difficult to draw firm conclusions about the true mode of inheritance of the NAT2 
857G-A SNP. It is interesting to note here that the 95% CI includes 1, and therefore does not 
rule out the possibility of heterosis. 
Table 29 Association between NAT2 857G-A and hepatotoxicity: results of the genetic model-free analysis, 
bivariate analysis and simple pairwise comparisons 
Analysis 
approach 
λ (95% CI) OR for GA vs GG 
(95% CI) 





0.46 (-0.16 to 1.08) 1.31 (1.04 to 1.65) 0.9% 1.80 (0.95 to 3.41) 1.0% 
Bivariate N/A 1.29 (1.01 to 1.65) 0.9% 1.96 (1.01 to 3.83) 1.0% 
Pairwise 
comparisons 
N/A 1.30 (1.03 to 1.64) 0.9% 1.97 (1.06 to 3.64) 1.0% 
CI: confidence interval; N/A: not applicable; OR: odds ratio 
 
5.5 Discussion 
In this chapter, we applied the genetic model-free method of meta-analysis to data for the 
association between genetic variants of the NAT2 gene and hepatotoxicity, obtained as part 
of the systematic review and meta-analysis described in Chapter 3 and Chapter 4. The 
analyses presented in this chapter ought to be considered as exploratory, as no 
adjustments have been made to account for multiple analysis approaches. Conclusions 
regarding the association between NAT2 genetic variants and ATDH ought to be based on 
results from the primary and secondary analyses presented in Chapter 4. 
Impact of meta-analysis approach 
Generally, results from the genetic model-free analyses and bivariate analyses were very 
similar to those obtained from the pairwise comparisons. There was no obvious pattern in 
terms of how the size or precision of the effect estimate was impacted by changing the 
analysis approach.  
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The largest impact in terms of effect size was seen for the analysis of the NAT2 341T-C SNP; 
the genetic model-free approach and bivariate approach both estimated an increase in 
odds of 96% for homozygous mutant-type (CC) individuals in comparison to homozygous 
wild-type (TT) individuals, while the simple pairwise analysis estimated an increase in odds 
of 51% for the same comparison. However, neither effect was shown to be statistically 
significant. When comparing results presented in this chapter, it is important to note that 
there were differences in how heterogeneity was estimated between the multivariate 
(bivariate and genetic-model free) and univariate (pairwise comparisons) approaches. 
Specifically, for the genetic model-free and the bivariate analyses, a maximum likelihood 
approach was implemented to estimate heterogeneity, in accordance with the methods 
implemented in the paper that outlines the genetic-model free approach.61 Alternatively, 
the pairwise comparisons made use of the DerSimonian and Laird ‘moment-based 
approach’ to estimate heterogeneity. It is possible that differences between the results of 
the multivariate methods and the univariate method for the NAT2 341T-C SNP may at least 
in part be attributed to differences between the methods used to estimate heterogeneity.  
Langan et al.207 conducted empirical research to explore the impact that choice of 
heterogeneity estimator may have on observed results from meta-analyses. The study 
identified that differences between heterogeneity estimators rarely had a major impact on 
the observed effect estimate. However, this study did not specifically consider the 
maximum likelihood approach, as this method has been reported to be inferior to the 
restricted maximum likelihood approach,208 which was included in the study. It is possible 
that differences between the maximum likelihood and DerSimonian and Laird ‘moment-
based’ approaches may be more pronounced.  
Riley et al.209 demonstrated that the extent to which results of bivariate random-effects 
meta-analyses differ from results of univariate random-effects meta-analyses is likely to 
vary according to the amount of missing data in the data set. This is due to the fact that 
when data are missing for one of the comparisons of interest (say, j=1), the differences 
between the within-study variances for this comparison of interest (the ν1is) are likely to be 
large; this allows more scope for the bivariate meta-analysis to ‘borrow strength’ from data 
for the related comparison (j=2). On examination of the NAT2 SNP data sets, we did not 
identify an obvious relationship between the amount of missing data and the extent to 
which results differed between the univariate and bivariate meta-analyses. We therefore 
concur with Riley and colleagues, who concluded that further work is required to 
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investigate how, and under what conditions, the results of bivariate and univariate random-
effects meta-analyses differ for a variety of missing data scenarios.  
For the analysis of the NAT2 857G-A SNP; the simple pairwise analysis and bivariate analysis 
demonstrated a statistically significant effect for the comparison of homozygous mutant-
type (AA) individuals versus homozygous wild-type (GG) individuals, while the result from 
the genetic model-free analysis did not reach statistical significance. Here, it seems unlikely 
that differences in the method used to estimate heterogeneity could explain the difference 
between the observed results, as results from the bivariate and pairwise analyses (which 
implement different methods of estimating heterogeneity) were very similar. It is more 
likely that differences between the observed results were due to the underlying 
assumptions of the genetic model-free approach, i.e. that the two effect sizes are related 
according to λ, and consequently share a common random component of variance. 
Based on our observations that differences between the genetic model-free, bivariate and 
univariate approaches may have a considerable impact on the magnitude of the observed 
effect size, and may also alter the statistical significance of an effect size, we consider it to 
be plausible that for some systematic reviews, the choice of meta-analysis method may 
impact the overall conclusions.  
Limitations 
When applying the genetic model-free method, the first step is to investigate whether the 
assumption of constant λ is reasonable. For the NAT2 282C-T, NAT2 341T-C, and NAT2 
803A-G SNPs, it was unclear whether the assumption of constant λ was valid. We consider 
that a limitation of the genetic model-free approach is that for genetic variants where data 
are sparse, it may often be difficult to make firm conclusions about the suitability of the 
genetic model-free approach. Even when data were not sparse, and we judged the 
assumption of constant λ to be reasonable (for NAT2 acetylator status, NAT2 481C-T, NAT2 
590G-A, and NAT2 857G-A), these judgements were subjective. It was therefore useful to 
examine the impact that using the bivariate approach had on the results for all the 
investigated genetic variants. Results were mostly similar between the bivariate and 
genetic model-free approaches; this provided reassurance that the results obtained were 
robust to changes in the assumption of constant λ.  
A further limitation of the analyses presented in this chapter is that we were only able to 
include data from studies that reported outcome data for each genotype group separately. 
For NAT2 acetylator status, 13 studies reported data for the rapid and intermediate 
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acetylator groups combined, and one study reported data for the slow and intermediate 
acetylator groups combined. It was not possible to include data on acetylator status from 
any of these 14 studies in the analyses presented in this chapter, and consequently 
information has been lost.  
Salanti and Higgins73 have developed methodology which allows the synthesis of data from 
studies, regardless of whether data has been reported for combined or separate genotype 
groups (as previously mentioned in Section 2.5). As the focus of this chapter was to 
investigate the impact of applying the genetic model-free approach, we have not applied 
the Salanti and Higgins73 method to our data. As the loss of data in some of the analyses 
conducted as part of our systematic review was considerable due to merged genotype 
groups, an exploration of the Salanti and Higgins73 method may have provided valuable 
insight into the robustness of our findings.  
As previously outlined, it is possible that differences between the methods used to 
estimate heterogeneity between the three analysis approaches may at least partially 
explain some of the differences in observed results. Future exploration of how results 
varied under the different analysis approaches when assuming a common method of 
estimating heterogeneity would provide additional insight into how much impact the 
different underlying assumptions of each analysis approach has on observed meta-analysis 
results.  
5.6 Conclusion 
We found that results were often very similar between the genetic model-free, bivariate 
and simple pairwise methods of meta-analysis. However, we also observed that results 
occasionally varied to the extent that conclusions of a review may change depending on the 
analysis approach chosen. It is therefore important that review authors carefully consider 
the available methods of meta-analysis, and pre-specify their analysis strategy in a detailed 
protocol. It may also be informative to investigate the impact of meta-analysis approach in 
sensitivity analyses.  
Improvements in the reporting of pharmacogenetic studies would help systematic review 
authors who wish to use the genetic model-free approach in their meta-analyses. If study 
authors routinely reported outcomes for each genotype group separately, this would give 
systematic reviewers greater freedom in terms of their analysis approach, and would 
reduce the likelihood of relevant data being excluded from meta-analyses.   
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6 Development of the STROPS (STrengthening the Reporting 
Of Pharmacogenetic Studies) guideline 
6.1 Introduction 
While conducting the work outlined in Chapter 3, Chapter 4 and Chapter 5 of this thesis, we 
hoped to identify challenges that systematic reviewers encounter when synthesising 
evidence from pharmacogenetic studies. A key theme that we observed was that 
improvements in the reporting of pharmacogenetic studies would enable systematic 
reviewers to conduct better-quality and more strongly powered meta-analyses. For 
example, lack of reporting of key patient characteristics, such as ethnicity, can severely 
hinder investigations of heterogeneity, which form a key part of any systematic review 
and/or meta-analysis. Additionally, if authors of a pharmacogenetic study do not report the 
number of participants in each genotype group and outcomes for each genotype group 
separately, systematic review authors are limited in terms of the analysis approaches 
available to them, and the study may even be excluded from meta-analyses.  
Cobos et al.210 also identified that there is room for improvement in the reporting of 
pharmacogenetic studies in their review of the methodological quality of pharmacogenetic 
studies with binary treatment response outcomes. In particular, study design 
characterisation was lacking in 43 (66%) of 65 included studies, while the majority (97%) of 
included studies did not report the sample size calculation or planned sample size. 
Furthermore, the issue of multiple testing was applicable to 59 included studies, although 
only 11 (19%) reported methods for addressing multiplicity. Finally, tests for HWE were 
reported fully (with population tested, test method, and p-value all provided) in 4 of 42 
papers (10%) that analysed allele frequencies. The authors of this review concluded that 
specific guidance on the reporting of pharmacogenetic studies would be valuable. 
Consequently, we decided to shift the focus of our work to the reporting of 
pharmacogenetic studies. Although reporting guidelines are available for observational 
studies11 and genetic association studies,199 there is currently no guideline for the reporting 
of pharmacogenetic studies that has been developed using widely accepted and robust 
methodology. Pharmacogenetic studies have different characteristics to other types of 
observational and indeed, genetic association studies. Although some items from existing 
guidelines can be applied to pharmacogenetic studies, there are many additional 
pharmacogenetic-specific characteristics that could be reported; clear guidance on which 
items are essential to report is needed.  
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We therefore decided to develop a reporting guideline for pharmacogenetic studies (and 
accompanying explanation and elaboration [E+E] document) using methodology proposed 
by EQUATOR (Enhancing the QUAlity and Transparency Of health Research).211 In this 
chapter, we describe the methods we used to develop the reporting guideline, and present 
the final version, referred to as the STROPS (STrengthening the Reporting of 
Pharmacogenetic Studies) guideline. The STROPS guideline is applicable to studies designed 
to identify pharmacogenetic associations, i.e. the study designs described in Table 1 of 
Chapter 1. The STROPS guideline will set a robust standard of reporting for 
pharmacogenetic studies, and consequently will facilitate the conduct of high-quality 
systematic reviews and meta-analyses. 
6.2 Methods  
The protocol outlining the pre-specified methods of this project has been published.212 The 
steering committee for the STROPS project included the following six individuals: Marty 
Chaplin (researcher into meta-analysis of pharmacogenetic studies), Jamie Kirkham 
(researcher into consensus methodology and developer of reporting guidelines), Kerry 
Dwan (researcher into systematic review methodology), Derek Sloan (clinical infectious 
diseases researcher), Gerry Davies (clinical pharmacogenetic researcher in infectious 
diseases) and Andrea Jorgensen (researcher into statistical methods for pharmacogenetics, 
including evidence synthesis methods). 
In accordance with the EQUATOR methodology for guideline development,211 we (the 
steering committee) developed the STROPS guideline according to the following stages: 
 Establish a preliminary checklist of reporting items to be considered for inclusion in the 
reporting guideline for pharmacogenetic studies (Stage 1). 
 Conduct a Delphi survey to gain consensus opinion on reporting items to be considered 
within a reporting guideline for pharmacogenetic studies (Stage 2). 
 Hold a consensus meeting to consider the results of the Delphi survey and to finalise 
the list of items for the reporting guideline (Stage 3). 
 Develop and publish the STROPS guideline and a detailed E+E document (Stage 4). 
 
Preliminary checklist of reporting items 
To establish a preliminary checklist of reporting items, we firstly included items from 
existing relevant guidelines. We considered all guidelines listed on the EQUATOR website213 
under the clinical area of genetics. Two authors (MC and ALJ) assessed guidelines to be 
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relevant if they were applicable to pharmacogenetics studies. Two authors (MC and ALJ) 
discussed whether items from these guidelines would ensure transparency of reporting of 
pharmacogenetic studies, and consequently decided whether to include each item in the 
preliminary checklist. For example, the GRIPS statement214 includes some items that can be 
applied to pharmacogenetic studies; however, we did not include all items from this 
guideline as many items are only relevant to studies where a genetic risk prediction model 
is being developed, and these studies are outside the remit of our guideline. We also 
considered items from the STROBE guideline,11 which is not listed on the EQUATOR website 
under the clinical area of genetics, but was judged to be applicable to pharmacogenetic 
studies by members of the steering committee. MC and ALJ modified some items from 
existing guidelines; the majority of these wording modifications were intended to make 
items more relevant to pharmacogenetic studies. 
Secondly, we supplemented this list with additional items thought to be important. These 
items were either suggested by steering committee members based on our own experience 
in pharmacogenetic research, or were drafted by MC and ALJ to cover issues identified by 
Jorgensen and Williamson18 that relate specifically to the conduct of pharmacogenetic 
research. Finally, we drafted help text for each item, to ensure that the language used was 
comprehensible to all Delphi participants. All steering committee members approved this 
preliminary checklist (including the wording of each item) before the Delphi survey began.  
Delphi survey 
Participants 
In March-April 2019, we invited three groups of stakeholders to participate in the Delphi 
survey. Stakeholder groups were chosen to encompass all aspects of pharmacogenetic 
research.  
 Those who undertake primary pharmacogenetic research 
We asked co-ordinators of ten national and international pharmacogenetics networks to 
forward the survey on to network members. We performed searches to ensure that all 
major networks across the globe were identified.  
 Those who systematically review pharmacogenetic research data 
We identified 89 contact authors of systematic reviews of pharmacogenetics studies 
identified by searching PubMed, using appropriate search terms such as 
‘pharmacogenetics’, ‘pharmacogenomics’, ‘systematic review’ and ‘meta-analysis’. An 
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information specialist helped us to design the search strategy. We used a snowball 
technique, asking contact authors to complete the survey and to forward the survey on to 
their co-authors. 
 Those who publish pharmacogenetic research 
We contacted 210 editors-in-chief of 168 journals that may publish pharmacogenetic 
studies. We used a snowball technique, asking editors-in-chief to participate in the survey, 
and also to forward the survey on to editors at their journal. We performed searches using 
Google to identify journals using search terms ‘pharmacogenetics’, ‘pharmacogenomics’, 
‘precision medicine’, ‘personalised/personalized medicine’ and ‘journal’. We also 
considered journals listed on the ‘SCImago Journal & Country Rank’ website215 under the 
category ‘Genetics’. 
Design 
The Delphi process consisted of two rounds of electronic-based survey, response and 
feedback. The first round survey (Round 1, March-May 2019) included scoring of reporting 
guideline items from the preliminary list formed at Stage 1 and invited additional items not 
included in this list. A second round survey (Round 2, May-July 2019) was then undertaken 
providing feedback from Round 1 and inviting participants to re-score the items. Any 
additional reporting items identified by participants in Round 1 (and approved by the 
steering committee) were included for scoring by participants in Round 2 of the Delphi 
process. 
The Delphi survey was conducted using DelphiManager,216 a web-based system designed by 
the COMET Initiative189 to facilitate the building and management of Delphi surveys.  
Recruitment process and ethical considerations  
We e-mailed the individuals listed above with information about the STROPS project and 
the Delphi process and an invitation to complete Round 1 of the Delphi survey within three 
weeks. We informed invitees that participation in the survey was optional, and that we 
would assume informed consent if an invitee responded to Round 1 of the survey. We 
informed invitees that all data would be anonymised; we allocated a unique identification 
number to each participant in the Delphi survey.  
We sent a reminder e-mail at the end of the second week to prompt completion of the 
survey. All participants who completed Round 1 of the Delphi survey were invited to 
146 
participate in Round 2. However, we informed invitees that completion of Round 1 did not 
necessitate completion of Round 2. 
The University of Liverpool ethics committee was consulted and confirmed ethical approval 
for this study (Reference: 3586).  
Participant characteristics 
We asked participants to provide their name, e-mail address and consent to be 
acknowledged as a participant in the Delphi survey in publications arising from this project.  
Delphi scoring 
Participants were asked to score each of the reporting guideline items listed using a scale of 
1 to 9, with 1 to 3 labelled ‘not important for inclusion in the guideline’, 4 to 6 labelled 
‘important but not critical for inclusion in the guideline’ and 7 to 9 labelled ‘critical for 
inclusion in the guideline’.217 Participants were also given the option to score a reporting 
guideline item as ‘unable to score’ if they were unable to offer an opinion on the 
importance of the item.  
Delphi Round 1 
Reporting guideline items were presented in the order in which they would be addressed in 
the pharmacogenetic study report and were grouped under relevant headings (i.e. title and 
abstract, introduction, methods, results, discussion and other information). Participants 
were asked to score each item as described previously. Participants were given the 
opportunity to provide free text feedback on each item; this feature ensured participants 
were able to comment on the wording of items or provide justification for their score. 
Participants were also given the chance to suggest items that they believed should be 
included in the reporting guideline. 
Round 1 analysis 
For each item, the number of participants who scored the item and the distribution of 
scores were summarised. Participants who scored an item as ‘unable to score’ were 
excluded from the analysis for that particular item. The steering committee reviewed all 
additional reporting items suggested by participants. If items were not already covered by 
the existing list, we added these items to the list of reporting items presented in Round 2, 
or we covered the item as part of the E+E text for existing items. We also reviewed free text 
participant feedback provided for each item, and amended the wording of items or the 
accompanying E+E text where appropriate. The wordings of additional or amended items 
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were constructed by MC and ALJ, and were approved by members of the steering 
committee. 
Delphi Round 2 
In Round 2, each participant was shown the number of respondents and distribution of 
scores for each item from Round 1, for each stakeholder group separately. Participants 
were also reminded how they personally scored each item in Round 1. Participants were 
asked to consider the responses from other Delphi participants, and to re-score the items. 
Additional items identified as part of Round 1 were scored by participants in Round 2. 
Round 2 analysis 
For each item, the number of respondents and the distribution of scores was summarised. 
Participants who scored an item as ‘unable to score’ were excluded from the analysis for 
that particular item.  
If participants that did not respond to Round 2 have different opinions to participants from 
the same stakeholder group who completed both rounds, then attrition bias has occurred 
and the results of the Delphi survey may be affected. We investigated the risk of attrition 
bias by calculating average Round 1 scores for each participant, and then producing 
boxplots to show the distributions of these average scores according to whether 
participants completed Round 2 or not, for each stakeholder group. We visually examined 
these plots to assess the likelihood of attrition bias.  
Consensus definition 
We defined that each stakeholder group had reached consensus for an item if at least 70% 
of members of that group scored the item as ‘critical for inclusion in the guideline’.  
Consensus meeting 
The steering committee and representatives from the stakeholder groups met to consider 
the results of the Delphi survey and to finalise the list of items for the reporting guideline. 
We aimed to include one or two representatives (with at least one being non-UK based) 
from each stakeholder group in the consensus meeting. We invited individuals to the 
consensus meeting using the following broad principles: i) Delphi participants who 
completed both rounds; (ii) a balance across the three stakeholder groups; (iii) a reasonable 
geographic spread. If an individual could not attend, they were replaced by someone else 
from the same stakeholder group. The meeting was conducted via the web conferencing 
software, Zoom.218 
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Prior to and during the meeting, participants were shown a summary of how each 
stakeholder group scored each reporting item at Round 2 of the Delphi survey, and the 
number of stakeholder groups who achieved consensus. Meeting attendees discussed each 
reporting item in turn, and made a decision on whether to include the item in the reporting 
guideline or not. Where necessary, attendees voted on whether an item ought to be 
included in the guideline using TurningPoint polling software;219 the item was retained if at 
least 70% of attendees voted for its inclusion. Items were considered in the order they were 
presented in the Delphi survey.  
Post-consensus meeting development 
We drafted the reporting guideline and E+E document concurrently. The purpose of the E+E 
document is to provide the rationale for and meaning of each reporting item alongside 
examples of good reporting practice. We also provided the origin of each reporting item in 
the E+E document. 
6.3 Results 
Preliminary checklist of reporting items 
We considered 12 guidelines listed on the EQUATOR website213 under the clinical area of 
genetics; we assessed two199, 214 to be applicable to pharmacogenetics studies. The 
preliminary checklist consisted of 92 reporting items (Appendix 7, Table 60). The items are 
labelled 1 to 85, as some items have subitems, for example, 52a, 52b, 52c. The checklist 
includes: 38 items from the STROBE statement,11 22 items from the STREGA statement,199 
20 items drafted by MC and ALJ to cover issues identified by Jorgensen and Williamson,18 
10 items suggested by members of the steering committee, and two items from the GRIPS 
statement.214 A total of 22 items from existing guidelines were modified; the majority of 
these modifications were intended to make items more relevant to pharmacogenetic 
studies.  
Delphi survey 
In Round 1 of the Delphi survey, participants were asked to score 92 reporting items (the 
preliminary checklist of reporting items). A total of 71 individuals completed Round 1: 15 
journal editors, 41 primary researchers and 15 systematic reviewers. A total of 10 
participants suggested 31 additional items at this stage. In addition, during Round 1 of the 
survey, Delphi invitees made us aware of two publications220, 221 which contained potentially 
relevant reporting items. After reviewing the additional reporting items suggested by 
participants and items from the two relevant publications, we included seven additional 
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items in the list of reporting items presented in Round 2 (Appendix 7, Table 2). We also 
covered some suggested reporting items by including additional detail in the E+E text for 
existing items. No items were amended based on participants’ free text comments, 
although alterations were made to the E+E text accompanying some items to address the 
given feedback. 
A total of 52 individuals scored 99 reporting items in Round 2 of the Delphi survey: 10 
journal editors, 31 primary researchers, and 11 systematic reviewers. The anonymised data 
from both rounds of the Delphi survey are available in the supplementary materials to the 
publication of the STROPS guideline.222  
As we asked network co-ordinators, systematic reviewers and journal editors to contact 
individuals on our behalf, it is impossible to determine a response rate to Round 1 of the 
Delphi survey. However, we considered the response received to Round 2 to be reasonable 
(overall: 52/71, 73%; journal editors: 10/15, 67%; systematic reviewers: 31/41, 76%; 
primary researchers: 11/15, 73%). Considering the boxplots presented in Figure 22 to Figure 
25, the distributions of Round 1 scores were similar between those who completed both 
rounds of the Delphi survey, and those who completed Round 1 only. There was therefore 
no evidence to suggest that attrition bias occurred.  
 
Figure 22 Attrition bias: All stakeholder groups 
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Figure 23 Attrition bias: Journal editors 
 
Figure 24 Attrition bias: Primary researchers 
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Figure 25 Attrition bias: Systematic reviewers 
 
Consensus meeting 
The consensus meeting took place in November 2019, including six steering committee 
members, and four representatives of stakeholder groups (one journal editor, based in 
Germany; one primary researcher, based in Switzerland; two systematic reviewers, based in 
the UK and Spain). Two steering committee members did not participate in voting (JK 
chaired and KD took notes), so there were eight voting individuals in attendance.  
Prior to the meeting, we provided consensus meeting attendees with a consensus matrix 
(Appendix 8), which documents the percentage of individuals within each stakeholder 
group scoring each item as ‘critical’ for inclusion in the guideline, at Round 1 and at Round 2 
of the Delphi Survey. A copy of the consensus meeting slides can be found in the 
supplementary materials to the publication of the STROPS guideline.222  
A summary of the decisions made at the consensus meeting (alongside the number of 
stakeholder groups reaching consensus in the Delphi survey for each item) are provided in 
Table 30. We decided whether to include or exclude items, and whether to combine 
multiple items under a single item. Where a vote was taken, this is indicated in the table. 
Otherwise, no vote was undertaken and the decisions made were based solely on 
consideration of the Delphi results and discussion. 
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Table 30 Summary of decisions made at consensus meeting 
Category # Criteria Consensus 
at Delphi 
Decision at consensus meeting 
Title and abstract 
Title and 
abstract 
1 Indicate the study’s pharmacogenetic design in the title and the abstract. 1 group Exclude after vote 
2 Provide in the abstract an informative and balanced summary of what was done and what was 
found. 
3 groups Include - add to E+E text that study 




3 Explain the scientific background and rationale for the investigation being reported. 3 groups Include 
4 Provide reasons for choosing the genes and SNPs genotyped. 3 groups Include 
5 If reasons for (4) include previous association studies, provide key details from these studies 
(effect size and standard error/confidence interval). 
1 group Exclude after vote  
Objectives  6 State specific objectives, including any pre-specified hypotheses. 3 groups Include 
7 State if the study is the first report of a pharmacogenetic association, a replication effort, or 
both.  
2 groups Include after vote 
Methods 
Study design 8 Present key elements of study design early in the paper. 3 groups Include 
Setting 9 Describe the setting, locations and relevant dates, including periods of recruitment, follow-up, 
and data collection. 
0 groups Include after vote 
Participants 10 Cohort study – Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up. 
3 groups Combine #10, #11 and #12 
11 Case-control study – Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. State whether true controls or population controls were 
used. Give the rationale for the choice of cases and controls. 
3 groups Combine #10, #11 and #12 
12 Cross-sectional study – Give the eligibility criteria, and the sources and methods of selection of 
participants. 
3 groups Combine #10, #11 and #12 
13 Report the drug and regime participants were exposed to, and the length of exposure. 3 groups Include 
14 Cohort study – For matched studies, give matching criteria and number in each genotype 
group. 
3 groups Combine #14, #15 
15 Case-control study – For matched studies, give matching criteria and the number of controls 
per case. 
3 groups Combine #14, #15 
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Category # Criteria Consensus 
at Delphi 
Decision at consensus meeting 
 
16 Give information on the criteria and methods for selection of subsets of participants from a 
larger study, when relevant.  
3 groups Include 
17 If other publications report results for the same patient cohort, or a subset of the patient 
cohort, provide information on this patient cohort overlap and references to the relevant 
publications. 
2 groups Include after vote 
18 Report disease/clinical indication of patients using a standardised ontology. 1 group Include and add ‘where possible’ to 
E+E text (standardised ontology may 
not always be available); vote taken on 
whether to include the item with the 
change to E+E text 
19 Confirm whether patients were blinded to their genotyping result. 1 group Exclude after vote 
Variables 20 Provide justification for choice of outcomes. 3 groups Include; reverse order of #20 and #21 
21 Clearly define all outcomes, potential confounders, and effect modifiers. Give diagnostic 
criteria, if applicable. 
3 groups Include; reverse order of #20 and #21 
22 Clearly define genetic exposures (genetic variants) using a widely used nomenclature system. 
Identify variables likely to be associated with population stratification (confounding by ethnic 
origin). 
3 groups Include 
23 Report the rs number of each genotyped SNP. 3 groups Include 
24 Report whether the outcomes measured (including definitions) are in line with core/preferred 
outcome sets for the particular topic of interest. 
1 group Exclude 
25 Clearly state how haplotypes or star alleles were defined. 3 groups Include 
26 Clearly state on which chromosomal strand the alleles are reported. 1 group Exclude 
27 If referring to the minor, wild-type or mutant allele of a variant, state which allele this is and 
for which given population/cohort. 
2 groups Include after vote 
28 If studying drug metabolites, provide references and links to structures and database 
identifiers. 
0 groups Exclude 
Data sources 
/measurement 
29 For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group. 
1 group Include after vote 
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Category # Criteria Consensus 
at Delphi 
Decision at consensus meeting 
 
30 Describe laboratory methods, including source and storage of DNA, genotyping methods and 
platforms (including the allele calling algorithm used, and its version), error rates and call rates. 
State the laboratory/centre where genotyping was done. Describe comparability of laboratory 
methods if there is more than one group. Specify whether genotypes were assigned using all of 
the data from the study simultaneously or in smaller batches. 
3 groups Include 
31 If study is case-control, confirm whether patients were genotyped in mixed batches. 0 groups Cover by adding to E+E text for #30  
32 Confirm whether genotyping personnel were blinded to outcome status. 0 groups Exclude 
33 Describe the primers used. 0 groups Exclude 
34 Describe genotype quality control methods. 1 group Include after vote 
35 Describe findings of genotype quality control methods. 0 groups Combine with #34 
Bias 36 Describe any efforts to address potential sources of bias.  1 group Exclude after vote 
37 For quantitative outcome variables, specify if any investigation of potential bias resulting from 
pharmacotherapy was undertaken. If relevant, describe the nature and magnitude of the 
potential bias, and explain what approach was used to deal with this. 
3 groups Include 
38 Report how adherence to treatment was assessed, and report the results of the assessment.  3 groups Include 
Study size 39 Explain how the study size was arrived at, or provide details of the a priori power to detect 
effect sizes of varying degrees. 
3 groups Include 
Quantitative 
variables  
40 Explain how quantitative variables (confounders and effect modifiers) were handled in the 
analyses. If applicable, describe which groupings were chosen, and why. 
3 groups Include 
41 If applicable, describe how effects of treatment on quantitative outcome variables were dealt 
with. 
2 groups Exclude 
Statistical 
methods 
42 Describe all statistical methods, including those used to control for confounding. 3 groups Include 
43 State software version used and options (or settings) chosen. 0 groups Exclude 
44 Describe any methods used to examine subgroups and interactions. 1 group Include after vote as subitem to #42 
45 Explain how missing data were addressed.  3 groups Include as subitem to #42 
46 Report any methods used to assess the assumption of missingness at random and the finding 
of such assessments. 
1 group Cover by adding to E+E text of item #45 
47 Cohort study – If applicable, explain how loss to follow-up was addressed. 1 group Include after vote as subitem to #42 
48 Case-control study – If applicable, explain how matching of cases and controls was addressed. 2 groups Include after vote as subitem to #42 
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Category # Criteria Consensus 
at Delphi 
Decision at consensus meeting 
 
49 Cross-sectional study – If applicable, describe analytical methods taking account of sampling 
strategy. 
1 group Include after vote as subitem to #42 
50 Describe any sensitivity analyses. 0 groups Include after vote as subitem to #42 
51 State whether Hardy-Weinberg equilibrium (HWE) was considered and, if so, how.  2 groups Combine #51, #52 (vote taken on 
whether to include or exclude this 
combined item) 
52 Where HWE test is undertaken, quote the p-value threshold applied to determine deviation 
from HWE. 
2 groups Combine #51, #52 (vote taken on 
whether to include or exclude this 
combined item) 
53 Describe any methods used for inferring genotypes or haplotypes.  2 groups Include 
54 Describe any methods used to assess or address population stratification.  1 group Include after vote 
55 Describe any methods used to assess and correct for relatedness among subjects. Report 
results of assessments for relatedness. 
1 group Include after vote; after the vote 
meeting participants decided to cover 
#55 by adding to the E+E text for #34 
56 Describe any assumptions made regarding mode of inheritance. 1 group Exclude after vote 
57 Provide justification for assumption of mode of inheritance or if no mode is assumed. 1 group Exclude  
58a Describe any methods used to address multiple comparisons or to control risk of false positive 




58b Describe any methods used to address multiple comparisons or to control risk of false positive 




58c Describe any methods used to address multiple comparisons or to control risk of false positive 








Participants 60a Report the numbers of individuals at each stage of the study – e.g., numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-




60b Give reasons for non-participation at each stage. 0 groups Cover by adding to E+E text of #60a 
60c Consider use of a flow diagram. 0 groups Cover by adding to E+E text of #60a 
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Category # Criteria Consensus 
at Delphi 
Decision at consensus meeting 
 
61 For each genetic variant, report numbers of individuals in whom genotyping was attempted 
and numbers of individuals in whom genotyping was successful. 
1 group Exclude after vote 
SNPs 62 Report any SNPs that were excluded from analysis, and provide reasons for these exclusions. 2 groups Include after vote 
Descriptive 
data 
63 Give characteristics of study participants (e.g., demographic, clinical, social) and information 
on potential confounders. 
3 groups Include 
64 Indicate the number of participants with missing data for each variable of interest. 3 groups Include by adding to E+E text for #63 
65 For a cohort study, consider giving information listed in (63) and (64) by genotype. 1 group Exclude after vote 
66 For a case-control study, give the information listed in (63) and (64) for cases and controls 
separately. 
0 groups Combine with #63 (add to E+E text) 
67 Report reasons for missing genotype data. 0 groups Exclude 
68 Cohort study – Summarize follow-up time, e.g. average and total amount. 2 groups Include after vote 
69 Where HWE tests have been undertaken, highlight SNPs that deviate from HWE. 3 groups Include 
70 Where population stratification is assessed, report the results. 3 groups Include 
Outcome data 71a For a cohort study, report all outcomes (phenotypes) investigated for each genotype category 
over time. 
3 groups Include 
71b For a case-control study, report numbers in each genotype category for all outcomes 
investigated. 
3 groups Include 
71c For a cross sectional study, report all outcomes (phenotypes) investigated for each genotype 
category. 
3 groups Include 
72 If a study includes more than one ethnic group, provide the summary data specified in (71) per 
ethnic group.  
3 groups Include 
Main results 73 Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (e.g., 95% confidence intervals). Make clear which confounders were adjusted for 
and why they were included. 
3 groups Include 
74 Report category boundaries when continuous variables were categorised. 3 groups Include 
75 If relevant, consider translating effect estimates to number needed to test to illustrate 
potential clinical utility of any significant findings. 
0 groups Exclude after vote 
76 Report results of any adjustments for multiple comparisons.  3 groups Cover by adding to E+E text of #73 
77 Report precise p-values for all associations.  3 groups Cover by adding to E+E text of #73 
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Category # Criteria Consensus 
at Delphi 
Decision at consensus meeting 
Other analyses 78 Report other analyses done – e.g., analyses of subgroups and interactions, and sensitivity 
analyses. 
2 groups Include 
79 If numerous genetic exposures (genetic variants) were examined, summarize results from all 
analyses undertaken. 
2 groups Include 
80 If detailed results are available elsewhere, state how they can be accessed. 3 groups Exclude after vote 
Discussion 
Key results 81 Summarize key results with reference to study objectives. 3 groups Include 
Limitations 82 Discuss limitations of the study, taking into account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any potential bias. 
3 groups Include 
83 Report on the risk of phenoconversion (genotype-phenotype mismatch) and its magnitude in 
the study population. 
1 group Exclude after vote 
Interpretation  84 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity 
of analyses, results from similar studies, and other relevant evidence. 
3 groups Include 
85 Report genotype frequencies from other studies. 0 groups Exclude 
Generalisability  86 Discuss the generalisability (external validity) of the study results. 3 groups Include 





88 State whether the protocol for the analysed data is publicly available and if so, how the 
protocol can be accessed. 
0 groups Exclude after vote 
89 State whether the study has been registered. If the study has been registered, provide details 
of the registry. 
2 groups Include after vote 
Ethical 
approval 
90a Report whether ethical approval was obtained for the collection of genetic data. 3 groups Include 
90b If ethical approval was obtained, report the committee that gave ethical approval and a 
reference ID. 
0 groups Cover by adding to E+E text of #90a  
Funding 91 Give the source of funding and the role of the funders for the present study and, if applicable, 
for the original study on which the present article is based. 
3 groups Include 
Databases 92 State whether databases for the analysed data are or will become publicly available and if so, 
how they can be accessed. 
1 group Include after vote 
E+E: explanation and elaboration document; HWE: Hardy-Weinberg equilibrium; SNP: single nucleotide polymorphism
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Post-consensus meeting development 
Following the consensus meeting, MC drafted the reporting guideline with guidance from 
other members of the steering committee. The following minor amendments were made 
to the reporting guideline: 
• We excluded item 14 and item 49; while searching for examples for these items, we 
found very few pharmacogenetic studies that used a matched cohort design, or a cross-
sectional design with a complex sampling strategy; these items would therefore be 
irrelevant to the vast majority of guideline users 
• We removed ‘Identify variables likely to be associated with population stratification 
(confounding by ethnic origin)’ from item 22, as this is covered by item 54 
• We added more terms (‘major’, ‘reference’, ‘risk’ and ‘effect’) that might be used to 
describe alleles to item 27 
• Although we decided to cover item 55 by adding to the E+E text for item 34 at the 
consensus meeting, the steering committee subsequently agreed that relatedness of 
participants is a separate issue to genotype quality control. We decided to keep item 55 
as a standalone item in the guideline 
• We introduced a new subitem to item 42 to cover confounding, and made item 42 a 
generic introduction to the statistical methods subitems 
• We modified item 68 to indicate that average and/or total follow-up time is sufficient 
• Although we voted to exclude item 80 from the ‘Other analyses’ section of the 
reporting guideline at the consensus meeting, the intention was to consider this item 
under the ‘Databases’ section. However, time constraints meant that we did not 
discuss this item again. The steering committee subsequently agreed that this item 
relates to additional results, rather than individual patient data in databases. We 
decided to keep the item in its original position, and add ‘i.e. in supplementary 
materials’ so that the meaning of the item is clear 
 
The resulting draft guideline was circulated to all members of the steering committee and 
consensus meeting attendees. All comments and revisions were taken into consideration 
and the checklist revised accordingly. 
The STROPS guideline 
In Table 31, we present the STROPS guideline. The accompanying E+E document is provided 
in Appendix 9.  
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Table 31 STROPS guideline 
Category # Criteria 
Abstract 
Abstract 1 Provide in the abstract an informative and balanced summary of what was 




2 Explain the scientific background and rationale for the investigation being 
reported. 
3 Provide reasons for choosing the genes and SNPs genotyped. 
Objectives  4 State specific objectives, including any pre-specified hypotheses. 
5 State if the study is the first report of a pharmacogenetic association, a 
replication effort, or both.  
Methods 
Study design 6 Present key elements of study design early in the paper. 
Setting 7 Describe the setting, locations and relevant dates, including periods of 
recruitment, follow-up, and data collection. 
Participants 8 Give the eligibility criteria, and the sources and methods of selection of 
participants. For a cohort study, describe methods of follow-up. For a case-
control study, state whether true controls or population controls were used. 
Give the rationale for the choice of cases and controls. 
9 Report the drug and regime participants were exposed to, and the length of 
exposure. 
10 For a matched case-control study, give matching criteria and the number of 
controls per case. 
11 Give information on the criteria and methods for selection of subsets of 
participants from a larger study, when relevant.  
12 If other publications report results for the same patient cohort, or a subset 
of the patient cohort, provide information on this patient cohort overlap and 
references to the relevant publications. 
13 Report disease/clinical indication of patients using a standardised ontology 
when possible. 
Variables 14 Clearly define all outcomes, potential confounders, and effect modifiers. 
Give diagnostic criteria, if applicable. 
15 Provide justification for choice of outcomes. 
16 Clearly define genetic exposures (genetic variants) using a widely used 
nomenclature system.  
17 Report the rs number of each genotyped SNP. 
18 Clearly state how haplotypes or star alleles were defined. 
19 If referring to the minor, major, wild-type, mutant, reference, risk or effect 




20 For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods 
if there is more than one group. 
21 Describe laboratory methods, including source and storage of DNA, 
genotyping methods and platforms (including the allele calling algorithm 
used, and its version), error rates and call rates. State the laboratory/centre 
where genotyping was done. Describe comparability of laboratory methods 
if there is more than one group. Specify whether genotypes were assigned 
using all of the data from the study simultaneously or in smaller batches. 
22 Describe genotype quality control methods and findings. 
23 For quantitative outcome variables, specify if any investigation of potential 
bias resulting from pharmacotherapy was undertaken. If relevant, describe 
the nature and magnitude of the potential bias, and explain what approach 
was used to deal with this. 
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Category # Criteria 
24 Report how adherence to treatment was assessed, and report the results of 
the assessment.  
Study size 25 Explain how the study size was arrived at, or provide details of the a priori 
power to detect effect sizes of varying degrees. 
Quantitative 
variables  
26 Explain how quantitative variables (confounders and effect modifiers) were 
handled in the analyses. If applicable, describe which groupings were 
chosen, and why. 
Statistical 
methods 
27 Address the following: 
a Describe methods used to control for confounding. 
b Describe any methods used to examine subgroups and interactions. 
c Explain how missing data were addressed.  
d Cohort study – If applicable, explain how loss to follow-up was addressed. 
e Case-control study – If applicable, explain how matching of cases and 
controls was addressed. 
f Describe any sensitivity analyses. 
28 State whether Hardy-Weinberg equilibrium (HWE) was considered and, if so, 
how.  
29 Describe any methods used for inferring genotypes or haplotypes.  
30 Describe any methods used to assess or address population stratification.  
31 Describe any methods used to assess and correct for relatedness among 
subjects. Report results of assessments for relatedness. 
32 Describe any methods used to address multiple comparisons or to control 
risk of false positive results due to a) multiple genetic variants b) multiple 
outcomes c) multiple assumptions regarding mode of inheritance. 
33 Describe any methods used to adjust for extent of adherence in the analyses.  
Results 
Participants 34 Report the numbers of individuals at each stage of the study – e.g., numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analysed. 




36 Give characteristics of study participants (e.g., demographic, clinical, social, 
ethnicity) and information on potential confounders. 
37 Cohort study – Summarize follow-up time, e.g. average and/or total amount. 
38 Where HWE tests have been undertaken, highlight SNPs that deviate from 
HWE. 
39 Where population stratification is assessed, report the results. 
Outcome data 40a For a cohort study, report all outcomes (phenotypes) investigated for each 
genotype category over time. 
40b For a case-control study, report numbers in each genotype category for all 
outcomes investigated. 
40c For a cross sectional study, report all outcomes (phenotypes) investigated for 
each genotype category. 
41 If a study includes more than one ethnic group, provide the summary data 
specified in (40) per ethnic group.  
Main results 42 Give unadjusted estimates and, if applicable, confounder-adjusted estimates 
and their precision (e.g., 95% confidence intervals). Make clear which 
confounders were adjusted for and why they were included. 
43 Report category boundaries when continuous variables were categorised. 
Other analyses 44 Report other analyses done – e.g., analyses of subgroups and interactions, 
and sensitivity analyses. 
45 If numerous genetic exposures (genetic variants) were examined, summarize 
results from all analyses undertaken. 
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46 If detailed results are available elsewhere, i.e. in supplementary materials, 
state how they can be accessed. 
Discussion 
Key results 47 Summarize key results with reference to study objectives. 
Limitations 48 Discuss limitations of the study, taking into account sources of potential bias 
or imprecision. Discuss both direction and magnitude of any potential bias. 
Interpretation  49 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence. 




51 State whether the study has been registered. If the study has been 
registered, provide details of the registry. 
Ethical 
approval 
52 Report whether ethical approval was obtained for the collection of genetic 
data. 
Funding 53 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is based. 
Databases 54 State whether databases for the analysed data are or will become publicly 
available and if so, how they can be accessed. 
HWE: Hardy-Weinberg equilibrium; SNP: single nucleotide polymorphism 
 
6.4 Discussion 
We conducted our project using robust methodology for developing reporting guidelines 
proposed by the EQUATOR network,211 in order to ensure that the resulting reporting 
guideline would be useful and widely disseminated. The EQUATOR approach includes a 
face-to-face consensus meeting, which follows the Delphi survey. This meeting usually 
involves the steering group and a selection of stakeholders who took part in the Delphi 
survey. Due to a lack of funding for this project to cover travel and accommodation costs, 
we were unable to arrange a face-to-face consensus meeting. Our meeting was conducted 
via conference call, and only involved steering committee members and one or two 
representatives of each stakeholder group to ensure easy communication between 
attendees. The majority of meeting attendees were therefore UK-based. However, we 
invited a large, international and multidisciplinary cohort to participate in the Delphi 
survey, and meeting attendees were able to base their decisions on the opinions of this 
wider cohort. 
We prioritised items for inclusion in the guideline if all stakeholder groups reached 
consensus; i.e. at least 70% of participants in each stakeholder group scored the item as 
‘critical’. We chose this threshold as consensus that an item ought to be included in the 
guideline requires agreement by the majority regarding critical importance of the outcome. 
This threshold has also been used previously in the development of the COS-STAR reporting 
guideline.223 Although the choice of this threshold is somewhat subjective, pre-specification 
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of the threshold in our protocol212 ought to provide assurance that we did not define 
consensus in a post-hoc way, and therefore our own opinions did not bias the results of the 
Delphi survey.224 
The final phase of activities described by Moher et al.211 in their guidance for guideline 
development relates to post-publication activities. To ensure that the guideline is widely 
disseminated and implemented, we circulated the published STROPS guideline to 
individuals who completed both Delphi rounds, and asked co-ordinators of 
pharmacogenetic networks to notify their members of the publication of the guideline. We 
also registered the guideline on the EQUATOR website.213 We also plan to present the 
guideline at conferences relevant to pharmacogenetic research, and seek guideline 
endorsement from relevant journals. In the long term, there are further actions that could 
be taken to maximise the impact and usefulness of the guideline for many years to come, 
and these will be discussed further in Section 7.4.  
It is important to note that the STROPS guideline is applicable only to studies designed to 
identify whether associations exist between genetic variants and treatment-related 
outcomes (i.e. study designs described in Table 1 of Chapter 1). Studies may be conducted 
to address other pharmacogenetic-related questions, as discussed in Section 1.5. For 
example, an RCT may be conducted to determine whether implementing genotype-guided 
prescribing of a particular drug leads to fewer toxicity events than standard prescribing 
practice. To the best of our knowledge, there are no reporting guidelines that specifically 
relate to these alternative types of pharmacogenetic study. Future research may be useful 
to determine whether specific reporting guidance for these types of studies would be 
beneficial to the field of pharmacogenetic research.  
6.5 Conclusion 
With the increasing number of meta-analyses of pharmacogenetic studies that are being 
undertaken, it is important that reporting of key data in study reports is improved in order 
to allow robust synthesis of the studies. There is currently no guideline for the reporting of 
pharmacogenetic studies that has been developed using a widely accepted and rigorous 
methodology. The STROPS guideline will first and foremost set a robust standard of 
reporting for pharmacogenetic studies, helping research authors to improve the 
completeness and transparency of their study reports. In turn, improvements in the 
reporting of pharmacogenetic studies will enable researchers to conduct high-quality 
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systematic reviews and meta-analyses, and thus improve the strength of the evidence base 
for pharmacogenetic associations.  
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7 Conclusions and further work 
7.1 Introduction 
The ultimate goal of conducting pharmacogenetic research is to identify associations 
between genetic variants and drug response, and knowledge of these associations can 
subsequently be used to inform clinical practice when making drug prescribing decisions, 
by way of genetic tests. However, before pharmacogenetic tests are introduced into clinical 
practice the evidence on their clinical utility needs to be strong, with the gold-standard 
approach to demonstrating clinical utility of genotype-guided in comparison to standard 
prescribing practices being the RCT. For researchers to consider spending valuable time and 
resources conducting RCTs of genotype-guided prescribing, the evidence base for the 
pharmacogenetic association of interest must be robust.  
Meta-analysis can be used to improve sample size and therefore increase the power to 
detect pharmacogenetic associations, whilst also allowing researchers to investigate the 
possibility that associations observed in individual studies may be spurious. It can also be 
used to explore heterogeneity in observed effects between studies. The aim of this work 
was to identify and resolve challenges that might prevent researchers from performing 
robust synthesis of pharmacogenetic evidence by way of a systematic review and meta-
analysis. 
7.2 Summary of main findings  
Methodology for meta-analysis of genetic association studies is well-established, and 
detailed guidance is available for reviewers in the HuGENet HuGE Review Handbook.24 The 
existing methodology and guidance can be applied when synthesising pharmacogenetic 
evidence, along with Jorgensen and Williamson’s quality assessment checklist for 
pharmacogenetic studies.18 
We applied the existing methodology and guidance to our systematic review and meta-
analysis of associations between genetic variants and anti-TB drug-related toxicity. Our 
review identified that NAT2 slow/intermediate acetylators are significantly more likely to 
experience hepatotoxicity than NAT2 rapid acetylators. We also observed possible 
associations between the CYP2E1 RsaI (rs2031920) and GSTM1 null polymorphisms and 
hepatotoxicity. To the best of our knowledge, no systematic reviews or meta-analyses have 
been conducted to investigate the association between anti-TB drug-related toxicity and 
genetic variants other than variants of the NAT2, CYP2E1, GSTM1 and GSTT1 genes. Our 
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review summarises the entire body of literature on genetic variants and anti-TB drug-
related toxicity outcomes, and therefore adds to the existing understanding of the factors 
that may influence an individual’s response to treatment with anti-TB drugs.  
We observed that although the evidence base for this topic is extensive, with 69 articles 
contributing data to our review, synthesising data from the included pharmacogenetic 
studies was very challenging for a variety of reasons. In particular, reporting of key details, 
such as aspects of methodological quality, patient cohort overlap, and the ethnicity of 
included patients, was generally poor across the included studies. 
A key feature of our systematic review was a thorough quality assessment using the 
checklist developed by Jorgensen and Williamson.18 The quality of included studies was 
variable, with several areas of concern. However, we also observed that it was often 
difficult to assess whether a study satisfied quality assessment criteria due to the fact that 
relevant information was not sufficiently reported in the study publication. We concluded 
that it is possible that improvements in the reporting of methodological aspects of 
pharmacogenetic studies would improve our confidence in the findings of these studies, 
and consequently, the pooled results from meta-analyses.  
We often found it difficult to determine whether patient cohorts from different articles 
were distinct, overlapping or identical. If we failed to identify multiple articles reporting 
data for overlapping or identical patient cohorts, some patients may have been double-
counted in the meta-analyses; this is a form of unit-of-analysis error. Alternatively, if we 
incorrectly assumed that multiple articles reported data for overlapping or identical patient 
cohorts, our decision to exclude all but one of these articles from meta-analyses would 
have led to an unnecessary loss of data.  
Further, only 24% of studies included in our systematic review reported ethnicity of the 
included patients; we were therefore unable to stratify our meta-analyses by ethnicity, as 
recommended in the HuGENet HuGE Review Handbook.24 Consequently, we were unable 
to explore heterogeneity due to differences in ethnicity, and it is possible that our results 
were confounded by population stratification.  
To synthesise data from the studies included in our systematic review, we initially applied 
standard methods of meta-analysis, which are subject to important limitations. We 
therefore decided it was important to also explore more complex methods of meta-
analysis, namely the genetic model-free and bivariate analysis approaches, which are 
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potentially able to overcome the limitations of the standard methods of meta-analysis. We 
applied these methods of meta-analysis for variants of the NAT2 gene only; these data 
were sufficient to allow us to investigate the impact of meta-analysis approach on results.  
For the majority of SNPs, results from the genetic model-free and bivariate methods were 
very similar to those obtained from simple pairwise comparisons. However, for two SNPs, 
we observed considerable differences between results obtained from these different 
methods, either in terms of magnitude or statistical significance of the observed effect 
sizes. Based on these observations, we concluded that it is plausible that for some 
systematic reviews, the choice of meta-analysis method may impact the overall 
conclusions. We also identified that improvements in the reporting of pharmacogenetic 
studies, i.e. reporting of outcomes for each genotype group separately, would enable 
systematic reviewers greater freedom in terms of their analysis approach, and ensure that 
relevant data are not excluded from meta-analyses unnecessarily.  
Due to the observations made while conducting the systematic review and meta-analyses 
(using both simple and more complex analysis methods), we identified the need to develop 
a reporting guideline for pharmacogenetic studies. We hoped that such a guideline would 
improve the transparency of reporting of pharmacogenetic studies and also facilitate future 
evidence synthesis. We used rigorous methodology to develop the guideline, including a 
two round Delphi survey and consensus meeting, both of which involved representatives 
from three key stakeholder groups. 
A total of 52 individuals completed both rounds of the Delphi survey, scoring potential 
reporting items with regards to their importance for inclusion in the final reporting 
guideline. At the consensus meeting, the six members of the steering committee and four 
representatives of the key stakeholder groups discussed each reporting item in turn and 
decided whether to include each item in the final guideline. Subsequently, the 54 item 
STROPS guideline was finalised and published.222 Initial dissemination activities included 
circulating the guideline to Delphi participants, asking co-ordinators of pharmacogenetic 
networks to notify network members of the guideline, and registering the guideline on the 
EQUATOR website.213 
The final guideline includes items that address each of the specific reporting issues 
identified while conducting our meta-analyses of pharmacogenetic data; it is reassuring to 
note that Delphi survey participants and consensus meeting attendees shared our opinions 
on the importance of these items. Adherence to the guideline by pharmacogenetic authors 
167 
will therefore ensure that future systematic reviewers do not face the same challenges that 
we encountered when synthesising pharmacogenetic evidence.  
7.3 Implications for practice and research 
The work presented in this thesis has both clinical and methodological implications. The 
findings of the systematic review and meta-analysis presented in Chapter 3 and Chapter 4 
have implications for the clinical management of TB, while our exploration of complex 
methods of analysis for variants of the NAT2 gene and ATDH has methodological 
implications. Finally, the development of the STROPS reporting guideline has implications 
for members of the pharmacogenetic research community.  
Clinical implications 
Isoniazid is the anti-TB drug for which mechanisms of the genetic contribution to ATDH 
have been most widely studied. This drug is also part of the four drug combination regimen 
recommended by the WHO for treatment of drug-susceptible TB; isoniazid use is therefore 
routine and widespread. Indeed, of the studies included in our systematic review of genetic 
influence on anti-TB drug-related toxicity, only two90, 173 reported using a regimen that did 
not contain isoniazid. Isoniazid is particularly important in the treatment of TB, as it is the 
mainstay of chemoprophylaxis in latent TB infection (LTBI). LTBI chemoprophylaxis is being 
rapidly expanded in recent strategies to eliminate TB as a public health problem, and it is 
therefore likely that global use of isoniazid will greatly increase over the coming years.  
Our systematic review provides evidence to support a relationship between genetic 
variants of the NAT2, CYP2E1 and GSTM1 genes and ATDH. Perhaps the most clinically 
meaningful finding came from the comparison of slow acetylators versus 
intermediate/rapid acetylators, for which we calculated an OR of 3.12 (95% CI: 2.45 to 
3.97). As the interpretation of ORs is not intuitive, and is also dependent on the underlying 
baseline risk of hepatotoxicity, it is useful to consider how the risk of hepatotoxicity would 
vary according to acetylator status in a hypothetical patient population. Specifically, we 
performed a random-effects meta-analysis of proportions in order to obtain a pooled 
estimate of baseline ATDH risk using data from studies included in the original meta-
analysis. The estimate of baseline ATDH risk among intermediate/rapid acetylators was 
13%; this value has been calculated solely to inform this discussion of clinical implications 
and is not referred to previously in this thesis. We then applied the OR of 3.12 obtained in 
our original meta-analysis of slow versus intermediate/rapid acetylators to the baseline risk 
of 13% to calculate the corresponding relative risk. Assuming a baseline risk of 13%, the risk 
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of hepatotoxicity would be approximately 2.5 times higher in slow acetylators than in 
rapid/intermediate acetylators. Clearly, this figure represents a clinically meaningful 
difference in hepatotoxicity risk between different acetylator groups.  
In current clinical practice, transaminase testing is a readily available biomarker of possible 
ATDH; however, baseline values have modest predictive value and routine monitoring is 
not generally recommended. The findings of our systematic review and meta-analysis 
suggest that pharmacogenetic testing could make a clinically useful contribution to risk 
stratification for ATDH, particularly in populations where slow acetylator status is common. 
However, the need for testing of a relatively large panel of SNPs and the current lack of a 
clear substitute to isoniazid for LTBI chemoprophylaxis mean that such a strategy may not 
be cost effective or feasible. Studies investigating the cost-effectiveness and/or feasibility 
of such a strategy would be beneficial. High-quality studies that do not have the 
methodological limitations identified in Chapter 3 would also strengthen the evidence 
base.  
A particularly concerning finding from our systematic review was that very few studies 
were conducted in Africa, where populations are most likely to be affected by TB. The lack 
of pharmacogenetic evidence on anti-TB drug related toxicity from African countries is, 
unfortunately, not surprising, considering that in general, the majority of pharmacogenetic 
studies have been performed in Asian and Caucasian populations.225 A lack of funding may 
explain the limited nature of pharmacogenetic research in Africa; local researchers often 
have to approach foreign funding bodies to support their studies.226 Due to the high level of 
disease burden across the African continent,227 and the impact that adverse events and 
poor drug efficacy can have on already overstrained health care systems, African 
populations are likely to benefit from stratified medicine strategies. It is important that 
steps are taken to reduce the possibility that the pharmacogenetic research community 
may contribute to already existing health disparities between Africa and the rest of the 
world. It is reassuring that in September 2018, the African Pharmacogenomics Consortium 
was formally launched, which aims to address challenges of conducting and applying 
pharmacogenetics research in Africa.228 
Despite the limitations of the identified evidence base, considering the approximately 2.5-
fold increased risk of ATDH in slow acetylators estimated in our systematic review, 
pharmacogenetic epidemiology should certainly be a factor in national policymaking on the 
need for transaminase monitoring during treatment of active TB and LTBI locally. 
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Methodological implications: Further analyses of NAT2 genetic variants and hepatotoxicity 
Based on the findings of Chapter 5 of this thesis, systematic reviewers of pharmacogenetic 
studies ought to be aware that choice of meta-analysis method may have an important 
impact on observed estimates of association, and subsequently on overall conclusions. It is 
therefore important for the method to be used for meta-analysis to be pre-specified in a 
protocol for the systematic review, so that readers are assured that results from meta-
analyses have not been selectively reported. It may also be informative to perform 
sensitivity analyses using alternative approaches to meta-analysis, as a way of investigating 
the robustness of results from the primary analysis.  
Ideally, primary researchers should consider the fact that results from their study may be 
pooled with other similar studies, and endeavour to make future evidence synthesis as 
easy as possible. In our experience, if all studies had reported outcome data for each 
genotype group separately, this would have given us greater freedom in terms of our 
analysis approach, and ensured that all relevant data could be included in each of our 
meta-analyses. We are hopeful that item 40 of the STROPS guideline will ensure that future 
studies report data for each genotype group. 
Methodological implications: STROPS guideline 
The primary intention of the STROPS guideline is to help researchers transparently and 
completely report their pharmacogenetic studies. However, the STROPS guideline could 
also be used by peer reviewers and journal editors to strengthen manuscript review. As we 
continue with our dissemination and implementation activities (which will be discussed 
further in Section 7.4), we hope that the vast majority of pharmacogenetic researchers will 
be made aware of the STROPS guideline, and will choose to use the checklist in their future 
work. We recommend that pharmacogenetic journals endorse the STROPS guideline in 
order to optimise use of the guideline by study authors, peer reviewers and editors. 
In addition, funders of pharmacogenetic research may consider introducing the STROPS 
guideline into their process for submission of applications.211 Encouraging grant recipients 
to adhere to the STROPS guideline when reporting pharmacogenetic research will ensure 
that findings are clear, detailed, and consequently have a greater impact, whether that is 
by means of stimulating further research, or by impacting clinical practice and/or policy. 
Furthermore, it has previously been hypothesised that the availability of reporting 
guidelines may have a positive impact on how researchers design and conduct their 
research.229 We would concur that familiarity with the STROPS guideline at early stages of 
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study design (such as when seeking funding) ought to ensure that researchers consider key 
methodological issues relating to pharmacogenetic studies, and plan appropriate strategies 
for handling these issues.  
However, it is important to note that the STROPS guideline is not a quality assessment tool 
and should not be used as such. Reporting each of the items in the checklist does not 
ensure that the study is methodologically sound. For example, authors could provide full 
details about the extent of missing data and how this was handled in the analyses, 
satisfying item 27c of the STROPS guideline, however the approach outlined may be 
inappropriate. If missing data were extensive and likely not to be missing at random, simply 
analysing the available data would introduce bias to the study. The STROPS guideline will 
ensure that sufficient information is available from study reports for readers to make 
judgements about methodological quality, but the actual judgements should be made using 
a tool designed specifically for quality assessment, such as Jorgensen and Williamson’s 
quality assessment tool.18  
7.4 Future work 
The work undertaken in this thesis has lead to the production of the STROPS reporting 
guideline. Initial dissemination activities included the notification of Delphi survey 
participants and co-ordinators of pharmacogenetic networks of the publication of the 
guideline, and the registration of the guideline on the EQUATOR website.213 In the 
immediate future, we intend to present the guideline at key pharmacogenetic conferences 
and to contact editors of pharmacogenetic journals and co-ordinators of pharmacogenetic 
networks to discuss formal endorsement. To ensure that the STROPS guideline continues to 
be a useful resource over many years to come, further actions can be taken in the long-
term.211  
The development of a website for this project would have several benefits. Firstly, a 
website provides a single location where all resources relating to the project can be held, 
including: the checklist itself (in both PDF and DOC file formats), the E+E document, the list 
of Delphi participants and consensus meeting attendees, and relevant methodological 
publications. Furthermore, it is possible that researchers may wish to translate the 
guideline into other languages; we would welcome such efforts as availability of the 
guideline in more languages would undoubtedly improve the global reach of our guideline. 
If the guideline were to be translated, we would seek to be as actively involved as possible, 
to ensure that translations would be completed using robust methods (including back 
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translation). Translated versions of the guideline could also be made available on the 
website. Finally, a website could be a platform for stakeholders to submit feedback and 
criticism of the published guideline. Engaging with users of the guideline is particularly 
important if the guideline is to be updated in the future.  
With regards to updating the guideline, it will be necessary to monitor the field closely for 
new methodological publications, and to regularly consider whether the time is right for an 
update of the guideline. Due to the time and effort involved in updating and implementing 
an existing guideline, we would aim to make infrequent, but major, updates to the 
guideline, rather than regularly making minor changes.  
Another area for future work would be the evaluation of impact of the reporting guideline; 
if poor impact is observed by ourselves or another set of researchers, we would consider 
strategies that could improve the impact of our guideline. In particular, we would consider 
encouraging journals to not only endorse the guideline, but also to maximise adherence by 
asking authors of pharmacogenetic studies to submit completed copies of the guideline 
checklist along with their manuscript, and/or asking peer reviewers to refer to the checklist 
when reviewing pharmacogenetic studies.  
In Chapter 2, we discussed how the focus of this work is aggregate data meta-analysis, 
whereby aggregate data available from study reports or communication with study authors 
are synthesised. An alternative approach is individual participant data (IPD) meta-analysis, 
which involves the collection of original research data, including detailed information for 
each individual participant. These data can then be re-analysed and included in meta-
analyses. IPD meta-analysis should ideally be performed within the context of a systematic 
review, whereby authors seek to synthesise evidence from all relevant studies. However, 
some authors may use IPD meta-analysis to synthesise evidence from two or more studies 
for which IPD is available, without systematically searching for other relevant studies. 
Researchers have previously used an IPD approach to synthesise data from multiple 
pharmacogenetic studies.230-233 In this work we did not specifically seek to identify and 
resolve chaIlenges that may limit the potential for researchers to perform high-quality IPD 
meta-analyses of pharmacogenetic studies.  
Nevitt et al.234 investigated data retrieval success rates across IPD meta-analyses of all 
types of study design, for which studies were identified using systematic methods. Only 188 
(25%) of 760 IPD meta-analyses published between 1987 and 2015 retrieved 100% of the 
eligible IPD for analysis; 324 (43%) of these IPD meta-analyses retrieved 80% or more of 
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relevant IPD. There was insufficient evidence to suggest that IPD retrieval rates have 
improved over time. These findings suggest that data retrieval is likely to be an obstacle for 
researchers conducting IPD meta-analyses of pharmacogenetic evidence within systematic 
reviews, although no formal review has been conducted in this area.  
Raza and Hall235 assert that effective sharing of genomic data does not occur in the UK, 
attributing this lack of sharing to ‘limited technical and resource capacity to curate and 
upload data; concerns around the longevity and sustainability of third-party managed 
databases; and uncertainty around the legitimacy of sharing potentially identifiable patient 
data –especially into publically accessible databases’. An investigation of IPD retrieval rates 
across IPD meta-analyses of pharmacogenetic studies would be beneficial; such work 
would highlight the need for initiatives to overcome barriers to data sharing specifically 
within the pharmacogenetic research community.  
Additionally, future work could also investigate whether challenges exist in the synthesis of 
pharmacogenetic evidence once IPD has been obtained; this work would apply to both IPD 
meta-analyses conducted in the context of a systematic review, and IPD meta-analyses for 
which systematic searches were not performed.  
7.5 Concluding remarks 
Stratified medicine is an evolving field that has the potential to transform mainstream 
health care by tailoring treatments to individuals. Using pharmacogenetic tests to guide 
prescribing practices can greatly improve outcomes for patients and ensure efficient use of 
health care providers’ budgets. However, uptake of pharmacogenetic tests in clinical 
practice globally has been poor, despite the wealth of pharmacogenetic research that has 
been conducted in recent years. It has become evident that action must be taken to 
harness the efforts of researchers conducting pharmacogenetic studies, ensuring that the 
valuable data obtained in individual studies have a meaningful impact on health care policy 
and practice. In the UK, there has recently been a government-backed drive to integrate 
genomic medicine into routine NHS practice;236 it is therefore now more important than 
ever to ensure that there is convincing evidence for actionable gene-drug associations.  
Systematic reviews and meta-analyses can be used to combine results from individual 
pharmacogenetic studies, and are generally considered to be the “gold standard” of 
evidence-based research. If a systematic review and meta-analysis provides strong 
evidence for a pharmacogenetic association, this may prompt researchers to conduct RCTs 
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of genotype-guided prescribing practices, and in turn convince public bodies to introduce 
pharmacogenetic testing into clinical practice.  
However, systematic reviews and meta-analyses rely heavily on information provided in 
the reports of included studies. This thesis has provided a detailed insight into the conduct 
of a systematic review and meta-analysis of associations between genetic variants and anti-
TB drug-related tocixity, and has highlighted many inadequacies in the reporting of 
pharmacogenetic studies. We believe that the introduction of the STROPS guideline to the 
pharmacogenetic research community will have a valuable impact on the clarity and 
completeness of future study reports, and will allow the evidence base for 
pharmacogenetic associations to be strengthened by facilitating evidence synthesis.  
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Appendix 1. Systematic review and meta-analysis of genetic variants and 
toxicity related to anti-tuberculosis drugs: Search strategy 
Databases searched 
Databases Date searched No. records retrieved 
MEDLINE (Ovid) and MEDLINE In-Process (Ovid)a 03/03/2016 3029 
EMBASE (Ovid) 03/03/2016 4778 
PubMeda,b 03/03/2016 379 
Web of science 03/03/2016 421 
Biosis 03/03/2016 328 
a Although PubMed includes MEDLINE (and PubMed is more up to date than MEDLINE), both 
databases were searched separately. The information specialist searched MEDLINE via Ovid first 
(due to the to ease of conducting effective searches of this database), and then searched PubMed 
for results from the last year that may have not yet been available in MEDLINE via Ovid.  
b A date limit was applied so that only records from 03/03/2015 to 03/03/2016 were searched. 
 
Search Strategy: EMBASE 
# Searches Results 
1 antitubercular agents/ or aminosalicylic acid/ or diarylquinolines/ or 
ethambutol/ or ethionamide/ or isoniazid/ or prothionamide/ or pyrazinamide/ 
or thioacetazone/ or antibiotics, antitubercular/ or capreomycin/ or cycloserine/ 
or enviomycin/ or rifabutin/ or rifampin/ or viomycin/ 
151901 
2 ((Antitubercul* or tuberculos* or TB) adj4 (agent* or drug* or antibiotic* or 
medicine* or medication* or treatment*)).tw. 
40664 
3 (aminosalicylic acid or diarylquinoline* or ethambutol* or ethionamide* or 
isoniazid* or prothionamide* or pyrazinamide* or thioacetazone* or 
capreomycin* or cycloserine* or enviomycin* or rifabutin* or rifampin* or 
viomycin*).tw. 
34743 
4 1 or 2 or 3 172588 
5 Polymorphism, Genetic/ 102257 
6 genetic predisposition to disease/ or anticipation, genetic/ 97585 
7 Pharmacogenetics/ 17431 
8 Genetic Association Studies/ 876 
9 ((Genetic or gene*) adj2 associat* adj2 (studies or study or analys*)).tw. 7890 
10 ((genetic* or gene*) adj3 (suscept* or predisposit* or anticipat*)).tw. 61544 
11 Polymorphism, Single Nucleotide/ 98303 
12 (single* adj2 nucleotid* adj2 polymorph*).tw. 75841 
13 (SNP or Genotyp* or Phenotyp* or Allele* or Pharmacogenet* or 
Pharmacogenom* or Polymorph*).tw. 
1171894 
14 ((gene* or genetic*) adj5 (mutat* or variant*)).tw. 294715 
15 Genotype/ or Phenotype/ or Alleles/ 777386 
16 or/5-15 1548879 
17 exp Tuberculosis/ 197008 
18 (TB or Tuberculosis*).tw. 187590 
19 Antitubercul*.tw. 16330 
20 or/17-19 253048 
21 4 and 16 and 20 5380 
22 animal/ not human/ 1357016 
23 21 not 22 5360 
24 limit 23 to em=188300-201608 4778 
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Appendix 2. Systematic review and meta-analysis of genetic variants and 
toxicity related to anti-tuberculosis drugs: Full quality assessment results  
Table 32 Full quality assessment results: choosing which genes and SNPs to genotype 
Group identifier (if 
applicable) and study name 























ADACS - Chen 2015 Y Y N N 
ADACS - Lv 2012 Y Y N N/A 
ADACS - Tang 2012 Y N N N/A 
ADACS - Tang 2013a Y Y N N/A 
ADACS - Tang 2013b Y Y N N 
ADACS - Wang 2015a Y Y N N 
ADACS - Wang 2015c Y Y N N 
An 2012 Y Y N N/A 
Azuma 2013 Y Y N N 
Bose 2011 Y Y N N 
Çetintaş 2008 Y N N N/A 
Chamorro 2013 Y Y N N 
Chang 2012 Y Y N N 
Chatterjee 2010 Y Y N N/A 
Cho 2007 Y N N N 
Costa 2012 Y Y N N 
Dhoro 2013 Y N N N/A 
Feng 2014 Y Y N N 
Fredj 2016 Y Y N N 
Gogtay 2016 Y Y N N/A 
GUPTA - Gupta 2013a Y Y N N 
GUPTA - Gupta 2013b Y Y N N 
He 2015 Y Y N N 
HIGUCHI - Higuchi 2007 Y N N N 
HIGUCHI - Nanashima 2012 Y Y N N 
Ho 2013 Y Y N N/A 
HUANG - Huang 2003 Y Y N N 
HUANG - Huang 2007 Y N N N 
Jung 2015 Y Y N N/A 
Khalili 2011 Y Y N N/A 
KIM - Kim 2009 Y Y N/A N/A 
KIM - Kim 2010 Y Y N N/A 
KIM - Kim 2011 Y Y N N/A 
KIM - Kim 2012a Y Y N N 
KIM - Kim 2012b Y Y N N/A 
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Group identifier (if 
applicable) and study name 























KIM - Kim 2012c Y Y N N 
KIM - Kim 2015 Y Y N N/A 
Kwon 2012 Y Y N/A N 
Lee 2010 Y Y N N 
LEIRO - Leiro 2008 Y Y N N 
LEIRO - Leiro-Fernandez 
2011 
Y Y N N/A 
Li 2012 Y N N N 
Liu 2014 Y Y N N/A 
Mahmoud 2012 Y Y N N 
Monteiro 2012 Y Y N N 
Ng 2014 Y Y N N 
NTUH - Wang 2011 Y N N N 
NTUH - Wang 2015b Y Y N N 
Ohno 2000 Y Y N N/A 
POSSUELO - Brito 2014 Y N N N/A 
POSSUELO - Possuelo 2008 Y Y N N 
Rana 2014 Y N N N 
Roy 2001 Y N N N 
Roy 2006 Y Y N N/A 
SANTOS - Fernandes 2015 Y N N N 
SANTOS - Santos 2013 Y N N N/A 
Sharma 2014 Y Y N N/A 
Shimizu 2006 Y Y N N/A 
Singla 2014 Y N N N 
Sotsuka 2011 Y Y N N 
Teixeira 2011 Y Y N N 
Vuilleumier 2006 Y N N N 
Wang 2010 Y N N N 
Xiang 2014 Y N N N 
YAMADA - Yamada 2009 Y Y N N 
YAMADA - Yamada 2010 Y Y N/A N 
Yimer 2011 Y N N N 
Yuliwulandari 2016 Y N N N 
Zaverucha-do-Valle 2014 Y N N N/A 
Zazuli 2015 Y N N N 
N: no; N/A: not applicable; SNP: single nucleotide polymorphism; Y: yes  
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Table 33 Full quality assessment results: sample size 
Group identifier (if 
applicable) and study name 
What is the 
sample size? 
Are details given of 
how the sample size 
was calculated? 
Are details given of the a priori 
power to detect effect sizes of 
varying degrees, or a justified 
specific effect size? 
ADACS - Chen 2015 445 N N 
ADACS - Lv 2012 445 N N 
ADACS - Tang 2012 445 N N 
ADACS - Tang 2013a 445 N N 
ADACS - Tang 2013b 445 N N 
ADACS - Wang 2015a 445 N N 
ADACS - Wang 2015c 445 N N 
An 2012 208 N N 
Azuma 2013 121 Y Y 
Bose 2011 218 N N 
Çetintaş 2008 100 N N 
Chamorro 2013 175 N N 
Chang 2012 98 N N 
Chatterjee 2010 151 N N 
Cho 2007 132 N N 
Costa 2012 129 N N 
Dhoro 2013 Unclear N N 
Feng 2014 346 N N 
Fredj 2016 71 N N 
Gogtay 2016 75 N N 
GUPTA - Gupta 2013a 296 N N 
GUPTA - Gupta 2013b 215 N N 
He 2015 254 Y N 
HIGUCHI - Higuchi 2007 100 N N 
HIGUCHI - Nanashima 2012 100 N N 
Ho 2013 348 N N 
HUANG - Huang 2003 318 N N 
HUANG - Huang 2007 230 N N 
Jung 2015 153 N N 
Khalili 2011 100 N N 
KIM - Kim 2009 226 N N 
KIM - Kim 2010 341 N N 
KIM - Kim 2011 221 N N 
KIM - Kim 2012a 221 N N 
KIM - Kim 2012b 226 N N 
KIM - Kim 2012c 306 N N 
KIM - Kim 2015 321 N N 
Kwon 2012 238 N N 
Lee 2010 140 N N 
LEIRO - Leiro 2008 95 N N 
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Group identifier (if 
applicable) and study name 
What is the 
sample size? 
Are details given of 
how the sample size 
was calculated? 
Are details given of the a priori 
power to detect effect sizes of 
varying degrees, or a justified 
specific effect size? 
LEIRO - Leiro-Fernandez 
2011 
117 Y N 
Li 2012 273 N N 
Liu 2014 163 Y Y 
Mahmoud 2012 66 N N 
Monteiro 2012 177 N N 
Ng 2014 127 N N 
NTUH - Wang 2011 360 N N 
NTUH - Wang 2015b 355 N N 
Ohno 2000 77 N N 
POSSUELO - Brito 2014 245 N N 
POSSUELO - Possuelo 2008 254 N N 
Rana 2014 300 N N 
Roy 2001 66 N N 
Roy 2006 109 N N 
SANTOS - Fernandes 2015 220 N N 
SANTOS - Santos 2013 270 N N 
Sharma 2014 314 N N 
Shimizu 2006 42 N N 
Singla 2014 408 N N 
Sotsuka 2011 144 N N 
Teixeira 2011 167 N N 
Vuilleumier 2006 89 N N 
Wang 2010 215 N N 
Xiang 2014 2244 N N 
YAMADA - Yamada 2009 170 N N 
YAMADA - Yamada 2010 170 N N 
Yimer 2011 353 N N 
Yuliwulandari 2016 241 N N 
Zaverucha-do-Valle 2014 131 Y Y 
Zazuli 2015 106 N N 
N: no; Y: yes   
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Table 34 Full quality assessment results: study design 
Group identifier (if 
applicable) and study name 
What is the study 
design? 
If study is case-
control are the two 
groups clearly 
defined? 
If study is case-
control were they 
genotyped in mixed 
batches? 
ADACS - Chen 2015 Case-control Y Unclear 
ADACS - Lv 2012 Case-control Y Unclear 
ADACS - Tang 2012 Case-control Y Unclear 
ADACS - Tang 2013a Case-control Y Unclear 
ADACS - Tang 2013b Case-control Y Unclear 
ADACS - Wang 2015a Case-control Y Unclear 
ADACS - Wang 2015c Case-control Y Unclear 
An 2012 Case-control Y Unclear 
Azuma 2013 RCT N/A N/A 
Bose 2011 Cohort N/A N/A 
Çetintaş 2008 Cohort N/A N/A 
Chamorro 2013 Cohort N/A N/A 
Chang 2012 Cohort N/A N/A 
Chatterjee 2010 Case-control Y Unclear 
Cho 2007 Cohort N/A N/A 
Costa 2012 Cohort N/A N/A 
Dhoro 2013 Case-control N Unclear 
Feng 2014 Case-control Y Unclear 
Fredj 2016 Cohort N/A N/A 
Gogtay 2016 Case-control Y Unclear 
GUPTA - Gupta 2013a Cohort N/A N/A 
GUPTA - Gupta 2013b Cohort N/A N/A 
He 2015 Case-control Y Y 
HIGUCHI - Higuchi 2007 Cohort N/A N/A 
HIGUCHI - Nanashima 2012 Cohort N/A N/A 
Ho 2013 Cohort N/A N/A 
HUANG - Huang 2003 Cohort N/A N/A 
HUANG - Huang 2007 Case-control Y Unclear 
Jung 2015 Cohort N/A N/A 
Khalili 2011 Case-control Y Unclear 
KIM - Kim 2009 Case-control Y Unclear 
KIM - Kim 2010 Case-control Y Unclear 
KIM - Kim 2011 Case-control Y Unclear 
KIM - Kim 2012a Case-control Y Unclear 
KIM - Kim 2012b Case-control Y Unclear 
KIM - Kim 2012c Case-control Y Unclear 
KIM - Kim 2015 Case-control Y Unclear 
Kwon 2012 Case-control Y Unclear 
Lee 2010 Cohort N/A N/A 
LEIRO - Leiro 2008 Case-control Y Unclear 
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Group identifier (if 
applicable) and study name 
What is the study 
design? 
If study is case-
control are the two 
groups clearly 
defined? 
If study is case-
control were they 
genotyped in mixed 
batches? 
LEIRO - Leiro-Fernandez 
2011 
Case-control Y Unclear 
Li 2012 Case-control N Unclear 
Liu 2014 Case-control Y Unclear 
Mahmoud 2012 Cohort N/A N/A 
Monteiro 2012 Cohort N/A N/A 
Ng 2014 Case-control Y Unclear 
NTUH - Wang 2011 Cohort N/A N/A 
NTUH - Wang 2015b Cohort N/A N/A 
Ohno 2000 Cohort N/A N/A 
POSSUELO - Brito 2014 Cohort N/A N/A 
POSSUELO - Possuelo 2008 Cohort N/A N/A 
Rana 2014 Cohort N/A N/A 
Roy 2001 Case-control Y Unclear 
Roy 2006 Cohort N/A N/A 
SANTOS - Fernandes 2015 Cohort N/A N/A 
SANTOS - Santos 2013 Cohort N/A N/A 
Sharma 2014 Case-control Y Unclear 
Shimizu 2006 Cohort N/A N/A 
Singla 2014 Cohort N/A N/A 
Sotsuka 2011 Cohort N/A N/A 
Teixeira 2011 Case-control Y Unclear 
Vuilleumier 2006 Cohort N/A N/A 
Wang 2010 Case-control Y Unclear 
Xiang 2014 Cohort N/A N/A 
YAMADA - Yamada 2009 Cohort N/A N/A 
YAMADA - Yamada 2010 Cohort N/A N/A 
Yimer 2011 Cohort N/A N/A 
Yuliwulandari 2016 Case-control Y Unclear 
Zaverucha-do-Valle 2014 Cohort N/A N/A 
Zazuli 2015 Cohort N/A N/A 
N: no; N/A: not applicable; RCT: randomised controlled trial; Y: yes
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Table 35 Full quality assessment results: reliability of genotypes 
Group identifier (if 











Were findings from 
quality control 
methods, if used, 
described? 





to outcome status? 
If human inference 
required was this 
independently 
undertaken by at 
least two people? 
ADACS - Chen 2015 Y N Y Y N Y Not mentioned 




ADACS - Tang 2012 Y Y Y Y N Y Y 
ADACS - Tang 2013a Y Y Y Y N Y Not mentioned 
ADACS - Tang 2013b Y Y Y Y N Y Not mentioned 
ADACS - Wang 2015a Y Y Y Y N Y Y 




An 2012 Y Y Not mentioned N/A N Not mentioned NK if applicable 
Azuma 2013 Y N Y N Y Y NK if applicable 
Bose 2011 Y Y Not mentioned N/A N Y NK if applicable 
Çetintaş 2008 Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A N Y NK if applicable 
Chamorro 2013 Y Y Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Y NK if applicable 
Chang 2012 Y N Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Y NK if applicable 
Chatterjee 2010 Y Y Not mentioned N/A Y Not mentioned NK if applicable 
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Group identifier (if 











Were findings from 
quality control 
methods, if used, 
described? 





to outcome status? 
If human inference 
required was this 
independently 
undertaken by at 
least two people? 
Cho 2007 Y Available upon 
request 
Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Y NK if applicable 
Costa 2012 Y Y - for a subset of 
genes (primers 
may be inherent to 
the assay used for 
other genes) 
Y N Y - for a subset of 
investigated genetic 
variants only 
Y NK if applicable 
Dhoro 2013 Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A Y Not mentioned NK if applicable 
Feng 2014 Y N Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Not mentioned NK if applicable 
Fredj 2016 Y Y Not mentioned N/A Y Y NK if applicable 
Gogtay 2016 Y Y Not mentioned N/A Y Not mentioned NK if applicable 
GUPTA - Gupta 2013a Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A N Y NK if applicable 
GUPTA - Gupta 2013b Y Y - for a subset of 
genes 
Not mentioned N/A N Y NK if applicable 
He 2015 Y Y Y N N Y Not mentioned 
HIGUCHI - Higuchi 2007 Y Y Not mentioned N/A Y Y NK if applicable 
HIGUCHI - Nanashima 2012 Y Y Not mentioned N/A N Y NK if applicable 
Ho 2013 Y Y Not mentioned N/A Y Y NK if applicable 
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Group identifier (if 











Were findings from 
quality control 
methods, if used, 
described? 





to outcome status? 
If human inference 
required was this 
independently 
undertaken by at 
least two people? 
HUANG - Huang 2003 Y Y - for a subset of 
genes 
Not mentioned N/A N Y NK if applicable 




N Y - for a subset of 
investigated genetic 
variants only 
Not mentioned NK if applicable 
Jung 2015 Y N Not mentioned N/A N Y NK if applicable 
Khalili 2011 Y Y Not mentioned N/A Y Not mentioned NK if applicable 
KIM - Kim 2009 Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Not mentioned NK if applicable 
KIM - Kim 2010 Y Y Not mentioned N/A Y Not mentioned NK if applicable 
KIM - Kim 2011 Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Not mentioned NK if applicable 
KIM - Kim 2012a Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A N Not mentioned NK if applicable 
KIM - Kim 2012b Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A Y Not mentioned NK if applicable 
KIM - Kim 2012c Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A N Y N/A 
KIM - Kim 2015 Y Y Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Not mentioned NK if applicable 
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Group identifier (if 











Were findings from 
quality control 
methods, if used, 
described? 





to outcome status? 
If human inference 
required was this 
independently 
undertaken by at 
least two people? 
Kwon 2012 Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A N Not mentioned NK if applicable 
Lee 2010 Y Y Not mentioned N/A N Y NK if applicable 
LEIRO - Leiro 2008 Y Y Not mentioned N/A N Not mentioned NK if applicable 
LEIRO - Leiro-Fernandez 
2011 
Y Y Not mentioned N/A Y Y Not mentioned 
Li 2012 Y N - primers may be 
inherent to the 
assay used) 
Y N Y - but only for 
haplotypes (not 
individual SNPs) 
Not mentioned NK if applicable 
Liu 2014 Y Y Not mentioned N/A N Not mentioned NK if applicable 
Mahmoud 2012 Y Y Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Y NK if applicable 
Monteiro 2012 Y Y Not mentioned N/A Y Y NK if applicable 
Ng 2014 Y Y Not mentioned N/A N Not mentioned NK if applicable 
NTUH - Wang 2011 Y Y Not mentioned N/A N Y NK if applicable 




Y N Y NK if applicable 
Ohno 2000 Y Y Not mentioned N/A Y Y NK if applicable 
POSSUELO - Brito 2014 Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Y NK if applicable 
POSSUELO - Possuelo 2008 Y Y Not mentioned N/A Y Y NK if applicable 
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Group identifier (if 











Were findings from 
quality control 
methods, if used, 
described? 





to outcome status? 
If human inference 
required was this 
independently 
undertaken by at 
least two people? 
Rana 2014 Y N Not mentioned N/A Y Y NK if applicable 
Roy 2001 Y N Not mentioned N/A N Not mentioned NK if applicable 
Roy 2006 N N Not mentioned N/A N Y NK if applicable 
SANTOS - Fernandes 2015 Y N - primers may be 
inherent to the 
assay used) 
Not mentioned N/A N Y NK if applicable 
SANTOS - Santos 2013 Y Y Not mentioned N/A Y Y NK if applicable 
Sharma 2014 Y Y Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Not mentioned NK if applicable 
Shimizu 2006 Y Y Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Y NK if applicable 
Singla 2014 Y Y Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Y NK if applicable 
Sotsuka 2011 Y N Not mentioned N/A Y Y NK if applicable 
Teixeira 2011 Y Y Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Not mentioned NK if applicable 
Vuilleumier 2006 Y Y - for a subset of 
genes (primers 
may be inherent to 
the assay used for 
other genes) 
Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Y NK if applicable 
Wang 2010 Y Y Not mentioned N/A N Not mentioned NK if applicable 
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Group identifier (if 











Were findings from 
quality control 
methods, if used, 
described? 





to outcome status? 
If human inference 
required was this 
independently 
undertaken by at 
least two people? 
Xiang 2014 Y Y Not mentioned N/A Y - for a subset of 
investigated genetic 
variants only 
Y NK if applicable 




YAMADA - Yamada 2010 Y Y Y Y N Y Y 
Yimer 2011 Y Y - for a subset of 
genes (primers 
may be inherent to 
the assay used for 
other genes) 
Not mentioned N/A N Y NK if applicable 
Yuliwulandari 2016 Y Y Not mentioned N/A N Not mentioned NK if applicable 
Zaverucha-do-Valle 2014 Y Y Not mentioned N/A N Y NK if applicable 
Zazuli 2015 Y Y Not mentioned N/A N Y NK if applicable 
N: no; N/A: not applicable; Y: yes  
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Table 36 Full quality assessment results: missing genotype data 
Group identifier (if applicable) 
and study name 
Is extent of missing 
data summarised? 
If yes, are reasons for 
missing data given? 
If yes, are checks for 
missingness at random 
reported?  
Are missing genotype 
data imputed?  
Does paper quote 
number of patients 
contributing to each 
analysis? 
If paper does quote 
number of patients 
contributing to 
analyses, does this 
agree to sample size? 
ADACS - Chen 2015 N N/A N/A N Y (we spotted errors in 
the reported numbers 
of patients 
contributing to each 
analysis, and emailed 
authors to obtain 
corrected data) 
N 
ADACS - Lv 2012 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
ADACS - Tang 2012 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
ADACS - Tang 2013a N N/A N/A N Y N 
ADACS - Tang 2013b N N/A N/A N Y N 
ADACS - Wang 2015a N N/A N/A N Y N 
ADACS - Wang 2015c N N/A N/A N Y N 
An 2012 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Azuma 2013 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Bose 2011 N N/A N/A N N N/A 
Çetintaş 2008 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Chamorro 2013 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Chang 2012 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Chatterjee 2010 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Cho 2007 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
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Group identifier (if applicable) 
and study name 
Is extent of missing 
data summarised? 
If yes, are reasons for 
missing data given? 
If yes, are checks for 
missingness at random 
reported?  
Are missing genotype 
data imputed?  
Does paper quote 
number of patients 
contributing to each 
analysis? 
If paper does quote 
number of patients 
contributing to 
analyses, does this 
agree to sample size? 
Costa 2012 Y N N N Y N 
Dhoro 2013 N N/A N/A N Y N 
Feng 2014 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Fredj 2016 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Gogtay 2016 Y Y N N Y N 
GUPTA - Gupta 2013a Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
GUPTA - Gupta 2013b Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
He 2015 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
HIGUCHI - Higuchi 2007 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
HIGUCHI - Nanashima 2012 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Ho 2013 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
HUANG - Huang 2003 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
HUANG - Huang 2007 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Jung 2015 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Khalili 2011 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
KIM - Kim 2009 N N/A N/A N Y N 
KIM - Kim 2010 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
KIM - Kim 2011 N N/A N/A N Y N 
KIM - Kim 2012a N N/A N/A N Y N 
KIM - Kim 2012b N N/A N/A N Y N 
KIM - Kim 2012c Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
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Group identifier (if applicable) 
and study name 
Is extent of missing 
data summarised? 
If yes, are reasons for 
missing data given? 
If yes, are checks for 
missingness at random 
reported?  
Are missing genotype 
data imputed?  
Does paper quote 
number of patients 
contributing to each 
analysis? 
If paper does quote 
number of patients 
contributing to 
analyses, does this 
agree to sample size? 
KIM - Kim 2015 N N/A N/A N Y N 
Kwon 2012 N N/A N/A N N N/A 
Lee 2010 N N/A N/A N Y N 
LEIRO - Leiro 2008 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
LEIRO - Leiro-Fernandez 2011 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Li 2012 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Liu 2014 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Mahmoud 2012 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Monteiro 2012 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Ng 2014 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
NTUH - Wang 2011 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
NTUH - Wang 2015b Y Y N N N N/A 
Ohno 2000 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
POSSUELO - Brito 2014 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
POSSUELO - Possuelo 2008 N N/A N/A N N N/A 
Rana 2014 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Roy 2001 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Roy 2006 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
SANTOS - Fernandes 2015 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
SANTOS - Santos 2013 N N/A N/A N Y N 
Sharma 2014 Y Y N N Y N 
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Group identifier (if applicable) 
and study name 
Is extent of missing 
data summarised? 
If yes, are reasons for 
missing data given? 
If yes, are checks for 
missingness at random 
reported?  
Are missing genotype 
data imputed?  
Does paper quote 
number of patients 
contributing to each 
analysis? 
If paper does quote 
number of patients 
contributing to 
analyses, does this 
agree to sample size? 
Shimizu 2006 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Singla 2014 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Sotsuka 2011 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Teixeira 2011 Y Y N N Y N 
Vuilleumier 2006 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Wang 2010 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Xiang 2014 Y - for a subset of 
investigated genetic 
variants only 
N N N Y N 
YAMADA - Yamada 2009 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
YAMADA - Yamada 2010 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Yimer 2011 Y N N N Y N 
Yuliwulandari 2016 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
Zaverucha-do-Valle 2014 Y N N N Y N 
Zazuli 2015 Y (no missing data) N/A (no missing data) N/A (no missing data) N/A (no missing data) Y Y 
N: no; N/A: not applicable; Y: yes
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Table 37 Full quality assessment results: population stratification 
Group identifier (if applicable) 
and study name 
Are tests undertaken for cryptic 
population stratification? 
If so, are results 
quoted?  
ADACS - Chen 2015 N N/A 
ADACS - Lv 2012 N N/A 
ADACS - Tang 2012 N N/A 
ADACS - Tang 2013a N N/A 
ADACS - Tang 2013b N N/A 
ADACS - Wang 2015a N N/A 
ADACS - Wang 2015c N N/A 
An 2012 N N/A 
Azuma 2013 N N/A 
Bose 2011 N N/A 
Çetintaş 2008 N N/A 
Chamorro 2013 N N/A 
Chang 2012 N N/A 
Chatterjee 2010 N N/A 
Cho 2007 N N/A 
Costa 2012 N N/A 
Dhoro 2013 N N/A 
Feng 2014 N N/A 
Fredj 2016 N N/A 
Gogtay 2016 N N/A 
GUPTA - Gupta 2013a N N/A 
GUPTA - Gupta 2013b N N/A 
He 2015 N N/A 
HIGUCHI - Higuchi 2007 N N/A 
HIGUCHI - Nanashima 2012 N N/A 
Ho 2013 N N/A 
HUANG - Huang 2003 N N/A 
HUANG - Huang 2007 N N/A 
Jung 2015 N N/A 
Khalili 2011 N N/A 
KIM - Kim 2009 N N/A 
KIM - Kim 2010 N N/A 
KIM - Kim 2011 N N/A 
KIM - Kim 2012a N N/A 
KIM - Kim 2012b N N/A 
KIM - Kim 2012c N N/A 
KIM - Kim 2015 N N/A 
Kwon 2012 N N/A 
Lee 2010 N N/A 
LEIRO - Leiro 2008 N N/A 
LEIRO - Leiro-Fernandez 2011 N N/A 
Li 2012 N N/A 
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Group identifier (if applicable) 
and study name 
Are tests undertaken for cryptic 
population stratification? 
If so, are results 
quoted?  
Liu 2014 N N/A 
Mahmoud 2012 N N/A 
Monteiro 2012 N N/A 
Ng 2014 N N/A 
NTUH - Wang 2011 N N/A 
NTUH - Wang 2015b N N/A 
Ohno 2000 N N/A 
POSSUELO - Brito 2014 N N/A 
POSSUELO - Possuelo 2008 N N/A 
Rana 2014 N N/A 
Roy 2001 N N/A 
Roy 2006 N N/A 
SANTOS - Fernandes 2015 Y Y 
SANTOS - Santos 2013 Y Y 
Sharma 2014 N N/A 
Shimizu 2006 N N/A 
Singla 2014 N N 
Sotsuka 2011 N N/A 
Teixeira 2011 N N/A 
Vuilleumier 2006 N N/A 
Wang 2010 N N/A 
Xiang 2014 N N/A 
YAMADA - Yamada 2009 N N/A 
YAMADA - Yamada 2010 N N/A 
Yimer 2011 N N/A 
Yuliwulandari 2016 N N/A 
Zaverucha-do-Valle 2014 N N/A 
Zazuli 2015 N N/A 
N: no; N/A: not applicable; Y: yes   
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Table 38 Full quality assessment results: Hardy-Weinberg equilibrium 
Group identifier 
(if applicable) and 
study name 
What test is 
undertaken to 



















SNPs found to 
deviate, are 














ADACS - Chen 
2015 
Chi square test Y Y (none 
deviated) 
N/A N/A 
ADACS - Lv 2012 Chi square test Y Y (none 
deviated) 
N/A N/A 
ADACS - Tang 
2012 
Chi square test Y N N/A N/A 
ADACS - Tang 
2013a 
Chi square test Y Y N N 
ADACS - Tang 
2013b 
Chi square test Y Y (none 
deviated) 
N/A N/A 
ADACS - Wang 
2015a 
Chi square test Y Y (none 
deviated) 
N/A N/A 
ADACS - Wang 
2015c 
Chi square test Y Y (none 
deviated) 
N/A N/A 
An 2012 Test not 
described, test 
only mentioned 
for subset of 
SNPs 
Y Y (none 
deviated) 
N/A N/A 
Azuma 2013 No test 
mentioned 
N/A N/A N/A N/A 
Bose 2011 No test 
mentioned 
N/A N/A N/A N/A 
Çetintaş 2008 No test 
mentioned 
N/A N/A N/A N/A 
Chamorro 2013 No test 
mentioned 
N/A N/A N/A N/A 
Chang 2012 Test not 
described 
N Y (none 
deviated) 
N/A N/A 
Chatterjee 2010 No test 
mentioned 
N/A N/A N/A N/A 
Cho 2007 No test 
mentioned 
N/A N/A N/A N/A 
Costa 2012 Test not 
described 
Y Y N Y 
Dhoro 2013 No test 
mentioned 
N/A N/A N/A N/A 
Feng 2014 Goodness of fit 
test 
Y Y (none 
deviated) 
N/A N/A 
Fredj 2016 Test not 
described 
N N N/A N/A 
Gogtay 2016 No test 
mentioned 
N/A N/A N/A N/A 




N/A N/A N/A N/A 
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Group identifier 
(if applicable) and 
study name 
What test is 
undertaken to 



















SNPs found to 
deviate, are 














GUPTA - Gupta 
2013b 
Chi square test Y N N/A N/A 
He 2015 No test 
mentioned 
N/A N/A N/A N/A 
HIGUCHI - Higuchi 
2007 
Chi square test Y N N/A N/A 
HIGUCHI - 
Nanashima 2012 
Chi square test Y Y (none 
deviated) 
N/A N/A 
Ho 2013 Chi square test N N N/A N/A 
HUANG - Huang 
2003 
Chi square test Y Y (none 
deviated) 
N/A N/A 
HUANG - Huang 
2007 
Chi square test Y Y (none 
deviated) 
N/A N/A 
Jung 2015 No test 
mentioned 
N/A N/A N/A N/A 
Khalili 2011 Chi square test Y Y (none 
deviated) 
N/A N/A 
KIM - Kim 2009 Chi square test Y Y N N 
KIM - Kim 2010 No test 
mentioned 
N/A N/A N/A N/A 
KIM - Kim 2011 Chi square test Y N N/A N/A 
KIM - Kim 2012a Chi square test Y N N/A N/A 
KIM - Kim 2012b Chi square test Y Y (none 
deviated) 
N/A N/A 
KIM - Kim 2012c No test 
mentioned 
N/A N/A N/A N/A 
KIM - Kim 2015 Chi square test Y N N/A N/A 
Kwon 2012 Chi square test Y N N/A N/A 
Lee 2010 No test 
mentioned 
N/A N/A N/A N/A 









N/A N/A N/A N/A 








Y Y (none 
deviated) 
N/A N/A 
Liu 2014 No test 
mentioned 
N/A N/A N/A N/A 
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Group identifier 
(if applicable) and 
study name 
What test is 
undertaken to 



















SNPs found to 
deviate, are 














Mahmoud 2012 Test not 
described 
Y N N/A N/A 
Monteiro 2012 No test 
mentioned 
N/A N/A N/A N/A 
Ng 2014 Chi square test N Y (none 
deviated) 
N/A N/A 




N/A N/A N/A N/A 




Y Y N N 
Ohno 2000 Test not 
described 
N N N/A N/A 









N/A N/A N/A N/A 
Rana 2014 Test not 
described, test 
only mentioned 
for subset of 
SNPs 
N N N/A N/A 
Roy 2001 No test 
mentioned 
N/A N/A N/A N/A 
Roy 2006 No test 
mentioned 





Y Y N N 
SANTOS - Santos 
2013 
Exact test Y Y (none 
deviated) 
N/A N/A 
Sharma 2014 No test 
mentioned 
N/A N/A N/A N/A 
Shimizu 2006 No test 
mentioned 
N/A N/A N/A N/A 
Singla 2014 No test 
mentioned 
N/A N/A N/A N/A 
Sotsuka 2011 No test 
mentioned 
N/A N/A N/A N/A 
Teixeira 2011 Chi square test 
(only mentioned 
for a subset of 
SNPs) 
Y N N/A N/A 
Vuilleumier 2006 Test not 
described 
N N N/A N/A 
Wang 2010 No test 
mentioned 
N/A N/A N/A N/A 
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Group identifier 
(if applicable) and 
study name 
What test is 
undertaken to 



















SNPs found to 
deviate, are 




























Y Y N Y 
Yimer 2011 Chi square test N N N/A N/A 
Yuliwulandari 
2016 





Chi square test Y N N/A N/A 
Zazuli 2015 Chi square test N Y (none 
deviated) 
N/A N/A 
HWE: Hardy-Weinberg equilibrium; N: no; N/A: not applicable; SNP: single nucleotide polymorphism; 
Y: yes   
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Table 39 Full quality assessment results: mode of inheritance 
Group identifier (if applicable) 
and study name 
Is a specific mode of inheritance 
assumed? If so which? 
Is justification provided for 
assumptions made 
regarding mode of 
inheritance? 
ADACS - Chen 2015 More than one mode assumed N 
ADACS - Lv 2012 None N 
ADACS - Tang 2012 More than one mode assumed N 
ADACS - Tang 2013a More than one mode assumed N 
ADACS - Tang 2013b More than one mode assumed N 
ADACS - Wang 2015a More than one mode assumed N 
ADACS - Wang 2015c More than one mode assumed N 
An 2012 Different modes for different SNPs N 
Azuma 2013 N/A - RCT not association study N/A 
Bose 2011 Unclear N/A 
Çetintaş 2008 Dominant N 
Chamorro 2013 Dominant Y 
Chang 2012 N/A - no homozygous MT pts N/A 
Chatterjee 2010 Dominant N 
Cho 2007 Unclear N/A 
Costa 2012 Different modes for different SNPs N 
Dhoro 2013 Dominant N 
Feng 2014 Dominant N 
Fredj 2016 Dominant N 
Gogtay 2016 Unclear N/A 
GUPTA - Gupta 2013a Dominant Y 
GUPTA - Gupta 2013b Unclear N/A 
He 2015 Dominant N 
HIGUCHI - Higuchi 2007 Unclear N/A 
HIGUCHI - Nanashima 2012 More than one mode assumed N 
Ho 2013 None N 
HUANG - Huang 2003 More than one mode assumed N 
HUANG - Huang 2007 Unclear N/A 
Jung 2015 Additive N 
Khalili 2011 None N 
KIM - Kim 2009 More than one mode assumed N 
KIM - Kim 2010 Dominant N 
KIM - Kim 2011 Dominant N 
KIM - Kim 2012a More than one mode assumed N 
KIM - Kim 2012b More than one mode assumed N 
KIM - Kim 2012c Dominant N 
KIM - Kim 2015 Dominant N 
Kwon 2012 Unclear N/A 
Lee 2010 Dominant N 
LEIRO - Leiro 2008 Dominant N 
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Group identifier (if applicable) 
and study name 
Is a specific mode of inheritance 
assumed? If so which? 
Is justification provided for 
assumptions made 
regarding mode of 
inheritance? 
LEIRO - Leiro-Fernandez 2011 None N 
Li 2012 None N 
Liu 2014 None N 
Mahmoud 2012 More than one mode assumed N 
Monteiro 2012 Dominant N 
Ng 2014 Dominant N 
NTUH - Wang 2011 Dominant N 
NTUH - Wang 2015b More than one mode assumed N 
Ohno 2000 None N 
POSSUELO - Brito 2014 Dominant N 
POSSUELO - Possuelo 2008 More than one mode assumed N 
Rana 2014 None N 
Roy 2001 Dominant Y 
Roy 2006 Dominant N 
SANTOS - Fernandes 2015 Unclear N/A 
SANTOS - Santos 2013 Different modes for different SNPs N 
Sharma 2014 Different modes for different SNPs Y 
Shimizu 2006 None N 
Singla 2014 More than one mode assumed N 
Sotsuka 2011 Different modes for different SNPs N 
Teixeira 2011 Different modes for different SNPs N 
Vuilleumier 2006 Different modes for different SNPs N 
Wang 2010 Different modes for different SNPs N 
Xiang 2014 Different modes for different SNPs Y 
YAMADA - Yamada 2009 Different modes for different SNPs N 
YAMADA - Yamada 2010 Different modes for different SNPs N 
Yimer 2011 Different modes for different SNPs N 
Yuliwulandari 2016 More than one mode assumed N 
Zaverucha-do-Valle 2014 Different modes for different SNPs N 
Zazuli 2015 Different modes for different SNPs N 
N: no; N/A: not applicable; RCT: randomised controlled trial; SNP: single nucleotide polymorphism; Y: 
yes   
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Table 40 Full quality assessment results: choice and definition of outcomes 
Group identifier (if 
applicable) and study 
name 
Does the paper 




provided for the 
choice of 
outcomes? 
Are results shown for all 
outcomes mentioned for all 
variants investigated in the 
paper? 
ADACS - Chen 2015 Y N Y 
ADACS - Lv 2012 Y Y Y 
ADACS - Tang 2012 Y Y Y 
ADACS - Tang 2013a Y Y Y 
ADACS - Tang 2013b Y Y Y 
ADACS - Wang 2015a Y Y Y 
ADACS - Wang 2015c Y Y Y 
An 2012 Y Y Y 
Azuma 2013 N Y N 
Bose 2011 N N Y 
Çetintaş 2008 Y Y Y 
Chamorro 2013 Y Y Y 
Chang 2012 Y Y Y 
Chatterjee 2010 Y Y Y 
Cho 2007 Y Y Y 
Costa 2012 Y N N 
Dhoro 2013 N Y N (but the authors provided 
reasons to measure 
outcomes only for some 
variants) 
Feng 2014 Y Y Y 
Fredj 2016 Y Y Y 
Gogtay 2016 Y Y Y 
GUPTA - Gupta 2013a Y Y Y 
GUPTA - Gupta 2013b Y Y Y 
He 2015 Y Y Y 
HIGUCHI - Higuchi 2007 N Y Y 
HIGUCHI - Nanashima 
2012 
Y Y Y 
Ho 2013 Y N N 
HUANG - Huang 2003 Y Y N (but the authors provided 
reasons to measure 
outcomes only for some 
variants) 
HUANG - Huang 2007 Y N N (but the authors provided 
reasons to measure 
outcomes only for some 
variants) 
Jung 2015 Y Y Y 
Khalili 2011 Y Y Y 
KIM - Kim 2009 Y Y N (but the authors provided 
reasons to measure 
outcomes only for some 
variants) 
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Group identifier (if 
applicable) and study 
name 
Does the paper 




provided for the 
choice of 
outcomes? 
Are results shown for all 
outcomes mentioned for all 
variants investigated in the 
paper? 
KIM - Kim 2010 Y Y Y 
KIM - Kim 2011 Y Y Y 
KIM - Kim 2012a Y Y Y 
KIM - Kim 2012b Y Y Y 
KIM - Kim 2012c Y Y Y 
KIM - Kim 2015 Y Y Y 
Kwon 2012 Y Y Y 
Lee 2010 Y Y N 
LEIRO - Leiro 2008 Y Y Y 
LEIRO - Leiro-Fernandez 
2011 
Y Y Y 
Li 2012 Y Y Y 
Liu 2014 Y Y Y 
Mahmoud 2012 Y Y Y 
Monteiro 2012 Y N Y 
Ng 2014 N N Y 
NTUH - Wang 2011 Y Y Y 
NTUH - Wang 2015b Y Y Y 
Ohno 2000 Y N Y 
POSSUELO - Brito 2014 Y Y Y 
POSSUELO - Possuelo 2008 Y N Y 
Rana 2014 Y Y N 
Roy 2001 Y Y Y 
Roy 2006 N Y N 
SANTOS - Fernandes 2015 Y Y Y 
SANTOS - Santos 2013 Y Y Y 
Sharma 2014 Y Y Y 
Shimizu 2006 Y Y Y 
Singla 2014 Y Y Y 
Sotsuka 2011 Y Y N 
Teixeira 2011 N N N 
Vuilleumier 2006 Y N Y 
Wang 2010 Y Y Y 
Xiang 2014 Y Y Y 
YAMADA - Yamada 2009 Y Y N 
YAMADA - Yamada 2010 Y Y Y 
Yimer 2011 Y Y Y 
Yuliwulandari 2016 N Y Y 
Zaverucha-do-Valle 2014 Y N N 
Zazuli 2015 Y Y Y 
N: no; Y: yes   
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Table 41 Full quality assessment results: treatment adherence 
Group identifier (if 
applicable) and study 
name 
Is adherence to treatment 
measured? 
If adherence is measured, are 
adjustments for non-adherence made in 
the analyses? 
ADACS - Chen 2015 N N/A 
ADACS - Lv 2012 N N/A 
ADACS - Tang 2012 N N/A 
ADACS - Tang 2013a N N/A 
ADACS - Tang 2013b N N/A 
ADACS - Wang 2015a N N/A 
ADACS - Wang 2015c N N/A 
An 2012 N N/A 
Azuma 2013 N N/A 
Bose 2011 N N/A 
Çetintaş 2008 N N/A 
Chamorro 2013 N N/A 
Chang 2012 N N/A 
Chatterjee 2010 N/A (DOTS) N/A 
Cho 2007 Y N/A 
Costa 2012 Y N/A 
Dhoro 2013 N N/A 
Feng 2014 N N/A 
Fredj 2016 N N/A 
Gogtay 2016 N N/A 
GUPTA - Gupta 2013a N N/A 
GUPTA - Gupta 2013b N N/A 
He 2015 N N/A 
HIGUCHI - Higuchi 2007 N N/A 
HIGUCHI - Nanashima 
2012 
N N/A 
Ho 2013 N N/A 
HUANG - Huang 2003 N N/A 
HUANG - Huang 2007 N N/A 
Jung 2015 N N/A 
Khalili 2011 N N/A 
KIM - Kim 2009 N N/A 
KIM - Kim 2010 N N/A 
KIM - Kim 2011 Y Y 
KIM - Kim 2012a Y Y 
KIM - Kim 2012b N N/A 
KIM - Kim 2012c Y Y 
KIM - Kim 2015 Y Y 
Kwon 2012 N N/A 
Lee 2010 N N/A 
LEIRO - Leiro 2008 Y Y 
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Group identifier (if 
applicable) and study 
name 
Is adherence to treatment 
measured? 
If adherence is measured, are 
adjustments for non-adherence made in 
the analyses? 
LEIRO - Leiro-Fernandez 
2011 
Y Y 
Li 2012 N N/A 
Liu 2014 N N/A 
Mahmoud 2012 N N/A 
Monteiro 2012 N N/A 
Ng 2014 N N/A 
NTUH - Wang 2011 N N/A 
NTUH - Wang 2015b N N/A 
Ohno 2000 N N/A 
POSSUELO - Brito 2014 N N/A 
POSSUELO - Possuelo 2008 Y N 
Rana 2014 N N/A 
Roy 2001 N N/A 
Roy 2006 N N/A 
SANTOS - Fernandes 2015 N N/A 
SANTOS - Santos 2013 N N/A 
Sharma 2014 N N/A 
Shimizu 2006 N N/A 
Singla 2014 N/A (DOTS) N/A 
Sotsuka 2011 N N/A 
Teixeira 2011 N N/A 
Vuilleumier 2006 Y Y 
Wang 2010 N N/A 
Xiang 2014 N N/A 
YAMADA - Yamada 2009 N N/A 
YAMADA - Yamada 2010 Y N 
Yimer 2011 N N/A 
Yuliwulandari 2016 N N/A 
Zaverucha-do-Valle 2014 N N/A 
Zazuli 2015 N/A (DOTS) N/A 
DOTS: directly observed treatment, short-course; N: no; N/A: not applicable; Y: yes   
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Appendix 3. Systematic review and meta-analysis of genetic variants and 
toxicity related to anti-tuberculosis drugs: Results of the sensitivity 
analyses  
NAT2 acetylator status 
Sensitivity analysis 1: Pairwise comparisons 
Slow versus rapid acetylator status 
 
Figure 26 NAT2 acetylator status and hepatotoxicity: slow versus rapid acetylator status 
*Vuilleumier 2006 and Yamada 2009 were both conducted in the latent TB population. 
**Caucasian: 38 (43%), Hispanic: 8 (9%), African: 22 (25%), South American: 15 (17%), Asian: 5 (6%), 
Middle Eastern: 1 (1%)  
*** Asian: 72 (42%), Caucasian: 49 (29%), South Asian: 22 (13%), Hispanic: 7 (4%), Middle Eastern: 8 
(5%), First nations: 5 (3%), other/mixed/unknown: 7 (4%) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio; RA: rapid acetylators; SA: slow 
acetylators; TB: tuberculosis 














Overall  (I-squared = 60.0%, p = 0.000)
Iran
Teixeira 2011
Yamada 2009* (GI: YAMADA)
Tunisia
Subtotal  (I-squared = .%, p = .)
Subtotal  (I-squared = .%, p = .)
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Chamorro 2013
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Subtotal  (I-squared = .%, p = .)
Subtotal  (I-squared = .%, p = .)
Vuilleumier 2006*
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Favours SA  Favours RA 
1.00013 7463
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Intermediate versus rapid acetylator status 
 
Figure 27 NAT2 acetylator status and hepatotoxicity: intermediate versus rapid acetylator status  
*Vuilleumier 2006 and Yamada 2009 were both conducted in the latent TB population. 
**Caucasian: 38 (43%), Hispanic: 8 (9%), African: 22 (25%), South American: 15 (17%), Asian: 5 (6%), 
Middle Eastern: 1 (1%)  
*** Asian: 72 (42%), Caucasian: 49 (29%), South Asian: 22 (13%), Hispanic: 7 (4%), Middle Eastern: 8 
(5%), First nations: 5 (3%), other/mixed/unknown: 7 (4%) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; IA: intermediate acetylators; OR: odds ratio; RA: rapid 
acetylators; TB: tuberculosis 
 
Sensitivity analysis 2: Slow versus rapid/intermediate acetylator status 
Results from this sensitivity analysis are presented in the main thesis (Section 4.2). 
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Subtotal  (I-squared = .%, p = .)
Khalili 2011
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Gupta 2013b (GI: GUPTA)
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Ohno 2000
Subtotal  (I-squared = .%, p = .)
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Fredj 2016
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Favours IA  Favours RA 
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CYP2E1 RsaI polymorphism 
Sensitivity analysis 1: Excluding studies where genotypes deviated from HWE  
 
Figure 28 CYP2E1 RsaI polymorphism and hepatotoxicity: homozygous mutant-type (TT) or heterozygous (CT) 
versus homozygous wild-type (CC), sensitivity analysis excluding studies where genotypes deviated from HWE 
(Rana 2014, Singla 2014 and Sotsuka 2011) 
* Yamada 2009 was conducted in the latent TB population. 
**Asian: 72 (42%), Caucasian: 49 (29%), South Asian: 22 (13%), Hispanic: 7 (4%), Middle Eastern: 8 
(5%), First Nations: 5 (3%), other/mixed/unknown: 7 (4%) 
It was not possible to test HWE for five studies that did not report data for each genotype group 
separately (Feng 2014, Wang 2011, Cho 2007, Brito 2014, Yamada 2009). 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; HWE: Hardy-Weinberg equilibrium; OR: odds ratio; TB: 
tuberculosis 
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Favours CT or TT  Favours CC 
1.005 90
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Sensitivity analysis 2: Pairwise comparisons  
Heterozygous (CT) versus homozygous wild-type (CC) 
 
Figure 29 CYP2E1 RsaI polymorphism and hepatotoxicity: heterozygous (CT) versus homozygous wild-type (CC)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
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Brazil
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Rana 2014
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Subtotal  (I-squared = 0.0%, p = 0.743)
Bose 2011
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Homozygous mutant-type (TT) versus homozygous wild-type (CC) 
 
Figure 30 CYP2E1 RsaI polymorphism and hepatotoxicity: homozygous mutant-type (TT) versus homozygous 
wild-type (CC) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
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CYP2E1 DraI polymorphism 
Sensitivity analysis 1: Excluding studies where genotypes deviated from HWE  
 
Figure 31 CYP2E1 DraI polymorphism and hepatotoxicity: homozygous mutant-type (AA) or heterozygous (TA) 
versus homozygous wild-type (TT), sensitivity analysis excluding two studies where genotypes deviated from 
HWE (Bose 2011 and Gupta 2013b) 
None of the included studies reported ethnicity so this information is not provided on the forest plot. 
It was not possible to test HWE for one study that did not report data for each genotype group 
separately (Brito 2014). 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; HWE: Hardy-Weinberg equilibrium; OR: odds ratio 
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Favours TA or AA  Favours TT 
1.074 13.5
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Sensitivity analysis 2: Pairwise comparisons  
Heterozygous (TA) versus homozygous wild-type (TT) 
 
Figure 32 CYP2E1 DraI polymorphism and hepatotoxicity: heterozygous (TA) versus homozygous wild-type (TT)  
None of the included studies reported ethnicity so this information is not provided on the forest plot. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  












Subtotal  (I-squared = .%, p = .)




Santos 2013 (GI: SANTOS)
Gupta 2013b (GI: GUPTA)
Bose 2011
Subtotal  (I-squared = 12.3%, p = 0.320)
Subtotal  (I-squared = .%, p = .)
Sotsuka 2011
Subtotal  (I-squared = .%, p = .)































































Favours TA Favours TT
224 
Homozygous mutant-type (AA) versus homozygous wild-type (TT) 
 
Figure 33 CYP2E1 DraI polymorphism and hepatotoxicity: homozygous mutant-type (AA) versus homozygous 
wild-type (TT)  
None of the included studies reported ethnicity so this information is not provided on the forest plot. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
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CYP2E1 PstI polymorphism 
Sensitivity analysis 1: Excluding studies where genotypes deviated from HWE 
 
Figure 34 CYP2E1 PstI polymorphism and hepatotoxicity: homozygous mutant-type (CC) or heterozygous (GC) 
versus homozygous wild-type (GG), sensitivity analysis excluding one study where genotypes deviated from HWE 
(Chamorro 2013) 
It was not possible to test HWE for two studies that did not report data for each genotype group 
separately (Brito 2014 and Feng 2014). 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; HWE: Hardy-Weinberg equilibrium; OR: odds ratio 






Overall  (I-squared = 48.1%, p = 0.073)
Zaverucha-do-Valle 2014
Study
Brito 2014 (GI: POSSUELO)
Tunisia
Subtotal  (I-squared = 0.0%, p = 0.825)
Subtotal  (I-squared = .%, p = .)
Fredj 2016
Brazil
Santos 2013 (GI: SANTOS)
China
Lee 2010
Subtotal  (I-squared = .%, p = .)
Taiwan
India
Subtotal  (I-squared = .%, p = .)
Roy 2006
Feng 2014
Subtotal  (I-squared = .%, p = .)





























































Favours GC or CC  Favours GG 
1.0114 87.9
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Sensitivity analysis 2: Pairwise comparisons  
Heterozygous (GC) versus homozygous wild-type (GG) 
 
Figure 35 CYP2E1 PstI polymorphism and hepatotoxicity: heterozygous (GC) versus homozygous wild-type (GG) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio;
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Homozygous mutant-type (CC) versus homozygous wild-type (GG) 
 
Figure 36 CYP2E1 PstI polymorphism and hepatotoxicity: homozygous mutant-type (CC) versus homozygous 
wild-type (GG) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
  










Subtotal  (I-squared = 0.0%, p = 0.729)
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Tunisia
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GSTM1 null polymorphism 
Sensitivity analysis 1: Excluding studies where genotypes deviated from HWE 
 
Figure 37 GSTM1 null polymorphism and hepatotoxicity: homozygous null versus heterozygous or homozygous 
present, sensitivity analysis excluding one study where genotypes deviated from HWE (Liu 2014) 
It was only possible to test deviation from HWE for one study (Liu 2014), which provided data for 
each genotype group separately. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; HWE: Hardy-Weinberg equilibrium; OR: odds ratio 
 
Sensitivity analysis 2: Pairwise comparisons  
As only one study reported on each genotype group separately for the GSTM1 gene, no 
meta-analysis was performed. Instead, we calculated ORs and corresponding 95% CIs, as 
shown in Table 42 below. 
Table 42 GSTM1 null polymorphism and hepatotoxicity: results of pairwise comparisons 






China NR Het vs Hom present 0.42 (0.02 to 8.18) 6 47 
Hom null vs Hom present 0.97 (0.35 to 2.71) 20 136 
CI: confidence interval; Het: heterozygous; Hom: homozygous; NR: not reported; OR: odds ratio 








Overall  (I-squared = 53.7%, p = 0.005)
Rana 2014
Teixeira 2011
Huang 2007 (GI: HUANG)
Subtotal  (I-squared = 0.0%, p = 0.720)




Subtotal  (I-squared = .%, p = .)
Leiro 2008 (GI: LEIRO)
Brito 2014 (GI: POSSUELO)
Subtotal  (I-squared = .%, p = .)
Feng 2014
Brazil
Tang 2012 (GI: ADACS)
Roy 2001
Monteiro 2012




Kim 2010 (GI: KIM)




























































































































GSTT1 null polymorphism 
Sensitivity analysis: Pairwise comparisons  
Heterozygous versus homozygous present  
 
Figure 38 GSTT1 null polymorphism and hepatotoxicity: heterozygous versus homozygous present  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
.





























Favours heterozygous Favours homozygous present
230 
Homozygous null versus homozygous present  
 
Figure 39 GSTT1 null polymorphism and hepatotoxicity: homozygous null versus homozygous present 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; OR: odds ratio   
NOTE: Weights are from random effects analysis
.
.






























Appendix 4. Systematic review and meta-analysis of genetic variants and 
toxicity related to anti-tuberculosis drugs: Forest plots for the secondary 
analyses 
Pairwise comparisons for NAT2 282C-T 
Heterozygous (CT) versus homozygous wild-type (CC) 
 
Figure 40 NAT2 282C-T and hepatotoxicity: heterozygous (CT) versus homozygous wild-type (CC) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 












































Favours CT  Favours CC 
1.05 6
232 
Homozygous mutant-type (TT) versus homozygous wild-type (CC) 
 
Figure 41 NAT2 282C-T and hepatotoxicity: homozygous mutant-type (TT) versus homozygous wild-type (CC)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 





Overall  (I-squared = 5.5%, p = 0.365)
Brazil
Wang 2015b (GI: NTUH)
Taiwan



































Favours TT  Favours CC 
1.03 33
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Pairwise comparisons for NAT2 341T-C 
Heterozygous (TC) versus homozygous wild-type (TT) 
 
Figure 42 NAT2 341T-C and hepatotoxicity: heterozygous (TC) versus homozygous wild-type (TT)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 









Subtotal  (I-squared = 0.0%, p = 0.933)
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Favours TC  Favours TT 
1.1 6
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Homozygous mutant-type (CC) versus homozygous wild-type (TT) 
 
Figure 43 NAT2 341T-C and hepatotoxicity: homozygous mutant-type (CC) versus homozygous wild-type (TT)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 





Overall  (I-squared = 0.0%, p = 0.625)




Subtotal  (I-squared = .%, p = .)
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Subtotal  (I-squared = 41.4%, p = 0.191)
Subtotal  (I-squared = .%, p = .)
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Favours CC  Favours TT 
1.0148 67.6
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Pairwise comparisons for NAT2 481C-T 
Heterozygous (CT) versus homozygous wild-type (CC) 
 
Figure 44 NAT2 481C-T and hepatotoxicity: heterozygous (CT) versus homozygous wild-type (CC)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 








Overall  (I-squared = 0.0%, p = 0.493)
Subtotal  (I-squared = 0.0%, p = 0.921)
Turkey
Gupta 2013b (GI: GUPTA)
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Favours CT  Favours TT 
1.015 66.6
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Homozygous mutant-type (TT) versus homozygous wild-type (CC) 
 
Figure 45 NAT2 481C-T and hepatotoxicity: homozygous mutant-type (TT) versus homozygous wild-type (CC)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 








Overall  (I-squared = 34.1%, p = 0.180)
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Lv 2012 (GI: ADACS)
Brazil
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Favours TT  Favours CC 
1.1 16
237 
Pairwise comparisons for NAT2 590G-A 
Heterozygous (GA) versus homozygous wild-type (GG) 
 
Figure 46 NAT2 590G-A and hepatotoxicity: heterozygous (GA) versus homozygous wild-type (GG)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 









Overall  (I-squared = 0.0%, p = 0.647)
Study
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Subtotal  (I-squared = 0.0%, p = 0.979)





Wang 2015b (GI: NTUH)
Subtotal  (I-squared = .%, p = .)
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Subtotal  (I-squared = 15.6%, p = 0.306)
Kim 2009 (GI: KIM)
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Favours GA  Favours GG 
1.0482 20.8
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Homozygous mutant-type (AA) versus homozygous wild-type (GG) 
 
Figure 47 NAT2 590G-A and hepatotoxicity: homozygous mutant-type (AA) versus homozygous wild-type (GG)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 













Subtotal  (I-squared = .%, p = .)
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Wang 2015b (GI: NTUH)
Subtotal  (I-squared = 0.0%, p = 0.410)
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Favours AA  Favours GG 
1.05 45
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Pairwise comparisons for NAT2 803A-G 
Heterozygous (GA) versus homozygous wild-type (AA) 
 
Figure 48 NAT2 803A-G and hepatotoxicity: heterozygous (GA) versus homozygous wild-type (AA)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 





Overall  (I-squared = 0.0%, p = 0.885)






































Favours GA  Favours AA 
1.0752 13.3
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Homozygous mutant-type (GG) versus homozygous wild-type (AA) 
 
Figure 49 NAT2 803A-G and hepatotoxicity: homozygous mutant-type (GG) versus homozygous wild-type (AA)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  





Overall  (I-squared = 0.0%, p = 0.508)
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Favours GG  Favours AA 
1.1 10
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Pairwise comparisons for NAT2 857G-A 
Heterozygous (GA) versus homozygous wild-type (GG) 
 
Figure 50 NAT2 857G-A and hepatotoxicity: heterozygous (GA) versus homozygous wild-type (GG)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 








Overall  (I-squared = 0.9%, p = 0.430)
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Tunisia
Subtotal  (I-squared = .%, p = .)
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Brazil
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China
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Santos 2013 (GI: SANTOS)
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Favours GA  Favours GG 
1.01 16
242 
Homozygous mutant-type (AA) versus homozygous wild-type (GG) 
 
Figure 51 NAT2 857G-A and hepatotoxicity: homozygous mutant-type (AA) versus homozygous wild-type (GG)  
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 








Overall  (I-squared = 11.3%, p = 0.341)
Study
Mahmoud 2012
Subtotal  (I-squared = 74.2%, p = 0.049)
Tunisia
Indonesia
Subtotal  (I-squared = 0.0%, p = 0.789)
Subtotal  (I-squared = .%, p = .)
Kim 2009 (GI: KIM)
Subtotal  (I-squared = .%, p = .)








Subtotal  (I-squared = .%, p = .)
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Wang 2015b (GI: NTUH)
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Favours AA  Favours GG 
1.00615 163
243 
Pairwise comparisons for CYP2E1 96-bp (deletion-insertion SNP) 
Heterozygous (DI) versus homozygous wild-type (DD) 
 
Figure 52 CYP2E1 96-bp SNP and hepatotoxicity: heterozygous (DI) versus homozygous wild-type (DD) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
.


























Favours DI  Favours DD 
1.01 6
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Homozygous mutant-type (II) versus homozygous wild-type (DD) 
 
Figure 53 CYP2E1 96-bp SNP and hepatotoxicity: homozygous mutant-type (II) versus homozygous wild-type 
(DD) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
.


























Favours II  Favours DD 
1.0102 97.7
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Pairwise comparisons for CYP2C9 rs4918758 
Heterozygous (TC) versus homozygous wild-type (TT) 
 
Figure 54 CYP2C9 rs4918758 and hepatotoxicity: heterozygous (TC) versus homozygous wild-type (TT) 
One of the studies (Kim 2009) reports WT to be C and MT to be T, but the other study (Tang 2013b), 
and the data, suggest that WT is T and MT is C. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; MT: mutant-type; OR: odds ratio; WT: wild-type
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 66.7%, p = 0.083)
Study
Kim 2009 (GI: KIM)
South Korea






















Favours TC  Favours TT 
1.4 4
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Homozygous mutant-type (CC) versus homozygous wild-type (TT)  
 
Figure 55 CYP2C9 rs4918758 and hepatotoxicity: homozygous mutant-type (CC) versus homozygous wild-type 
(TT) 
One of the studies (Kim 2009) reports WT to be C and MT to be T, but the other study (Tang 2013b), 
and the data, suggest that WT is T and MT is C. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; MT: mutant-type; OR: odds ratio; WT: wild-type
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 0.0%, p = 0.665)
South Korea
























Favours CC  Favours TT 
1.2 2
247 
Pairwise comparisons for CYP2B6 rs3745274 
Heterozygous (GT) versus homozygous wild-type (GG) 
 
Figure 56 CYP2B6 rs3745274 and hepatotoxicity: heterozygous (GT) versus homozygous wild-type (GG) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
.


























Favours GT  Favours GG 
1.5 4
248 
Homozygous mutant-type (TT) versus homozygous wild-type (GG). 
 
Figure 57 CYP2B6 rs3745274 and hepatotoxicity: homozygous mutant-type (TT) versus homozygous wild-type 
(GG) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 4.2%, p = 0.307)

























Favours TT  Favours GG 
1.05 6
249 
Pairwise comparisons for ABCB1 rs1045642 
Heterozygous (CT) versus homozygous wild-type (CC) 
 
Figure 58 ABCB1 rs1045642 and hepatotoxicity: heterozygous (CT) versus homozygous wild-type (CC) 
One of the studies (Kim 2012b) reports WT to be T and MT to be C, but the other study (Yimer 2011), 
and the data, suggest that WT is C and MT is T. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; MT: mutant-type; OR: odds ratio; WT: wild-type  
NOTE: Weights are from random effects analysis
.
.


























Favours CT  Favours CC 
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Homozygous mutant-type (TT) versus homozygous wild-type (CC) 
 
Figure 59 ABCB1 rs1045642 and hepatotoxicity: homozygous mutant-type (TT) versus homozygous wild-type 
(CC) 
One of the studies (Kim 2012b) reports WT to be T and MT to be C, but the other study (Yimer 2011), 
and the data, suggest that WT is C and MT is T. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; MT: mutant-type; OR: odds ratio; WT: wild-type   
NOTE: Weights are from random effects analysis
.
.


























Favours TT  Favours CC 
1.3 11
251 
Pairwise comparisons for NQO1 609C-T (rs1800566) 
Heterozygous (CT) versus homozygous wild-type (CC) 
 
Figure 60 NQO1 609C-T (rs1800566) and hepatotoxicity: heterozygous (CT) versus homozygous wild-type (CC) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 0.0%, p = 0.538)
Taiwan
























Favours CT  Favours CC 
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Homozygous mutant-type (TT) versus homozygous wild-type (CC) 
 
Figure 61 NQO1 609C-T (rs1800566) and hepatotoxicity: homozygous mutant-type (TT) versus homozygous wild-
type (CC) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 0.0%, p = 0.658)
Huang 2007 (GI: HUANG)
ID























Favours TT  Favours CC 
1.1 6
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Pairwise comparisons for PXR rs3814055 
Heterozygous (CT) versus homozygous wild-type (CC) 
 
Figure 62 PXR rs3814055 and hepatotoxicity: heterozygous (CT) versus homozygous wild-type (CC) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 0.0%, p = 0.601)
ID
Zazuli 2015
Subtotal  (I-squared = .%, p = .)
Indonesia
Taiwan
Subtotal  (I-squared = 0.0%, p = 0.323)
Wang 2015b (deviation cohort) (GI: NTUH)
Study
































Favours CT  Favours CC 
1.376 2.66
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Homozygous mutant-type (TT) versus homozygous wild-type (CC) 
 
Figure 63 PXR rs3814055 and hepatotoxicity: homozygous mutant-type (TT) versus homozygous wild-type (CC) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 23.4%, p = 0.271)





Wang 2015b (validation cohort) (GI: NTUH)
Subtotal  (I-squared = .%, p = .)

































Favours TT  Favours CC 
1.0304 32.9
255 
Pairwise comparisons for PXR rs12488820 
Heterozygous (CT) versus homozygous wild-type (CC) 
No meta-analysis was performed as no patients had heterozygous genotype in either 
patient cohort. 
Homozygous mutant-type (TT) versus homozygous wild-type (CC) 
 
Figure 64 PXR rs12488820 and hepatotoxicity: homozygous mutant-type (TT) versus homozygous wild-type (CC) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
  
NOTE: Weights are from random effects analysis
.
Overall  (I-squared = 0.0%, p = 0.911)
ID
Wang 2015b (validation cohort) (GI: NTUH)






















Favours TT  Favours CC 
1.0945 10.6
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Pairwise comparisons for PXR rs2461823 
Heterozygous (GA) versus homozygous wild-type (GG) 
 
Figure 65 PXR rs2461823 and hepatotoxicity: heterozygous (GA) versus homozygous wild-type (GG) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
Overall  (I-squared = 0.0%, p = 0.771)
Wang 2015b (deviation cohort) (GI: NTUH)
ID
Taiwan





















Favours GA  Favours GG 
1.417 2.4
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Homozygous mutant-type (AA) versus homozygous wild-type (GG) 
 
Figure 66 PXR rs2461823 and hepatotoxicity: homozygous mutant-type (AA) versus homozygous wild-type (GG) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
  
NOTE: Weights are from random effects analysis
.
Overall  (I-squared = 0.0%, p = 0.591)
Taiwan
ID
Wang 2015b (validation cohort) (GI: NTUH)





















Favours AA  Favours GG 
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Pairwise comparisons for PXR rs7643645 
Heterozygous (AG) versus homozygous wild-type (AA) 
 
Figure 67 PXR rs7643645 and hepatotoxicity: heterozygous (AG) versus homozygous wild-type (AA) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
Overall  (I-squared = 48.6%, p = 0.163)
Taiwan
ID
Wang 2015b (validation cohort) (GI: NTUH)





















Favours AG  Favours AA 
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Homozygous mutant-type (GG) versus homozygous wild-type (AA) 
 
Figure 68 PXR rs7643645 and hepatotoxicity: homozygous mutant-type (GG) versus homozygous wild-type (AA) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
Overall  (I-squared = 0.0%, p = 0.385)
Taiwan
ID
Wang 2015b (validation cohort) (GI: NTUH)
Study




















Favours GG  Favours AA 
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Pairwise comparisons for PXR rs6785049 
Heterozygous (GA) versus homozygous wild-type (GG) 
 
Figure 69 PXR rs6785049 and hepatotoxicity: heterozygous (GA) versus homozygous wild-type (GG) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
Overall  (I-squared = 0.0%, p = 0.508)
Taiwan
ID
Wang 2015b (validation cohort) (GI: NTUH)





















Favours GA  Favours GG 
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Homozygous mutant-type (AA) versus homozygous wild-type (GG) 
 
Figure 70 PXR rs6785049 and hepatotoxicity: homozygous mutant-type (AA) versus homozygous wild-type (GG) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
Overall  (I-squared = 0.0%, p = 0.862)
























Favours AA  Favours GG 
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Pairwise comparisons for PXR rs3814057 
Heterozygous (AC) versus homozygous wild-type (AA) 
 
Figure 71 PXR rs3814057 and hepatotoxicity: heterozygous (AC) versus homozygous wild-type (AA) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
Overall  (I-squared = 0.0%, p = 0.426)
Wang 2015b (validation cohort) (GI: NTUH)
Taiwan
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Homozygous mutant-type (CC) versus homozygous wild-type (AA) 
 
Figure 72 PXR rs3814057 and hepatotoxicity: homozygous mutant-type (CC) versus homozygous wild-type (AA) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
Overall  (I-squared = 0.0%, p = 0.334)
Wang 2015b (deviation cohort) (GI: NTUH)























Favours CC  Favours AA 
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264 
Pairwise comparisons for SLCO1B1 rs4149013 
Heterozygous (AG) versus homozygous wild-type (AA) 
 
Figure 73 SLCO1B1 rs4149013 and hepatotoxicity: heterozygous (AG) versus homozygous wild-type (AA) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 0.0%, p = 0.838)
Study
























Favours AG  Favours AA 
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Homozygous mutant-type (GG) versus homozygous wild-type (AA) 
 
Figure 74 SLCO1B1 rs4149013 and hepatotoxicity: homozygous mutant-type (GG) versus homozygous wild-type 
(AA) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
  
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 0.0%, p = 0.470)
Chen 2015 (GI: ADACS)
ID
China
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Pairwise comparisons for SLCO1B1 rs4149014  
Heterozygous (GT) versus homozygous wild-type (TT) 
 
Figure 75 SLCO1B1 rs4149014 and hepatotoxicity: heterozygous (GT) versus homozygous wild-type (TT) 
One of the studies (Kim 2012b) reports WT to be G and MT to be T, but the other study (Chen 2015), 
and the data, suggest that WT is T and MT is G. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; MT: mutant-type; OR: odds ratio; WT: wild-type 
  
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 0.0%, p = 0.811)
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Homozygous mutant-type (GG) versus homozygous wild-type (TT) 
 
Figure 76 SLCO1B1 rs4149014 and hepatotoxicity: homozygous mutant-type (GG) versus homozygous wild-type 
(TT) 
One of the studies (Kim 2012b) reports WT to be G and MT to be T, but the other study (Chen 2015), 
and the data, suggest that WT is T and MT is G. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; MT: mutant-type; OR: odds ratio; WT: wild-type  
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 81.5%, p = 0.020)
South Korea
Chen 2015 (GI: ADACS)
Study
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Favours GG  Favours TT 
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Pairwise comparisons for SLCO1B1 rs2306283 
Heterozygous (GA) versus homozygous wild-type (GG) 
 
Figure 77 SLCO1B1 rs2306283 and hepatotoxicity: heterozygous (GA) versus homozygous wild-type (GG) 
Three of the studies (Chen 2015, Li 2012 and Yimer 2011) report WT to be A and MT to be G, but the 
other study (Kim 2012b), and the data, suggest that WT is G and MT is A. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; MT: mutant-type; OR: odds ratio; WT: wild-type 
  




Overall  (I-squared = 0.0%, p = 0.751)
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South Korea
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ID
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Subtotal  (I-squared = .%, p = .)
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Homozygous mutant-type (AA) versus homozygous wild-type (GG) 
 
Figure 78 SLCO1B1 rs2306283 and hepatotoxicity: homozygous mutant-type (AA) versus homozygous wild-type 
(GG) 
3 of the studies (Chen 2015, Li 2012 and Yimer 2011) report WT to be A and MT to be G, but the 
other study (Kim 2012b), and the data, suggest that WT is G and MT is A. 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; MT: mutant-type; OR: odds ratio; WT: wild-type  
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Pairwise comparisons for SLCO1B1 rs4149056 
Heterozygous (TC) versus homozygous wild-type (TT) 
 
Figure 79 SLCO1B1 rs4149056 and hepatotoxicity: heterozygous (TC) versus homozygous wild-type (TT) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
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Homozygous mutant-type (CC) versus homozygous wild-type (TT) 
 
Figure 80 SLCO1B1 rs4149056 and hepatotoxicity: homozygous mutant-type (CC) versus homozygous wild-type 
(TT) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
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SOD2 rs4880: Homozygous mutant-type (CC) or heterozygous (CT) versus homozygous wild-
type (TT) 
 
Figure 81 SOD2 rs4880 and hepatotoxicity: homozygous mutant-type (CC) or heterozygous (CT) versus 
homozygous wild-type (TT) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio  
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 40.9%, p = 0.193)
South Korea
Huang 2007 (GI: HUANG)
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Pairwise comparisons for UGT1A1 rs4148323 
Heterozygous (GA) versus homozygous wild-type (GG) 
 
Figure 82 UGT1A1 rs4148323 and hepatotoxicity: heterozygous (GA) versus homozygous wild-type (GG) 
Red dashed line indicates the value of the pooled effect estimate from the meta-analysis.  
CI: confidence interval; GI: group identifier; OR: odds ratio 
 
Homozygous mutant-type (TT) versus homozygous wild-type (CC) 
No meta-analysis was performed as only one study identified patients with homozygous 
mutant-type genotype.   
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 0.0%, p = 0.954)
Chang 2012
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Appendix 5. Further analyses of the association between NAT2 genetic 
variants and hepatotoxicity: Investigating the assumption of constant λ 
NAT2 acetylator status 
 
Figure 83 NAT2 acetylator status: Graph showing the log OR for intermediate versus rapid acetylators against 
the log OR for slow versus rapid acetylators for each study 
Equation for line of best fit: y=0.19x 
Labels for each study are provided in Table 43. 
Log OR1: log odds ratio for intermediate versus rapid acetylators; log OR2: log odds ratio for slow 
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Table 43 Labels for each study included in Figure 83 and corresponding λ 
Graph label Study λ 
1 An 2012 0.04 
2 Lv 2012 (GI: ADACS) -3.79 
3 Xiang 2014 0.64 
4 Ho 2013 0.38 
5 Azuma 2013 0.03 
6 Higuchi 2007 (GI: HIGUCHI) 0.31 
7 Ohno 2000 0.21 
8 Shimizu 2006 0.35 
9 Sotsuka 2011 0.28 
10 Yuliwulandari 2016 0.04 
11 Gupta 2013b (GI: GUPTA) -0.10 
12 Khalili 2011 0.21 
13 Fredj 2016 -2.63 
14 Mahmoud 2012 0.33 
15 Çetintaş 2008 -0.40 
16 Vuilleumier 2006 0.86 
17 Leiro-Fernandez 2011 (GI: LEIRO) 24.72 
18 Teixeira 2011 0.40 
19 Santos 2013 (GI: SANTOS) -0.72 
20 Chamorro 2013 -0.71 
21 Yamada 2009 (GI: YAMADA) 0.61 
GI: group identifier 
 
 
Figure 84 NAT2 acetylator status: Graph showing the bootstrapped 95% CIs for λ for each study 
Labels for each study are provided in Table 44. 
CI: confidence interval  
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Table 44 Labels for each study included in Figure 84 and corresponding limits of the bootstrapped 95% CI for λ 
Graph label Study Lower limit for λ Upper limit for λ 
1 An 2012 -0.54 0.40 
2 Lv 2012 (GI: ADACS) -8.48 9.07 
3 Xiang 2014 -1.13 2.10 
4 Ho 2013 -0.40 0.70 
5 Azuma 2013 -0.53 0.38 
6 Higuchi 2007 (GI: HIGUCHI) -0.20 0.74 
7 Ohno 2000 -0.10 0.49 
8 Shimizu 2006 -0.20 0.85 
9 Sotsuka 2011 -4.65 6.00 
10 Yuliwulandari 2016 -2.62 0.64 
11 Gupta 2013b (GI: GUPTA) -7.92 5.89 
12 Khalili 2011 -2.16 0.57 
13 Fredj 2016 -4.98 12.02 
14 Mahmoud 2012 -4.87 4.19 
15 Çetintaş 2008 -3.44 0.38 
16 Vuilleumier 2006 -22.52 4.58 
17 Leiro-Fernandez 2011 (GI: LEIRO) -15.21 13.76 
18 Teixeira 2011 -7.60 6.79 
19 Santos 2013 (GI: SANTOS) -15.19 10.42 
20 Chamorro 2013 -14.83 13.50 
21 Yamada 2009 (GI: YAMADA) -3.08 2.60 
CI: confidence interval; GI: group identifier 
 
Interpretation 
A reasonable amount of studies report data for this SNP, and the bootstrapped CIs overlap, 
so the assumption of constant λ seems reasonable here.  
Conclusion 





Figure 85 NAT2 282C-T: Graph showing the log OR for CT versus CC against the log OR for TT versus CC for each 
study (all studies) 
Equation for line of best fit: y=0.17x 
Log OR1: log odds ratio for CT versus CC; log OR2: log odds ratio for TT versus CC; OR: odds ratio 
 
 
Figure 86 NAT2 282C-T: Graph showing the log OR for CT versus CC against the log OR for TT versus CC for each 
study (sensitivity analysis excluding Santos 2013 due to deviation from HWE) 
Equation for line of best fit: y=0.12x  
HWE: Hardy-Weinberg equilibrium; log OR1: log odds ratio for CT versus CC; log OR2: log odds ratio 
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Table 45 NAT2 282C-T: λ for each study  
Study  λ 
An 2012 0.13 
Wang 2015b (GI: NTUH) -1.25 
Yuliwulandari 2016 0.18 
Santos 2013 (GI: SANTOS) 0.70 
GI: group identifier  
 
 
Figure 87 NAT2 282C-T: Graph showing the bootstrapped 95% CIs for λ for each study 
CI: confidence interval 
 
Table 46 NAT2 282C-T: Limits of the bootstrapped 95% CI for λ for each study  
Study Lower limit for λ Upper limit for λ 
An 2012 -0.26 0.42 
Wang 2015b (GI: NTUH) -9.96 13.67 
Yuliwulandari 2016 -1.14 0.71 
Santos 2013 (GI: SANTOS) -3.66 7.73 
CI: confidence interval; GI: group identifier 
 
Interpretation  
Although there is overlap in the bootstrapped Cls for λ, there are few studies and it is 
therefore difficult to assess the validity of the assumption of constant λ.  
Conclusion 




Figure 88 NAT2 341T-C: Graph showing the log OR for TC versus TT against the log OR for CC versus TT for each 
study (all studies) 
Equation for line of best fit: y=-0.06x 
Log OR1: log odds ratio for TC versus TT; log OR2: log odds ratio for CC versus TT; OR: odds ratio 
 
 
Figure 89 NAT2 341T-C: Graph showing the log OR for TC versus TT against the log OR for CC versus TT for each 
study (sensitivity analysis excluding Lee 2010 due to deviation from HWE) 
Equation for line of best fit: y=0.05x  
HWE: Hardy-Weinberg equilibrium; log OR1: log odds ratio for TC versus TT; log OR2: log odds ratio 
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Table 47 NAT2 341T-C: λ for each study 
Study  λ 
An 2012 5.57 
Lee 2010 -0.25 
Wang 2015b (GI: NTUH) 0.14 
Yuliwulandari 2016 0.44 
Santos 2013 (GI: SANTOS) -0.75 
GI: group identifier 
 
 
Figure 90 NAT2 341T-C: Graph showing the bootstrapped 95% CIs for λ for each study 
CI: confidence interval 
 
Table 48 NAT2 341T-C: Limits of the bootstrapped 95% CI for λ for each study 
Study Lower limit for λ Upper limit for λ 
An 2012 -1.62 1.22 
Lee 2010 -10.43 13.60 
Wang 2015b (GI: NTUH) -7.38 4.86 
Yuliwulandari 2016 -1.68 1.18 
Santos 2013 (GI: SANTOS) -12.07 27.30 
CI: confidence interval; GI: group identifier 
 
Interpretation  
Although there is overlap in the bootstrapped CIs for λ, there are few studies and 
considerable variability in the estimates of λ from each of these studies, so the validity of 
the assumption of constant λ is unclear.  
Conclusion  




Figure 91 NAT2 481C-T: Graph showing the log OR for CT versus CC against the log OR for TT versus CC for each 
study  
Equation for line of best fit: y=0.42x 
Log OR1: log odds ratio for CT versus CC; log OR2: log odds ratio for TT versus CC; OR: odds ratio 
 
Table 49 NAT2 481C-T: λ for each study 
Study  λ 
An 2012 5.57 
Lv 2012 (GI: ADACS) 0.28 
Xiang 2014 -2.61 
Wang 2015b (GI: NTUH) 1.00 
Yuliwulandari 2016 0.03 
Gupta 2013b (GI: GUPTA) 0.36 
Mahmoud 2012 0.22 
Çetintaş 2008 -10.43 
Santos 2013 (GI: SANTOS) -4.77 
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Figure 92 NAT2 481C-T: Graph showing the bootstrapped 95% CIs for λ for each study 
CI: confidence interval 
 
Table 50 NAT2 481C-T: Limits of the bootstrapped 95% CI for λ for each study 
Study Lower limit for λ Upper limit for λ 
An 2012 -1.62 1.22 
Lv 2012 (GI: ADACS) -1.44 4.08 
Xiang 2014 -16.51 15.04 
Wang 2015b (GI: NTUH) -2.24 15.48 
Yuliwulandari 2016 -2.04 1.05 
Gupta 2013b (GI: GUPTA) -0.08 0.86 
Mahmoud 2012 -3.02 2.21 
Çetintaş 2008 -12.89 16.47 
Santos 2013 (GI: SANTOS) -27.30 19.05 
CI: confidence interval; GI: group identifier 
 
Interpretation  
A reasonable amount of studies report data for this SNP, and the bootstrapped CIs overlap, 
so the assumption of constant λ seems reasonable here. 
Conclusion 





Figure 93 NAT2 590G-A: Graph showing the log OR for AG versus GG against the log OR for AA versus GG for 
each study (all studies) 
Equation for line of best fit: y=0.28x 
Log OR1: log odds ratio for AG versus GG; log OR2: log odds ratio for AA versus GG; OR: odds ratio 
 
 
Figure 94 NAT2 590G-A: Graph showing the log OR for AG versus GG against the log OR for AA versus GG for 
each study (sensitivity analysis excluding Xiang 2014 and Santos 2013 (due to deviation from HWE) 
Equation for line of best fit: y=0.26x 
HWE: Hardy-Weinberg equilibrium; log OR1: log odds ratio for AG versus GG; log OR2: log odds ratio 
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Table 51 NAT2 590G-A: λ for each study 
Study λ 
An 2012 0.23 
Lv 2012 (GI: ADACS) 9.73 
Xiang 2014 2.13 
Lee 2010 0.21 
Wang 2015b (GI: NTUH) 1.90 
Kim 2009 (GI: KIM) 0.41 
Yuliwandari 2016 0.13 
Gupta 2013b (GI: GUPTA) -0.74 
Mahmoud 2012 -0.20 
Çetintaş 2008 0.44 
Santos 2013 (GI: SANTOS) 5.11 
GI: group identifier 
 
 
Figure 95 NAT2 590G-A: Graph showing the bootstrapped 95% CIs for λ for each study 
CI: confidence interval   
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Table 52 NAT2 590G-A: Limits of the bootstrapped 95% CI for λ for each study 
Study Lower limit for λ Upper limit for λ 
An 2012 -0.17 0.85 
Lv 2012 (GI: ADACS) -9.24 7.61 
Xiang 2014 -11.97 8.80 
Lee 2010 -3.69 3.42 
Wang 2015b (GI: NTUH) -5.74 7.84 
Kim 2009 (GI: KIM) 0.03 1.25 
Yuliwandari 2016 -0.86 0.76 
Gupta 2013b (GI: GUPTA) -8.68 14.92 
Mahmoud 2012 -4.36 3.91 
Çetintaş 2008 0.01 1.16 
Santos 2013 (GI: SANTOS) -29.57 388.87 
CI: confidence interval; GI: group identifier 
 
Interpretation 
A reasonable amount of studies report data for this SNP, and the bootstrapped CIs overlap, 
so the assumption of constant λ seems reasonable here. 
Conclusion 





Figure 96 NAT2 803A-G: Graph showing the log OR for GA versus AA against the log OR for GG versus AA for 
each study 
Equation for line of best fit: y=0.24x  
Log OR1: log odds ratio for GA versus AA; log OR2: log odds ratio for GG versus AA; OR: odds ratio 
 
Table 53 NAT2 803A-G: λ for each study 
Study  λ 
An 2012 5.57 
Wang 2015b (GI: NTUH) 0.40 
Yuliwulandari 2016 -10.59 
Santos 2013 (GI: SANTOS) -0.24 
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Figure 97 NAT2 803A-G: Graph showing the bootstrapped 95% CIs for λ for each study 
CI: confidence interval 
 
Table 54 NAT2 803A-G: Limits of the bootstrapped 95% CI for λ for each study 
Study Lower limit for λ Upper limit for λ 
An 2012 -1.62 1.22 
Wang 2015b (GI: NTUH) -4.91 9.46 
Yuliwulandari 2016 -3.37 3.56 
Santos 2013 (GI: SANTOS) -5.09 5.47 
CI: confidence interval; GI: group identifier 
 
Interpretation  
Although there is overlap in the bootstrapped CIs for λ, there are few studies and 
considerable variability in the estimates of λ from each of these studies, so the validity of 
the assumption of constant λ is unclear. 
Conclusion 




Figure 98 NAT2 857G-A: Graph showing the log OR for AG versus GG against the log OR for AA versus GG 
acetylators for each study 
Equation for line of best fit: y=0.14x 
Log OR1: log odds ratio for AG versus GG; log OR2: log odds ratio for AA versus GG; OR: odds ratio 
 
Table 55 NAT2 857G-A: λ for each study 
Study  λ 
An 2012 5.28 
Lv 2012 (GI: ADACS) -0.16 
Xiang 2014 -1.48 
Lee 2010 -0.05 
Wang 2015b (GI: NTUH) 0.39 
Kim 2009 (GI: KIM) 0.64 
Yuliwulandari 2016 0.24 
Mahmoud 2012 -0.29 
Çetintaş 2008 1.22 
Santos 2013 (GI: SANTOS) 0.36 
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Figure 99 NAT2 857G-A: Graph showing the bootstrapped 95% CIs for λ for each study 
CI: confidence interval 
 
Table 56 NAT2 857G-A: Limits of the bootstrapped 95% CI for λ for each study 
Study Lower limit for λ Upper limit for λ 
An 2012 -17.32 22.66 
Lv 2012 (GI: ADACS) -3.47 1.46 
Xiang 2014 -1.83 1.01 
Lee 2010 -0.50 0.27 
Wang 2015b (GI: NTUH) -3.50 4.32 
Kim 2009 (GI: KIM) -2.39 1.87 
Yuliwulandari 2016 -5.43 5.06 
Mahmoud 2012 -9.27 11.69 
Çetintaş 2008 -5.68 2.53 
Santos 2013 (GI: SANTOS) -0.28 1.57 
CI: confidence interval; GI: group identifier 
 
Interpretation  
A reasonable amount of studies report data for this SNP, and the bootstrapped CIs overlap, 
so the assumption of constant λ seems reasonable here. 
Conclusion 
Perform genetic model-free analysis, and bivariate analysis to investigate the robustness of 
results.  
290 
Appendix 6. Further analyses of the association between NAT2 genetic 
variants and hepatotoxicity: Results of the sensitivity analyses 
NAT2 282C-T  
Table 57 Association between NAT2 282C-T and hepatotoxicity: sensitivity analysis excluding Santos 2013  
Analysis approach λ (95% CI) OR for CT vs CC  
(95% CI) 
I2 OR for TT vs CC 
 (95% CI) 
I2 
Genetic model-free 0.13 (-0.19 to 0.44) 1.21 (0.73 to 1.98) 0.0% 4.30 (2.38 to 7.77) 0.0% 
Bivariate N/A 1.21 (0.73 to 1.98) 0.0% 4.30 (2.38 to 7.77) 0.0% 
Pairwise comparisons N/A 1.20 (0.72 to 2.00) 0.0% 4.68 (2.52 to 8.70) 0.0% 
CI: confidence interval; N/A: not applicable; OR: odds ratio 
 
NAT2 341T-C 
Table 58 Association between NAT2 341T-C and hepatotoxicity: sensitivity analysis excluding Lee 2010 
Analysis approach λ (95% CI) OR for TC vs TT 
 (95% CI) 
I2 OR for CC vs TT  
(95% CI) 
I2 
Genetic model-free 0.14 (-0.44 to 0.73) 1.12 (0.68 to 1.84) 0.0% 2.26 (0.95 to 5.36) 0.0% 
Bivariate N/A 1.11 (0.68 to 1.83) 0.0% 2.25 (0.95 to 5.36) 0.0% 
Pairwise comparisons N/A 1.12 (0.68 to 1.85) 0.0% 1.80 (0.67 to 4.84) 0.0% 
CI: confidence interval; N/A: not applicable; OR: odds ratio 
 
NAT2 590G-A 
Table 59 Association between NAT2 590G-A and hepatotoxicity: sensitivity analysis excluding Xiang 2014 and 
Santos 2013 
Analysis approach λ (95% CI) OR for AG vs GG 
(95% CI) 
I2 OR for AA vs GG 
(95% CI) 
I2 
Genetic model-free 0.30 (0.06 to 0.55) 1.29 (1.01 to 1.64) 0.0% 2.30 (1.32 to 4.03) 54.7% 
Bivariate N/A 1.30 (1.00 to 1.69) 0.0% 2.29 (1.28 to 4.10) 54.7% 
Pairwise 
comparisons 
N/A 1.27 (1.02 to 1.59) 0.0% 2.29 (1.28 to 4.12) 54.7% 
CI: confidence interval; N/A: not applicable; OR: odds ratio
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Appendix 7. Development of the STROPS guideline: Reporting items scored in 
the Delphi survey 
Table 60 Reporting items scored at Round 1 and Round 2 of the Delphi survey 
Reporting item Help text 
1. Indicate the study’s 
pharmacogenetic design in the 
title and the abstract. 
N/A 
2. Provide in the abstract an 
informative and balanced 
summary of what was done and 
what was found. 
Provide the key information that enables readers to 
understand the research question, methods, results and 
conclusions of the study. 
3. Explain the scientific 
background and rationale for the 
investigation being reported. 
Provide the rationale for conducting the pharmacogenetic 
study in the context of existing research in this health area, 
i.e. what is known on a topic and what gaps in current 
knowledge are addressed by the study.  
4. Provide reasons for choosing 
the genes and SNPs genotyped. 
Explain how the investigated genes and SNPs were chosen, 
with reference to relevant functional/animal studies, previous 
association studies, and any procedures used such as the 
‘tagging SNP’ approach, or by assessing the likelihood of each 
individual SNP affecting the gene function with priority given 
to those with the most likely functional effect.  
5. If reasons for #4 include 
previous association studies, 
provide key details from these 
studies (effect size and standard 
error/confidence interval). 
N/A 
6. State specific objectives, 
including any pre-specified 
hypotheses. 
Provide the objectives for the study, specifying the relevant 
population, genetic variants, drugs and outcomes. 
7. State if the study is the first 
report of a pharmacogenetic 
association, a replication effort, or 
both.  
N/A 
8. Present key elements of study 
design early in the paper. 
Present key elements of study design so that readers can 
understand the basics of the study, e.g. for a cohort study, 
state that the study used a cohort design, describe the group 
of people that comprised the cohort and the time period for 
which they were followed; for a case-control design, state 
that the study used a case-control design, describe the cases 
and controls and their source population, etc; for a post-hoc 
pharmacogenetic analysis of a RCT, state how the subjects 
included in the analysis were chosen, including which arm of 
the RCT they were from. 
9. Describe the setting, locations 
and relevant dates, including 
periods of recruitment, follow-up, 
and data collection. 
Provide sufficient information to enable readers to assess the 
context and generalisability of a study's results.  
10. Cohort study – Give the 
eligibility criteria, and the sources 
and methods of selection of 
participants. Describe methods of 
follow-up. 
Provide sufficiently detailed descriptions of the study 
participants to help readers understand the applicability of 
the results. Include details of follow-up procedures, including 
any procedures to minimise non-response/loss to follow-up. 
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Reporting item Help text 
11. Case-control study – Give the 
eligibility criteria, and the sources 
and methods of case 
ascertainment and control 
selection. State whether true 
controls or population controls 
were used. Give the rationale for 
the choice of cases and controls. 
Provide sufficiently detailed descriptions of cases and controls 
to help readers understand the applicability of the results. 
True controls are controls who have been exposed to the 
relevant treatment but have not developed the outcome of 
interest. Population controls are sometimes used in genetic 
studies for convenience; they are individuals who have 
already been genotyped that can be assumed to be controls, 
although we cannot ascertain whether they would have 
developed the outcome of interest if they had been exposed 
to the relevant treatment.  
12. Cross-sectional study – Give 
the eligibility criteria, and the 
sources and methods of selection 
of participants. 
Provide sufficiently detailed descriptions of the study 
participants to help readers understand the applicability of 
the results. 
13. Report the drug and regime 
participants were exposed to, and 
the length of exposure. 
Provide details of drug and regime, and length of exposure. 
This could be fixed across all participants, case/control 
specific, or variable. If variable, summarise in patient 
characteristics table.  
14. Cohort study – For matched 
studies, give matching criteria and 
number in each genotype group. 
Provide details of variables that were used to match 
individuals from each genotype group at the start of follow-up 
to make groups more comparable, and the numbers in each 
group. 
15. Case-control study – For 
matched studies, give matching 
criteria and the number of 
controls per case. 
Provide details of variables that were used to match cases and 
controls to ensure similarity between these groups, and the 
number of controls recruited per case. 
16. Give information on the 
criteria and methods for selection 
of subsets of participants from a 
larger study, when relevant.  
If one or more sub-samples from a larger study are used for 
the investigation of a genetic association, provide details of: 
inclusion and exclusion criteria, sources and methods of 
selection for these sub-samples, and state whether these 
methods were pre-specified or post-hoc. 
17. If other publications report 
results for the same patient 
cohort, or a subset of the patient 
cohort, provide information on 
this patient cohort overlap and 
references to the relevant 
publications. 
If other publications report results for the same patient 
cohort, or a subset of the patient cohort, report the numbers 
of patients in the current study for whom other publications 
report data for, rationale for the multiple publications, and 
provide references to the other publications. 
18. Provide justification for choice 
of outcomes. 
Explain why the outcomes are important, e.g. clinical 
importance, importance to patients, occurrence in previously 
developed core outcome sets, identification of a significant 
association in previous studies, etc. 
19. Clearly define all outcomes, 
potential confounders, and effect 
modifiers. Give diagnostic criteria, 
if applicable. 
Clearly define all outcomes, and all variables considered for 
and included in the analysis. Provide details of the diagnostic 
criteria for disease outcomes if applicable.  
20. Clearly define genetic 
exposures (genetic variants) using 
a widely used nomenclature 
system. Identify variables likely to 
be associated with population 
stratification (confounding by 
ethnic origin). 
The Human Gene Nomenclature Committee have published 
guidelines for human gene nomenclature.1,2 Standard 
reference numbers are provided in dbSNP,3 the National 
Center for Biotechnology Information's database of genetic 
variation. Guidelines are available for variations not listed in 
dbSNP.4,5  
 
Principle components analysis can be undertaken to infer 
continuous axes of genetic variation that reduce the data to a 
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Reporting item Help text 
small number of dimensions.6 The resulting principle 
components can be included as variables in analyses of 
association as a means of adjusting for population structure. 
 
1. Wain HM, Bruford EA, Lovering RC, Lush MJ, Wright MW, 
Povey S. Guidelines for human gene nomenclature. Genomics 
2002;79(4):464-70. 
2. Wain HM, Lush M, Ducluzeau F, Povey S. Genew: the 
human gene nomenclature database. Nucleic Acids Res 
2002;30(1):169-71. 
3. Sherry ST, Ward M-H, Kholodov M, Baker J, Phan L, 
Smigielski EM, et al. dbSNP: the NCBI database of genetic 
variation. Nucleic Acids Res 2001;29(1):308-11. 
4. Antonarakis SE, Group NW. Recommendations for a 
nomenclature system for human gene mutations. Hum Mutat 
1998;11(1):1-3. 
5. Dunnen JT, Antonarakis SE. Mutation nomenclature 
extensions and suggestions to describe complex mutations: a 
discussion. Hum Mutat 2000;15(1):7-12. 
6. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick 
NA, Reich D. Principal components analysis corrects for 
stratification in genome-wide association studies. Nat Genet 
2006;38(8):904-9. 
21. Report the rs number of each 
genotyped SNP. 
An ‘rs’ number (reference SNP ID number) is an identification 
tag assigned by NCBI to a group (or cluster) of SNPs that map 
to an identical location. The rs ID number, or rs tag, is 
assigned after submission of a SNP to dbSNP.  
22. Report whether the outcomes 
measured (including definitions) 
are in line with core/preferred 
outcome sets for the particular 
topic of interest. 
A core/preferred outcome set is an agreed standardised set of 
outcomes that should be measured and reported, as a 
minimum, in all clinical studies in specific areas of health or 
health care. The COMET database1 lists references to planned, 
ongoing and completed core outcome set work for a wide 
range of health topics.  
 
1. COMET Initiative. Core Outcome Measures in Effectiveness 
Trials [cited 2020 10 July]. Available from: http://www.comet-
initiative.org/. 
23. For each variable of interest, 
give sources of data and details of 
methods of assessment 
(measurement). Describe 
comparability of assessment 
methods if there is more than one 
group. 
Provide information on how all genetic exposures, 
confounders, and outcomes were measured. Report whether 
there were any differences in how data were collected in 
different patient groups (e.g. cases and controls). 
24. Describe laboratory methods, 
including source and storage of 
DNA, genotyping methods and 
platforms (including the allele 
calling algorithm used, and its 
version), error rates and call rates. 
State the laboratory/centre 
where genotyping was done. 
Describe comparability of 
laboratory methods if there is 
more than one group. Specify 
Provide sufficient details to enable the reader to assess the 
potential extent of genotyping errors (a source of information 
bias). Report whether there were any differences in 
laboratory methods in different patient groups (e.g. cases and 
controls). 
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whether genotypes were assigned 
using all of the data from the 
study simultaneously or in smaller 
batches. 
25. If study is case-control, 
confirm whether patients were 
genotyped in mixed batches. 
Report whether cases and controls were put into combined 
batches for genotyping purposes (to ensure genotyping 
quality is comparable across groups), rather than analysed in 
separate batches. 
26. Confirm whether genotyping 
personnel were blinded to 
outcome status. 
N/A 
27. Describe the primers used. Report details of any primers that were used, or if primers 
were inherent to the assay used, state this and provide 
information on the assay. 
28. Describe genotype quality 
control methods. 
Provide details of genotype quality control methods, for 
example, using negative controls, or re-genotyping/re-
sequencing in all or a random sample of patients. 
29. Describe findings of genotype 
quality control methods 
Provide sufficient information to enable readers to assess the 
risk of bias due to incorrect genotype allocation. 
30. Describe any efforts to 
address potential sources of bias.  
Bias is a systematic deviation of a study’s result from a true 
value, due to flawed information or subject selection. Report 
all potential sources of bias, and any steps taken to reduce 
the likelihood of bias occurring. 
31. For quantitative outcome 
variables, specify if any 
investigation of potential bias 
resulting from pharmacotherapy 
was undertaken. If relevant, 
describe the nature and 
magnitude of the potential bias, 
and explain what approach was 
used to deal with this. 
Bias from pharmacotherapy may occur when quantitative 
outcome variables are affected by treatment with drugs other 
than the study drug (e.g. outcome variables include 
biochemical markers of hepatotoxicity, and several patients 
are taking concomitant hepatotoxic medications).  
32. Report how adherence to 
treatment was assessed, and 
report the results of the 
assessment.  
Provide details on assessments of patient adherence, 
including limitations of the chosen method.  
33. Explain how the study size was 
arrived at, or provide details of 
the a priori power to detect effect 
sizes of varying degrees. 
Report the calculation performed to obtain the study sample 
size, providing references to any specific methodology. Or, if 
sample size was predetermined (for example, secondary 
analyses of a published dataset), provide details of a priori 
power calculations for a range of plausible effect sizes. 
34. Explain how quantitative 
variables (confounders and effect 
modifiers) were handled in the 
analyses. If applicable, describe 
which groupings were chosen, 
and why. 
Explain how quantitative data (in relation to effect modifiers 
and confounders) were collected and analysed. Continuous 
variables may be grouped into categories to create a new 
categorical variable; explain why and how quantitative data 
were grouped.  
35. If applicable, describe how 
effects of treatment on 
quantitative outcome variables 
were dealt with. 
If any quantitative outcome variables may be affected by 
treatment with drugs other than the study drug, report 
whether any of the available methods for adjusting for 
treatment effects1 were used to deal with this potential bias.  
 
1. Tobin MD, Sheehan NA, Scurrah KJ, Burton PR. Adjusting for 
treatment effects in studies of quantitative traits: 
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antihypertensive therapy and systolic blood pressure. Stat 
Med 2005;24(19):2911-35. 
36. Describe all statistical 
methods, including those used to 
control for confounding. 
Report which analyses were pre-specified and which were 
exploratory based on data inspection. If groups being 
compared are not similar regarding some characteristics, 
adjustment should be made for possible confounding 
variables. Provide details of procedures of variable selection 
and model comparison.  
37. State software version used 
and options (or settings) chosen. 
Provide details of any specialized software/packages used to 
analyse the data. 
38. Describe any methods used to 
examine subgroups and 
interactions. 
Explain what methods were used to examine whether 
associations differed across subgroups, or to examine 
interactions. An ‘interaction’ occurs when one factor modifies 
the effect of another, and is also sometimes referred to as 
‘effect modification'. Report whether these analyses were 
pre-planned or not. 
39. Explain how missing data were 
addressed.  
Confirm whether analyses were restricted to individuals with 
complete data on the required variables, or whether any 
imputation of missing data was performed.  
40. Report any methods used to 
assess the assumption of 
missingness at random and the 
finding of such assessments. 
Data are said to be ‘missing at random’ if the fact that they 
are missing is unrelated to actual values of the missing data. 
Data that are missing at random may not be important. 
Analyses based on the available data will tend to be unbiased, 
although based on a smaller sample size than the original data 
set. 
41. Cohort study – If applicable, 
explain how loss to follow-up was 
addressed. 
Individuals who withdrew from the study before the end of 
their observation period are ‘lost to follow-up’. Report how 
many individuals were lost to follow-up, and whether these 
individuals were excluded or whether censoring strategies 
were used. Describe any censoring strategies. 
42. Case-control study – If 
applicable, explain how matching 
of cases and controls was 
addressed. 
If a matched design was used, describe in detail what 
statistical methods were used to take into account the 
matching of cases and controls.  
43. Cross-sectional study – If 
applicable, describe analytical 
methods taking account of 
sampling strategy. 
Sampling may be more complex than taking a simple random 
sample from the source population. For example, it may 
include several stages and clustering of participants. If a 
complex sampling strategy is used, estimates of association 
may be more or less precise than those derived from a simple 
random sample. If a complex sampling strategy was used, 
clearly state the methods used to adjust for this, so that 
readers may understand how the chosen sampling method 
influenced the precision of the obtained estimates. 
44. Describe any sensitivity 
analyses. 
Provide details of any analyses that were performed to 
investigate whether the results of the main analysis are 
consistent with those obtained with alternative analysis 
strategies or assumptions. Report whether these analyses 
were pre-planned or not. 
45. State whether HWE was 
considered and, if so, how.  
Describe any statistical tests or measures of departure from 
HWE, and any methods used to allow for deviations from 
HWE. 
46. Where HWE test is 
undertaken, quote the p-value 
State how small a p-value from a HWE test had to be to 
indicate a statistically significant deviation from HWE. 
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threshold applied to determine 
deviation from HWE. 
47. Describe any methods used 
for inferring genotypes or 
haplotypes.  
Provide statistical methods and software used to infer 
genotype phase and haplotypes. See the STREGA statement1 
for further information.  
 
1. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, Von 
Elm E, et al. STrengthening the REporting of Genetic 
Association Studies (STREGA): an extension of the STROBE 
statement. Hum Genet 2009;125(2):131-51. 
48. Describe any methods used to 
assess or address population 
stratification.  
Explicitly document any methods used to assess the presence 
of population stratification or adjust for population 
stratification in the analyses. If no methods were used, state 
this.  
49. Describe any methods used to 
assess and correct for relatedness 
among subjects. Report results of 
assessments for relatedness. 
For pharmacogenetic studies, it is not uncommon for some 
participants to be related. Authors should report any methods 
used to assess relatedness, results of these assessments, and 
any methods used to correct for relatedness. 
50. Describe any assumptions 
made regarding mode of 
inheritance. 
The mode of inheritance for a particular SNP determines the 
observed trait for each given combination of parental alleles - 
some different modes of inheritance are summarised by 
Jorgensen and Williamson.1 If a particular mode of inheritance 
is assumed in the analyses, i.e. genotypes are grouped 
according to the resulting observed trait, state this. If more 
than one approach is used in the analysis, assuming different 
modes of inheritance, then report on all analyses performed. 
 
1. Jorgensen AL, Williamson PR. Methodological quality of 
pharmacogenetic studies: issues of concern. Stat Med 
2008;27(30):6547-69. 
51. Provide justification for 
assumption of mode of 
inheritance or if no mode is 
assumed. 
For each analysis where a particular mode of inheritance is 
assumed, or no mode of inheritance is assumed, justify this 
approach, for example by summarising previous research on 
the mode of inheritance for the relevant SNP. If multiple 
analyses are performed making different assumptions, justify 
this decision.  
52a. Describe any methods used 
to address multiple comparisons 
or to control risk of false positive 
findings due to investigating 
multiple genetic variants. 
Provide sufficient detail to enable the reader to assess the 
likelihood of false positive results (type 1 errors) being 
reported. 
52b. Describe any methods used 
to address multiple comparisons 
or to control risk of false positive 
findings due to investigating 
multiple outcomes. 
Provide sufficient detail to enable the reader to assess the 
likelihood of false positive results (type 1 errors) being 
reported. 
52c. Describe any methods used 
to address multiple comparisons 
or to control risk of false positive 
findings due to investigating 
multiple assumptions regarding 
mode of inheritance. 
Provide sufficient detail to enable the reader to assess the 
likelihood of false positive results (type 1 errors) being 
reported. 
53. Describe any methods used to 
adjust for extent of adherence in 
the analyses.  
N/A 
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54a. Report the numbers of 
individuals at each stage of the 
study – e.g., numbers potentially 
eligible, examined for eligibility, 
confirmed eligible, included in the 
study, completing follow-up, and 
analysed. 
Give an account of the numbers of individuals considered at 
each stage of recruiting study participants, from the choice of 
a target population to the inclusion of participants' data in the 
analysis.  
54b. Give reasons for non-
participation at each stage. 
Provide transparent information on reasons for non-
participation/exclusion of participants at each stage, to allow 
the reader to judge whether the study population was 
representative of the target population, and whether bias was 
possibly introduced.  
54c. Consider use of a flow 
diagram. 
A flow diagram can be an efficient and transparent way to 
convey the information described in #54a and #54b, which 
may otherwise require a lengthy description in the text.  
55. For each genetic variant, 
report numbers of individuals in 
whom genotyping was attempted 
and numbers of individuals in 
whom genotyping was successful. 
N/A 
56. Report any SNPs that were 
excluded from analysis, and 
provide reasons for these 
exclusions. 
Examples of possible reasons for excluding SNPs are the 
failure of the HWE test, or excessive missing data, etc. 
57. Give characteristics of study 
participants (e.g., demographic, 
clinical, social) and information on 
potential confounders. 
Report participant characteristics with appropriate summary 
measures. For example, for continuous data, mean and 
standard deviation, or median and range; for dichotomous 
data, numbers and proportions. 
58. Indicate the number of 
participants with missing data for 
each variable of interest. 
Report the amount of missing genotype data, missing data for 
potential confounders, and missing data for other important 
patient characteristics and outcomes.  
59. For a cohort study, consider 
giving information listed in #57 
and #58 by genotype. 
Where several genetic variants have been considered, this 
may not be practical. 
60. For a case-control study, give 
the information listed in #57 and 
#58 for cases and controls 
separately. 
N/A 
61. Report reasons for missing 
genotype data. 
Report any reasons that genotype data were missing and 
report how much of the missing data was attributed to each 
reason. 
62. Cohort study – Summarize 
follow-up time, e.g. average and 
total amount. 
Average follow-up can be summarised using the mean and/or 
median follow-up time. Total amount of follow-up may be 
reported using total person-years of follow-up, or some 
indication of the completeness of follow-up.1  
 
1. Clark TG, Altman DG, De Stavola BL. Quantification of the 
completeness of follow-up. Lancet 2002;359(9314):1309-10. 
63. Where HWE test undertaken, 
highlight SNPs that deviate from 
HWE. 
Report any SNPs for which a HWE test indicated deviation for 
HWE.  
64. Where population 
stratification is assessed, report 
the results. 
Report the results of any tests performed to detect the 
presence of population stratification. 
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65a. For a cohort study, report all 
outcomes (phenotypes) 
investigated for each genotype 
category over time. 
For outcomes that relate to the occurrence of some event, 
report the number of events that occurred. If the risk of an 
event occurring changes over follow-up time, present the 
numbers and rates of events in appropriate intervals of 
follow-up or as a Kaplan-Meier life table or plot. For other 
outcomes, present appropriate summary measures (e.g. 
means and standard deviations) over time. 
65b. For a case-control study, 
report numbers in each genotype 
category for all outcomes 
investigated. 
Report numbers of cases and controls in each genotype 
category. 
65c. For a cross sectional study, 
report all outcomes (phenotypes) 
investigated for each genotype 
category. 
For outcomes that relate to the occurrence of some event, 
report the number of events that occurred. For other 
outcomes, present appropriate summary measures (e.g. 
means and standard deviations). 
66. If a study includes more than 
one ethnic group, provide the 
summary data specified in #65 
per ethnic group.  
If the study includes patients belonging to different ethnic 
groups, provide all outcome data stratified by ethnicity. 
67. Give unadjusted estimates 
and, if applicable, confounder-
adjusted estimates and their 
precision (e.g., 95% confidence 
intervals). Make clear which 
confounders were adjusted for 
and why they were included. 
Provide both unadjusted measures of association and 
measures of association adjusted for potential confounders, 
to enable readers to compare both measures and assess how 
the measure of association is impacted by adjusting for 
confounders. List all potential confounder variables 
considered, and the criteria/rationale for excluding or 
including variables in statistical models.  
68. Report category boundaries 
when continuous variables were 
categorized. 
If continuous outcomes were categorised, report the range of 
values covered by each category.  
69. If relevant, consider 
translating effect estimates to 
number needed to test to 
illustrate potential clinical utility 
of any significant findings. 
In pharmacogenetic studies, a ‘number needed to test’ can be 
calculated to demonstrate the clinical relevance of study 
findings. For example, ‘12 tuberculosis patients (95% 
confidence interval: 7 to 23) would need to be tested for the 
genetic variant (and possibly put on alternative therapy 
dependent on the results of the test) to prevent one case of 
hepatotoxicity’. 
70. Report results of any 
adjustments for multiple 
comparisons.  
For example, report Bonferroni adjusted p-values, or false 
discovery rates. 
71. Report precise p-values for all 
associations.  
Report the precise p-values for all associations, as opposed to 
only indicating whether an association was found to be 
statistically significant or not. For example, stating p<0.05 or 
p>0.05, or indicating statistical significance (or a lack of) by 
using asterisks (*) is not sufficient to satisfy this criterion. 
Reporting of p-values may be subject to journal guidelines; p-
values below a certain threshold e.g. p<0.0001 may need to 
be reported as such. 
72. Report other analyses done – 
e.g., analyses of subgroups and 
interactions, and sensitivity 
analyses. 
Report the results of any analyses performed in addition to 
the main analysis. It may be impractical to present detailed 
findings for all analyses performed; in this case, present 
detailed results for important results only. Less important 
results can be summarised briefly in the text i.e. ‘results of the 
sensitivity analysis were consistent with the results of the 
main analysis’ and detailed in full in supplementary materials.  
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73. If numerous genetic exposures 
(genetic variants) were examined, 
summarize results from all 
analyses undertaken. 
Report results for all genetic variants that were investigated in 
the study, rather than selectively reporting only ‘interesting’ 
or significant results. Full results can be provided in 
supplementary materials if necessary. 
74. If detailed results are available 
elsewhere, state how they can be 
accessed. 
Report what results are available, and where to find these 
results. Provide sufficient details that a reader would easily be 
able to locate these resources. 
75. Summarize key results with 
reference to study objectives. 
Remind the reader of the main findings of the study with a 
short summary. This helps the reader to assess whether the 
author's interpretation and suggested implications are 
supported by the findings. 
76. Discuss limitations of the 
study, taking into account sources 
of potential bias or imprecision. 
Discuss both direction and 
magnitude of any potential bias. 
Help the reader to interpret the validity and health care 
relevance of the study findings. Limitations might relate to, 
for example, characteristics of included patients, methods of 
outcome measurement, multiplicity of analyses, missing data, 
etc.  
77. Give a cautious overall 
interpretation of results 
considering objectives, 
limitations, multiplicity of 
analyses, results from similar 
studies, and other relevant 
evidence. 
When interpreting results, authors should consider the 
position of the study on the discovery to verification 
continuum. Consider potential sources of bias, residual 
confounding (due to unmeasured variables or imprecise 
measurement of confounders), the results of relevant 
sensitivity analyses, the issue of multiplicity and subgroup 
analyses. Authors should address the real range of 
uncertainty in estimates, which is larger than the statistical 
uncertainty reflected in confidence intervals. 
78. Report genotype frequencies 
from other studies. 
If allelic frequencies have previously been reported for 
individuals from the same population, quote these for 
comparison purposes.  
79. Discuss the generalisability 
(external validity) of the study 
results. 
Consider the extent to which the results of the study can be 
applied to other circumstances, i.e. different 
populations/settings/countries. 
80. Discuss, if pertinent, the 
health care relevance of the study 
results. 
Consider 1) the efforts it takes to obtain the additional 
genotype information, 2) the impact the results might have on 
medical or public health decision making and on expected 
health benefits, and 3) the extent to which these benefits will 
outweigh the potential harms related to genetic testing and 
the cost of implementation. Describe what evidence is still 
needed before health care implementation can be 
considered. 
81. State whether the protocol for 
the analysed data is publicly 
available and if so, how the 
protocol can be accessed. 
If the protocol is available, provide sufficient details that a 
reader would easily be able to locate this resource.  
82. State whether the study has 
been registered. If the study has 
been registered, provide details of 
the registry. 
Studies can be registered on many different official platforms; 
the most widely used platform is ClinicalTrials.gov. 
83a. Report whether ethical 
approval was obtained for the 
collection of genetic data. 
N/A 
83b. If ethical approval was 
obtained, report the committee 




Reporting item Help text 
84. Give the source of funding and 
the role of the funders for the 
present study and, if applicable, 
for the original study on which 
the present article is based. 
Role of funders: State which part of the study the funders 
took direct responsibility for, e.g., study design, data 
collection, analysis, drafting of manuscript, decision to 
publish.  
85. State whether databases for 
the analysed data are or will 
become publicly available and if 
so, how they can be accessed. 
If databases are available, provide sufficient details that a 
reader would easily be able to locate these resources.  
COMET: Core Outcome Measures in Effectiveness Trials; HWE: Hardy-Weinberg equilibrium; N/A: 
not applicable; RCT: randomised controlled trial; SNP: single nucleotide polymorphism  
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Clearly state how haplotypes or 
star alleles were defined. 
Even when referring to well-defined star alleles or haplotypes, 
it is good practice to provide full details in the current 
publication using standard nomenclature. For example, 
‘NAT2*5A was defined as rs1801280 c.341 allele C and 
rs1799929 c.481 allele T’. 
Clearly state on which 
chromosomal strand the alleles 
are reported. 
If the chromosomal strand for which alleles are reported is 
not stated, it is difficult to know which allele is associated with 
the phenotype of interest for A/T or G/C SNPs. A statement 
such as ‘the A allele (positive chromosomal strand) is 
associated with...’ is clear.  
If studying drug metabolites, 
provide references and links to 
structures and database 
identifiers. 
e.g. PubChem Compound IDs 
(https://pubchem.ncbi.nlm.nih.gov/) 
Report disease/clinical indication 
of patients using a standardised 
ontology. 
e.g. SNOMED CT; Mesh 
If referring to the minor, wild-
type or mutant allele of a variant, 
state which allele this is and for 
which given population/cohort. 
The minor (less frequent) allele in one population may be the 
major (more frequent) allele in a different population. The 
allele and population should be clearly stated if using the 
terms ‘minor’, ‘wild-type’ or ‘mutant’, e.g. ‘the minor allele, T, 
in Gujarati Indians’.  
Report on the risk of 
phenoconversion (genotype-
phenotype mismatch) and its 
magnitude in the study 
population. 
For more information, see: 
 
Shah RR, Smith RL. Addressing phenoconversion: the Achilles' 
heel of personalized medicine. Br J Clin Pharmacol 
2015;79(2):222-40. 
Confirm whether patients were 
blinded to their genotyping result. 
N/A 
N/A: not applicable; SNP: single nucleotide polymorphism 
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Appendix 8. Development of the STROPS guideline: Consensus matrix 
Category # Criteria Consensus Round 1 Consensus Round 2 




JE (n=10) PR 
(n=31) 
SR (n=11) 
Title and abstract 
Title and abstract 1 Indicate the study’s pharmacogenetic design in the title and the 
abstract. 
60% 60% 67% 50% 70% 55% 
2 Provide in the abstract an informative and balanced summary 
of what was done and what was found. 




3 Explain the scientific background and rationale for the 
investigation being reported. 
80% 88% 87% 90% 97% 91% 
4 Provide reasons for choosing the genes and SNPs genotyped. 87% 85% 87% 90% 97% 91% 
5 If reasons for (4) include previous association studies, provide 
key details from these studies (effect size and standard 
error/confidence interval). 
80% 40% 43% 70% 45% 27% 
Objectives  6 State specific objectives, including any pre-specified 
hypotheses. 
73% 90% 87% 70% 94% 91% 
7 State if the study is the first report of a pharmacogenetic 
association, a replication effort, or both.  
67% 66% 87% 60% 74% 91% 
Methods 
Study design 8 Present key elements of study design early in the paper. 80% 76% 87% 70% 74% 91% 
Setting 9 Describe the setting, locations and relevant dates, including 
periods of recruitment, follow-up, and data collection. 
60% 73% 53% 40% 61% 36% 
Participants 10 Cohort study – Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe methods of 
follow-up. 
93% 90% 87% 90% 94% 91% 
11 Case-control study – Give the eligibility criteria, and the sources 
and methods of case ascertainment and control selection. State 
whether true controls or population controls were used. Give 
the rationale for the choice of cases and controls. 
87% 85% 93% 90% 94% 91% 
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12 Cross-sectional study – Give the eligibility criteria, and the 
sources and methods of selection of participants. 
87% 88% 93% 90% 94% 91% 
13 Report the drug and regime participants were exposed to, and 
the length of exposure. 
93% 83% 87% 90% 90% 100% 
14 Cohort study – For matched studies, give matching criteria and 
number in each genotype group. 
87% 90% 86% 100% 94% 91% 
15 Case-control study – For matched studies, give matching 
criteria and the number of controls per case. 
87% 88% 86% 100% 94% 91% 
16 Give information on the criteria and methods for selection of 
subsets of participants from a larger study, when relevant.  
67% 83% 87% 70% 90% 91% 
17 If other publications report results for the same patient cohort, 
or a subset of the patient cohort, provide information on this 
patient cohort overlap and references to the relevant 
publications. 
47% 66% 80% 50% 74% 91% 
18 Report disease/clinical indication of patients using a 
standardised ontology. 
NS NS NS 44% 65% 73% 
19 Confirm whether patients were blinded to their genotyping 
result. 
NS NS NS 80% 52% 64% 
Variables 20 Provide justification for choice of outcomes. 80% 71% 80% 80% 84% 82% 
21 Clearly define all outcomes, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable. 
87% 88% 93% 90% 87% 100% 
22 Clearly define genetic exposures (genetic variants) using a 
widely used nomenclature system. Identify variables likely to be 
associated with population stratification (confounding by ethnic 
origin). 
87% 85% 93% 90% 97% 91% 
23 Report the rs number of each genotyped SNP. 87% 81% 87% 90% 94% 82% 
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24 Report whether the outcomes measured (including definitions) 
are in line with core/preferred outcome sets for the particular 
topic of interest. 
73% 59% 67% 80% 66% 64% 
25 Clearly state how haplotypes or star alleles were defined. NS NS NS 80% 73% 82% 
26 Clearly state on which chromosomal strand the alleles are 
reported. 
NS NS NS 60% 59% 73% 
27 If referring to the minor, wild-type or mutant allele of a variant, 
state which allele this is and for which given population/cohort. 
NS NS NS 80% 67% 82% 
28 If studying drug metabolites, provide references and links to 
structures and database identifiers. 
NS NS NS 40% 48% 64% 
Data sources/ 
measurement 
29 For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability 
of assessment methods if there is more than one group. 
67% 49% 53% 70% 61% 55% 
30 Describe laboratory methods, including source and storage of 
DNA, genotyping methods and platforms (including the allele 
calling algorithm used, and its version), error rates and call 
rates. State the laboratory/centre where genotyping was done. 
Describe comparability of laboratory methods if there is more 
than one group. Specify whether genotypes were assigned 
using all of the data from the study simultaneously or in smaller 
batches. 
73% 61% 53% 80% 81% 73% 
31 If study is case-control, confirm whether patients were 
genotyped in mixed batches. 
40% 48% 50% 30% 58% 36% 
32 Confirm whether genotyping personnel were blinded to 
outcome status. 
60% 49% 53% 40% 55% 46% 
33 Describe the primers used. 47% 33% 27% 50% 29% 9% 
34 Describe genotype quality control methods. 80% 43% 47% 90% 52% 46% 
35 Describe findings of genotype quality control methods. 60% 43% 47% 60% 42% 46% 
Bias 36 Describe any efforts to address potential sources of bias.  60% 76% 53% 60% 84% 55% 
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37 For quantitative outcome variables, specify if any investigation 
of potential bias resulting from pharmacotherapy was 
undertaken. If relevant, describe the nature and magnitude of 
the potential bias, and explain what approach was used to deal 
with this. 
80% 60% 54% 90% 73% 73% 
38 Report how adherence to treatment was assessed, and report 
the results of the assessment.  
80% 59% 53% 90% 81% 73% 
Study size 39 Explain how the study size was arrived at, or provide details of 
the a priori power to detect effect sizes of varying degrees. 
87% 81% 64% 90% 84% 73% 
Quantitative variables  40 Explain how quantitative variables (confounders and effect 
modifiers) were handled in the analyses. If applicable, describe 
which groupings were chosen, and why. 
71% 78% 69% 80% 87% 73% 
41 If applicable, describe how effects of treatment on quantitative 
outcome variables were dealt with. 
79% 71% 57% 90% 77% 46% 
Statistical methods 42 Describe all statistical methods, including those used to control 
for confounding. 
64% 90% 86% 80% 97% 82% 
43 State software version used and options (or settings) chosen. 57% 44% 33% 60% 42% 18% 
44 Describe any methods used to examine subgroups and 
interactions. 
57% 73% 64% 60% 87% 64% 
45 Explain how missing data were addressed.  71% 68% 67% 80% 81% 73% 
46 Report any methods used to assess the assumption of 
missingness at random and the finding of such assessments. 
69% 54% 43% 70% 66% 46% 
47 Cohort study – If applicable, explain how loss to follow-up was 
addressed. 
64% 63% 43% 60% 77% 36% 
48 Case-control study – If applicable, explain how matching of 
cases and controls was addressed. 
71% 68% 43% 70% 83% 27% 
49 Cross-sectional study – If applicable, describe analytical 
methods taking account of sampling strategy. 
64% 63% 43% 80% 69% 27% 
50 Describe any sensitivity analyses. 31% 69% 53% 22% 67% 36% 
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51 State whether HWE was considered and, if so, how.  71% 71% 64% 90% 80% 64% 
52 Where HWE test is undertaken, quote the p-value threshold 
applied to determine deviation from HWE. 
79% 64% 50% 80% 77% 36% 
53 Describe any methods used for inferring genotypes or 
haplotypes.  
64% 78% 67% 70% 90% 55% 
54 Describe any methods used to assess or address population 
stratification.  
57% 85% 67% 60% 97% 64% 
55 Describe any methods used to assess and correct for 
relatedness among subjects. Report results of assessments for 
relatedness. 
43% 72% 40% 60% 81% 27% 
56 Describe any assumptions made regarding mode of inheritance. 50% 70% 47% 60% 73% 36% 
57 Provide justification for assumption of mode of inheritance or if 
no mode is assumed. 
50% 65% 47% 60% 77% 55% 
58a Describe any methods used to address multiple comparisons or 
to control risk of false positive results due to investigating 
multiple genetic variants. 
86% 80% 80% 90% 97% 82% 
58b Describe any methods used to address multiple comparisons or 
to control risk of false positive results due to investigating 
multiple outcomes. 
86% 78% 80% 90% 93% 82% 
58c Describe any methods used to address multiple comparisons or 
to control risk of false positive results due to investigating 
multiple assumptions regarding mode of inheritance. 
57% 78% 64% 50% 86% 73% 
59 Describe any methods used to adjust for extent of adherence in 
the analyses.  
67% 63% 50% 89% 74% 50% 
Results 
Participants 60a Report the numbers of individuals at each stage of the study – 
e.g., numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-up, 
and analysed. 
67% 85% 87% 90% 90% 91% 
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60b Give reasons for non-participation at each stage. 40% 63% 53% 30% 58% 46% 
60c Consider use of a flow diagram. 40% 51% 47% 30% 48% 36% 
61 For each genetic variant, report numbers of individuals in 
whom genotyping was attempted and numbers of individuals in 
whom genotyping was successful. 
53% 60% 73% 50% 63% 73% 
SNPs 62 Report any SNPs that were excluded from analysis, and provide 
reasons for these exclusions. 
73% 68% 80% 50% 81% 82% 
Descriptive data 63 Give characteristics of study participants (e.g., demographic, 
clinical, social) and information on potential confounders. 
80% 88% 100% 100% 94% 100% 
64 Indicate the number of participants with missing data for each 
variable of interest. 
73% 61% 73% 90% 71% 91% 
65 For a cohort study, consider giving information listed in (63) and 
(64) by genotype. 
47% 50% 71% 30% 50% 73% 
66 For a case-control study, give the information listed in (63) and 
(64) for cases and controls separately. 
67% 60% 71% 60% 67% 64% 
67 Report reasons for missing genotype data. 53% 46% 53% 40% 42% 36% 
68 Cohort study – Summarize follow-up time, e.g. average and 
total amount. 
60% 78% 60% 70% 87% 64% 
69 Where HWE tests have been undertaken, highlight SNPs that 
deviate from HWE. 
80% 66% 77% 90% 79% 73% 
70 Where population stratification is assessed, report the results. 93% 73% 80% 90% 87% 73% 
Outcome data 71a For a cohort study, report all outcomes (phenotypes) 
investigated for each genotype category over time. 
57% 83% 100% 70% 80% 91% 
71b For a case-control study, report numbers in each genotype 
category for all outcomes investigated. 
79% 85% 100% 90% 87% 91% 
71c For a cross sectional study, report all outcomes (phenotypes) 
investigated for each genotype category. 
57% 85% 100% 70% 90% 91% 
72 If a study includes more than one ethnic group, provide the 
summary data specified in (71) per ethnic group.  
86% 78% 73% 90% 84% 73% 
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JE (n=10) PR 
(n=31) 
SR (n=11) 
Main results 73 Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (e.g. 95% confidence 
intervals). Make clear which confounders were adjusted for and 
why they were included. 
86% 88% 92% 100% 97% 100% 
74 Report category boundaries when continuous variables were 
categorised. 
69% 83% 100% 70% 97% 100% 
75 If relevant, consider translating effect estimates to number 
needed to test to illustrate potential clinical utility of any 
significant findings. 
62% 57% 53% 60% 62% 46% 
76 Report results of any adjustments for multiple comparisons.  86% 81% 87% 80% 94% 100% 
77 Report precise p-values for all associations.  64% 73% 87% 70% 87% 91% 
Other analyses 78 Report other analyses done – e.g., analyses of subgroups and 
interactions, and sensitivity analyses. 
50% 75% 71% 50% 83% 91% 
79 If numerous genetic exposures (genetic variants) were 
examined, summarize results from all analyses undertaken. 
36% 76% 73% 20% 74% 73% 
80 If detailed results are available elsewhere, state how they can 
be accessed. 
86% 73% 67% 80% 81% 82% 
Discussion 
Key results 81 Summarize key results with reference to study objectives. 100% 85% 100% 100% 97% 100% 
Limitations 82 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias. 
93% 85% 100% 100% 97% 100% 
83 Report on the risk of phenoconversion (genotype-phenotype 
mismatch) and its magnitude in the study population. 
NS NS NS 78% 50% 46% 
Interpretation  84 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence. 
86% 83% 93% 100% 90% 100% 
85 Report genotype frequencies from other studies. 57% 37% 47% 50% 23% 36% 
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JE (n=10) PR 
(n=31) 
SR (n=11) 
Generalisability  86 Discuss the generalisability (external validity) of the study 
results. 
71% 73% 73% 90% 81% 73% 
87 Discuss, if pertinent, the health care relevance of the study 
results. 




88 State whether the protocol for the analysed data is publicly 
available and if so, how the protocol can be accessed. 
64% 53% 53% 30% 58% 46% 
89 State whether the study has been registered. If the study has 
been registered, provide details of the registry. 
79% 63% 53% 80% 71% 36% 
Ethical approval 90a Report whether ethical approval was obtained for the collection 
of genetic data. 
86% 95% 80% 100% 97% 73% 
90b If ethical approval was obtained, report the committee that 
gave ethical approval and a reference ID. 
43% 54% 53% 50% 55% 27% 
Funding 91 Give the source of funding and the role of the funders for the 
present study and, if applicable, for the original study on which 
the present article is based. 
64% 63% 87% 80% 81% 82% 
Databases 
92 State whether databases for the analysed data are or will 
become publicly available and if so, how they can be accessed. 
71% 54% 60% 70% 65% 46% 
Consensus definition: Support from at least 70% of participants scoring ‘Critical’, i.e. score 7-9 (from a 1-9 scale). Green shading indicates the stakeholder group reached 
consensus for the item. 
Participants were excluded from the calculations (denominators) if they did not score an item. 
HWE: Hardy-Weinberg equilibrium; JE: journal editors; NS: not scored; PR: primary researchers; SNP: single nucleotide polymorphism; SR: systematic reviewers
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Appendix 9: Development of the STROPS guideline: Explanation and 
elaboration document 
Abstract 
1. Provide in the abstract an informative and balanced summary of what was done and what 
was found. 
Explanation 
Study authors should provide the key information that enables readers to understand the 
research question, study design, methods, results and conclusions of the study. This item is 
from the STROBE statement1 (Item 1b); further guidance and rationale for this item is 
detailed in the STROBE explanation and elaboration paper.2 An example abstract is 
provided below; however it is important to note that journals may specify their own set of 
guidelines, which authors ought to follow in terms of abstract structure and content.  
Example 
“INTRODUCTION: Approximately 30% of patients with epilepsy are resistant to treatment 
with anti-epileptic drugs (AEDs). The ABC drug transporter proteins are hypothesized to 
mediate drug resistance in epilepsy. More recently, a non-ABC putative transporter, RLIP76, 
has also been proposed to be involved in the mechanism of pharmacoresistance. One 
previous association study of six polymorphisms in RLIP76 failed to find any association 
with drug resistance in a retrospective cohort of epilepsy patients. We aimed to look for an 
association with outcomes reflecting drug response in a larger prospective cohort, with 
gene-wide coverage. 
PATIENTS AND METHODS: We investigated the role of common polymorphisms in RLIP76 in 
epilepsy pharmacoresistance by genotyping 23 common RLIP76 polymorphisms in a 
prospective cohort of 503 epilepsy patients, from the standard and new anti-epileptic drugs 
(SANAD) prospective study of new and old AEDs. A total of 13 of these were tested for 
association with four outcomes reflecting response to drugs: time to first seizure, time to 
12-month remission, time to withdrawal due to inadequate seizure control, and time to 
withdrawal due to unacceptable adverse drug events. 
RESULTS: No significant associations, allowing for multiple testing, were found in the whole 
cohort. There was also no effect in a subgroup of patients on carbamazepine, which is 
thought to be a RLIP76 substrate, although two polymorphisms were associated with time 
to first seizure (p=0.007). 
DISCUSSION: We failed to demonstrate any association between RLIP76 polymorphisms 
and four different measures of drug response in the larger cohort, but a subgroup analysis 
of patients receiving carbamazepine suggested an association that should be investigated 
further. 
CONCLUSIONS: Our data suggest that common variants in RLIP76 are unlikely to contribute 
to epilepsy drug response”.3 
Introduction: Background/rationale 
2. Explain the scientific background and rationale for the investigation being reported. 
Explanation 
Study authors should provide the rationale for conducting the pharmacogenetic study in 
the context of existing research in this health area, i.e. what is known on a topic and what 
311 
gaps in current knowledge are addressed by the study. This item is from the STROBE 
statement1 (Item 2); further guidance and rationale for this item is detailed in the STROBE 
explanation and elaboration paper.2 
Example 
“Inhaled corticosteroids (ICS) are recommended for adults and children with asthma and 
for chronic obstructive pulmonary disease (COPD). Although ICS are generally well tolerated 
and have fewer systemic adverse effects than do oral corticosteroids, some patients can 
still develop systemic adverse effects. Adrenal suppression is a clinically important adverse 
effect, particularly in children with asthma, in whom the diagnosis of adrenal suppression 
can be challenging because presentation can range from asymptomatic biochemical 
changes to nonspecific lethargy to florid adrenal crisis and death (…). 
Interindividual variation in susceptibility to adrenal suppression is striking (…). The reasons 
for the interindividual variability in both adults and children remain unclear, because 
clinical factors only account for a small proportion of the variance.  
Previous pharmacogenomic studies in patients with asthma using corticosteroids have 
focused on efficacy. As far as we know, no studies examining the pharmacogenomics of 
corticosteroid-induced adrenal suppression have been reported. The aim of the 
Pharmacogenetics of Adrenal Suppression with Inhaled Steroids (PASS) study was to 
undertake a pharmacogenomics assessment of factors predisposing to corticosteroid-
induced adrenal suppression among children with asthma using ICS as part of their 
treatment”.4 
3. Provide reasons for choosing the genes and SNPs genotyped. 
Explanation 
It is important that researchers conducting a candidate gene study choose the genes and 
SNPs to be investigated in a systematic way, using prior knowledge to guide their decisions. 
Study authors should explain how the investigated genes and SNPs were chosen, with 
reference to relevant functional/animal studies, previous association studies, and any 
procedures used, such as examining linkage disequilibrium patterns (the "tagging SNP" 
approach), or assessing the likelihood of each individual SNP affecting the gene function 
with priority given to those with the most likely functional effect. Clear rationale instils 
confidence in the reader that all analyses performed have been reported, rather than only 
statistically significant or interesting results (i.e. selective reporting of results).  
It is important to note that for next generation sequencing (NGS), criteria may be applied to 
prioritise genetic variants for association analyses. In this case, filtering options ought to be 
specified.  
The origin of this item is Jorgensen and Williamson’s quality assessment checklist for 
pharmacogenetic studies.5 
Example 
“More recently, a novel putative mechanism of epilepsy multidrug resistance has been 
described. RLIP76, also known as RALBP1, is alleged to be a non-ABC multispecific 
transporter, which transports a variety of drugs, with a similar substrate specificity to PGP 
[P-glycoprotein]. A study by Awasthi et al. showed that RLIP76 was upregulated in brain 
tissue from drug-resistant epilepsy patients, and colocalized with PGP in endothelial cells. 
RLIP76 was shown to transport both phenytoin and carbamazepine in an isolated artificial 
liposome system and in crude membrane vesicles. Furthermore, RLIP76 blockade with anti-
RLIP76 antibodies altered phenytoin and carbamazepine transport to a much greater extent 
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than did PGP blockade, indicating the potential importance of RLIP76 in AED [anti-epileptic 
drug] transport. 
(...) All SNPs in the RLIP76 gene in HapMap Phase 1, and exonic and untranslated region 
SNPs from dbSNP, were selected for genotyping. Primer design was successful for 23 
polymorphisms (Figure 1), which were genotyped on the Sequenom MALDI-TOF mass 
extension platform at the Sanger Institute (...)”.3 
Introduction: Objectives 
4. State specific objectives, including any pre-specified hypotheses. 
Explanation 
Study authors should provide the objectives for the study, specifying the relevant 
population, genetic variants, drugs and outcomes. This item is from the STROBE statement1 
(Item 3); further guidance and rationale for this item is detailed in the STROBE explanation 
and elaboration paper.2 
Example 
“The primary objective of this study was to determine, in a large patient cohort, whether 
c.516G>T and c.983T>C polymorphisms are predisposing factors for nevirapine 
hypersensitivity in a Malawian HIV-infected adult population. Secondly, we aimed to 
investigate whether carriage of HLA-C*04:01 in combination with variants of CYP2B6 
increases the risk for nevirapine hypersensitivity”.6 
5. State if the study is the first report of a pharmacogenetic association, a replication effort, 
or both. 
Explanation 
This item is from the STREGA statement7 (Item 3), although we modified the item to be 
more applicable to pharmacogenetic studies. In the STREGA statement, the item reads: 
“State if the study is the first report of a genetic association (…)”. Further guidance and 
rationale for this item is detailed in the STREGA statement publication. 
Example 
“As far as we know, no studies examining the pharmacogenomics of corticosteroid-induced 
adrenal suppression have been reported. The aim of the Pharmacogenetics of Adrenal 
Suppression with Inhaled Steroids (PASS) study was to undertake a pharmacogenomic 
assessment of factors predisposing to corticosteroid-induced adrenal suppression among 
children with asthma using ICS [inhaled corticosteroids] as part of their treatment. 
Validation was undertaken in both a paediatric asthma cohort (enrolled to the PASS study) 
and an adult COPD [chronic obstructive pulmonary disease] cohort (enrolled to the 
Pharmacogenomics of Adrenal Suppression in COPD [PASIC] study)”.4 
Methods: Study design 
6. Present key elements of study design early in the paper. 
Explanation 
Study authors should state the study design used, and present key features of the study 
design so that readers can understand the basics of the study, e.g. for a cohort study: 
describe the group of people that comprised the cohort and the time period for which they 
were followed; for a case-control design: describe the cases and controls and their source 
population; for a post-hoc pharmacogenetic analysis of a randomised controlled trial (RCT): 
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state how the subjects included in the analysis were chosen, including which arm of the RCT 
they were from. This item is from the STROBE statement1 (Item 4); further guidance and 
rationale for this item is detailed in the STROBE explanation and elaboration paper.2 
Example 
“Blood samples, demographic and clinical data from patients initiating warfarin for venous 
thromboembolism or atrial fibrillation between November 2004 and March 2006 were 
collected, as described previously (…). 
In this prospective cohort study (...), all patients received usual clinical care with doses 
being determined either by the anticoagulant clinic or attending physician. There were four 
fixed study visits for each patient, the first at the time of initiation of warfarin (index visit), 
then at 1 week, 8 weeks and 26 weeks of warfarin therapy”.8 
Methods: Setting 
7. Describe the setting, locations and relevant dates, including periods of recruitment, follow-
up, and data collection. 
Explanation 
Study authors should provide sufficient information to enable readers to assess the context 
and generalisability of a study's results. It is advisable to specify dates rather than length of 
time periods, i.e. the dates that recruitment began and ended, the dates that follow-up 
began and ended, and the date of data collection. This item is from the STROBE statement1 
(Item 5), although we modified the item to be applicable to pharmacogenetic studies. We 
removed the reference to periods of “exposure”, as pharmacogenetic studies do not 
investigate the effects of “exposures”, (other than genotype, which is fixed over time). 
Further guidance and rationale for this item is detailed in the STROBE explanation and 
elaboration paper.2 
Example 
“This prospective study was conducted at National Taiwan University Hospital, a tertiary-
care center in Taiwan (...).  
From March 2007 to February 2010, adult patients (>16 years) with culture-confirmed 
pulmonary TB [tuberculosis] were enrolled as the derivation cohort. Mycobacterial culture 
and drug susceptibility testing were performed as previously described. Subjects were 
excluded if they were pregnant, had a life expectancy 6 months, had abnormal baseline 
liver function test (LFT), or had Mycobacterium tuberculosis (MTB) isolates resistant to INH 
[isoniazid], RMP [rifampin], or both. From March 2010 to February 2013, TB patients 
fulfilling these criteria were enrolled as the validation cohort (...). 
The LFT was checked at 2, 4, 6, 8, 12, and 16 weeks after the start of anti-TB treatment or 




8. Give the eligibility criteria, and the sources and methods of selection of participants. For a 
cohort study, describe methods of follow-up. For a case-control study, state whether true 
controls or population controls were used. Give the rationale for the choice of cases and 
controls. 
Explanation 
Study authors should provide sufficiently detailed descriptions of the study participants to 
help readers understand the applicability of the results. In a case-control study, true 
controls are controls who have been exposed to the relevant treatment but have not 
developed the outcome of interest. If historical controls have been used, specify the setting 
in which this data was collected. Population controls are individuals who have already been 
genotyped that can be assumed to be controls, although we cannot ascertain whether they 
would have developed the outcome of interest if they had been exposed to the relevant 
treatment.  
This item is derived from the STROBE statement1 (item 6a); we added the specification that 
study authors should state whether true controls or population controls were used, as the 
use of population controls is a common feature in pharmacogenetic studies. Further 
guidance and rationale for this item is detailed in the STROBE explanation and elaboration 
paper.2 
Example: Cohort study 
“Patients initiated onto warfarin irrespective of indication were recruited from the Royal 
Liverpool and Broadgreen University Hospitals Trust and University Hospital Aintree 
between November 2004 and March 2006. The only exclusion criterion was inability or 
refusal to give informed consent (…). 
There were four fixed study visits for each patient, the first at the time of initiation of 
warfarin (index visit), then at 1 week, 8 weeks and 26 weeks of warfarin therapy (…). At the 
index visit, patient demographics were recorded and baseline INR [international normalised 
ratio], clotting factor activity and protein levels were measured (Table 1). At the remaining 
follow-up visits INR was again measured, and dose changes since the previous visit were 
recorded. In addition to the four fixed study visits, patients also attended anticoagulant 
clinic according to their clinical needs. This meant that, at the end of follow-up, data on 
warfarin dose changes and INR levels were available longitudinally for each patient, which 
together provided a complete picture of treatment progress from warfarin initiation 
onwards. For patients who missed one or more fixed follow-up visits, INR measurements 
and dose changes missing as a consequence were obtained from clinical records”.10 
Example: Case-control study with population controls 
“From a cohort of ~600,000 patients receiving statins identified in the CPRD [the UK Clinical 
Practice Research Datalink] (www.cprd.com), a case-control design was used to identify 
suitable patients for the study, as previously described. Participation was restricted to 
white people ≥18 years of age and with the first ever statin prescription at least 1 year after 
the start of CPRD data collection. 
All cases conformed to internationally agreed standards for statin-induced myopathy and 
rhabdomyolysis. Cases were categorized into two groups: (i) myopathy: patients who 
discontinued their implicated statin with a rise in CK [creatine kinase] > 4 × ULN [upper limit 
of normal]; and (ii) severe myopathy: individuals with a history of rhabdomyolysis or CK > 
10 × ULN after statin exposure (…).  
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Population control genotype data for the initial discovery case-control GWAS [genome-wide 
association study] was obtained from the Wellcome Trust Case-Control Consortium 2 
(WTCCC2) cohort of 2,501 individuals from the UK Blood Service”.11 
Example: Case-control study with true controls 
“The study cohort consisted of older adults with polypharmacy and history of 
cardiovascular disease to ensure homogeneity of the study sample. The cases were 
presented by eligible individuals with the history of FH [frequent hospitalisations]. The 
controls included eligible patients with infrequent hospitalizations (IHs) randomly drawn 
from the study cohort, based on case–control matching criteria. On the basis of a previous 
work, cases (FH) were defined as individuals who were hospitalized at least 3 times during 
the past 2 years”.12 
This article provides a reference to previous work conducted to justify their choice of cases 
and controls. 
9. Report the drug and regime participants were exposed to, and the length of exposure. 
Explanation 
The purpose of pharmacogenetic studies is to explore how genetic variants influence 
individuals’ responses to drugs. Study authors should provide details of drug and regime, 
length of exposure, and route of administration. This could be fixed across all participants 
or variable. If variable, authors should provide this information in the text or in a table of 
patient characteristics. We recommend that authors use generic drug terms from a 
standardised database e.g. DrugBank where possible. This item was conceived by members 
of the Steering Committee.  
Example 
“All patients received oral INH (300 mg), rifampicin (600 mg), pyrazinamide (20 mg/kg body 
weight), and ethambutol (800 mg) daily for the first 2 months. Pyrazinamide was then 
discontinued, while INH, rifampicin and ethambutol were continued for another 4 
months”.13 
10. For a matched case-control study, give matching criteria and the number of controls per 
case. 
Explanation 
Study authors should provide details of variables that were used to match individuals to 
make case and control groups more comparable. This item is from the STROBE statement1 
(item 6b), although we modified the item to be more applicable to pharmacogenetic 
studies. We removed the reference to matched cohort studies; following searches of the 
literature we found very few pharmacogenetic studies that used a matched cohort design, 
and this item would therefore be irrelevant to the vast majority of guideline users. Further 
guidance and rationale for this item is detailed in the STROBE explanation and elaboration 
paper.2 
Example 
“For each case, two controls were recruited, within the same cohort and on the same ATD 
[anti-tuberculosis drug] (INH, RIF, PZA) [isoniazid, rifampicin, pyrazinamide] but with serum 
ALT [alanine aminotransferase] levels <3 times ULN [upper limit of normal], serum bilirubin 
<1 mg/dL and no history of severe nausea, vomiting within the first 3 months of initiation of 
therapy. Controls were matched with cases on the basis of age, sex, disease severity and 
drug dosage”.14 
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11. Give information on the criteria and methods for selection of subsets of participants from 
a larger study, when relevant.  
Explanation 
If one or more sub-samples from a larger study are used for the investigation of a 
pharmacogenetic association, authors should provide details of: inclusion and exclusion 
criteria, sources and methods of selection for these sub-samples, and state whether these 
methods were pre-specified or post-hoc. This item is from the STREGA statement7 (Item 
6a); rationale for this item is detailed in the STREGA statement publication. 
Example 
“In a post hoc analysis of a 4.3 year placebo-controlled randomized trial with 390 patients 
with Type 2 diabetes [T2D] already on insulin, we analyzed the influence of polymorphisms 
in genes coding for ATM and the transporters OCT1 and MATE1 (…). The HOME trial is a 4.3 
year randomized placebo controlled trial that included 390 Caucasian patients aged 30–80 
years with T2D treated with insulin. Patient selection, study design, data collection and 
power analysis have been described previously. Figure 1 shows the trial design and the 
recruitment plus retention of patients for the current study”.15  
Figure 1 of this publication provides information on the criteria for including patients in the 
post-hoc pharmacogenetic analysis of the RCT. 
12. If other publications report results for the same patient cohort, or a subset of the patient 
cohort, provide information on this patient cohort overlap and references to the relevant 
publications. 
Explanation 
In pharmacogenetic research, it is common for multiple articles to report data for the same 
patient cohort (or for overlapping patient cohorts); different articles may report on 
different outcomes and genetic variants. To aid interpretation, it is useful to highlight 
overlapping or identical cohorts across articles. This item was conceived by members of the 
Steering Committee.  
Example 
“Given the association between CYP4F2 and warfarin dose requirements, and the emerging 
evidence that this P450 isoform is involved in the metabolism of vitamin K1, we have 
undertaken a comprehensive analysis of CYP4F2 SNPs and haplotypes in a prospectively 
recruited cohort of patients from two UK clinics (...). 
Patients (n = 311) were recruited prospectively as they were initiated onto warfarin at two 
hospitals in Liverpool, the Royal Liverpool and Broadgreen University Hospitals Trust and 
University Hospital Aintree (...). Analyses of association between the CYP2C9 and VKORC1, 
and 27 other genes, and the response to warfarin are reported in the accompanying 
manuscript”.16 
The article provides a reference to the accompanying manuscript in the text.  
13. Report disease/clinical indication of patients using a standardised ontology when 
possible. 
Explanation 
To aid interpretation, authors should use controlled vocabularies such as MeSH and 
SNOMED to describe the disease/clinical indication of patients. This item was suggested by 
Delphi participants at Round 1 of the survey.  
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Example 
“We included children aged 5–18 years with asthma using ICS [inhaled corticosteroids] as 
part of their treatment”.4 
Methods: Variables 
14. Clearly define all outcomes, potential confounders, and effect modifiers. Give diagnostic 
criteria, if applicable. 
Explanation 
Study authors should define all outcomes, and all variables considered for and included in 
the analysis. If outcomes are categorised into “primary” and “secondary” outcomes, this 
should be specified. Authors should use controlled vocabularies such as MeSH and 
SNOMED to describe phenotypes.  
This item is from the STROBE statement1 (item 7), although we modified the item to be 
applicable to pharmacogenetic studies. We removed reference to “predictors” from the 
item as this is not relevant to pharmacogenetic studies, and to “exposures”, as the 
exposure in a pharmacogenetic study is the genetic variant; definition of genetic variants is 
covered in the STROPS guideline item 16. Further guidance and rationale for this item is 
detailed in the STROBE explanation and elaboration paper.2 
Example 
“For this GWAS [genome-wide association study], we used the following outcome 
measures: (1) Mean weekly dose (MWD): mean dose received weekly during a minimum 
follow-up time of 14 days post-loading; the loading period, that is, the first 3 days of 
treatment, was not included in the calculations. (2) Stable mean weekly dose (SMWD): 
mean weekly dose for at least three consecutive visits where INRs [international normalised 
ratios] were within the targeted range, spanning a minimum of 14 days and with at least 7 
days separating the first and middle INR measurements, and the middle and last one. (3) 
INR >4.0 in the first week on warfarin (...).  
Non-genetic variables used for testing univariately for association with each outcome were 
age, height, weight, BMI [body mass index], gender, loading dose, total follow-up time, 
dosing method (manual or computerised), mean target INR, blood count (haemoglobin, 
platelets, white cells, neutrophils, basophils, lymphocytes, monocytes, eosinophils), 
potassium, bicarbonate, chloride, urea, creatinine, triglycerides, albumin, total protein, 
bilirubin, ALT [alanine transaminase], alkaline phosphate, gamma GT, fibrinogen, 
coagulation factors II, V, VII, IX and X, Proteins C and S, current smoking status, number of 
cigarette smoked per day, ex-smoker status, alcohol consumption, interacting co-
medication (binary), non-interacting co-medication (binary), sum of effect of interacting co-
medications. The coagulation factors were measured as described by Jorgensen et al. For 
each variable, either a linear (quantitative outcomes) or logistic (binary outcome) 
regression was used to test for association with outcome in R, and variables found to be 
significant univariately (P ≤0.05) were included as covariates in the linear or logistic 
regressions used to test for association between each SNP and outcome in turn”.8 
15. Provide justification for choice of outcomes. 
Explanation 
Study authors should explain why the outcomes are important, e.g. clinical importance, 
importance to patients, inclusion in previously developed core outcome sets, identification 
of a significant association in previous studies, etc. A core outcome set is an agreed 
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standardised set of outcomes that should be measured and reported, as a minimum, in all 
clinical studies in specific areas of health or health care. The COMET database17 lists 
references to planned, ongoing and completed core outcome set work for a wide range of 
health topics. Providing a clear justification for the choice of outcomes provides 
reassurance to the reader that selective reporting of results has not occurred, i.e. results 
have not been omitted from the report due to the significance or perceived importance of 
the estimate of association. The origin of this item is Jorgensen and Williamson’s quality 
assessment checklist for pharmacogenetic studies.5 
Example 
“Guidelines for TB management recommend a combination regimen including isoniazid 
(INH), rifampin, ethambutol, and pyrazinamide as the first-line treatment. This regimen 
often causes adverse drug reactions, such as hepatitis, cutaneous reactions, gastrointestinal 
upset, and drug fever. Although mild reactions can be tolerated or managed with 
symptomatic therapy, serious cases require discontinuation of medication and prolongation 
of the treatment period (…).  
Previous studies in an Indian and a Taiwanese population reported that homozygous null 
mutations in GSTM1 increased the risk of ATD-induced hepatitis. In contrast to these 
findings, a subsequent study in Spain failed to validate this association, reporting instead 
that null mutations in GSTT1 were associated with ATD-induced hepatotoxicity. Thus, the 
association between null mutations of GSTT1 or GSTM1 and ATD-induced hepatitis remains 
unclear and needs to be replicated in other ethnic groups. 
ATD-induced cutaneous reactions, such as rashes, can be serious adverse reactions and 
their incidence is higher than that of hepatitis and gastrointestinal reactions. Despite the 
clinical significance of ATD-induced cutaneous reactions, not much is known about genetic 
predisposition to these reactions. It is suggested that, like drug-induced liver injury, 
hypersensitivity reactions to reactive metabolites underlie the mechanisms of drug 
eruption. Langerhans cells and epidermal keratinocytes have been suggested to play pivotal 
roles in the development of drug-induced hypersensitivity reactions in the skin. Drug 
metabolites transferred into or bioactivated in the skin can induce an immune response 
after haptenization. Detoxification by GST enzymes may be involved in the development of 
cutaneous reactions to ATD. Therefore, we hypothesized that null mutations of GSTT1 and 
GSTM1 genes are associated with ATD-induced cutaneous reactions. To our knowledge, 
there is no published report on the association between genetic polymorphisms in GST 
enzymes and ATD-induced skin reactions. In this study, we examined whether null 
mutations in GSTT1 and GSTM1 were associated with the development of ATD-induced 
hepatitis and adverse cutaneous reactions in a Korean population”.18 
16. Clearly define genetic exposures (genetic variants) using a widely-used nomenclature 
system.  
Explanation 
Study authors should state all genetic variants that were screened (including SNPs, indels, 
copy number variations, and structural variations) and specify the tissue source of DNA, as 
recommended by McDonagh et al.19 This information could be provided in supplementary 
materials if necessary. It is also useful for study authors to provide references to any 
databases and resources used for the selection of variants. 
The Human Gene Nomenclature Committee have published guidelines for human gene 
nomenclature.20,21 The Human Genome Variation Society has detailed information about 
how to describe variant locations (http://varnomen.hgvs.org/recommendations/general/), 
as recommended by McDonagh et al.19 and Thorn et al.22  
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This item is from the STREGA statement7 (Item 7b); further guidance is detailed in the 
STREGA statement publication.  
Example 
“Venous blood sample collection followed informed consent from the parents or guardians 
of the participants and DNA was extracted using a standard salting-out method (…). 
SNPs were submitted to Illumina (CA, USA) Technical Support for evaluation using the Assay 
Design Tool. SNPs were scored (varying from 0–1) by the Assay Design Tool based on 
compatibility to successful GoldenGate genotyping. A total of 14 SNPs with a score above 
0.6 were selected for genotyping (summarized in Table 1)”.23 
Table 1 of this article gives gene names, rs numbers, and HGVS names for all the genotyped 
SNPs. 
17. Report the rs number of each genotyped SNP. 
Explanation 
An "rs" number (reference SNP ID number) is an identification tag assigned by NCBI 
(National Center for Biotechnology Information) to a group (or cluster) of SNPs that map to 
an identical location. The rs ID number, or rs tag, is assigned after submission of an SNP to 
dbSNP.24 Reporting an rs number for each genotyped SNP allows the reader to identify the 
same SNP across multiple articles. Guidelines are available for variations not listed in 
dbSNP.25,26 In particular, submission ID or the position of the SNP and reference sequence 
ID for the chromosome should be specified. This item was conceived by members of the 
Steering Committee. 
Example  
“A total of 448 individuals were genotyped for the rs4149056 SNP in SLCO1B1 and 
rs4693075 in COQ2”.27 
18. Clearly state how haplotypes or star alleles were defined. 
Explanation 
Even when referring to well-defined star alleles or haplotypes, authors should provide full 
details in the current publication using standard nomenclature. This allows the reader to 
identify the same haplotypes/star alleles across multiple articles, and can provide 
reassurance that haplotypes/star alleles have been defined according to widely accepted 
nomenclature. Standard nomenclature for some haplotypes are available on the PharmVar 
database.28,29 This item was suggested by Delphi participants at Round 1 of the survey. 
Example  
“SULT4A1-1 status was assigned to all CATIE subjects (…) using rs2285162 (A) and 
rs2285167 (G) as the haplotype tagging SNPs”.30 
19. If referring to the minor, major, wild-type, mutant, reference, risk or effect allele of a 
variant, state which allele this is and for which given population/cohort.  
Explanation 
The allele and population should be clearly stated if using any of these terms. For many 
genetic variants, the minor/mutant/risk/effect (less frequent) allele in one population may 
be the major/wild-type/reference (more frequent) allele in a different population. This item 
was suggested by Delphi participants at Round 1 of the survey.  
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Example 
“The risk allele (T) frequency was highest in East Asians…”.31 
Methods: Data sources/measurement 
20. For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group. 
Explanation 
Authors should provide information on how all confounders and outcomes were measured. 
It is also important to report any differences in how data were collected in different patient 
groups (e.g. cases and controls). This item is from the STROBE statement1 (item 8); further 
guidance and rationale for this item is provided in the STROBE explanation and elaboration 
paper.2 
Example 
“Warfarin dose and INR [international normalised ratio] values for each POC [point of care] 
testing event is routinely collected for all patients using warfarin at our institution, and this 
data were extracted onto our study database. From this information, each patient’s full 
dose and INR history could be determined. 
Data were also collected on indication for treatment, target INR, age, gender, height, 
weight, BMI [body mass index], haemorrhagic complications, serial serum albumin 
concentration(s) (as many children were hypoalbuminaemic at onset of therapy), and 
height and weight measurements. Clinical data were collected from hospital notes and the 
cardiac liaison team database”.32 
21. Describe laboratory methods, including source and storage of DNA, genotyping methods 
and platforms (including the allele calling algorithm used, and its version), error rates and call 
rates. State the laboratory/centre where genotyping was done. Describe comparability of 
laboratory methods if there is more than one group. Specify whether genotypes were 
assigned using all of the data from the study simultaneously or in smaller batches. 
Explanation 
Authors should provide sufficient details to enable the reader to assess the potential extent 
of genotyping errors (a source of information bias). It is important to report any differences 
in laboratory methods in different patient groups (e.g. cases and controls). Furthermore, if 
the study uses a case-control design, authors should report whether cases and controls 
were put into mixed batches for genotyping purposes (to ensure genotyping quality is 
comparable across groups), rather than analysed in separate batches. It is important to 
note that for next generation sequencing (NGS), library preparation, instrument, coverage 
level, pipeline and tools for variant calling should also be specified. This item is from the 
STREGA statement7 (Item 8b); further guidance and rationale for this item is detailed in the 
STREGA statement publication. 
Examples 
 “Whole blood on FTA® cards was obtained from 37 deceased Finnish individuals (...). All 
subjects and toxicology data were collected according to the ethical handling of human 
subject practices of the University of Helsinki. Anonymized DNA samples were transferred 
to University of North Texas Health Science Center (UNTHSC) and handled according to the 
UNTHSC Institutional Review Board Protocol Number 2016-051 (...). 
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DNA was extracted from FTA cards using the QIAGEN® QIAamp® DNA Blood Mini Kit and 
total human DNA was quantitated using the ThermoFisher Scientific Quantifiler™ Trio DNA 
Quantification Kit according to the respective manufacturers’ recommendations (...). 
Genotyping was performed using the Illumina Infinium® LCG Assay and Infinium® 
Omni2.5Exome-8 v1.3 BeadChip according to the manufacturer’s recommended protocol. 
Template DNA input ranged from 200 to 1 ng genomic DNA. Image acquisition was 
performed on the Illumina HiScan™ System using the iScan Control Software (...). 
“BeadChip images were analyzed in GenomeStudio® Genotyping Module v2.0.2, following 
the manufacturer’s recommended quality control procedures including a Genotype Call 
(GenCall) Score cutoff of 0.15.” 
This article33 provides detailed information on call rates and evaluation of genotyping errors 
in supplementary materials to the publication.  
“Samples pertaining to matched cases and controls were analyzed in the same batch, and 
laboratory personnel were unable to distinguish between cases and controls”.34 
22. Describe genotype quality control methods and findings. 
Explanation 
It is important to report any quality control methods and findings so that the reader is able 
to assess how reliable the genotyping results, and consequently, the findings of a study are. 
Genotype quality control methods include using negative controls, and re-genotyping all or 
a random sample of patients. The origin of this item is Jorgensen and Williamson’s quality 
assessment checklist for pharmacogenetic studies.5 
Example 
“Samples were genotyped at Affymetrix’s service laboratory on the Genome-Wide Human 
SNP Array 6.0. Genotype data quality control was via the standard protocol that was 
established for the WTCCC2 studies (supplementary methods). Specifically, concordance 
check was performed on 116 SNPs by 1779 individuals overlapped between this GWA 
[genome-wide association] data and the WTCCC1 T2D [type 2 diabetes] case control study. 
Based on the concordance rate of 99.73%, individuals with more than 10% discordance 
were removed from the current study. After such stringent QC [quality control], the clean 
data set included 705125 autosomal SNPs on 3736 samples, of whom 1024 have definable 
metformin response”.35 
23. For quantitative outcome variables, specify if any investigation of potential bias resulting 
from pharmacotherapy was undertaken. If relevant, describe the nature and magnitude of 
the potential bias, and explain what approach was used to deal with this. 
Explanation 
Bias from pharmacotherapy may occur when quantitative outcome variables are affected 
by treatment with drugs other than the study drug (e.g. outcome variables include 
biochemical markers of hepatotoxicity, and several patients are taking concomitant 
hepatotoxic medications). This item is from the STREGA statement7 (Item 9b); further 
guidance and rationale for this item is detailed in the STREGA statement publication. 
Example 
“…use of drugs with anti- or pro-emetic effects may also influence the occurrence and 
intensity of nausea and vomiting in cancer patients, but have not been thoroughly 
investigated yet (…).  
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All regressions were stratified by country and use of antiemetics was included as a binary 
stratification variable (antiemetics used/not used) for each country”.36 
24. Report how adherence to treatment was assessed, and report the results of the 
assessment. 
Explanation 
In general, treatment adherence is not an issue of great concern for non-pharmacogenetic 
studies of drug efficacy. This is because the aim of these trials is to estimate how effective 
the drug will be when used in a real-world setting; in reality, patients are likely to 
occasionally be non-adherent with the prescribed regimen, so the trial results will be 
reflective of clinical practice. However, the aim of pharmacogenetic studies is to identify 
associations between genetic variants and drug response outcomes. Treatment adherence 
is therefore an important issue in pharmacogenetic studies; taking too much or too little of 
the prescribed drug undoubtedly may impact drug response outcomes. Providing 
information on treatment adherence assessment methods and results allows the reader to 
consider whether adherence may have had an impact on outcomes. The origin of this item 
is Jorgensen and Williamson’s quality assessment checklist for pharmacogenetic studies.5 
Example 
“Treatment compliance was assessed by comparing the number of administered treatment 
doses to the number of treatment doses scheduled each month. There were no 
consistently missing doses corresponding to more than 10 days of monthly scheduled doses 
of medication for all the patients”.13  
Methods: Study size 
25. Explain how the study size was arrived at, or provide details of the a priori power to 
detect effect sizes of varying degrees. 
Explanation 
Study authors ought to report the calculation performed to obtain the study sample size, 
providing references to any specific methodology. Or, if sample size was predetermined (for 
example, if the study reports secondary analyses of a published dataset), provide details of 
a priori power calculations for a range of plausible effect sizes. This item is derived from the 
STROBE statement1 (item 10); we added the detail that providing power calculations for a 
range of plausible effect sizes is sufficient to address this item, as it is not uncommon for 
sample size to be predetermined in pharmacogenetic studies. For example, in a post-hoc 
pharmacogenetic analysis of a RCT, sample size would be limited by the number of 
participants included in the RCT who it would be possible to obtain genotype information 
for. Further guidance and rationale for this item is detailed in the STROBE explanation and 
elaboration paper.2 
Examples 
“As we are investigating a wide range of gene-outcome associations it is difficult to provide 
precise power calculations in advance. However, we can calculate power for some 
simplistic analyses. A key variable is the minor allele frequency (MAF) among controls. For 
rarer variants to be clinically important, their effect size (odds ratio (OR)) must be large. We 
therefore specify two benchmarks for the power analyses: we seek to have good power for 
(a) OR=3 and a rare variant (MAF=5%); (b) OR=2 and a common variant (MAF=20%). 
Assuming a type I error rate of 5% and 80% power, for scenario a) we would require 115 
cases and 230 controls and for scenario b) we would require 123 cases and 246 controls. If 
we increased our sample size to 250 cases and 500 controls we would have 80% power to 
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observe and odds ratio of 2.2 for a MAF of 5%, and an odds ratio as small as 1.6 for a MAF 
of 20%. Please note that these effect sizes are for a single causal variant. We expect to 
realise much larger overall effect sizes via combinations of causal variants”.37 
“The target sample size for the primary analysis cohort was 500. To arrive at this estimate 
we considered two possible scenarios: (a) an odds ratio (OR) of 3 for association between a 
rare variant (minor allele frequency=5%) and the primary outcome; (b) an OR of 2 for 
association between a common variant (minor allele frequency=20%) and the primary 
outcome. A liberal type 1 error rate of 5% was assumed on the basis that validation cohorts 
would also be analysed to help eliminate false positives arising from the initial analyses. 
Assuming first of all prevalence of impaired adrenal response in children with asthma using 
inhaled steroid to be 17% (based on a the [sic] lower end of the range of previously 
published rates of adrenal suppression) the power for scenario a) was calculated as 77% 
and the power for scenario b) was calculated as 75%. If the prevalence was 40% (the upper 
end of the range of published estimates), the power increased to 91% for both scenarios. A 
prevalence of 20% would ensure power of at least 80% in both scenarios”.4 (Supplementary 
Appendix). 
Methods: Quantitative variables 
26. Explain how quantitative variables (confounders and effect modifiers) were handled in the 
analyses. If applicable, describe which groupings were chosen, and why. 
Explanation 
If continuous variables have been grouped into categories to create a new categorical 
variable, it is important to explain why and how quantitative data were grouped. This item 
is from STROBE1 (item 11), although we added detail to make it clear that the item relates 
to confounders and effect modifiers, rather than quantitative outcome variables. Further 
guidance and rationale for this item is detailed in the STROBE explanation and elaboration 
paper.2 
Example 
“The potential genetic risk scores ranged from 0 to 3 (…). The risk scores were dichotomized 
as low risk (0–1 points) and high risk (2–3 points) because only a small number of subjects 
had a score of 0 and 3, and they responded similarly to those with a score of 1 and 2, 
respectively”.38 
Methods: Statistical methods 
27. Address the following:  
a) Describe methods used to control for confounding. 
b) Describe any methods used to examine subgroups and interactions. 
c) Explain how missing data were addressed.  
d) Cohort study – If applicable, explain how loss to follow-up was addressed. 
e) Case-control study – If applicable, explain how matching of cases and controls was 
addressed. 
f) Describe any sensitivity analyses. 
Explanation 
All statistical methods should be reported clearly, including details of which analyses were 
pre-specified and which were exploratory based on data inspection. Details of any software 
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used should also be provided. The STROBE explanation and elaboration document2 advises 
that sufficient detail should be provided that a statistically competent reader with access to 
the data set would be able to verify reported results based on the reported methods. In 
particular: 
a) If adjustments were made for confounding factors, authors ought to provide details 
of procedures of variable selection and model comparison.  
b) Study authors should explain any methods used to examine whether associations 
differed across subgroups, or to examine interactions. An "interaction" occurs when 
one factor modifies the effect of another, and is also sometimes referred to as 
‘effect modification'.  
c) Authors should confirm whether analyses were restricted to individuals with 
complete data on the required variables, or whether any imputation of missing 
data was performed. Data are said to be ‘missing at random’ if the fact that they 
are missing is unrelated to actual values of the missing data. Data that are missing 
at random may not be important. Analyses based on the available data will tend to 
be unbiased, but will also be based on a smaller sample size than the original data 
set. If authors assessed the assumption of missingness at random, the methods and 
findings of these assessments should be provided.  
d) For a cohort study, authors ought to report how many individuals were lost to 
follow-up, and whether these individuals were excluded or whether censoring 
strategies were used.  
e) For a matched case-control study, authors should describe in detail what statistical 
methods were used to account for the matching of cases and controls. 
f) Provide details of any sensitivity analyses i.e. analyses performed to investigate 
whether the results of the main analysis are consistent with those obtained with 
alternative analysis approaches.  
This item is from STROBE1 (items 12a, 12b, 12c, 12d and 12e). Further guidance and 
rationale for this item is provided in the STROBE explanation and elaboration paper.2  
Examples 
a) “First, a univariate multinomial logistic regression model was fitted for each non-
genetic factor in turn, to identify which non-genetic factors to adjust for in the SNP 
association analyses. Next, multivariable multinomial logistic regression models 
were fitted for each SNP in turn. For each SNP, two models were fitted. The first 
model included covariates to represent all non-genetic factors with p<0.25 
univariately. Stepwise variable selection was applied to this baseline model to 
remove any covariates no longer significant in the multivariable model. The final 
model following variable selection was called the ‘baseline model’. The second 
model (‘the genetic model’) was the same as the baseline model but also included a 
covariate to represent the SNP. The likelihood ratio test was applied to compare 
the two models and thus assess for statistical significance of the SNP”.39 
b) “In the multivariate logistic regression analysis, an interaction variable between sex 
and PXR genotypes and haplotypes was also included”.9 
c) “For some of the non-genetic variables there was a considerable amount of missing 
data (see Table 1). In order to minimise the impact of this, multiple imputation 
using chained equations, specifically the predictive mean matching method, was 
used to impute data for height, weight and albumin at the start of warfarin 
treatment (all variables had <30% missing observations). Multiple imputation was 
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not used for these variables at the time stable dose was achieved, as the amount of 
missingness was deemed too high (>40%). Instead, these variables were excluded 
from the list of potential covariates”.32  
d) “For analyzing EFS [event-free survival] and PFS [progression-free survival], patients 
who stopped imatinib or switched treatment during follow-up were censored at the 
time of stopping or switching. However, these patients could be informative, as 
their reason for stopping/switching is related to the events investigated. Therefore, 
2 sensitivity analyses were undertaken to determine whether censoring was 
informative. The first assumed that these patients were at high risk of an event and 
that all censored observations were therefore EFS/PFS events occurring 
immediately after censoring. The second assumed that these patients were at low 
risk of an event and assumed that all EFS/PFS events happened after the latest 
follow-up; their censoring time was changed to the time of last follow-up”.40 
e) “The Wilcoxon signed-rank test was used while comparing the means of continuous 
variables from matched samples. The exact McNemar’s test was used on paired 
nominal data”.12  
f) “Sensitivity analyses were also undertaken, in which each analysis was repeated, 
but cases without evidence of H. pylori infection were excluded”.41  
28. State whether Hardy-Weinberg equilibrium was considered and, if so, how.  
Explanation 
Authors should describe any statistical tests or measures of departure from Hardy-
Weinberg equilibrium (HWE), and any methods used to allow for deviations from HWE. 
Where HWE tests have been undertaken, it is important to state the p-value threshold 
applied to determine deviation from HWE. This item is from the STREGA statement7 (item 
12f); further guidance and rationale for this item is provided in the STREGA statement 
publication. 
Example 
“Prior to analysis, each SNP was tested for Hardy–Weinberg Equilibrium (HWE) using 
Fisher’s exact test. Those with a p-value of less than 0.001 were excluded from further 
analyses”.3 
29. Describe any methods used for inferring genotypes or haplotypes.  
Explanation 
Study authors ought to provide details of any statistical methods or software used to infer 
genotype phase and haplotypes. This item is from the STREGA statement7 (item 12g); 
further guidance and rationale for this item is provided in the STREGA statement 
publication. 
Example 
“We used multiple imputation methods to infer remaining missing genotype values on the 
basis of the correlational structure of the observed genotypes (…). 
2677G→T/A and 1236C→T were successfully genotyped in 96% and 94% of individuals, 
respectively (…). Based on these genotypes, haplotypes were inferred with PHASE”.42 
This article refers to the software program, PHASE,43 which can be used to estimate 
haplotypes.  
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30. Describe any methods used to assess or address population stratification.  
Explanation 
Authors should explicitly document any methods used to assess the presence of population 
stratification or adjust for population stratification in the analyses. If no methods were 
used, this should be made clear in the study report. This item is from the STREGA 
statement7 (item 12g); further guidance and rationale for this item is provided in the 
STREGA statement publication. 
Example 
“In the primary analysis cohort, to test for association, regression models assuming an 
additive genetic model were fitted in SNPtest using each SNP as a covariate in an 
independent model. To adjust for population substructure we included up to five principal 
components as covariates in this genome-wide analysis, subject to the principal 
components being significantly associated with the outcome univariately (p<0.05). If no 
principal components were significantly associated with the outcome, the first two principal 
components were included as covariates in genome-wide analysis”.4 (Supplementary 
Appendix). 
This article refers to the software program, SNPtest,44 which can be used to analyse single 
SNP associations in genome-wide studies.  
31. Describe any methods used to assess and correct for relatedness among subjects. Report 
results of assessments for relatedness. 
Explanation 
It is not uncommon in pharmacogenetic studies for some participants to be related. 
Authors should report any methods used to assess relatedness, results of these 
assessments, and any methods used to correct for relatedness. This item is from the 
STREGA statement7 (item 12j), although we added the specification that results of 
assessments for relatedness ought to be provided. Further guidance and rationale for this 
item is provided in the STREGA statement publication. 
Example 
“Patients within the primary analysis cohort were excluded from association analyses if any 
of the following criteria were met: (...) c) the pairwise identity by descent (IBD) statistic of 
relatedness was >0.1875 (patient with lowest call rate of the pair excluded)”.4 
(Supplementary Appendix). 
“92 (18%) children failed genotype quality control, of whom (...) nine did not meet identity-
by descent criteria”.4 
32. Describe any methods used to address multiple comparisons or to control risk of false 
positive results due to investigating:  
a) multiple genetic variants 
b) multiple outcomes 
c) multiple assumptions regarding mode of inheritance. 
Explanation 
Pharmacogenetic studies that perform a large number of statistical tests are at risk of type 
1 errors. This item is derived from STREGA7 (item 12i), but we modified the item to specify 
different possible sources of multiplicity in pharmacogenetic studies, i.e. multiple 
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outcomes, genetic variants, and assumptions regarding mode of inheritance. Mode of 
inheritance refers to the way in which a genetic trait is passed from one generation to the 
next, e.g. dominant, recessive, co-dominant inheritance. Authors may undertake multiple 
analyses, each making a different assumption about the underlying mode of inheritance, or 
making no assumption about the mode of inheritance. Study authors should provide 
sufficient detail to enable the reader to assess the likelihood of false positive results (type 1 
errors) being reported. Rationale for this item is provided in the STREGA statement.  
Example 
“To account for multiple testing, the false discovery rate (FDR) was calculated in addition to 
the P value for each test of association. In calculating the FDR, all tests for association 
undertaken on the dataset, including those referred to in an accompanying manuscript, 
were taken into account”.16 
33. Describe any methods used to adjust for extent of adherence in the analyses. 
Explanation 
As discussed under item 24, treatment adherence is an important issue in pharmacogenetic 
studies. It is important to take treatment adherence into consideration in statistical 
analyses for pharmacogenetic studies, as recommended by Jorgensen and Williamson in 
their quality assessment checklist for pharmacogenetic studies5 (the origin of this reporting 
item). 
Generally, adjusting for a non-confounding covariate (such as treatment adherence) can 
explain variability in the outcome, consequently reducing noise and increasing power to 
detect pharmacogenetic associations.45 However, it is important to note that when the drug 
response outcome is binary, and individuals are recruited according to case or control 
status, adjusting for the covariate can actually reduce power.46 Nevertheless, methods have 
been developed to overcome this issue,47-49 which account for non-confounding covariates 
while increasing power to detect genetic associations in case-control studies. It is therefore 
advisable to account for treatment adherence when investigating pharmacogenetic 
associations, even in the analyses of case-control studies, providing careful consideration is 
given to the choice of analysis method.  
Example 
“Repeating analyses of genetic association but adjusting for adherence: For any of the 
outcomes found significantly associated with nonadherence in the univariate analyses, the 
analyses of association with each of the 196 SNPs as previously reported in Jorgensen et al. 
were repeated, but this time after adjusting for adherence. To do this, for each SNP in turn, 
two proportional hazard regression models were compared using the likelihood ratio test. 
The first model included a covariate representing adherence status; the second was the 
same but also included a covariate to represent the SNP.  
Finally, for the outcome of stable dose, an alternative approach was also adopted where 
the outcome itself was reduced by the estimated proportion of doses missed and the 
analyses for association with clinical and genetic factors as reported in Jorgensen et al. 
repeated with this revised outcome. For testing for association with genetic factors, two 
tests of association were undertaken for each SNP. The first made no assumptions 
regarding the underlying mode of inheritance and used ANOVA [analysis of variance] to test 
for association and the second assumed an additive mode of inheritance and used 
univariate linear regression. For testing for association with clinical factors, Student’s t-test 




34. Report the numbers of individuals at each stage of the study – e.g., numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-
up, and analysed. 
Explanation 
Authors ought to report the numbers of individuals considered at each stage of recruiting 
study participants, alongside reasons for non-participation at each stage. This allows the 
reader to judge whether the study population was representative of the target population, 
and whether bias was possibly introduced. A flow diagram can be an efficient and 
transparent way to convey this information. This item is from STROBE1 (item 13a). Further 
guidance and rationale for this item is provided in the STROBE explanation and elaboration 
paper.2 
Example 
“From October 2007 to June 2008, a total of 4488 newly diagnosed patients with sputum 
smear positive pulmonary TB [tuberculosis] were recruited from four provinces (Zhejiang, 
Guangxi, Chongqing, Jilin) in China (…). A total of 4304 patients finished the follow-up (…). 
Patients with any of the following were excluded from the present study: (i) abnormal 
serum ALT [alanine aminotransferase], AST [aspartate aminotransferase] or total bilirubin 
levels before anti-TB treatment; (ii) carriers of the hepatitis B or C virus; (iii) alcoholic liver 
disease or habitual alcohol drinking; (iv) the concomitant use of hepatotoxic drugs; and (v) a 
history of chronic liver disease or systemic diseases that may cause liver dysfunction. 
Among the remained patients, those fulfilled the criteria of ATDH [anti-TB drug-induced 
hepatotoxicity] were assigned into the case group. Incidence density sampling method was 
adopted to select controls from patients free of ATDH up to the date when the paired cases 
were diagnosed with ATDH. For each ATDH case, four controls were randomly selected and 
matched with age (within 5 years old), sex, treatment history, disease severity, drug dosage 
and place of sample collection. Finally, 89 patients with ATDH and 356 matched controls 
were included in the study”.51 
Results: SNPs 
35. Report any SNPs that were excluded from analysis, and provide reasons for these 
exclusions. 
Explanation 
Authors should provide explicit statements of why variants considered important initially 
were excluded from analyses, for example, due to excessive missing data.5 This provides 
assurance to the reader that no additional investigations have been undertaken, and that 
all analyses have been fully reported. The origin of this item is Jorgensen and Williamson’s 
quality assessment checklist for pharmacogenetic studies.5 
Example 
“Of the 23 SNPs genotyped across RLIP76 (Table 1), six SNPs failed successful genotyping, 
three SNPs were found to have a MAF of less than 1% (indeed one was monomorphic), and 
one SNP was found to deviate from HWE”.3  
Table 1 of this publication provides the rs number of each genotyped SNP, whether the SNP 
was included in analyses, and reasons for exclusion where applicable.  
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Results: Descriptive data 
36. Give characteristics of study participants (e.g., demographic, clinical, social) and 
information on potential confounders. 
Explanation 
Study authors ought to report participant characteristics (e.g. age, sex, ethnicity, special 
characteristics such as pregnancy and concomitant medications) with appropriate summary 
measures. For example, for continuous data, mean and standard deviation, or median and 
range; for dichotomous data, numbers and proportions. For a case-control study, this 
information ought to be provided for cases and controls separately. It is also important to 
indicate the number of participants with missing data for each variable. 
This item is from the STROBE statement1 (Item 14a), although we removed the reference to 
“exposures”, as the exposure in a pharmacogenetic study is the genetic variant. We would 
expect information on patient genotypes to be reported with the outcome data; it is not 
mandatory to provide this information as part of the baseline characteristics of the study 
population. Further guidance and rationale for this item is detailed in the STROBE 
explanation and elaboration paper.2 
Example 
“The baseline demographic factors including underlying comorbidities are summarized in 
Table 1. The majority of patients (n=309), 60% of whom were inpatients, had a target INR 
[international normalised ratio] range of 2–3, with the remaining two patients having a 
target range of 3–4. The majority of the patients were White with atrial fibrillation being 
the most common indication for warfarin therapy. There was significant variation in the 
loading doses prescribed. Sixty-three percent were given 10 mg on the first 2 days, 17% 
were given 10 mg on day 1 followed by 5 mg on day 2, 7% were given 3 mg on both days 
whereas 5% were given 5 mg on both days”.10 
Table 3 of this publication summarises key baseline characteristics for patients included in 
this study; footnotes are used to indicate the amount of missing data for each variable. 
37. Cohort study – Summarize follow-up time, e.g. average and/or total amount. 
Explanation 
Average follow-up can be summarised using the mean and/or median follow-up time. Total 
amount of follow-up may be reported using total person-years of follow-up, or some 
indication of the completeness of follow-up.52 This item is derived from the STROBE 
statement1 (Item 14c); we modified the item slightly to indicate that average and/or total 
follow-up time would satisfy this criteria. Further guidance and rationale for this item is 
detailed in the STROBE explanation and elaboration paper.2 
Example 
“In our study, patients were entered into the study at the time they started antiepileptic 
drug treatment, and were followed-up prospectively to determine their response to 
medication, including both seizure control and adverse events (...). 
Follow-up ranged from 84 days to 2296 days (median 934, mean 1041)”.42 
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38. Where HWE tests have been undertaken, highlight SNPs that deviate from HWE. 
Explanation 
Although deviations from HWE may be due to disturbing factors which the researcher has 
no control over, it is also possible that deviation may be caused by genotyping errors,53 by 
the existence of population stratification or by biased selection of controls.54 In the quality 
assessment checklist for pharmacogenetic studies (the origin of this item),5 Jorgensen and 
Williamson recommend that study authors highlight any SNPs that were found to deviate 
from HWE. 
Example 
“The rs3813867 SNP was not in Hardy-Weinberg equilibrium and was therefore excluded 
from (...) analysis”.55 
39. Where population stratification is assessed, report the results. 
Explanation 
Study authors ought to report the results of any tests performed to detect the presence of 
population stratification. If tests determine that population stratification is present, this 
indicates that the study is at risk of confounding. Therefore, any associations detected may 
be spurious findings. It is essential that readers are informed of the results of any tests for 
population stratification to enable appropriate interpretation of study findings. The origin 
of this item is Jorgensen and Williamson’s quality assessment checklist for pharmacogenetic 
studies.5 
Example 
“The data collected showed that the African, European, and Amerindian ancestry mean 
ratios were not significantly different between the two groups examined (p > 0.05). Figure 1 
shows the individual parental ethnic contribution of the case group (patients with 
hepatotoxicity) and control group (patients without hepatotoxicity) estimated through 48 
AIMs [ancestry informative markers]”.56 
Results: Outcome data 
40a) For a cohort study, report all outcomes (phenotypes) investigated for each genotype 
category over time. 
40b) For a case-control study, report numbers in each genotype category for all outcomes 
investigated. 
40c) For a cross sectional study, report all outcomes (phenotypes) investigated for each 
genotype category. 
Explanation 
All outcome data should be reported clearly, including the amount of missing 
genotype/outcome data. This item is derived from STREGA7 (item 15); we modified the item 
to specify that all investigated outcomes ought to be reported, to emphasise the 
importance of not selectively reporting results. Specific guidance on how to report outcome 
data for each type of study design are as follows: 
a) Cohort study: For outcomes that relate to the occurrence of some event, report the 
number of events that occurred. If the risk of an event occurring changes over 
follow-up time, present the numbers and rates of events in appropriate intervals of 
331 
follow-up or as a Kaplan-Meier life table or plot. For other outcomes, present 
appropriate summary measures (e.g. means and standard deviations) over time.  
b) Case-control study: Report numbers of cases and controls in each genotype 
category.  
c) Cross-sectional study: For outcomes that relate to the occurrence of some event, 
report the number of events that occurred. For other outcomes, present 
appropriate summary measures (e.g. means and standard deviations). 
Example: Cohort study 
In a cohort study conducted by Ramsey et al.,30 the authors report change in PANSS-T 
(Positive and Negative Syndrome Scale total score) (summarised by means and standard 
deviations in Table 2), response rate and completer status (summarised by percentage of 
responders and completers in Table 3) and weight gain (summarised by mean and standard 
errors in Figure 1) for each haplotype group.  
Example: Case-control study 
“Associations between -308G/A and ATD [anti-tuberculosis drug]-induced hepatitis: The 
genotype frequencies in the case and control groups (...) are presented in Table 2”.57 
Table 2 of this publication reports the number and percentage of cases and controls in each 
genotype group (AA, AG, or GG). 
Example: Cross-sectional 
In a cross-sectional study conducted by Ebid et al.,58 the numbers of responders and non-
responders to metformin and glimepiride combination therapy in each genotype group is 
presented in Table 2 of the publication for the two investigated SNPs (SLC22A1 rs622342 
and ABCC8 rs757110).  
41. If a study includes more than one ethnic group, provide the summary data specified in 
(40) per ethnic group. 
Explanation 
Due to the possibility of confounding by population stratification, it is advisable to present 
results stratified by ethnicity. Furthermore, a significant association between a SNP and a 
treatment response outcome does not necessarily indicate a causal relationship; it is 
possible that the association only exists due to the SNP of interest being in strong linkage 
disequilibrium with the causal SNP. Patterns of linkage disequilibrium vary from one 
population to the next,59 and therefore differences in estimates of association may be 
observed between different populations.. This provides further rationale for stratifying 
results by ethnicity. This item was conceived by members of the Steering Committee. 
Example 
In a case-control study conducted by Ng et al.,60 the number of cases and controls in each 
NAT2 acetylator group (assigned by genotype) is presented in Table 3 of the publication, for 
the overall study population, for patients from Europe, and for patients from the Indian 
subcontinent.  
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Results: Main results 
42. Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (e.g., 95% confidence intervals). Make clear which confounders were adjusted for 
and why they were included. 
Explanation 
Providing both unadjusted measures of association and measures of association adjusted 
for potential confounders enables readers to compare both measures and assess how the 
measure of association is impacted by adjusting for confounders. Study authors ought to 
list all potential confounder variables considered, and the criteria/rationale for excluding or 
including variables in statistical models. It is also useful for authors to: 
• Clearly state which allele/genotype of the variant is associated with the phenotype and 
the direction of the association, when associations are reported 
• Report results of any adjustments for multiple comparisons, for example, Bonferroni 
adjusted p-values, or false discovery rates. 
• Report precise p-values for all associations, as opposed to only indicating whether an 
association was found to be statistically significant or not. For example, stating p<0.05 
or p>0.05, or indicating statistical significance (or a lack of) by using asterisks (*) is not 
appropriate. 
This item is from the STROBE statement1 (Item 16a), further guidance and rationale for this 
item is detailed in the STROBE explanation and elaboration paper.2 
Example 
In a retrospective cohort study conducted by Higashi et al.,61 the authors present 
unadjusted and unadjusted estimates in Table 5, and specify that warfarin daily dose is the 
only covariate included in the adjusted model. The authors explain that covariates were 
included in the model if the hazard ratio changed by more than 5% upon inclusion of the 
covariate in the model. 
43. Report category boundaries when continuous variables were categorised. 
Explanation 
If continuous outcomes were categorised, study authors ought to report the range of 
values covered by each category. This item is from the STROBE statement1 (Item 16b), 
further guidance and rationale for this item is detailed in the STROBE explanation and 
elaboration paper.2 
Example 
“(…) patients were divided according to the HbA1C level obtained at the patient clinic 
appointment and classified into responders or non-responders. Responders were defined 
as patients who received metformin and glimepiride combination therapy for at least 
6 months, and their HbA1C was less than 7%. Non-responders were considered to be on 
combination therapy for at least 6 months, and their HbA1C was equal or higher than 
7%”.58 
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Results: Other analyses 
44. Report other analyses done – e.g., analyses of subgroups and interactions, and sensitivity 
analyses. 
Explanation 
It may be impractical to present detailed findings for all analyses performed; in this case, 
authors should present detailed results for important results only. Less important results 
can be summarised briefly in the text and detailed in full in supplementary materials. This 
item is from the STROBE statement1 (Item 17), further guidance and rationale for this item 
is detailed in the STROBE explanation and elaboration paper.2  
Example 
“In a sensitivity analysis in which only those patients without any evidence of H. pylori 
infection (n=376) were analysed as cases, there was no significant interaction seen with 
CYP2C19*17 (P=0.068) (see Supplementary Data online)”.41 
45. If numerous genetic exposures (genetic variants) were examined, summarize results from 
all analyses undertaken. 
Explanation 
This item encourages authors to report results for all genetic variants that were 
investigated in the study, rather than selectively reporting only "interesting" or statistically 
significant results. Full results can be provided in supplementary materials if necessary. This 
item is from the STREGA statement7 (item 17b), further guidance and rationale for this item 
is detailed in the STREGA statement publication. 
Example 
“In the logistic regression analyses using an additive model, only one SNP, CYP2C19*17, was 
significantly associated with the presence of PUD [peptic ulcer disease] (odds ratio 1.47 
(95% confidence interval (CI) 1.12 to 1.92); P=0.005, Table 3)”.41 
Table 3 of this publication provides the results of logistic regression analyses for all 
analysed SNPs.  
46. If detailed results are available elsewhere, i.e. in supplementary materials, state how they 
can be accessed. 
Explanation 
Study authors ought to report what results are available, and provide sufficient details that 
a reader would easily be able to locate these resources. This item is derived from the 
STREGA statement7 (item 17c), although we modified the item to indicate that we are 
referring to supplementary materials to the study publication. Further guidance and 
rationale for this item is detailed in the STREGA statement publication. 
Example 
“Supplementary material is linked to the online version of the paper at 
http://www.nature.com/cpt”.41 
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Discussion: Key results 
47. Summarize key results with reference to study objectives. 
Explanation 
A short summary of the main findings of the study helps the reader to assess whether the 
author's interpretation and suggested implications are supported by the findings. This item 
is from the STROBE statement1 (item 18); further guidance and rationale for this item is 
detailed in the STROBE explanation and elaboration paper.2 
Example 
“In this large study in Malawian and Ugandan adults treated with nevirapine, we have been 
able to show an association between nevirapine-induced SJS/TEN [Stevens-Johnson 
syndrome/toxic epidermal necrolysis] and the c.983T>C polymorphism. The carriage 
frequency in nevirapine control individuals was 16% compared with 32% in those with 
nevirapine-induced SJS/TEN (P=0.0005, FDR [false discovery rate]=0.015) (Table 4). This 
association was not observed with any other nevirapine-induced hypersensitivity 
phenotype”.6 
Discussion: Limitations 
48. Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias. 
Explanation 
Discussing the limitations of the study helps the reader to interpret the validity and health 
care relevance of the study findings. Limitations might relate to, for example, 
characteristics of included patients, methods of outcome measurement, multiplicity of 
analyses, missing data, etc. This item is from the STROBE statement1 (item 19); further 
guidance and rationale for this item is detailed in the STROBE explanation and elaboration 
paper.2 
Example 
 “A limitation of our study is the size of the replication cohort, which was smaller than the 
discovery cohort and therefore lacked the statistical power to truly replicate the association 
observed between c.983T>C and nevirapine-induced SJS/TEN [Stevens-Johnson 
syndrome/toxic epidermal necrolysis]. However, nevirapine hypersensitivity is a rare 
phenotype and it was difficult to identify a larger number of patients. The replication cohort 
also consisted of both Malawian and Ugandan patients, which may introduce some 
population stratification. However, our data show that the frequency of c.983T>C 
polymorphism in the overall combined Malawian discovery and replication patients (0.18) 
was comparable to that observed in the Ugandan patients (0.15)”.6  
Discussion: Interpretation  
49. Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence.  
Explanation 
When interpreting results, authors should consider potential sources of bias, residual 
confounding (due to unmeasured variables or imprecise measurement of confounders), the 
results of relevant sensitivity analyses and subgroup analyses. Authors should discuss the 
real range of uncertainty with regards to reported results, which is greater than the 
statistical uncertainty demonstrated by confidence intervals. This item is from the STROBE 
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statement1 (item 20); further guidance and rationale for this item is detailed in the STROBE 
explanation and elaboration paper.2 
Example 
“Utilizing a variety of outcomes reflecting drug response, we have not demonstrated a 
significant association with any of 13 common SNPs in the RLIP76 gene in the whole cohort, 
either when investigated univariately or by way of multiple regression, taking the genetic 
region spanned by the SNPs as a whole. Three SNPs demonstrated low p-values when 
undertaking the univariate analyses, but these, with p-values of 0.02-0.04, would not 
survive correction for multiple testing to account for the number of analyses being 
undertaken. Furthermore, each of these SNPs was found to be ''nominally significant'' for 
only one of any of the four outcomes investigated. Following backward variable selection, 
one SNP was found to be nominally associated with time to first seizure (SNP rs167897) and 
another was found to be nominally associated with time to 12-month remission (SNP 
rs12457094), but once again, the resulting p-values would not survive correction for 
multiple testing. 
In the subgroup analysis, including only those patients on carbamazepine, the only AED 
[anti-epileptic drug] used in the SANAD cohort that may be a substrate for RLIP76, 
univariate testing of the 13 SNPs demonstrated four SNPs with p-values less than 0.05, but 
once again, no SNP demonstrated a significant association with more than one of the four 
outcomes, and furthermore, once again these p-values would not survive correction for 
multiple testing. When investigating the genetic region as a whole, a nominally significant 
association was found with the outcome of time to first seizure (p=0.05), and the resulting 
models following backward variable selection gave p-values of less than 0.05 for all four 
outcomes (minimum: p=0.007). One SNP in particular, rs329017, was retained in the final 
model for three of the four outcomes. While once again these p-values would not survive 
correction for multiple testing, this is the strongest evidence for any influence 
of RLIP76 genetic variation on drug response; the smaller size of the carbamazepine-treated 
subgroup may have limited the power to detect a stronger association. 
The lack of definitively positive findings suggests that RLIP76 genotypes probably have no 
influence on drug response in epilepsy patients as a whole, which is consistent with those 
reported recently. Subgroup analysis in patients on carbamazepine alone, however, does 
raise candidate polymorphisms for further analysis. Even under the assumption that none 
of these results are significant, this does not exclude a genetic influence on drug response 
mediated by RLIP76 since common polymorphisms analyzed may not represent all common 
variants throughout the gene. Alternatively, genetic contributions may arise from rare 
variants, in which case our study may have lacked power to detect an association. In 
addition, genetic factors influencing RLIP76 expression or function may be remote from 
the RLIP76 gene itself”.3 
The article provides a reference to a previous study which also investigated the association 
between RLIP76 genotypes and drug response in epilepsy patients, and makes comparisons 
between the findings of the two studies. 
Discussion: Generalisability 
50. Discuss the generalisability (external validity) of the study results. 
Explanation 
Study authors ought to consider the extent to which the results of the study can be applied 
to other circumstances, i.e. different populations/settings/countries. This item is from the 
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STROBE statement1 (item 21); further guidance and rationale for this item is detailed in the 
STROBE explanation and elaboration paper.2 
Example 
“Our data show that the frequency of c.983T>C polymorphism in the overall combined 
Malawian discovery and replication patients (0.18) was comparable to that observed in the 
Ugandan patients (0.15), and to that reported in a Mozambican population (0.14). Although 
genetic differences do exist between these African cohorts, it would appear from our study 
that CYP2B6 c.983T>C is likely to be generalizable across other sub-Saharan-African 
populations”.6 
Other information: Study registration 
51. State whether the study has been registered. If the study has been registered, provide 
details of the registry. 
Explanation 
Studies can be registered on many different official platforms; the most widely used 
platform is ClinicalTrials.gov. This platform provides information on how registering studies 
fulfils a number of purposes and benefits many different groups of people. This item was 
conceived by members of the Steering Committee. 
Example 
“Clinical Trials.gov Identifier: NCT 00824772”.62 
Other information: Ethical approval 
52. Report whether ethical approval was obtained for the collection of genetic data. 
Explanation 
If ethical approval was obtained, authors should also report the committee that gave 
ethical approval and a reference ID. This item was conceived by members of the Steering 
Committee. 
Example 
“Ethical approval for this study was granted by North West 3 Research Ethics Committee 
(10/H1002/57)”.39 
Other information: Funding 
53. Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based. 
Explanation 
The role of the funders relates to which part of the study the funders took direct 
responsibility for, e.g., study design, data collection, analysis, drafting of manuscript, 
decision to publish. This item is from the STROBE statement1 (item 22); further guidance 
and rationale for this item is detailed in the STROBE explanation and elaboration paper.2 
Example 
“Role of the funding source: The sponsors of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding 
author had full access to all the data in the study and had final responsibility for the 
decision to submit for publication (…). 
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Other information: Databases 
54. State whether databases for the analysed data are or will become publicly available and if 
so, how they can be accessed. 
Explanation 
If databases are available, study authors should provide sufficient details that a reader 
would easily be able to locate these resources. This item is from the GRIPS statement63 
(item 24); further guidance and rationale for this item is detailed in the GRIPS explanation 
and elaboration paper.64 
Example 
“The complete data set of genotypes and clinical variables, as well as the full genotype 
quality-control data, is available to registered PharmGKB users at www.pharmgkb.org (full 
data set accession number, PA162355460)”.65 
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Glossary of terms 
Term Definition 
Adverse effect Undesired pharmacological outcome resulting from an intervention, 
such as medication or surgery 
Allele A variant form of a gene. For example, at a SNP where individuals 
may either have a ‘C’ nucleotide base or a ‘T’ nucleotide base, the 
possible alleles for this SNP are C and T.  
Amino acid Organic molecules which serve as the building blocks of proteins 
Assay Used in genetic research to perform genotyping 
Candidate gene study A study in which researchers investigate a small set of SNPs. SNPs 
are selected on the basis of how likely they are to be associated with 
the outcome of interest. 
Chromosome Thread-like structures that are made up of tightly coiled DNA.  
Human cells contain two sets of 23 chromosomes, with one set 
inherited from each parent. 
DNA DNA stands for deoxyribonucleic acid. DNA is a long molecule that 
contains an organism’s genetic information. 
Enzyme Substance produced by an organism that increases the rate of 
biochemical reactions, without itself being altered in the process 
Excretion Process by which metabolic waste is removed from an organism 
Gamete Male or female reproductive cell that contains half the genetic 
material of the organism 
Gene Small section of DNA that contains the information required to build 
a specific molecule (usually a protein) 
Gene expression Process by which the information from a gene is used in the 
synthesis of a functional product (usually a protein) 
Genome The complete set of genetic information for an organism 
Genome-wide association 
study (GWAS) 
A genetic association study in which researchers genotype hundreds 
of thousands of SNPs to provide coverage of the entire human 
genome 
Genotype Noun: set of two alleles (one on each chromosome) observed at a 
particular locus 
Verb: process of identifying which two alleles an individual 
possesses at a particular locus 
Heterozygous/heterozygote An individual with different alleles on each chromosome at the locus 
for a particular SNP has the heterozygous genotype, or is a 
heterozygote. 
Homozygous/homozygote An individual with the same allele on each chromosome at the locus 
for a particular SNP has the homozygous genotype, or is a 
homozygote. 
Intergenic region Sections of DNA between genes. Intergenic DNA makes up a large 
proportion of the human genome, but mostly has no recognised 
function. 
In vitro Study of biological properties that occurs outside a living organism 
Linkage disequilibrium Extent to which the frequency of a combination of alleles at two loci 
differs to the frequency that would be expected if the loci were 
independent and associated randomly 
Locus/loci Specific physical location on a chromosome. The plural of locus is 
loci. 
Metabolism The complete set of biochemical processes that occur within an 
organism to sustain life 




Natural selection Process whereby heritable traits which increase an organism’s 
chances of survival and successful reproduction become more 
common in a population over time 
Nucleotide Structural component of DNA. Each nucleotide consists of a 
nitrogenous base (adanine [A], cytosine [C], guanine [G], or thymine 
[T]), a sugar molecule, and a phosphate group. 
Pharmacodynamics Study of the physiological and biochemical effects of drug exposure 
on the body 
Pharmacogenetic test A test that is used to determine an individuals genotype at one or 
more loci. Results may be used to inform choice of treatment 
regimen. 
Pharmacokinetics Study of how the body affects an administered drug. 
Pharmacokinetics explores what happens to a drug from the 
moment it is administered up until the point that it is completely 
eliminated from the body. 
Phenotype Observable, physical properties of an organism including 
appearance, development, and behaviour, for example, blue eye 
colour, or A+ blood type. An individual’s phenotype is determined by 
both genotype and environmental factors. 
Platform (genotyping) Technology which facilitates the process of genotyping 
Primer Short, single-stranded DNA sequence that is complementary to a 
known section of DNA. Primers are required for the replication of 
DNA during the genotyping process. 
Promoter region Sequence of DNA that initiates transcription of the genes that follow 
it. In other words, promoter regions are required to turn certain 
genes ‘on’ and ‘off’. 
Protein Large molecules consisting of one or more chains of amino acids. All 
organisms produce proteins, which have a variety of functions, such 
as catalysing reactions, transporting oxygen, and defending 
organisms from infection. 
Single nucleotide 
polymorphism (SNP) 
A locus where the type of nucleotide base (A, T, C, or G) present can 
differ between individuals 
Stratified medicine An approach based on identifying groups of patients with distinct 
mechanisms of disease, or responses to treatment, which allows 
treatment of an individual to be tailored according to their specific 
characteristics 
Trait A feature or characteristic of an organism that can be determined by 
genes, the environment, or both, for example, eye colour or blood 
type 
Wild-type allele The allele that is most commonly observed at a particular locus for a 
given population 
 
